0001567892-19-000009 | 10-K | XBRL Viewer

$ 834.9

$ 799.9

$ 825.5

$ 755.3

$ 792.3

$ 793.9

$ 824.5

$ 810.9

$ 829.9

$ 811.2

$ 3,215.6

$ 3,221.6

$ 3,380.8

383.2

360.0

^[1]

1,744.4

1,564.1

1,523.2

363.3

^[2]

366.4

^[2]

394.0

^[2]

347.5

^[2]

421.0

^[2]

400.6

^[2]

416.1

^[2]

419.8

^[2]

446.7

451.2

^[1]

1,471.2

1,657.5

1,857.6

321.1

221.8

^[1]

834.1

849.7

913.7

66.1

61.3

^[1]

361.1

276.9

261.2

214.3

0.0

3,893.1

63.7

16.9

0.0

0.8

(56.9)

0.0

3.8

4.1

103.0

31.2

32.7

214.3

3,893.1

63.7

16.9

(0.8)

(56.9)

Operating (loss) income

(158.6)

(164.0)

^[1]

(3,720.9)

492.9

633.1

(91.3)

(97.8)

(370.2)

(369.1)

(384.6)

0.5

0.2

8.2

4.6

1.3

(Loss) income from continuing operations before income taxes

(49.1)

0.1

^[1]

30.9

(66.8)

(16.4)

(298.5)

66.5

(4,052.0)

61.6

233.4

(121.7)

(37.3)

(430.1)

(1,709.6)

(255.6)

Income from discontinued operations, net of tax expense of $1.4, $5.4, $43.5, and $15.3

(3,718.4)

^[3]

114.2

^[3]

3.2

^[3]

(20.9)

^[3]

1,607.4

^[3]

64.3

^[3]

70.6

^[3]

28.9

^[3]

(176.8)

103.8

(3,621.9)

1,771.2

489.0

0.0

(0.4)

12.4

2.9

1.3

(0.6)

(7.8)

370.3

23.6

107.3

14.9

363.2

154.7

$ (3,718.4)

$ 113.8

$ 15.6

$ (18.0)

$ 1,608.7

$ 63.7

$ 62.8

$ 399.2

$ (153.2)

$ 211.1

$ (3,607.0)

$ 2,134.4

$ 643.7

Basic earnings per share (Note 10):

Income from discontinued operations, net of income taxes

$ (44.64)

^[4]

$ 1.37

^[4]

$ 0.04

^[4]

$ (0.24)

^[4]

$ 17.43

^[4]

$ 0.66

^[4]

$ 0.72

^[4]

$ 0.28

^[4]

$ (1.67)

$ 0.90

$ (43.12)

$ 18.13

$ 4.42

0.22

0.93

0.18

3.72

1.40

Basic weighted-average shares outstanding

$ (1.45)

$ 1.83

$ (42.94)

$ 21.85

$ 5.82

105.7

115.4

84.0

97.7

110.6

Diluted earnings per share (Note 10):

Income from discontinued operations, net of income taxes

$ (44.64)

^[4]

$ 1.34

^[4]

$ 0.04

^[4]

$ (0.24)

^[4]

$ 17.40

^[4]

$ 0.66

^[4]

$ 0.72

^[4]

$ 0.28

^[4]

$ (1.67)

$ 0.89

$ (43.12)

$ 18.09

$ 4.39

0.22

0.92

0.18

3.71

1.39

Diluted weighted-average shares outstanding

$ (1.45)

$ 1.82

$ (42.94)

$ 21.80

$ 5.77

105.7

116.3

84.0

97.9

111.5

[1]	Financial data for this period has been adjusted to reflect the change in accounting for pension and postretirement costs with the adoption of Accounting Standards Update ("ASU") 2017-07. See Note 4 for further information on this ASU.
[2]	Financial data for each period has been adjusted to reflect the change in accounting for pension and postretirement costs with the adoption of ASU 2017-07. See Note 4 for further information.
[3]	(Loss) income from continuing operations for the quarter ended December 28, 2018 reflects impairment charges for goodwill and an IPR&D asset. See Note 13 for further information. Income from continuing operations for the quarter ended December 29, 2017 reflects one-time effects for the completion of the reorganization of the Company's legal entity ownership and the impact of the TCJA.
[4]	Quarterly and annual computations are prepared independently. Therefore, the sum of each quarter may not necessarily total the fiscal period amounts noted elsewhere within this Annual Report on Form 10-K.

Consolidated and Combined Statements of Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016
Income Statement [Abstract]
Tax (benefit) expense on income (loss) from discontinued operations	$ 15.3	$ 1.4	$ 5.4	$ 43.5

Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.

+ References + Details

Consolidated and Combined Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended										12 Months Ended
	Dec. 28, 2018	Sep. 28, 2018	Jun. 29, 2018	Mar. 30, 2018	Dec. 29, 2017	Sep. 29, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 30, 2016	Dec. 25, 2015	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016
Net (loss) income	$ (3,718.4)	$ 113.8	$ 15.6	$ (18.0)	$ 1,608.7	$ 63.7	$ 62.8	$ 399.2	$ (153.2)	$ 211.1	$ (3,607.0)	$ 2,134.4	$ 643.7
Other comprehensive (loss) income, net of tax
Unrecognized gain on investments									0.0		0.0	1.5	0.0
Currency translation adjustments									(21.1)		(12.2)	11.3	(58.6)
Unrecognized gain on derivatives, net of tax expense of $0.2, $0.3, $0.2, and $-									0.2		0.7	1.0	0.5
Unrecognized gain (loss) on benefit plans, net of tax expense (benefit) of $0.5, $30.8, ($15.0), and ($19.3)									34.0		1.6	45.8	(28.4)
Total other comprehensive (loss) income, net of tax									13.1		(9.9)	59.6	(86.5)
Comprehensive (loss) income									$ (140.1)		$ (3,616.9)	$ 2,194.0	$ 557.2

Organization, Consolidation and Presentation of Financial Statements [Abstract]

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Consolidated and Combined Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016
Statement of Comprehensive Income [Abstract]
Unrecognized loss on derivatives, tax	$ 0.0	$ (0.2)	$ (0.3)	$ (0.2)
Unrecognized gain (loss) on benefit plans, tax	$ 19.3	$ (0.5)	$ (30.8)	$ 15.0

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 28, 2018	Dec. 29, 2017
Current Assets:
Cash and cash equivalents	$ 348.9	$ 1,260.9
Accounts receivable, less allowance for doubtful accounts of $5.0 and $3.9	623.3	445.8
Inventories	322.3	340.4
Prepaid expenses and other current assets	132.7	84.1
Notes receivable	0.0	154.0
Total current assets	1,427.2	2,285.2
Property, plant and equipment, net	982.0	966.8
Goodwill	0.0	3,482.7
Intangible assets, net	8,282.8	8,375.0
Other assets	185.3	171.2
Total Assets	10,877.3	15,280.9
Current Liabilities:
Current maturities of long-term debt	22.4	313.7
Accounts payable	147.5	113.3
Accrued payroll and payroll-related costs	124.0	98.5
Interest Payable, Current	77.6	57.0
Taxes Payable, Current	25.0	15.8
Accrued and other current liabilities	547.2	452.1
Total current liabilities	943.7	1,050.4
Long-term debt	6,069.2	6,420.9
Pension and postretirement benefits	60.5	67.1
Environmental liabilities	59.7	73.2
Deferred income taxes	324.3	689.0
Other income tax liabilities	228.0	94.1
Other liabilities	304.6	364.2
Total Liabilities	7,990.0	8,758.9
Shareholders' Equity:
Preferred shares, $0.20 par value, 500,000,000 authorized; none issued or outstanding	0.0	0.0
Ordinary A shares, €1.00 par value, 40,000 authorized; none issued or outstanding	0.0	0.0
Ordinary shares, $0.20 par value, 500,000,000 authorized; 92,705,747 and 92,196,662 issued; 83,323,877 and 86,336,232 outstanding	18.5	18.4
Ordinary shares held in treasury at cost, 9,381,870 and 5,860,430	(1,617.4)	(1,564.7)
Additional paid-in capital	5,528.2	5,492.6
Retained (deficit) earnings	(1,017.7)	2,588.6
Accumulated other comprehensive loss	(24.3)	(12.9)
Total Shareholders' Equity	2,887.3	6,522.0
Total Liabilities and Shareholders' Equity	$ 10,877.3	$ 15,280.9

Consolidated Balance Sheets (Parenthetical)	Dec. 28, 2018 $ / shares shares	Dec. 28, 2018 € / shares shares	Dec. 29, 2017 $ / shares shares	Dec. 29, 2017 € / shares shares
Preferred shares, par value (in usd per share) \| $ / shares	$ 0.20		$ 0.20
Preferred shares, shares authorized (in shares)	500,000,000	500,000,000	500,000,000	500,000,000
Preferred shares, shares issued (in shares)	0	0	0	0
Preferred shares, shares outstanding (in shares)	0	0	0	0
Ordinary A shares, par value (in eur per share) \| € / shares		€ 1.00		€ 1.00
Ordinary A shares, shares authorized (in shares)	40,000	40,000	40,000	40,000
Ordinary A shares, shares issued (in shares)	0	0	0	0
Ordinary A shares, shares outstanding (in shares)	0	0	0	0
Ordinary shares, par value (in usd per share) \| $ / shares	$ 0.20		$ 0.20
Ordinary shares, shares authorized (in shares)	500,000,000	500,000,000	500,000,000	500,000,000
Ordinary shares, shares issued (in shares)	92,705,747	92,705,747	92,196,662	92,196,662
Ordinary shares, shares outstanding (in shares)	83,323,877	83,323,877	86,336,232	86,336,232
Ordinary shares held in treasury (in shares)	9,381,870	9,381,870	5,860,430	5,860,430

Consolidated and Combined Statements of Cash Flows - USD ($)	3 Months Ended	12 Months Ended
	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016
Restricted Cash and Investments, Current	$ 100,000	$ 0	$ 0	$ 100,000
Restricted Cash and Investments, Noncurrent	19,000,000.0	18,600,000	18,200,000	19,000,000.0
Cash and Cash Equivalents, Including Restricted Cash	361,100,000	367,500,000	1,279,100,000	299,600,000
Cash and cash equivalents	342,000,000.0	348,900,000	1,260,900,000	280,500,000
Cash Flows from Operating Activities:
Net (loss) income	(153,200,000)	(3,607,000,000.0)	2,134,400,000	643,700,000
Adjustments to reconcile net cash provided by operating activities:
Depreciation and amortization	203,200,000	852,100,000	808,300,000	834,500,000
Share-based compensation	11,000,000.0	34,600,000	59,200,000	42,900,000
Deferred income taxes	(204,300,000)	(541,500,000)	(1,744,100,000)	(432,900,000)
Non-cash impairment charges	214,300,000	3,893,100,000	63,700,000	16,900,000
Inventory provisions	8,500,000	37,900,000	34,100,000	29,200,000
Gain (Loss) on Disposition of Business	0	800,000	(418,100,000)	(95,300,000)
Other non-cash items	(9,200,000)	(50,900,000)	(21,400,000)	29,600,000
Changes in assets and liabilities, net of the effects of acquisitions:
Accounts receivable, net	(36,500,000)	(145,800,000)	(16,200,000)	31,200,000
Inventories	26,300,000	63,100,000	(23,600,000)	(17,300,000)
Accounts payable	5,400,000	24,600,000	(25,800,000)	(9,700,000)
Income taxes	600,000	99,000,000.0	(34,200,000)	93,900,000
Other	(109,100,000)	5,500,000	(89,000,000.0)	17,900,000
Net cash from operating activities	195,600,000	665,500,000	727,300,000	1,184,600,000
Cash Flows from Investing Activities:
Capital expenditures	(65,200,000)	(127,000,000.0)	(186,100,000)	(182,900,000)
Acquisitions, net of cash acquired	1,800,000	(699,900,000)	(76,300,000)	(245,400,000)
Proceeds from Divestiture of Businesses, Net of Cash Divested	0	313,000,000.0	576,900,000	266,700,000
Other	10,200,000	33,600,000	3,900,000	6,000,000.0
Net cash from investing activities	(77,200,000)	(480,300,000)	318,400,000	(155,600,000)
Cash Flows from Financing Activities:
Issuance of external debt	190,000,000.0	690,300,000	1,465,000,000.0	98,300,000
Repayment of external debt and capital lease obligation	(86,700,000)	(1,693,600,000)	(917,200,000)	(568,600,000)
Debt financing costs	0	(12,100,000)	(12,700,000)	(100,000)
Proceeds from exercise of share options	400,000	1,000,000.0	4,100,000	14,000,000.0
Repurchase of shares	(158,800,000)	(57,500,000)	(651,700,000)	(652,900,000)
Other	1,200,000	(23,100,000)	(17,700,000)	(53,000,000.0)
Net cash from financing activities	(53,900,000)	(1,095,000,000.0)	(130,200,000)	(1,162,300,000)
Effect of currency rate changes on cash	(3,000,000.0)	(1,800,000)	2,500,000	300,000
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	61,500,000	(911,600,000)	918,000,000.0	(133,000,000.0)
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	95,400,000	309,700,000	339,100,000	332,400,000
Cash paid for income taxes, net	$ 95,600,000	$ 12,400,000	$ 73,400,000	$ 165,400,000

Consolidated and Combined Statement of Changes in Shareholders' Equity Statement - USD ($) $ in Millions	Total	Ordinary Shares	Treasury Shares	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income
Beginning balance, shares at Sep. 25, 2015		117,500,000	1,200,000
Beginning balance, value at Sep. 25, 2015	$ 5,311.2	$ 23.5	$ (109.7)	$ 5,357.6	$ 38.9	$ 0.9
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	643.7				643.7
Currency translation adjustments	(58.6)					(58.6)
Change in derivatives, net of tax	0.5					0.5
Minimum pension liability, net of tax	(28.4)					(28.4)
Unrecognized gain on investments	$ 0.0
Share options exercised, shares	413,830	400,000
Share options exercised, value	$ 14.0	$ 0.1		13.9
Vesting of restricted shares, shares		200,000
Vesting of restricted shares, value	0.0	$ 0.0		0.0
Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation	$ (1.7)			(1.7)
Treasury Stock, Shares, Acquired	9,800,000
Treasury Stock, Value, Acquired, Cost Method	$ (652.9)
Share-based compensation	42.9			42.9
Ending balance, shares at Sep. 30, 2016		118,100,000	11,000,000.0
Ending balance, value at Sep. 30, 2016	5,270.7	$ 23.6	$ (762.6)	5,412.7	682.6	(85.6)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(153.2)				(153.2)
Currency translation adjustments	(21.1)					(21.1)
Change in derivatives, net of tax	0.2					0.2
Minimum pension liability, net of tax	34.0					34.0
Unrecognized gain on investments	$ 0.0
Share options exercised, shares	16,382	100,000
Share options exercised, value	$ 0.4	$ 0.0		0.4
Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation	$ (0.1)			(0.1)
Treasury Stock, Shares, Acquired	2,500,000
Treasury Stock, Value, Acquired, Cost Method	$ (158.8)		158.8
Share-based compensation	11.0			11.0
Stock Issued During Period, Value, Treasury Stock Reissued	(1.2)		$ (1.6)		(0.4)
Ending balance, shares at Dec. 30, 2016		118,200,000	13,500,000
Ending balance, value at Dec. 30, 2016	4,984.3	$ 23.6	$ (919.8)	5,424.0	529.0	(72.5)
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification	(72.1)				(72.1)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	2,134.4
Currency translation adjustments	11.3					11.3
Change in derivatives, net of tax	1.0					1.0
Minimum pension liability, net of tax	45.8					(45.8)
Unrecognized gain on investments	1.5					1.5
Treasury Stock, Shares, Retired		(26,500,000)
Stock Repurchased and Retired During Period, Value	$ 0.0	$ (5.3)		(5.3)
Treasury Stock, Shares, Retired			(26,500,000)
Share options exercised, shares	113,605	100,000
Share options exercised, value	$ 4.1	$ 0.0		4.1
Vesting of restricted shares, shares		400,000
Vesting of restricted shares, value	(0.1)	$ (0.1)		0.0
Treasury Stock, Shares, Acquired			18,900,000
Treasury Stock, Value, Acquired, Cost Method	(651.7)		$ 651.7
Share-based compensation	59.2			59.2
Stock Issued During Period, Value, Treasury Stock Reissued	(4.1)		$ (6.8)		2.7
Ending balance, shares at Dec. 29, 2017		92,200,000	5,900,000
Ending balance, value at Dec. 29, 2017	6,522.0	$ 18.4	$ (1,564.7)	5,492.6	2,588.6	(12.9)
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification	1.1				2.6	(1.5)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(3,607.0)
Currency translation adjustments	(12.2)					(12.2)
Change in derivatives, net of tax	0.7					0.7
Minimum pension liability, net of tax	1.6					1.6
Unrecognized gain on investments	$ 0.0
Share options exercised, shares	39,949	0
Share options exercised, value	$ 1.0	$ 0.0		1.0
Vesting of restricted shares, shares		500,000	100,000
Vesting of restricted shares, value	2.2	$ (0.1)	$ 2.3	0.0
Treasury Stock, Shares, Acquired			3,600,000
Treasury Stock, Value, Acquired, Cost Method	(55.2)		$ 55.2
Share-based compensation	$ 34.6			34.6
Stock Issued During Period, Shares, Treasury Stock Reissued	(200,000)
Stock Issued During Period, Value, Treasury Stock Reissued	$ (2.9)		$ (4.8)		(1.9)
Ending balance, shares at Dec. 28, 2018		92,700,000	9,400,000
Ending balance, value at Dec. 28, 2018	$ 2,887.3	$ 18.5	$ (1,617.4)	$ 5,528.2	$ (1,017.7)	$ (24.3)

Background and Basis of Presentation (Notes)

12 Months Ended

Dec. 28, 2018

Background and Basis of Presentation

Background

Mallinckrodt plc and its subsidiaries (collectively, "Mallinckrodt" or "the Company"), is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. As of December 28, 2018, areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. Our core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities.

Our business is operated in two reportable segments, which are further described below:


•	Specialty Brands includes innovative specialty pharmaceutical brands; and


•	Specialty Generics and Amitiza includes niche specialty generic drug products, active pharmaceutical ingredients ("API(s)") and Amitiza^® (lubiprostone) ("Amitiza").

In May 2015, the Board of Directors of Mallinckrodt plc approved the migration of the Company’s principal executive offices from Ireland to the United Kingdom. The Company remains incorporated in Ireland and continues to be subject to United States ("U.S.") Securities and Exchange Commission ("SEC") reporting requirements and the applicable corporate governance rules of the New York Stock Exchange.

Basis of Presentation

The consolidated financial statements have been prepared in U.S. dollars and in accordance with accounting principles generally accepted in the U.S. ("GAAP"). The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results may differ from those estimates. The consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries and entities in which they own or control more than 50% of the voting shares, or have the ability to control through similar rights. All intercompany balances and transactions have been eliminated in consolidation and all normal recurring adjustments necessary for a fair presentation have been included in the results reported.

The results of entities disposed of are included in the consolidated financial statements up to the date of disposal and, where appropriate, these operations have been reflected as discontinued operations. Divestitures of product lines not meeting the criteria for discontinued operations have been reflected in operating (loss) income.

On December 6, 2018, the Company announced its plans to spin off a new company consisting of the Specialty Generics/API business and the Amitiza product to the Company's shareholders ("the Separation"). The Separation is expected to create two independent, appropriately capitalized, publicly traded companies – one focused on innovative specialty pharmaceutical brands, the other concentrated primarily in niche specialty generic products and API manufacturing – each positioned to optimize future success as they pursue independent growth strategies. The Company anticipates that the transaction will be in the form of a distribution of new publicly traded stock in the new company that is intended to be generally tax-free for U.S. federal income tax purposes to the Company's shareholders. Completion of the transaction is expected to be subject to certain conditions, including, among others, receipt of regulatory approvals, assurance as to the tax-free status of the spin-off of the business to the Company's shareholders, the effectiveness of a Form 10 registration statement to be filed with the SEC and final approval by the Company's Board of Directors. The Company currently expects completion of the transaction in the second half of 2019; however, there can be no assurance regarding the ultimate timing of the proposed transaction or that the transaction will be completed.

Beginning in the first quarter through the third quarter of fiscal 2018, the historical financial results attributable to "the Specialty Generics Disposal Group" were reflected in the Company's interim condensed consolidated financial statements as discontinued operations. The Specialty Generics Disposal Group included (1) the Company's Specialty Generics business comprised of what was the Company's Specialty Generics segment in fiscal 2017, with the exception of BioVectra, Inc. - a wholly owned subsidiary of the Company that operates a contract manufacturing business in Canada ("BioVectra"); (2) certain of the Company's non-promoted brands business, which was previously reflected in the Company's Specialty Brands segment; and (3) the Company's ongoing, post-divestiture supply agreement with the acquirer of the contrast media and delivery systems ("CMDS") business, which was previously reflected in the Company's Other non-operating segment. As a result of the Separation announcement, the Specialty Generics Disposal Group no longer met the requirements to be classified as held-for-sale, and the historical financial results attributable to the Specialty

Generics Disposal Group have been recast in the Company's consolidated financial statements as continuing operations. Prior year amounts have been recast to conform to current presentation. See further discussion in Note 23.

Fiscal Year

The Company reports its results based on a "52-53 week" year ending on the last Friday of December. Fiscal 2018 and 2017 each consisted of 52 weeks and fiscal 2016 consisted of 53 weeks. On May 17, 2016, the Board of Directors of the Company approved a change in the Company’s fiscal year end to the last Friday in December from the last Friday in September. The change in fiscal year became effective for the Company’s 2017 fiscal year, which began on December 31, 2016 and ended on December 29, 2017. As a result of the change in fiscal year end, the Company filed a Transition Report on Form 10-Q on February 7, 2017 covering the period from October 1, 2016 through December 30, 2016 ("the three months ended December 30, 2016") with the comparable period from September 26, 2015 through December 25, 2015. Fiscal 2016 covers the period from September 26, 2015 through September 30, 2016.

Transition Period (Notes)

12 Months Ended

Dec. 28, 2018

Transition Period [Text Block]



2.	Transition Period

The Company is presenting audited financial statements for the three month period ended December 30, 2016. The following tables provide certain unaudited comparative financial information for the same period of the prior year.



Consolidated Statements of Income	Three Months Ended
	December 30, 2016			(unaudited) December 25, 2015 ⁽¹⁾
Net sales	$	829.9		$	811.2
Cost of sales	383.2			360.0
Gross profit	446.7			451.2

Selling, general and administrative expenses	321.1			221.8
Research and development expenses	66.1			61.3
Restructuring charges, net	3.8			4.1
Non-restructuring impairment charges	214.3			—
Operating (loss) income	(158.6		)	164.0

Interest expense	(91.3		)	(97.8		)
Interest income	0.5			0.2
Other (expense) income, net	(49.1		)	0.1
(Loss) income from continuing operations before income taxes	(298.5		)	66.5

Benefit from income taxes	(121.7		)	(37.3		)
(Loss) income from continuing operations	(176.8		)	103.8

Income from discontinued operations	23.6			107.3

Net (loss) income	$	(153.2	)	$	211.1

Basic earnings per share (Note 10):
(Loss) income from continuing operations	$	(1.67	)	$	0.90
Income from discontinued operations, net of income taxes	0.22			0.93
Net (loss) income	$	(1.45	)	$	1.83

Basic weighted-average shares outstanding	105.7			115.4

Diluted earnings per share (Note 10):
(Loss) income from continuing operations	$	(1.67	)	$	0.89
Income from discontinued operations, net of income taxes	0.22			0.92
Net (loss) income	$	(1.45	)	$	1.82

Diluted weighted-average shares outstanding	105.7			116.3


(1)	Financial data for this period has been adjusted to reflect the change in accounting for pension and postretirement costs with the adoption of Accounting Standards Update ("ASU") 2017-07. See Note 4 for further information on this ASU.



Consolidated Statements of Cash Flows	Three Months Ended
	December 30, 2016			(unaudited) December 25, 2015
Cash Flows From Operating Activities:
Net (loss) income	$	(153.2	)	$	211.1
Adjustments to reconcile net cash provided by operating activities:
Depreciation and amortization	203.2			206.0
Share-based compensation	11.0			8.5
Deferred income taxes	(204.3		)	(108.9		)
Non-cash impairment charges	214.3			—
Inventory provisions	8.5			1.2
Gain on disposal of discontinued operations	—			(97.0		)
Other non-cash items	(9.2		)	2.9
Changes in assets and liabilities, net of the effects of acquisitions:
Accounts receivable, net	36.5			68.4
Inventories	(26.3		)	(14.5		)
Accounts payable	5.4			(13.0		)
Income taxes	0.6			82.3
Other	109.1			(35.6		)
Net cash from operating activities	195.6			311.4
Cash Flows From Investing Activities:
Capital expenditures	(65.2		)	(49.0		)
Acquisitions and intangibles, net of cash acquired	(1.8		)	—
Proceeds from disposal of discontinued operations, net of cash	—			263.7
Other	(10.2		)	0.7
Net cash from investing activities	(77.2		)	215.4
Cash Flows From Financing Activities:
Issuance of external debt	190.0			62.0
Repayment of external debt and capital leases	(86.7		)	(129.6		)
Debt financing costs	—			(0.1		)
Proceeds from exercise of share options	0.4			3.6
Repurchase of shares	(158.8		)	(275.4		)
Other	1.2			(30.0		)
Net cash from financing activities	(53.9		)	(369.5		)
Effect of currency rate changes on cash	(3.0		)	(1.5		)
Net change in cash, cash equivalents and restricted cash	61.5			155.8
Cash, cash equivalents and restricted cash at beginning of period	299.6			432.6
Cash, cash equivalents and restricted cash at end of period	$	361.1		$	588.4

Cash and cash equivalents at end of period	$	342.0		$	521.9
Restricted cash included in prepaid expenses and other assets at end of period	0.1			47.5
Restricted cash included in other long-term assets at end of period	19.0			19.0
Cash, cash equivalents and restricted cash at end of period	$	361.1		$	588.4

Summary of Significant Accounting Policies

12 Months Ended

Dec. 28, 2018

Accounting Policies [Abstract]

Summary of Significant Accounting Policies



3.	Summary of Significant Accounting Policies

Revenue Recognition

Product Sales Revenue

The Company sells its products through independent channels, including direct to retail pharmacies, end user customers and through distributors who resell the products to retail pharmacies, institutions and end user customers, while certain products are sold and distributed to hospitals. The Company also enters into arrangements with indirect customers, such as health care providers and payers, wholesalers, government agencies, institutions, managed care organizations and group purchasing organizations to establish contract pricing for certain products that provide for government-mandated and/or privately-negotiated rebates, sales incentives, chargebacks, distribution service agreements fees, fees for services and administration fees, and discounts with respect to the purchase of the Company's products.

Reserve for Variable Considerations

Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves result from estimated chargebacks, rebates, product returns and other sales deductions that are offered within contracts between the Company and its customers, health care providers and payers relating to the Company’s sales of its products. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, estimated future trends, estimated customer inventory levels, current contracted sales terms with customers, level of utilization of the Company’s products and other competitive factors. Overall, these reserves reflect the Company’s best estimate of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration which is included in the transaction price may be constrained (reduced), and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. The Company adjusts reserves for chargebacks, rebates, product returns and other sales deductions to reflect differences between estimated and actual experience. Such adjustments impact the amount of net sales recognized in the period of adjustment.

Product sales are recognized when the customer obtains control of the Company's product. Control is transferred either at a point in time, generally upon delivery to the customer site, or in the case of certain of the Company's products, over the period in which the customer has access to the product and related services. Revenue recognized over time is based upon either consumption of the product or passage of time based upon the Company's determination of the measure that best aligns with how the obligation is satisfied. The Company's considerations of why such measures provide a faithful depiction of the transfer of its products are as follows:


•	For those contracts whereby revenue is recognized over time based upon consumption of the product, the Company either has:


1.	the right to invoice the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date, for which the practical expedient to recognize in proportion to the amount it has the right to invoice has been applied, or


2.	the remaining goods and services to which the customer is entitled is diminished upon consumption.

•

For those contracts whereby revenue is recognized over time based upon the passage of time, the benefit that the customer receives from unlimited access to the Company's product does not vary, regardless of consumption. As a result, the Company's obligation diminishes with the passage of time; therefore, it was determined that ratable recognition of the transaction price over the contract period is the measure that best aligns with how the obligation is satisfied.

Transaction price allocated to the remaining performance obligations

The majority of the Company's contracts are less than one year; therefore, the related disclosure of the amount of transaction price allocated to the performance obligations that are unsatisfied at period end has been omitted.

Cost to obtain a contract

As the majority of the Company's contracts are short-term in nature, sales commissions are generally expensed when incurred as the amortization period would have been less than one year. These costs are recorded within selling, general and administrative expense ("SG&A") in the consolidated statements of income. For contracts that extend beyond one year, the incremental expense recognition matches the recognition of related revenue.

Costs to fulfill a contract

The Company capitalizes the costs associated with the devices used in the Company's portfolio of drug-device combination products, which are used in satisfaction of future performance obligations. Capital expenditures for these devices represent cash outflows for the Company's cost to produce the asset, which is classified in property, plant and equipment, net on the consolidated balance sheets and expensed to cost of sales over the useful life of the equipment.

Product Royalty Revenues

In relation to the Company's acquisition of Sucampo Pharmaceuticals, Inc. ("Sucampo") in fiscal 2018, as discussed further in Note 7, it acquired an arrangement under which the Company licenses certain rights to Amitiza to a third party in exchange for royalties on net sales of the product. The Company recognizes such royalty revenue as the related sales occur.

Contract Balances

Accounts receivable are recorded when the right to consideration becomes unconditional. Payments received from customers are typically based upon payment terms of 30 days. The Company does not maintain contract asset balances aside from the accounts receivable balance as presented on the consolidated balance sheets as costs to obtain a contract are expensed when incurred as the amortization period would have been less than one year. These costs are recorded within SG&A on the consolidated statements of income. Contract liabilities are recorded when cash payments are received in advance of the Company's performance, including amounts which are refundable.

Taxes collected from customers relating to product sales and remitted to governmental authorities are accounted for on a net basis. Accordingly, such taxes are excluded from both net sales and expenses.

For additional information, refer to Note 5.

Shipping and Handling Costs

Shipping costs, which are costs incurred to physically move product from the Company's premises to the customer's premises, are classified as SG&A. Handling costs, which are costs incurred to store, move and prepare product for shipment, are classified as cost of sales. Shipping costs included in SG&A expenses in continuing operations were as follows:



	Fiscal Year Ended						Three Months Ended
	December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016
Shipping and handling costs	$	12.8	$	13.9	$	12.4	$	3.4

Research and Development

Internal research and development costs are expensed as incurred. Research and development ("R&D") expenses include salary and benefits, allocated overhead and occupancy costs, clinical trial and related clinical manufacturing costs, contract services, medical affairs and other costs.

Upfront and milestone payments made to third parties under license arrangements are expensed as incurred up to the point of regulatory approval of the product. Milestone payments made to third parties upon or subsequent to regulatory approval are capitalized as an intangible asset and amortized to cost of sales over the estimated useful life of the related product.

Currency Translation

For the Company's non-U.S. subsidiaries that transact in a functional currency other than U.S. dollars, assets and liabilities are translated into U.S. dollars using fiscal year-end exchange rates. Revenues and expenses are translated at the average exchange rates in effect during the related month. The net effect of these translation adjustments is shown in the consolidated financial statements as a component of accumulated other comprehensive loss. For subsidiaries operating in highly inflationary environments or where the functional currency is different from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date the assets and liabilities were acquired or assumed, while monetary assets and liabilities are translated at fiscal year-end exchange rates. The Company also entered into derivative instruments to mitigate the exposure of movements in certain of these foreign currency transactions. The Company recognized the following during the respective periods:



	Fiscal Year Ended									Three Months Ended
	December 28, 2018			December 29, 2017			September 30, 2016			December 30, 2016
Foreign currency (losses), gains	$	(3.1	)	$	2.5		$	(3.6	)	$	9.0
Derivative hedge gains (losses)	2.7			(4.1		)	0.2			(8.9		)

Cash and Cash Equivalents

The Company classifies cash on hand and deposits in banks, including commercial paper, money market accounts and other investments it may hold from time to time, with an original maturity to the Company of three months or less, as cash and cash equivalents.

Accounts Receivable and Allowance for Doubtful Accounts

Trade accounts receivable are presented net of an allowance for doubtful accounts. The allowance for doubtful accounts reflects an estimate of losses inherent in the Company's accounts receivable portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other available evidence. Accounts receivable are written off when management determines they are uncollectible. Trade accounts receivable are also presented net of reserves related to chargebacks and rebates payable to customers for whom the Company has trade accounts receivable and the right of offset exists.

Inventories

Inventories are recorded at the lower of cost or net realizable value, primarily using the first-in, first-out convention. The Company reduces the carrying value of inventories for those items that are potentially excess, obsolete or slow-moving based on changes in customer demand, technology developments or other economic factors.

Property, Plant and Equipment

Property, plant and equipment are stated at cost. Major renewals and improvements are capitalized, while routine maintenance and repairs are expensed as incurred. Depreciation for property, plant and equipment assets, other than land and construction in process, is generally based upon the following estimated useful lives, using the straight-line method:



Buildings	10	to	45 years
Leasehold improvements	1	to	20 years
Capitalized software	1	to	10 years
Machinery and equipment	1	to	20 years

The Company capitalizes certain computer software and development costs incurred in connection with developing or obtaining software for internal use.

Upon retirement or other disposal of property, plant and equipment, the cost and related amount of accumulated depreciation are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds is included in net income.

The Company assesses the recoverability of assets or asset groups using undiscounted cash flows whenever events or circumstances indicate that the carrying value of an asset or asset group may not be recoverable. If an asset or asset group is found to be impaired, the amount recognized for impairment is equal to the difference between the carrying value of the asset or asset group and its fair value.

Acquisitions

Amounts paid for acquisitions are allocated to the tangible assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The Company then allocates the purchase price in excess of net tangible assets acquired to identifiable intangible assets, including purchased R&D. The fair value of identifiable intangible assets is based on detailed valuations. The Company allocates any excess purchase price over the fair value of the net tangible and intangible assets acquired to goodwill.

The Company's purchased R&D represents the estimated fair value as of the acquisition date of in-process projects that have not reached technological feasibility. The primary basis for determining technological feasibility of these projects is obtaining regulatory approval.

The fair value of in-process research and development ("IPR&D") is determined using the discounted cash flow method. In determining the fair value of IPR&D, the Company considers, among other factors, appraisals, the stage of completion of the projects, the technological feasibility of the projects, whether the projects have an alternative future use and the estimated residual cash flows that could be generated from the various projects and technologies over their respective projected economic lives. The

discount rate used includes a rate of return which accounts for the time value of money, as well as risk factors that reflect the economic risk that the cash flows projected may not be realized.

The fair value attributable to IPR&D projects at the time of acquisition is capitalized as an indefinite-lived intangible asset and tested annually for impairment until the project is completed or abandoned. Upon completion of the project, the indefinite-lived intangible asset is then accounted for as a finite-lived intangible asset and amortized on a straight-line basis over its estimated useful life. If the project is abandoned, the indefinite-lived intangible asset is charged to expense.

Goodwill and Other Intangible Assets

Goodwill represents the excess of the purchase price of an acquired entity over the amounts assigned to assets and liabilities assumed in a business combination. The Company tests goodwill for impairment on the first day of the fourth quarter of each fiscal year, or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. The impairment test is comprised of comparing the carrying value of a reporting unit to its estimated fair value. The Company estimates the fair value of a reporting unit through internal analyses and valuation, utilizing an income approach (a level three measurement technique) based on the present value of future cash flows. The fair value of the Company's reporting units is reconciled to its share price and market capitalization as a corroborative step. If the carrying value of a reporting unit exceeds its fair value, the Company will recognize the excess of the carrying value over the fair value as a goodwill impairment loss.

Intangible assets acquired in a business combination are recorded at fair value, while intangible assets acquired in other transactions are recorded at cost. Intangible assets with finite useful lives are subsequently amortized, generally using the straight-line method, over the following estimated useful lives of the assets, except for customer relationships which are amortized over the estimated pattern of benefit from these relationships:



Completed technology	5	to	25 years
License agreements	7	to	30 years
Trademarks	13	to	30 years
Customer relationships			12 years

Amortization expense related to completed technology and certain other intangible assets is included in cost of sales, while amortization expense related to intangible assets that contribute to the Company's ability to sell, market and distribute products is included in SG&A.

When a triggering event occurs, the Company evaluates potential impairment of finite-lived intangible assets by first comparing undiscounted cash flows associated with the asset, or the asset group they are part of, to its carrying value. If the carrying value is greater than the undiscounted cash flows, the amount of potential impairment is measured by comparing the fair value of the assets, or the asset group they are part of, with their carrying value. The fair value of the intangible asset, or the asset group they are part of, is estimated using an income approach. If the fair value is less than the carrying value of the intangible asset, or the asset group they are part of, the amount recognized for impairment is equal to the difference between the carrying value of the asset and the fair value of the asset. The Company assesses the remaining useful life and the recoverability of finite-lived intangible assets whenever events or circumstances indicate that the carrying value of an asset may not be recoverable. The Company annually tests the indefinite-lived intangible assets for impairment, or whenever events or changes in circumstances indicate that the carrying value may not be recoverable by either a qualitative or income approach. The Company will compare the fair value of the assets with their carrying value and record an impairment when the carrying value exceeds the fair value.

Contingencies

The Company is subject to various patent infringement claims, product liability matters, government investigations, environmental matters, employee disputes, contractual disputes and other commercial disputes, and other legal proceedings in the ordinary course of business as further discussed in Note 20. The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. The Company discounts environmental liabilities using a risk-free rate of return when the obligation is fixed or reasonably determinable. The impact of the discount in the consolidated balance sheets was not material in any period presented. Legal fees, other than those pertaining to environmental and asbestos matters, are expensed as incurred. Insurance recoveries related to potential claims are recognized up to the amount of the recorded liability when coverage is confirmed and the estimated recoveries are probable of payment. Assets and liabilities are not netted for financial statement presentation.

Share-Based Compensation

The Company recognizes the cost of employee services received in exchange for awards of equity instruments based on the grant-date fair value of those awards. That cost is recognized over the period during which an employee is required to provide service in exchange for the award, the requisite service period (generally the vesting period).

Restructuring

The Company recognizes charges associated with board approved restructuring programs designed to transform its business and improve its cost structure. Restructuring charges can include severance costs, infrastructure charges, distributor contract cancellations and other items. The Company accrues for costs when they are probable and reasonably estimable.

Income Taxes

Deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been reflected in the consolidated financial statements. Deferred tax assets and liabilities are determined based on the differences between the book and tax bases of assets and liabilities and operating loss carryforwards, using tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided to reduce net deferred tax assets if, based upon the available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. Deferred tax liabilities are also recorded for deferred tax obligations related to installment sale arrangements. The deferral of tax payments to the U.S. Internal Revenue Service ("IRS") are subject to interest, which is accrued and included within interest expense.

The Company determines whether it is more likely than not that a tax position will be sustained upon examination. The tax benefit of any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the uncertainty. To the extent a full benefit is not expected to be realized on the uncertain tax position, an income tax liability is established. Interest and penalties on income tax obligations, associated with uncertain tax positions, are included in the provision for income taxes.

The calculation of the Company's tax liabilities involves dealing with uncertainties in the application of complex tax regulations in a multitude of jurisdictions across the Company's global operations. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from current estimates of the tax liabilities. If the Company's estimate of tax liabilities proves to be less than the ultimate assessment, an additional charge to expense would result. If payment of these amounts ultimately proves to be less than the recorded amounts, the reversal of the liabilities may result in income tax benefits being recognized in the period when it is determined that the liabilities are no longer necessary. A significant portion of these potential tax liabilities are recorded in other income tax liabilities on the consolidated balance sheets as payment is not expected within one year.

Recently Issued Accounting Standards

12 Months Ended

Dec. 28, 2018

Recently Issued Accounting Pronouncements [Abstract]

Recently Issued Accounting Standards



4.	Recently Issued Accounting Standards

Adopted

In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, Disclosure Update and Simplification, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders' equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders' equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule was effective for all filings made on or after November 5, 2018. The Company has complied with all relevant disclosure requirements, with the exception of the expanded interim disclosure requirements for changes in shareholders' equity, which is required in the first interim reporting period after the effective date. The interim analysis of changes in shareholders' equity will be effective for the Company's quarterly reporting in the year ending December 27, 2019.

The Financial Accounting Standards Board ("FASB") issued ASU 2018-05, "Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118 (SEC Update)" in March 2018. This update adds SEC paragraphs pursuant to the SEC's Staff Accounting Bulletin ("SAB") 118, which provides guidance on accounting for the tax effects of the Tax Cuts and Jobs Act ("TCJA" or "U.S. Tax Reform") that was enacted in December 2017. SAB 118 provides a measurement period that should not extend beyond one year from the TCJA enactment date for companies to complete the accounting for the tax effects of the TCJA. The Company adopted this standard in fiscal 2018. See Note 9 for additional details of the Company's assessment of impact of this adoption.

The FASB issued ASU 2017-09, "Compensation - Stock Compensation: Scope of Modification Accounting," in May 2017. Under the new guidance, the effects of a modification should be accounted for unless all of the following are met: (1) the fair value or calculated intrinsic value of the modified award is the same as the fair value of the original award immediately before the original award is modified; (2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified; and (3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The Company adopted this standard in fiscal 2018 and will apply this standard to prospective modifications. The adoption of this standard did not result in any material changes to the consolidated financial statements.

The FASB issued ASU 2017-07, "Compensation - Retirement Benefits: Improving the Presentation of Net Periodic Pension Cost and Net Periodic Post Retirement Benefit Cost," in March 2017. This update requires that the service cost component be disaggregated from the other components of net benefit cost. Service cost should be reported in the same line item or items as other compensation costs arising from services rendered by pertinent employees during the period. The other components of net benefit cost should be presented in the income statement separately from the service cost component and outside a subtotal of income from operations, if one is presented. The Company adopted this guidance in fiscal 2018 which required retroactive application resulting in the reclassification of the following:



	Fiscal Year Ended				Three Months Ended
	December 29, 2017		September 30, 2016		December 30, 2016
Cost of sales	$	1.2	$	2.6	$	0.9
Selling, general and administrative expenses	71.2		11.6		47.2
Research and development expenses	0.4		1.0		0.1
Restructuring charges, net	—		0.6		—
Other income (expense), net	$	72.8	$	15.8	$	48.2

The adoption of this standard did not result in any material changes to the consolidated financial statements.

The FASB issued ASU 2017-01, "Business Combinations (Topic 805): Clarifying the Definition of a Business," in January 2017. This update provides a screen to determine whether or not a set of assets is a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set of assets is not a business. If the screen is not met, the amendments in this update (1) require that to be considered a business, a set of assets must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) remove the evaluation of whether a market participant could replace missing elements. The Company adopted this standard in fiscal 2018, which did not have a material impact to the consolidated financial statements.

The FASB issued ASU 2016-16, "Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory," in October 2016. This update simplifies the practice in how income tax consequences of an intra-entity transfer of an asset other than inventory should be recognized. Upon adoption, the entity must recognize such income tax consequences when the intra-entity transfer occurs rather than waiting until such time as the asset has been sold to an outside party. The Company early adopted this standard in fiscal 2017, which resulted in a $75.0 million decrease to beginning retained earnings with an offsetting decrease of $67.2 million to other assets and a $7.8 million decrease to prepaid expenses on the consolidated balance sheet. The prior periods were not restated.

The FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments,” in August 2016 and ASU 2016-18 "Statement of Cash Flows (Topic 230): Restricted Cash," in November 2016. These updates provide guidance for nine targeted clarifications with respect to how cash receipts and cash payments are classified in the statements of cash flows, with the objective of reducing diversity in practice. The Company early adopted these standards in fiscal 2017 and revised the prior year statement of cash flow. The adoption of ASU 2016-18, regarding presentation of restricted cash, increased the net cash used in investing activities during fiscal 2016 by $47.3 million. The adoption of ASU 2016-15, regarding the other targeted clarifications, did not result in any material changes to the consolidated financial statements.

The FASB issued ASU 2016-09, "Stock Compensation," in March 2016. This update simplifies several aspects of the accounting for share-based payment award transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification of certain tax effects within the statement of cash flows. Upon adoption, the entity must recognize the incremental income tax expense or benefit related to share option exercises and restricted share unit vesting in the statement of income, whereas these tax effects are presently recognized directly in shareholders' equity. In addition, the incremental tax benefit associated with these events will be classified as a cash inflow from operating activity as compared with a financing activity, as required under current guidance. The Company adopted this guidance in fiscal 2017, which resulted in a $2.9 million increase to beginning retained earnings to recognize net operating loss carryforwards, net of a valuation allowance, attributable to excess tax benefits on stock compensation that had not been previously recognized in additional paid-in capital.

The FASB issued ASU 2016-01, "Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities," in January 2016. This update addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments. Under the new guidance, equity investments, other than equity method investments, are to be measured at fair value with changes in fair value recognized through net income. The Company adopted this guidance in fiscal 2018, resulting in a $1.5 million increase to beginning retained earnings with an offsetting decrease to other accumulated comprehensive loss relating to the unrealized gain on its investment in Mesoblast Limited ("Mesoblast"). The adoption of this standard did not result in any material changes to the consolidated financial statements.

The FASB issued ASU 2014-09, "Revenue from Contracts with Customers," in May 2014. The issuance of ASU 2014-09 and International Financial Reporting Standards ("IFRS") 15, "Revenue from Contracts with Customers," completes the joint effort by the FASB and the International Accounting Standards Board to clarify the principles for recognizing revenue and develop a common revenue standard for GAAP and IFRS. Under the new guidance, an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services, applying the following steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract(s); (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract(s); and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The FASB subsequently issued additional ASUs to clarify the guidance of ASU 2014-09. The ASUs issued include ASU 2016-08, "Revenue from Contracts with Customers;" ASU 2016-10 "Revenue from Contracts with Customers, Identifying Performance Obligations and Licensing;" and ASU 2016-12 "Narrow-Scope Improvements and Practical Expedients."

The Company adopted ASU 2014-09 and its related amendments (collectively known as “ASC 606”) effective on December 30, 2017 using the modified retrospective transition approach. The adoption of ASC 606 represents a change in accounting principle that more closely aligns revenue recognition with the delivery of the Company's products and will provide financial statement readers with enhanced disclosures, which have been included in Note 5. The cumulative effect of applying the new standard to contracts not completed at December 30, 2017 was recorded as a $1.1 million increase, net of tax, to beginning retained earnings. The prior periods were not restated. The adoption of this standard did not result in any material changes to the consolidated financial statements.

Not Yet Adopted

The FASB issued ASU 2018-15, "Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract," in August 2018. This update aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The amendments in this update also require the entity (customer) to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement. Upon adoption, the update will be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. This standard is effective for the Company in the first quarter of fiscal 2020; however, early adoption is permitted. The Company intends to adopt this standard in the first quarter of 2019 and does not believe the standard will have a material impact on the consolidated financial statements.

The FASB issued ASU 2018-02, "Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income," in February 2018. This update allows a reclassification from accumulated other comprehensive income ("AOCI") to retained earnings for the tax effects resulting from TCJA that are stranded in AOCI. This standard is effective for the Company in the first quarter of fiscal 2019. The Company has assessed the impact of this standard and determined the standard will not result in any material changes to the consolidated financial statements.

The FASB issued ASU 2017-12, "Derivatives and Hedging: Targeted Improvements to Accounting for Hedging Activities," in August 2017. This update simplifies the application of hedge accounting and enhances the economics of the entity’s risk management activities in its financial statements. The update amends the guidance on designation and measurement for qualifying hedging relationships requiring the application of a modified retrospective approach on the date of adoption. This standard is effective for the Company in the first quarter of fiscal 2019. The Company has assessed the impact of this standard and determined the standard will not result in any material changes to the consolidated financial statements.

The FASB issued ASU 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments," in June 2016. This update calls for financial assets to be measured at their net amount to be collected, or net of credit losses. Credit losses are to be measured on a probability weighted approach comprised of historical loss experience, current economic conditions, and reasonable and supportable forecasts. This standard is effective for the Company in the first quarter of fiscal 2020. The Company is assessing the impact of this guidance on the consolidated financial statements.

The FASB issued ASU 2016-02, "Leases," in February 2016. This update was issued to increase transparency and comparability among organizations by recognizing all lease transactions (with terms in excess of 12 months) on the balance sheet as a lease liability and a right-of-use asset (as defined). This standard is effective for the Company in the first quarter of fiscal 2019. The FASB subsequently issued additional ASUs to clarify the guidance of ASU 2016-02. The ASUs issued include ASU 2018-01 "Leases: Land

Easement Practical Expedient for Transition to Topic 842;" ASU 2018-10 "Codification Improvements to Topic 842, Leases;" ASU 2018-11 "Leases (Topic 842: Targeted Improvements; and ASU 2018-20 "Leases (Topic 842): Narrow-Scope Improvements for Lessors." The Company has identified its population of lease agreements and embedded leases. The Company expects to elect the package of practical expedients, the lessor expedient, and the modified transition approach expedient. Although the Company is in process of finalizing the impact on its consolidated financial statements, it anticipates that the most significant change will be related to the Company recording additional assets and corresponding liabilities on the consolidated balance sheet for operating leases of approximately $85.0 million. This estimate may change depending on the Company’s lease activity.

Revenue from Contracts with Customers (Notes)

12 Months Ended

Dec. 28, 2018

Revenue from Contract with Customer [Abstract]

Revenue from Contract with Customer [Text Block]



5.	Revenue from Contracts with Customers

Product Sales Revenue

See Note 22 for presentation of the Company’s net sales by product family.

Reserves for variable consideration

The following table reflects activity in the Company’s sales reserve accounts:



	Rebates and Chargebacks			Product Returns			Other Sales Deductions			Total
Balance as of December 29, 2017	$	327.4		$	34.5		$	14.7		$	376.6
Provisions	2,281.3			39.3			66.9			2,387.5
Payments or credits	(2,254.4		)	(39.8		)	(64.5		)	(2,358.7		)
Balance as of December 28, 2018	$	354.3		$	34.0		$	17.1		$	405.4

Product sales transferred to customers at a point in time and over time accounted for 82.9% and 17.1% of net sales, respectively, for fiscal 2018.

Transaction price allocated to the remaining performance obligations

The following table includes estimated revenue from contracts extending greater than one year for certain of the Company’s hospital products that are expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied at December 28, 2018:



Fiscal 2019	$	145.0
Fiscal 2020	127.3
Fiscal 2021	32.6
Thereafter	3.2

Costs to fulfill a contract

As of December 28, 2018, the total net book value of the devices used in the Company’s portfolio of drug-device combination products, which are used in satisfying future performance obligations, was $28.4 million and are classified in property, plant and equipment, net, on the consolidated balance sheet. The associated depreciation expense recognized during fiscal 2018 was $7.4 million.

Product Royalty Revenues

In relation to the Company’s acquisition of Sucampo on February 13, 2018, as discussed in further detail in Note 7, it acquired an arrangement under which the Company licenses certain rights to Amitiza to a third party in exchange for royalties on net sales of the product. The Company recognizes such royalty revenue as the related sales occur. The associated royalty revenue recognized during fiscal 2018 was $81.3 million.

Contract Liabilities

The following table reflects the balance of the Company's contract liabilities at the end of the respective periods:



	December 28, 2018		December 29, 2017
Accrued and other current liabilities	$	20.4	$	14.0
Other liabilities	15.1		6.6
Contract liabilities	$	35.5	$	20.6

Revenue recognized during fiscal 2018 from amounts included in contract liabilities at the beginning of the period was approximately $12.5 million.

Discontinued Operations and Divestitures

12 Months Ended

Dec. 28, 2018

Discontinued Operations [Abstract]

Discontinued Operations and Divestitures



6.	Discontinued Operations and Divestitures

Discontinued Operations

The below businesses met the discontinued operations criteria and, accordingly, were included in discontinued operations for all periods presented.

Nuclear Imaging: On January 27, 2017, the Company completed the sale of its Nuclear Imaging business to IBA Molecular ("IBAM") for approximately $690.0 million before tax impacts, including up-front considerations of approximately $574.0 million, up to $77.0 million of contingent considerations and the assumption of certain liabilities. The Company recorded a pre-tax gain on the sale of the business of $362.8 million during fiscal 2017, which excluded any potential proceeds from the contingent consideration.

During fiscal 2018, the Company received a total of $15.0 million in contingent consideration related to the sale of the Nuclear Imaging business, consisting of a $6.0 million cash payment and the issuance of $9.0 million par value non-voting preferred equity certificates. The preferred equity certificates accrue interest at a rate of 10.0% per annum and are redeemable on the retirement date of July 27, 2025, or earlier if elected by the issuer, for cash at a price equal to the par value and any accrued but unpaid interest. The Company recorded a tax expense of $1.4 million associated with the $6.0 million contingent consideration cash payment. The $9.0 million in preferred equity certificates is presented as a non-cash investing activity on the consolidated statements of cash flows. The $13.6 million of contingent consideration received, net of tax, was recorded as income from discontinued operations.

The following table summarizes the financial results of the Nuclear Imaging business for respective periods as presented in the consolidated statements of income:



	Fiscal Year Ended					Three Months Ended
Major line items constituting income from discontinued operations	December 29, 2017			September 30, 2016		December 30, 2016
Net sales	$	31.6		$	418.6	$	99.4
Cost of sales	15.6			216.6		44.7
Selling, general and administrative	7.8			83.7		16.4
Restructuring charges, net	—			2.3		—
Other	(0.2		)	5.7		0.2
Income from discontinued operations	8.4			110.3		38.1
Gain on disposal of discontinued operations	362.8			—		—
Income from discontinued operations, before income taxes	371.2			110.3		38.1
Income tax expense	5.2			49.0		15.3
Income from discontinued operations, net of tax	$	366.0		$	61.3	$	22.8

The following table summarizes significant cash and non-cash transactions of the Nuclear Imaging business that are included within the consolidated statements of cash flows for the respective periods:



	Fiscal Year Ended				Three Months Ended
	December 29, 2017		September 30, 2016		December 30, 2016
Depreciation	$	—	$	20.9	$	—
Capital expenditures	0.3		9.7		2.0

CMDS: On November 27, 2015, the Company completed the sale of the CMDS business to Guerbet S.A. ("Guerbet") for cash consideration of approximately $270.0 million.

Subsequent to the sale of the CMDS business, the Company continues to supply certain products under a supply agreement with Guerbet.

The following table summarizes the financial results of the CMDS business for fiscal 2016 as presented in the consolidated statement of income:



	Fiscal Year Ended
Major line items constituting (loss) income from discontinued operations	September 30, 2016
Net sales	$	61.0
Cost of sales	46.9
Selling, general and administrative	20.3
Other	1.2
Loss from discontinued operations	(7.4		)
Gain on disposal of discontinued operations	95.3
Income from discontinued operations, before income taxes	87.9
Income tax benefit	(2.5		)
Income from discontinued operations net of tax	$	90.4

The Company incurred $1.6 million of capital expenditures related to the CMDS business that are included within the consolidated statement of cash flows for fiscal 2016.

Mallinckrodt Baker: During fiscal 2010, the Specialty Chemicals business (formerly known as "Mallinckrodt Baker") was sold because its products and customer base were not aligned with the Company's long-term strategic objectives. During fiscal 2018 and 2017, the Company recorded a loss, net of tax of $0.3 million and $0.6 million, respectively. During fiscal 2016 and the three months ended December 30, 2016, the Company recorded a gain, net of tax, of $3.0 million and $0.6 million, respectively. The gains and losses were primarily related to the indemnification obligations to the purchaser, which are discussed in Note 19.

Divestitures

PreveLeak/Recothrom: On March 16, 2018, the Company completed the sale of a portion of its Hemostasis business, inclusive of its PreveLeak™ Surgical Sealant ("PreveLeak") and RECOTHROM^® Thrombin topical (Recombinant) ("Recothrom") products to Baxter International Inc. ("Baxter") for approximately $185.0 million, with a base payment of $153.0 million, inclusive of existing inventory and subject to a closing inventory adjustment, with the remainder in potential future milestones. Baxter assumed other expenses, including contingent liabilities associated with PreveLeak. During fiscal 2018, the Company recorded a pre-tax loss on the sale of $0.8 million, which excluded any potential proceeds from the potential future milestones and reflected a post-sale closing inventory adjustment of $13.7 million. The financial results of the PreveLeak and Recothrom operations are presented within continuing operations as this divestiture did not meet the criteria for discontinued operations classification.

As part of the divestiture and calculation of the loss, the Company wrote off intangible assets of $49.9 million and goodwill of $51.5 million during the first quarter of fiscal 2018, from the Specialty Brands segment, ascribed to the PreveLeak and Recothrom operations. The remaining items included in the gain calculation are primarily attributable to inventory transferred, contingent consideration transferred and transaction costs incurred by the Company.

Intrathecal Therapy: On March 17, 2017, the Company completed its sale of its Intrathecal Therapy business to Piramal Enterprises Limited's subsidiary in the U.K., Piramal Critical Care ("Piramal"), for approximately $203.0 million, including fixed consideration of $171.0 million and contingent consideration of up to $32.0 million. The $171.0 million of fixed consideration consisted of $17.0 million received at closing and a $154.0 million note receivable due one year from the transaction closing date. The Company recorded a pre-tax gain on the sale of the business of $56.6 million during fiscal 2017, which excluded any potential proceeds from the contingent consideration and reflects a post-sale working capital adjustment. In fiscal 2018, the Company received $154.0 million from Piramal for the settlement of the aforementioned note receivable. The financial results of the Intrathecal Therapy business are presented within continuing operations as this divestiture did not meet the criteria for discontinued operations classification.

During fiscal 2017, as part of the divestiture and calculation of the gain, the Company wrote off intangible assets of $48.7 million and goodwill of $49.8 million, from the Specialty Brands segment, ascribed to the Intrathecal Therapy business. The Company is committed to reimburse up to $7.3 million of product development expenses incurred by Piramal, of which $3.1 million and $6.5 million was included in accrued and other current liabilities on the consolidated balance sheets as of December 28, 2018 and December 29, 2017, respectively. The remaining items included in the gain calculation were attributable to inventory transferred and transaction costs incurred by the Company.

Acquisitions and License Agreements

12 Months Ended

Dec. 28, 2018

Business Combinations [Abstract]

Acquisitions and License Agreements



7.	Acquisitions and License Agreements

Business Acquisitions

Sucampo Pharmaceuticals, Inc.

In February 2018, the Company acquired Sucampo through the acquisition of all the outstanding common stock of Sucampo. Consideration for the transaction consisted of approximately $1.2 billion, including the assumption of Sucampo's third-party debt ("the Sucampo Acquisition"). The acquisition was funded through the issuance of a $600.0 million aggregate principal amount of senior secured term loan, a $900.0 million borrowing under the Company's revolving credit facility, as discussed further in Note 14, and cash on hand. Sucampo's primary commercialized product was Amitiza, a leading global product in the branded constipation market. Through this acquisition, the Company acquired VTS-270, a Phase 3 development product for Niemann-Pick Type C, a complicated, ultra-rare neurodegenerative disease that typically presents in childhood and is ultimately fatal. Also acquired was an option to exercise a collaborative agreement with Cancer Prevention Pharmaceuticals ("CPP") associated with the development of CPP-1X/sulindac, a Phase 3 development product for Familial Adenomatous Polyposis ("FAP"). Refer to the License Agreements section below for further information on the CPP agreement.

Upon completion of the Sucampo Acquisition, Sucampo’s 3.25% convertible senior notes due 2021 ("the Sucampo Notes") became eligible to receive increased consideration in conjunction with a make-whole fundamental change, such that each $1,000 principal face amount of Sucampo Notes could be converted into $1,221 cash. As of December 28, 2018, the issued convertible debt of $300.0 million had been converted and paid in full by the Company.

Ocera Therapeutics, Inc.

In December 2017, the Company acquired Ocera Therapeutics, Inc. ("Ocera") for upfront consideration of approximately $42.4 million, of which $1.9 million of the consideration was paid subsequent to December 29, 2017, and contingent consideration up to $75.0 million based on the successful completion of certain development and sales milestones ("the Ocera Acquisition"). Through this acquisition, the Company acquired Ocera’s primary development product MNK-6105/6106, an ammonia scavenger, which is being studied for treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia, a complication of acute or chronic liver disease. The Ocera Acquisition was funded with cash on hand.

InfaCare Pharmaceutical Corporation

On September 25, 2017, the Company acquired InfaCare Pharmaceutical Corporation ("InfaCare") in a transaction valued at approximately $80.4 million, with additional payments of up to $345.0 million dependent on regulatory and sales milestones ("the InfaCare Acquisition"). Consideration for the transaction consisted of approximately $37.2 million in cash paid to the prior shareholders of InfaCare and the assumption of approximately $43.2 million of debt and other liabilities, which was repaid in conjunction with the InfaCare Acquisition. Through this acquisition, the Company acquired InfaCare's development product stannsoporfin, a heme oxygenase inhibitor, which is under investigation for its potential to reduce the production of bilirubin, the elevation of which can contribute to serious consequences in infants. The InfaCare Acquisition was funded with cash on hand. See further discussion related to the stannsoporfin developmental product in Notes 13 and 21.

Stratatech Corporation

In August 2016, the Company acquired Stratatech Corporation ("Stratatech") for upfront consideration of $76.0 million, and contingent milestone payments, which are primarily regulatory, and royalty obligations that could result in up to $121.0 million of additional consideration ("the Stratatech Acquisition"). Through this acquisition, the Company acquired Stratatech's development products including StrataGraft^® regenerative skin tissue ("StrataGraft") and a technology platform for genetically enhanced skin tissues. The Stratatech Acquisition was funded through cash on hand.

Hemostasis Products

In February 2016, the Company acquired three commercial stage topical hemostasis drugs from The Medicines Company ("the Hemostasis Acquisition") - Recothrom, PreveLeak, and RAPLIXA^TM (Fibrin Sealant (Human)) ("Raplixa") - for upfront consideration of $173.5 million, inclusive of existing inventory, and contingent sales-based milestone payments that could result in up to $395.0 million of additional consideration. The Hemostasis Acquisition was funded through cash on hand. As the Company shifted its focus to the critical care, autoimmune and rare disease spaces, the Company sold the Recothrom and PreveLeak assets and discontinued marketing of Raplixa. See further discussion in Notes 6, 13, and 21.

Fair Value Allocation

The following amounts represent the allocation of the fair value of the identifiable assets acquired and liabilities assumed for the respective acquisitions:



	Sucampo		Ocera ⁽¹⁾		InfaCare ⁽²⁾		Stratatech		Hemostasis ⁽³⁾
Acquisition Date	February 2018		December 2017		September 2017		August 2016		February 2016
Cash	$	149.6	$	1.0	$	1.3	$	0.2	$	3.3
Accounts receivable	35.7		—		—		1.3		—
Inventory	153.2		—		—		—		94.6
Intangible assets	919.5		64.5		113.5		99.8		132.7
Goodwill (non-tax deductible) ⁽⁴⁾	248.6		18.0		11.4		55.1		3.3
Other assets, current and non-current	25.8		0.4		0.1		1.9		7.9
Total assets acquired	1,532.4		83.9		126.3		158.3		241.8
Current liabilities	109.4		12.0		14.5		4.3		3.6
Other liabilities (non-current)	33.3		—		—		—		10.6
Deferred tax liabilities, net (non-current)	175.8		16.7		8.7		22.1		2.1
Contingent consideration (non-current)	—		12.8		35.0		54.9		52.0
Debt	366.3		—		30.0		1.0		—
Total liabilities assumed	684.8		41.5		88.2		82.3		68.3
Net assets acquired	$	847.6	$	42.4	$	38.1	$	76.0	$	173.5


(1)	Of the $42.4 million net assets acquired for Ocera, $40.5 million and $1.9 million was paid in fiscal 2017 and 2018, respectively.


(2)	During fiscal 2018, the Company reduced the contingent consideration liability related to this acquisition to zero through the recognition of a $35.0 million fair value adjustment. Refer to Note 21 for further information.


(3)	During fiscal 2017, the Company recorded a non-restructuring impairment charge relating to its Raplixa intangible asset and reduced the associated contingent consideration liability. During fiscal 2018, the Company sold its Recothrom and PreveLeak assets to Baxter. Refer to Notes 6, 13 and 21, respectively, for further information.


(4)	Refer to Note 13 for further information relating to the full goodwill impairment recorded in fiscal 2018.

The following reconciles the total consideration to net assets acquired:



	Sucampo		Ocera ⁽¹⁾			InfaCare			Stratatech			Hemostasis
Total consideration, net of cash	$	698.0	$	63.4		$	71.8		$	130.7		$	222.2
Plus: cash assumed in acquisition	149.6		1.0			1.3			0.2			3.3
Total consideration	847.6		64.4			73.1			130.9			225.5
Less: non-cash contingent consideration	—		(22.0		)	(35.0		)	(54.9		)	(52.0		)
Net assets acquired	$	847.6	$	42.4		$	38.1		$	76.0		$	173.5


(1)	$1.9 million of the total consideration, net of cash was paid in fiscal 2018, subsequent to the Company's December 11, 2017 acquisition date.

Intangible assets acquired consist of the following:



Acquisition	Intangible Asset Acquired	Amount		Amortization Period	Discount Rate		Segment
Sucampo	Completed technology - Amitiza	$	634.0	9 years	14.0	%	Specialty Generics and Amitiza
Sucampo	Completed technology - Other	11.0		8 years	14.0	%	Specialty Generics and Amitiza
Sucampo	In-process research and development - VTS-270	274.5		Non-Amortizable	15.0	%	Specialty Brands
Ocera	In-process research and development - MNK-6105/6106	64.5		Non-Amortizable	15.5	%	Specialty Brands
InfaCare	In-process research and development - stannsoporfin	113.5		Non-Amortizable	13.5	%	Specialty Brands
Stratatech	In-process research and development - StrataGraft	99.8		Non-Amortizable	16.5	%	Specialty Brands
Hemostasis	Completed technology - Raplixa ⁽¹⁾	73.0		15 years	17.0	%	Specialty Brands
Hemostasis	Completed technology - Recothrom ⁽²⁾	42.7		13 years	16.0	%	Specialty Brands
Hemostasis	Completed technology - PreveLeak ⁽²⁾	17.0		13 years	17.0	%	Specialty Brands


(1)	During fiscal 2017, the Company recorded a non-restructuring impairment charge relating to the Raplixa intangible asset. Refer to Note 13 for further information.


(2)	During fiscal 2018, the Company sold the Recothrom and PreveLeak assets to Baxter. Refer to Note 6 for further information.

The fair value of the intangible assets was determined using the income approach. The fair value of the IPR&D, completed technology and trademark was determined using the income approach, which is a valuation technique that provides an estimate of fair value of the assets based on the market participant expectations of cash flows the asset would generate. The discount rates were developed after assigning a probability of success to achieving the projected cash flows based on the current stage of development, inherent uncertainty in the Food and Drug Administration ("FDA") approval process and risks associated with commercialization of a new product. Based on the Company's preliminary estimate, the excess of purchase price over net tangible and intangible assets acquired resulted in goodwill, which represents future product development, the assembled workforce, and the tax status of the transaction. The goodwill is not deductible for U.S. income tax purposes.

Financial Results

The amount of net sales and operating losses included in the Company's fiscal 2018 consolidated statement of income related to the Sucampo Acquisition were $190.5 million and $369.1 million, respectively. Included within Sucampo's results was $62.9 million of amortization associated with intangibles recognized from this acquisition and $118.8 million of expense associated with fair value adjustments of acquired inventory. During fiscal 2018, 2017 and 2016 and the three months ended December 30, 2016, the Company in total recognized $120.8 million, $10.1 million, $24.3 million and $3.6 million, respectively, of expense associated with fair value adjustments of acquired inventory. This expense was included within cost of sales.

Acquisition-Related Costs - Acquisition-related costs incurred for each of the acquisitions discussed above were as follows:



	Fiscal Year Ended						Three Months Ended
Acquisition-related costs	December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016
Sucampo	$	5.2	$	4.2	$	—	$	—
Ocera	0.5		0.9		—		—
InfaCare	—		1.2		—		—
Stratatech	—		—		3.7		—
Hemostasis	—		—		2.7		0.1
Other	0.1		0.1		0.5		—
Total acquisition-related costs	$	5.8	$	6.4	$	6.9	$	0.1

License Agreements

CPP

In April 2018, the Company exercised the option under its collaborative agreement with CPP to negotiate terms of an exclusive license to commercialize CPP-1X/sulindac in North America. In addition, the Company provided CPP with a $10.0 million upfront

R&D payment for expenses related to the FAP pivotal trial incurred during the "Negotiation Period," or the period from the exercise date through the execution of such license agreement. CPP shall return to the Company any portion of the R&D payment that is not utilized during the Negotiation Period. Of the $10.0 million upfront payment, $7.3 million was utilized during fiscal 2018 and recorded as R&D expense within the consolidated statements of income. The remaining $2.7 million was included in prepaid expenses and other current assets on the consolidated balance sheet as of December 28, 2018.

In August 2018, the license agreement with CPP was executed and the Company paid $5.0 million upfront with cash on hand and gained exclusive rights to develop and commercialize the product in North America, if approved. The agreement includes additional payments of up to $185.0 million dependent on developmental, regulatory and sales milestones, subject to reduction up to $15.0 million related to amounts provided by the Company in advance of entering into this agreement, and provides for both parties' reimbursement of R&D expenses from future profits. Following the commercialization of the product, CPP and the Company will share profits in accordance with the agreement. The Company will manage the development of the product in North America.

Xenon Gas for Inhalation

In October 2017, the Company entered into a licensing agreement for development and commercialization of NeuroproteXeon Inc.'s ("NeuroproteXeon" and "the Xenon Licensing Agreement") investigational, pharmaceutical-grade xenon gas for inhalation therapy being evaluated to improve survival and functional outcomes for patients resuscitated after a cardiac arrest. If approved, xenon gas for inhalation will expand the Company's portfolio of hospital drug-device combination products providing therapies for critically ill patients. The Company paid $10.0 million upfront with cash on hand to reimburse NeuroproteXeon for certain product development costs, and gained exclusive rights to commercialize the therapy, if approved, in the U.S., Canada, Japan and Australia. The Xenon Licensing Agreement includes additional payments of up to $25.0 million dependent on developmental, regulatory and sales milestones. In addition, NeuroproteXeon will receive tiered royalties on applicable worldwide net sales and a transfer price for commercial product supply. NeuroproteXeon will continue to be responsible for the cost of development and will manage the development of the product in collaboration with the Company. During fiscal 2018, the Company paid a milestone payment of $5.0 million related to the first patient enrolled in a Phase 3 trial. The initial $10.0 million upfront cash payment and the $5.0 million milestone payment were both recorded within R&D expense during fiscal 2017 and fiscal 2018, respectively. Of the remaining $20.0 million additional payments, certain payments may be expensed as R&D, cost of sales, or capitalized as an intangible asset dependent upon the successful completion of certain milestone events.

Mesoblast

In January 2017, $21.5 million of consideration was remitted to Mesoblast in exchange for equity shares and rights to a nine month exclusivity period related to any potential commercial and development agreements the Company may enter into for Mesoblast's therapy products used to treat acute graft versus host disease and/or chronic lower back pain. As a result of this transaction the Company recorded an available for sale investment of $19.7 million included within prepaid and other current assets and an intangible asset of $1.8 million in the consolidated balance sheet as of March 31, 2017. This intangible asset was fully amortized as of December 29, 2017 as the nine month exclusivity period had ended. During fiscal 2018, all of the Company's shares were sold for gross proceeds of $25.5 million resulting in a $3.4 million gain being recognized within other income (expense), net within the consolidated statement of income.

Ofirmev

As part of the acquisition of Cadence Pharmaceuticals, Inc. ("Cadence" or "Cadence Acquisition") in March 2014, the Company acquired the exclusive development and commercialization rights to Ofirmev^® in the U.S. and Canada, as well as the rights to the patents and technology, which were originally in-licensed by Cadence from Bristol-Myers Squibb Company ("BMS") in March 2006. BMS sublicensed these rights to Cadence under a license agreement with SCR Pharmatop S.A. ("Pharmatop"), and the Company has the right to grant sublicenses to third parties. Under this license agreement, the Company made the final milestone payment of $15.0 million in fiscal 2018. In addition, the Company is obligated to pay royalties on sales of the product. During fiscal 2018, 2017, 2016 and the three months ended December 30, 2016, the Company paid royalties of $76.9 million, $53.9 million, $46.3 million and $14.7 million, respectively, which were recorded within cost of sales on the consolidated statements of income.

Assertio Therapeutics, Inc. (formerly known as Depomed, Inc.)

In 2009, the Company licensed worldwide rights to utilize Assertio Therapeutics, Inc. (formerly known as Depomed, Inc.) Acuform gastric retentive drug delivery technology for the exclusive development of four products. Under this license agreement, the Company may be obligated to pay up to $64.0 million in development milestone payments. Through fiscal 2018, approximately $22.0 million of these payments have been made by the Company, and as of December 28, 2018, the Company has no remaining obligations

under this arrangement. During fiscal 2014, upon approval by the FDA for XARTEMIS™ XR (oxycodone HCl and acetaminophen) extended release tablets CII ("Xartemis"), the Company made a milestone payment of $10.0 million, which was capitalized as an intangible asset. During the three months ended December 30, 2016, the Company elected to discontinue this product and recorded a $7.3 million non-restructuring impairment charge associated with the Xartemis intangible asset.

Advanced Accelerator Applications

In 2007, the Company's Nuclear Imaging business entered into a license agreement with BioSynthema, Inc. ("BioSynthema"), which was subsequently amended in 2010 when Advanced Accelerator Applications ("AAA") acquired BioSythema. Pursuant to the amended agreement, upon the first commercial sale of Lutathera^® ("Lutathera"), AAA is to provide the Company with a royalty based on net sales of the product through January 1, 2020. In early 2018, the FDA approved Lutathera for treatment of gastroenteropancreatic neuroendocrine tumors and commercial sales commenced. During fiscal 2018, in relation to this agreement, the Company recognized royalty income of $15.5 million, which was recognized within other income (expense), net in the consolidated statement of income.

Restructuring and Related Charges

12 Months Ended

Dec. 28, 2018

Restructuring and Related Activities [Abstract]

Restructuring and Related Charges



8.	Restructuring and Related Charges

During fiscal 2013, the Company launched a restructuring program designed to improve its cost structure ("the 2013 Mallinckrodt Program"). The 2013 Mallinckrodt Program included actions across the Specialty Brands, Specialty Generics and former Global Medical Imaging segments, as well as within corporate functions. The Company expected to incur charges of $100.0 million to $125.0 million under this program as the specific actions required to execute on these initiatives were identified and approved. As of December 28, 2018, the 2013 Mallinckrodt Program is complete.

In July 2016, the Company's Board of Directors approved a $100.0 million to $125.0 million restructuring program ("the 2016 Mallinckrodt Program") designed to further improve its cost structure, as the Company continues to transform its business. The 2016 Mallinckrodt Program included actions across the Specialty Brands and Specialty Generics and Amitiza segments, as well as within corporate functions. As of December 28, 2018, the 2016 Mallinckrodt Program is substantially complete.

In February 2018, the Company's Board of Directors approved a $100.0 million to $125.0 million restructuring program ("the 2018 Mallinckrodt Program") that is of similar design as the 2016 Mallinckrodt Program. The utilization of the 2018 Mallinckrodt Program commenced upon substantial completion of the 2016 Mallinckrodt Program. There is no specified time period associated with the 2018 Mallinckrodt Program.

In addition to the 2018, 2016 and the 2013 Mallinckrodt Programs, the Company has taken restructuring actions to generate synergies from its acquisitions.

Net restructuring and related charges by segment from continuing operations are as follows:



	Fiscal Year Ended									Three Months Ended
	December 28, 2018			December 29, 2017			September 30, 2016			December 30, 2016
Specialty Brands	$	52.2		$	25.4		$	23.3		$	2.6
Specialty Generics and Amitiza	29.0			7.7			3.4			0.8
Corporate	27.0			3.3			10.9			1.9
Restructuring and related charges, net	108.2			36.4			37.6			5.3
Less: accelerated depreciation	(5.2		)	(5.2		)	(4.9		)	(1.5		)
Restructuring charges, net	$	103.0		$	31.2		$	32.7		$	3.8

Charges in other income (expense) ⁽¹⁾	$	—		$	—		$	0.6		$	—

(1) Charges incurred under restructuring programs related to pension that were reclassified to other income (expense), net due to the adoption of ASU 2017-07.

Net restructuring and related charges by program from continuing operations are comprised of the following:



	Fiscal Year Ended									Three Months Ended
	December 28, 2018			December 29, 2017			September 30, 2016			December 30, 2016
2018 Mallinckrodt Program	$	5.2		$	—		$	—		$	—
2016 Mallinckrodt Program	71.6			36.2			8.3			5.2
2013 Mallinckrodt Program	—			(0.7		)	25.6			—
Acquisition programs	31.4			0.9			3.7			0.1
Total programs	108.2			36.4			37.6			5.3
Less: non-cash charges, including accelerated depreciation and impairments	(5.2		)	(5.2		)	(4.9		)	(1.5		)
Total charges expected to be settled in cash	$	103.0		$	31.2		$	32.7		$	3.8

Charges in other income (expense) ⁽¹⁾	$	—		$	—		$	0.6		$	—

(1) Charges incurred under restructuring programs related to pension that were reclassified to other income (expense) due to the adoption of ASU 2017-07.

The following table summarizes cash activity for restructuring reserves, substantially all of which related to contract termination costs, employee severance and benefits and exiting of certain facilities:



	2018 Mallinckrodt Program		2016 Mallinckrodt Program			2013 Mallinckrodt Program			Acquisition Programs			Total
Balance at September 25, 2015	$	—	$	—		$	8.0		$	10.0		$	18.0
Charges from continuing operations	—		6.4			24.0			5.0			35.4
Charges from discontinued operations	—		—			2.5			—			2.5
Changes in estimate from continuing operations	—		—			(1.4		)	(1.3		)	(2.7		)
Changes in estimate from discontinued operations	—		—			(0.3		)	—			(0.3		)
Cash payments	—		(0.2		)	(20.3		)	(13.2		)	(33.7		)
Reclassifications ⁽¹⁾	—		—			(0.7		)	—			(0.7		)
Balance at September 30, 2016	—		6.2			11.8			0.5			18.5
Charges from continuing operations	—		3.7			—			0.1			3.8
Cash payments	—		(0.4		)	(6.7		)	(0.4		)	(7.5		)
Balance at December 30, 2016	—		9.5			5.1			0.2			14.8
Charges from continuing operations	—		35.8			—			0.9			36.7
Changes in estimate from continuing operations	—		(4.8		)	(0.7		)	—			(5.5		)
Cash payments	—		(26.1		)	(4.4		)	(0.3		)	(30.8		)
Reclassifications	—		0.3			—			—			0.3
Balance at December 29, 2017	—		14.7			—			0.8			15.5
Charges from continuing operations	2.2		76.9			—			29.9			109.0
Changes in estimate from continuing operations	—		(5.3		)	—			(0.7		)	(6.0		)
Cash payments	—		(23.4		)	—			(22.2		)	(45.6		)
Reclassifications	—		(1.9		)	—			—			(1.9		)
Balance at December 28, 2018	$	2.2	$	61.0		$	—		$	7.8		$	71.0


(1)	Represents the reclassification of pension and other postretirement benefits from restructuring reserves to pension and postretirement obligations.

Net restructuring and related charges, including associated asset impairments, incurred cumulative to date related to the 2018, 2016 and 2013 Mallinckrodt Programs are as follows:



	2018 Mallinckrodt Program		2016 Mallinckrodt Program		2013 Mallinckrodt Program
Specialty Brands	$	3.0	$	81.7	$	18.8
Specialty Generics and Amitiza	—		14.6		18.3
Discontinued Operations	—		—		69.9
Corporate	2.2		25.9		17.7
	$	5.2	$	122.2	$	124.7

In fiscal 2018, the Company discontinued the marketing of Raplixa after an evaluation of strategic options and incurred restructuring expenses of $51.1 million under the 2016 Mallinckrodt Program, consisting primarily of contract termination costs related to the production of Raplixa. Amounts paid in the future may differ from the amount currently recorded.

All of the restructuring reserves are included in accrued and other current liabilities on the Company's consolidated balance sheets.

Income Taxes

12 Months Ended

Dec. 28, 2018

Income Tax Disclosure [Abstract]

Income Taxes



9.	Income Taxes

On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the TCJA. The TCJA reduces the U.S. federal corporate statutory rate from 35% to 21%, requires companies to pay a one-time transition tax on certain undistributed earnings of foreign subsidiaries of U.S. entities and creates new taxes on certain foreign sourced earnings. As of December 28, 2018, the Company has completed its accounting for all of the tax effects of the TCJA.

During fiscal 2017 the Company recorded a deferred tax benefit of $444.8 million for the provisional estimate of the remeasurement of its net U.S. deferred tax liabilities for the reduction in the U.S. federal corporate statutory tax rate to 21%. The provisional estimate was affected by other analyses related to the TCJA, including, but not limited to, having a U.S. tax return year that straddles the effective date of the statutory rate change and that is different than the Company's financial statement year. During fiscal 2018, on the basis of additional analysis related to certain tax calculations, the Company recognized an additional deferred tax benefit of $8.5 million, impacting the effective tax rate by 0.2%.

The one-time transition tax under the TCJA is based upon the amount of post-1986 cumulative undistributed earnings of certain of the Company's subsidiaries which was deferred from U.S. income tax under previous U.S. law. During fiscal 2017, the Company estimated this item would not result in any current or future tax. During fiscal 2018, no adjustments to the one-time transition tax have been made.

TCJA subjects a U.S. shareholder to current tax on global intangible low-taxed income (“GILTI”) earned by certain foreign subsidiaries. The FASB Staff Question & Answer Topic 740 No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred. The Company has elected to recognize the tax on GILTI as a period expense in the period the tax is incurred.

The U.K. and non-U.K. components of (loss) income from continuing operations before income taxes were as follows:



	Fiscal Year Ended									Three Months Ended
	December 28, 2018			December 29, 2017			September 30, 2016			December 30, 2016
U.K.	$	(233.7	)	$	(165.9	)	$	(275.3	)	$	(97.4	)
Non-U.K.	(3,818.3		)	227.5			508.7			(201.1		)
Total	$	(4,052.0	)	$	61.6		$	233.4		$	(298.5	)

Significant components of income taxes related to continuing operations are as follows:



	Fiscal Year Ended									Three Months Ended
	December 28, 2018			December 29, 2017			September 30, 2016			December 30, 2016
Current:
U.K.	$	(0.2	)	$	0.4		$	0.3		$	—
Non-U.K.	113.0			37.7			120.5			82.0
Current income tax provision	112.8			38.1			120.8			82.0
Deferred:
U.K.	1.4			0.6			0.7			(0.5		)
Non-U.K.	(544.3		)	(1,748.3		)	(377.1		)	(203.2		)
Deferred income tax benefit	(542.9		)	(1,747.7		)	(376.4		)	(203.7		)
Total	$	(430.1	)	$	(1,709.6	)	$	(255.6	)	$	(121.7	)

The fiscal 2018 U.K. current income tax provision reflects a tax benefit of $8.5 million from utilization of net operating loss carryforwards. The fiscal 2018 non-U.K. current income tax provision reflects a tax benefit of $13.7 million from utilization of net operating loss carryforwards.

The fiscal 2017 U.K. current income tax provision reflects a tax benefit of $14.3 million from utilization of net operating loss carryforwards. The fiscal 2017 non-U.K. current income tax provision reflects a tax benefit of $57.2 million from utilization of net operating loss carryforwards and $5.6 million of U.S. credits. In addition, the non-U.K. current income tax provision includes a tax benefit of $27.2 million related to carryback claims filed in fiscal 2017. The U.S. credit utilization is comprised of credit carryforwards and credits generated during fiscal 2017.

The fiscal 2016 U.K. current income tax provision reflects a tax benefit of $1.0 million from utilization of net operating loss carryforwards. The fiscal 2016 non-U.K. current income tax provision reflects a tax benefit of $29.2 million from utilization of net operating loss carryforwards and $9.5 million of U.S. credits. The non-U.K. net operating loss utilization is comprised of $17.9 million of net operating losses acquired in conjunction with the Hemostasis Acquisition and the remainder of the utilization relates to net operating loss carryforwards. The U.S. credit utilization is comprised of credit carryforwards and credits generated during fiscal 2016.

The three months ended December 30, 2016 non-U.K. current income tax provision reflects a tax benefit of $0.3 million from utilization of net operating loss carryforwards and $2.0 million of U.S. credits. The U.S. credit utilization is comprised of credit carryforwards and credits generated during the three months ended December 30, 2016.

During fiscal years 2018, 2017, and 2016 net cash payments for income taxes was $12.4 million, $73.4 million and $165.4 million, respectively. During the three months ended December 30, 2016 net cash payments for income taxes was $95.6 million.

The Company has a provincial tax holiday in Canada that expires on April 1, 2027. The tax holiday reduced non-U.K. tax expense by $1.0 million, $1.8 million and $1.0 million for the fiscal years 2018, 2017 and 2016, respectively. Due to an operating loss, there is no benefit from the tax holiday for the three months ended December 30, 2016.

The reconciliation between U.K. income taxes at the statutory rate and the Company's provision for income taxes on continuing operations is as follows:



	Fiscal Year Ended									Three Months Ended
	December 28, 2018			December 29, 2017			September 30, 2016			December 30, 2016
(Benefit) provision for income taxes at U.K. statutory income tax rate ⁽¹⁾	$	(770.1	)	$	11.7		$	46.6		$	(59.7	)
Adjustments to reconcile to income tax provision:
Rate difference between U.K. and non-U.K. jurisdictions ^{(2) (4)}	(235.7		)	(219.9		)	(249.3		)	(123.0		)
Valuation allowances, nonrecurring	—			(3.7		)	2.1			—
Adjustments to accrued income tax liabilities and uncertain tax positions	60.1			5.1			(14.9		)	0.9
Interest and penalties on accrued income tax liabilities and uncertain tax positions	13.1			0.2			(16.4		)	(0.1		)
Investment in partnership	—			—			—			(12.7		)
Credits, principally research and orphan drug ⁽³⁾	(25.9		)	(13.8		)	(33.7		)	(0.7		)
Impairments non deductible	788.7			—			—			75.3
Permanently nondeductible and nontaxable items	7.2			6.4			7.9			1.6
Pension plan settlement, release of tax effects lodged in other comprehensive income	—			(2.4		)	—			—
Divestitures ⁽⁷⁾	(2.7		)	18.2			—			—
U.S. Tax Reform ⁽⁵⁾	(8.5		)	(456.9		)	—			—
Legal Entity Reorganization ⁽⁶⁾	(256.0		)	(1,054.8		)	—			—
Other	(0.3		)	0.3			2.1			(3.3		)
Benefit for income taxes	$	(430.1	)	$	(1,709.6	)	$	(255.6	)	$	(121.7	)


(1)	The statutory tax rate reflects the U.K. statutory tax rate of 19% for fiscal 2018 and 2017 and 20% for fiscal 2016 and the three months ended December 30, 2016.


(2)	Includes the impact of certain recurring valuation allowances for U.K. and non-U.K. jurisdictions.


(3)	During fiscal 2018, the research and orphan drug credits increased in conjunction with the Company's increased investment in qualified research. During fiscal 2016, the Company realized a tax benefit of $27.4 million resulting from a U.K. tax credit on a dividend between affiliates.


(4)	During the three months ended December 30, 2016, the rate difference between U.K. and non-U.K. jurisdictions was favorably impacted by a benefit of $16.1 million on a $102.0 million settlement with the Federal Trade Commission and a benefit of $34.5 million on a $207.0 million goodwill impairment in the Specialty Generics reporting unit.

(5)

For fiscal 2018, the Company completed its analysis of the TCJA and recognized an additional tax benefit. Other line items, to the extent U.S. related, are reflected at the current U.S. statutory income tax rate of 21%. For fiscal 2017, the benefit reflects the redetermination of the Company’s end of year net deferred tax liabilities as a result of the new U.S. statutory income tax rate of 21%. Other line items, to the extent U.S. related, are reflected at the former U.S. statutory income tax rate of 35%.


(6)	Associated unrecognized tax benefit netted within this line.


(7)	During fiscal 2018, the Company completed the sale of a portion of its Hemostasis business. During fiscal 2017, the Company completed the sale of the Intrathecal Therapy Business.

The rate difference between U.K. and non-U.K. jurisdictions changed from $219.9 million of tax benefit to $235.7 million of tax benefit for fiscal 2017 to fiscal 2018, respectively. The $15.8 million increase in the tax benefit included a $90.3 million increase attributable to the non-restructuring impairment charges in fiscal 2018, a $22.2 million increase attributable to the divestiture of the Intrathecal Therapy business in fiscal 2017 and of the PreveLeak and Recothrom assets in fiscal 2018; partially offset by decreases of $80.2 million to the tax benefit attributable to the impact of U.S. Tax Reform, an $11.8 million decrease related to recent acquisitions, and a $4.7 million decrease attributable to changes in operating income and fiscal 2017 one-time items that did not recur in fiscal 2018.

The rate difference between U.K. and non-U.K. jurisdictions changed from $249.3 million of tax benefit to $219.9 million of tax benefit for fiscal 2016 to fiscal 2017, respectively. The $29.4 million decrease in the tax benefit included $37.6 million of decreases primarily attributed to the divestiture of the Intrathecal Therapy business and the planned divestiture of the PreveLeak and Recothrom assets and fiscal 2016 one-time items that did not recur in fiscal 2017, and $15.2 million of decreases to the tax benefit associated with the impact of U.S. Tax Reform on a U.S. tax return year that straddles the effective date of the statutory rate change; partially offset by increases of $23.4 million to the tax benefit attributed to changes in operating income and termination and settlement of the Company's funded U.S. pension plan in fiscal 2017.

During fiscal 2018, the Company initiated a reorganization of its intercompany financing and associated legal entity ownership in response to the changing global tax environment. As a result, the Company recognized current income tax expense of $25.5 million and a deferred income tax benefit of $281.5 million with a corresponding reduction to net deferred tax liabilities. The

reduction in net deferred tax liabilities is comprised of a $310.6 million decrease in interest-bearing deferred tax obligations, a $58.9 million increase in deferred tax liabilities associated with its investment in partnership, a $58.9 million decrease in deferred tax liabilities predominately associated with intangible assets, a $39.7 million increase related to a change in valuation allowances, a $9.3 million decrease in various other net deferred tax liabilities and a $1.3 million decrease associated with generation of tax loss and credit carryforwards.

The following table summarizes the activity related to the Company's unrecognized tax benefits, excluding interest:



	Fiscal Year Ended									Three Months Ended
	December 28, 2018			December 29, 2017			September 30, 2016			December 30, 2016
Balance at beginning of period	$	182.5		$	118.7		$	89.2		$	114.8
Additions related to current year tax positions	19.6			79.9			63.8			5.0
Additions related to prior period tax positions	125.1			0.3			10.8			—
Reductions related to prior period tax positions	(32.7		)	(13.6		)	(37.8		)	(1.1		)
Reductions related to disposition transactions	—			—			(6.6		)	—
Settlements	(2.0		)	—			(2.6		)	—
Lapse of statute of limitations	(4.8		)	(2.8		)	(2.0		)	—
Balance at end of period	$	287.7		$	182.5		$	114.8		$	118.7

Unrecognized tax benefits, excluding interest, are reported in the following consolidated balance sheet captions in the amounts shown:



	December 28, 2018		December 29, 2017
Accrued and other current liabilities	$	1.0	$	1.5
Other income tax liabilities	189.9		82.6
Deferred income taxes (non-current liability)	96.8		98.4
	$	287.7	$	182.5

Included within total unrecognized tax benefits at December 28, 2018, December 29, 2017, September 30, 2016 and December 30, 2016, were $275.8 million, $180.8 million, $113.1 million and $116.9 million respectively, of unrecognized tax benefits, which if favorably settled would benefit the effective tax rate. The remaining unrecognized tax benefits for each period would be offset by the write-off of related deferred and other tax assets, if recognized. During fiscal 2018, the Company recorded $33.2 million of additional interest and penalties through tax provision and acquisition accounting and decreased accrued interest by $3.2 million related to prior period reductions, settlements and lapse of statute of limitations. During fiscal 2017, 2016 and the three months ended December 30, 2016, the Company had net interest and penalties activity of zero, an increase of $1.9 million and a decrease of $0.2 million, respectively. The total amount of accrued interest and penalties related to uncertain tax positions was $37.1 million, $7.1 million, $7.4 million and $7.1 million, respectively.

It is reasonably possible that within the next twelve months, as a result of the resolution of various U.K. and non-U.K. examinations and appeals and the expiration of various statutes of limitation, that the unrecognized tax benefits could decrease by up to $136.9 million. Interest and penalties could decrease by up to $32.8 million.

Income taxes payable, including uncertain tax positions and related interest accruals, is reported in the following consolidated balance sheet captions in the amounts shown:



	December 28, 2018		December 29, 2017
Income taxes payable	$	25.0	$	15.8
Other income tax liabilities	228.0		94.1
	$	253.0	$	109.9

Tax receivables and payments associated with deferred intercompany transactions are included in the following consolidated balance sheet captions in the amounts shown:



	December 28, 2018		December 29, 2017
Other assets	$	3.0	$	—
Prepaid expenses and other current assets	16.2		6.1
	$	19.2	$	6.1

Certain of the Company’s subsidiaries continue to be subject to examination by the IRS for tax years as early as 2014. As of December 28, 2018, the primary unresolved issue relates to transfer pricing, which could have a significant impact to the consolidated financial statements if not resolved favorably. The Company believes its allowances for income tax contingencies are adequate. The Company has not received a proposed assessment for the unresolved issues and does not expect a final resolution of these issues in the next 12 months. In addition, the earliest open years for state tax jurisdictions are 2009 and a number of tax periods from 2013 to present are subject to examination by tax authorities in various jurisdictions, including Ireland, Luxembourg, Switzerland and the U.K.

Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes. The components of the net deferred tax (liability) asset at the end of each fiscal year were as follows:



	December 28, 2018			December 29, 2017
Deferred tax assets:
Accrued liabilities and reserves	$	56.3		$	62.7
Tax loss and credit carryforwards	1,987.8			1,734.5
Intangible assets	757.7			575.1
Other	204.6			113.3
	3,006.4			2,485.6
Deferred tax liabilities:
Intangible assets	(264.7		)	(181.0		)
Interest-bearing deferred tax obligations	(227.5		)	(553.5		)
Investment in partnership	(170.2		)	(108.8		)
Other	(42.9		)	(47.0		)
	(705.3		)	(890.3		)
Net deferred tax asset before valuation allowances	2,301.1			1,595.3
Valuation allowances	(2,604.9		)	(2,267.9		)
Net deferred tax liability	$	(303.8	)	$	(672.6	)

The deferred tax asset valuation allowances of $2,604.9 million and $2,267.9 million at December 28, 2018 and December 29, 2017, respectively, relate primarily to the uncertainty of the utilization of certain deferred tax assets, driven by U.K. and non-U.K. net operating losses, credits and intangible assets. The Company believes that it will generate sufficient future taxable income to realize the tax benefits related to the remaining net deferred tax assets.

Deferred taxes are reported in the following consolidated balance sheet captions in the amounts shown:



	December 28, 2018			December 29, 2017
Other assets	$	20.5		$	16.4
Deferred income taxes (non-current liability)	(324.3		)	(689.0		)
Net deferred tax liability	$	(303.8	)	$	(672.6	)

Non-current deferred tax liability decreased from $689.0 million at December 29, 2017 to $324.3 million at December 28, 2018, primarily due to $281.5 million of decreases associated with the deferred tax benefit recognized from the reorganization of the Company's intercompany financing and associated legal entity ownership, $135.9 million of decreases predominately related to the generation of net operating losses and other operational activity, $49.1 million of decreases related to impairments, $28.9 million of decreases associated with the amortization of intangibles, $23.6 million of decreases associated with inventory step up amortization, $8.5 million of decreases associated with the impact of U.S. Tax Reform and $6.5 million of decreases related to reductions of deferred tax assets associated with legal settlements. These decreases are partially offset by $169.3 million of increases related to recent acquisitions.

The sale of a portion of the Hemostasis business, inclusive of the PreveLeak and Recothrom products, was completed on March 16, 2018. This divestiture resulted in a net deferred tax liability decrease of $2.7 million. A significant component of this decrease includes a decrease of $2.7 million of deferred tax liability associated with inventories. In addition, there was a decrease of $1.5 million associated with other deferred tax assets, a decrease of $2.7 million of deferred tax assets associated with tax loss and credit carryforwards, and a decrease of $4.2 million of deferred tax assets associated with intangible assets, all of which were offset by a reduction in valuation allowance of $8.4 million.

The Sucampo Acquisition resulted in a net deferred tax liability increase of $175.8 million. Significant components of this increase include $179.3 million of deferred tax liabilities associated with intangible assets and a $25.7 million deferred tax liability associated with inventories. The increase in deferred tax liabilities is partially offset by $25.1 million of deferred tax assets associated with tax loss and credit carryforwards, and various other net deferred tax assets of $4.1 million.

The Company refined its acquisition accounting estimate associated with the measurement of its acquired Ocera net deferred tax liabilities in fiscal 2018, resulting in a decrease to the acquired net deferred tax liabilities from $23.2 million to $16.7 million prior to recording the impact from the TCJA.

As of December 28, 2018, the Company had approximately $1,817.8 million of net operating loss carryforwards in certain non-U.K. jurisdictions measured at the applicable statutory rates, of which $1,484.4 million have no expiration and the remaining $333.4 million will expire in future years through 2039. The Company had $108.2 million of U.K. net operating loss carryforwards measured at the applicable statutory rates at December 28, 2018, which have no expiration date.

As of December 28, 2018, the Company also had $61.8 million of tax credits available to reduce future income taxes payable, primarily in jurisdictions within the U.S., of which $4.6 million have no expiration and the remainder will expire in future years through 2039.

As of December 28, 2018, the Company’s financial reporting basis in international subsidiaries that may be subject to tax was in excess of its corresponding tax basis by $41.6 million. Such excess amount is considered to be indefinitely reinvested and it is not practicable to determine the cumulative amount of tax liability that would arise if this indefinitely reinvested amount were realized due to a variety of factors including the complexity of the Company’s legal entity structure as well as the timing, extent, and nature of any hypothetical realization. The net increase, as compared to the period ending December 29, 2017, was attributable to the finalization of the impacts of the TCJA as well as income and losses attributed to current year activity. The Company has recorded a deferred tax liability of $9.1 million for amounts not considered to be indefinitely reinvested.

Earnings (Loss) per Share

12 Months Ended

Dec. 28, 2018

Earnings (Loss) per Share [Abstract]

Earnings (Loss) per Share



10.	(Loss) Earnings per Share

Basic (loss) earnings per share is computed by dividing net (loss) income by the number of weighted-average shares outstanding during the period. Diluted (loss) earnings per share was computed using the weighted-average shares outstanding and, if dilutive, potential ordinary shares outstanding during the period. Potential ordinary shares represent the incremental ordinary shares issuable for restricted share units and share option exercises. The Company calculated the dilutive effect of outstanding restricted share units and share options on (loss) earnings per share by application of the treasury stock method.

Dilutive securities, including participating securities, are not included in the computation of loss per share when the Company reports a net loss from continuing operations as the impact would be anti-dilutive.



	Fiscal Year Ended							Three Months Ended
	December 28, 2018			December 29, 2017		September 30, 2016		December 30, 2016
(Loss) earnings per share numerator:
(Loss) income from continuing operations attributable to common shareholders	$	(3,621.9	)	$	1,771.2	$	489.0	$	(176.8	)
Income from discontinued operations	14.9			363.2		154.7		23.6
Net (loss) income attributable to common shareholders	$	(3,607.0	)	$	2,134.4	$	643.7	$	(153.2	)
(Loss) earnings per share denominator:
Weighted-average shares outstanding - basic	84.0			97.7		110.6		105.7
Impact of dilutive securities	—			0.2		0.9		—
Weighted-average shares outstanding - diluted	84.0			97.9		111.5		105.7
Basic (loss) earnings per share attributable to common shareholders:
(Loss) income from continuing operations	$	(43.12	)	$	18.13	$	4.42	$	(1.67	)
Income from discontinued operations	0.18			3.72		1.40		0.22
Net (loss) income attributable to common shareholders	$	(42.94	)	$	21.85	$	5.82	$	(1.45	)
Diluted (loss) earnings per share attributable to common shareholders:
(Loss) income from continuing operations	$	(43.12	)	$	18.09	$	4.39	$	(1.67	)
Income from discontinued operations	0.18			3.71		1.39		0.22
Net (loss) income attributable to common shareholders	$	(42.94	)	$	21.80	$	5.77	$	(1.45	)

The computation of diluted earnings per share for fiscal 2018, 2017, 2016 and the three months ended December 30, 2016, excludes approximately 3.3 million, 4.2 million, 1.7 million and 2.4 million, respectively, of equity award shares because the effect would have been anti-dilutive. As the Company incurred a net loss in fiscal 2018 and the three months ended December 30, 2016, there was no allocation of the undistributed loss to participating securities because the effect would have been anti-dilutive to basic and diluted earnings per share.

Inventories

12 Months Ended

Dec. 28, 2018

Inventory, Net [Abstract]

Inventories



11.	Inventories

Inventories are comprised of the following at the end of each period:



	December 28, 2018		December 29, 2017
Raw materials and supplies	$	69.2	$	70.0
Work in process	167.6		167.1
Finished goods	85.5		103.3
Inventories	$	322.3	$	340.4

Property, Plant and Equipment

12 Months Ended

Dec. 28, 2018

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment



12.	Property, Plant and Equipment

The gross carrying amount and accumulated depreciation of property, plant and equipment at the end of each period was as follows:



	December 28, 2018			December 29, 2017
Land	$	43.9		$	44.0
Buildings	379.5			355.5
Capitalized software	130.8			109.0
Machinery and equipment	1,137.3			1,123.8
Construction in process	244.7			209.7
	1,936.2			1,842.0
Less: accumulated depreciation	(954.2		)	(875.2		)
Property, plant and equipment, net	$	982.0		$	966.8

Depreciation expense for continuing operations was as follows:



	Fiscal Year Ended						Three Months Ended
	December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016
Depreciation expense	$	111.9	$	113.8	$	113.3	$	27.5

Goodwill and Intangible Assets

12 Months Ended

Dec. 28, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets



13.	Goodwill and Intangible Assets

The changes in the carrying amount of goodwill by segment were as follows:



	December 28, 2018					December 29, 2017
	Gross Carrying amount		Accumulated Impairment			Gross Carrying amount		Accumulated Impairment
Specialty Brands	$	3,672.8	$	(3,672.8	)	$	3,482.7	$	—
Specialty Generics	207.0		(207.0		)	207.0		(207.0		)
Total	$	3,879.8		($3,879.8	)	$	3,689.7	$	(207.0	)

During the fiscal year ended December 28, 2018, the gross carrying value of goodwill in the Specialty Brands segment increased by $190.1 million. The increase was primarily attributable to the Sucampo Acquisition, which yielded $248.6 million of goodwill, partially offset by $51.5 million of goodwill ascribed to the sale of a portion of the Company's Hemostasis business, inclusive of the PreveLeak and Recothrom products. The remaining change in goodwill was related to purchase accounting adjustments during the twelve month measurement period for previous acquisitions.

Goodwill Impairment Analysis

Fiscal Year ended December 28, 2018

The Company performed its annual goodwill impairment analysis for the Specialty Brands reporting unit as of the first day of the fourth quarter. The Company’s 2018 annual assessment first considered its internally developed future cash flows, which reflect the Company's overall strategy, future growth and value proposition. There continues to be a disparity between the Company's anticipated future performance and present uncertainty reflected in its market capitalization, driven by a sustained decrease in its share price. The Company continues to believe that its share price has been adversely affected primarily by uncertainties regarding patient withdrawal issues impacting net sales of H.P. Acthar^® Gel ("H.P. Acthar Gel"), ongoing Inomax^® ("Inomax") patent litigation and the perceived value of its various pipeline products. Given the passage of time since first experiencing a substantial decline in its share price during the three months ended December 29, 2017 and the fact that the aforementioned uncertainties are not expected to be resolved in the near-term, the Company's annual goodwill impairment analysis resulted in the recognition of a full goodwill impairment of $3,672.8 million.

For purposes of the 2018 goodwill impairment assessment for the Specialty Brands reporting unit, the Company made various assumptions regarding estimated future cash flows, discount rate and other factors in determining the respective fair value of the reporting unit using the income approach. The projections of future cash flows were discounted based on a weighted average cost of capital of 12.5% that was determined from relevant market comparisons, adjusted upward for specific reporting unit risks. A terminal value growth rate was applied to the terminal year cash flows, representing the Company's estimate of stable cash flows. The fair value of the Specialty Brands reporting unit represents the sum of the discounted cash flows from the discrete period and the terminal year cash flows.

The Three Months Ended December 30, 2016

The Specialty Generics reporting unit has experienced customer consolidation and increased competition that have and are expected to result in further downward pressure to net sales and operating income in this reporting unit. During the three months ended December 30, 2016, the FDA approved new products that were expected to compete with the Company's methylphenidate HCl extended-release tablets USP (CII) ("Methylphenidate ER") products and at that time one competitor had launched their Methylphenidate ER products. Additional products expected to compete with the Company's Methylphenidate ER products were launched during fiscal 2017. All of these products have a class AB rating compared with the class BX rating on the Company's

Methylphenidate ER products. The Company determined that these events represented a triggering event and the Company performed an assessment of the goodwill associated with the Specialty Generics reporting unit as of December 30, 2016.

The Company's projections in the Specialty Generics reporting unit included long-term net sales and operating income at lower than historical levels primarily attributable to customer consolidation and increased competition, including the competition effects on Methylphenidate ER. The Company utilized a weighted average cost of capital of 9.5% which reflects the Company's risk premium associated with the projected cash flows. These assumptions resulted in a fair value of the Specialty Generics reporting unit that was less than its net book value. As this impairment analysis was performed prior to the Company's adoption of ASU 2017-04 in fiscal 2017, the Company performed step two of the goodwill impairment test and recognized a $207.0 million goodwill impairment in the Specialty Generics segment.

Intangible Assets

The gross carrying amount and accumulated amortization of intangible assets at the end of each period were as follows:



	December 28, 2018				December 29, 2017
	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Amortizable:
Completed technology	$	10,467.9	$	2,980.6	$	9,882.8	$	2,260.8
License agreements	120.1		70.1		177.1		121.1
Trademarks	81.9		18.1		82.1		14.5
Customer relationships	27.5		14.1		29.5		12.2
Other	—		—		8.6		8.6
Total	$	10,697.4	$	3,082.9	$	10,180.1	$	2,417.2
Non-Amortizable:
Trademarks	$	35.0			$	35.0
In-process research and development	633.3				577.1
Total	$	668.3			$	612.1

The Company recorded impairment charges totaling $220.3 million, $63.7 million, $16.9 million, and $7.3 million during fiscal 2018, 2017, 2016 and the three months ended December 30, 2016, respectively. The fiscal 2018 and 2017 impairment charges primarily related to the MNK-1411 and Raplixa intangible assets respectively, and were a result of lower than previously anticipated pricing assumptions and commercial opportunities, respectively, for the products. The fiscal 2016 impairment charge primarily related to IPR&D assets acquired as part of the CNS Therapeutics acquisition in fiscal 2013, and resulted from delays in anticipated FDA approval, higher than expected development costs and lower than previously anticipated commercial opportunities. The impairment charge recorded during the three months ended December 30, 2016 related to the impairment of licenses associated with the Xartemis product upon the Company's election to discontinue the product. The valuation method used to approximate fair value in each of these periods was based on the estimated discounted cash flows for the respective asset.

Stannsoporfin

On May 3, 2018, in a joint meeting, the FDA's Gastrointestinal Drugs Advisory Committee and Pediatric Advisory Committee (the "Advisory Committee") recommended that the risk benefit profile of the Company's stannsoporfin IPR&D product does not support approval for the treatment of newborns ≥35 weeks of gestational age with indicators of hemolysis who are at risk of developing hyperbilirubinemia (severe jaundice).

On August 9, 2018, the Company received a complete response letter from the FDA related to its new drug application ("NDA") for stannsoporfin. In the letter, the FDA provided guidance regarding areas of further evaluation for resubmitting the stannsoporfin NDA for the treatment of newborns ≥35 weeks of gestational age with indicators of hemolysis who are at risk of developing hyperbilirubinemia. While the timing of the development program has shifted outward, the Company continues to have conversations with the FDA to determine the best path forward. The Company will continue to assess the impact of any changes to planned revenue or earnings on the fair value of the associated IPR&D asset of $113.5 million included within intangible assets, net on the consolidated balance sheet as of December 28, 2018. Refer to Note 21 for the associated impact on the Company's contingent consideration liability related to stannsoporfin.

VTS-270

VTS-270 is the Company’s development product to treat Niemann-Pick Type C, a complicated, ultra-rare neurodegenerative disease that typically presents in childhood and is ultimately fatal. The results of the Company’s recently completed registration trial for the product did not show a statistically significant separation from placebo. Neither the VTS-270 nor the placebo arm showed disease progression as would be expected for a neurodegenerative condition over 52 weeks of observation. The Company is in the process of evaluating this portion of the study in order to ensure the data was properly captured and of the highest quality. The FDA indicated to the Company at a Type A meeting in August 2018 that their view on the potential approvability will be based on the totality of data, not a single study or endpoint. Accordingly, the Company’s review of the data from the Phase 2b/3 trial, including the longer term open label portion, continues to proceed and is being assessed in combination with several other available data sources. The Company expects that a better understanding of the potential benefit of VTS-270 will emerge as it carefully considers the totality of data available and continues to work with the primary investigators and the FDA to determine the best path forward. The Company will continue to assess the impact of any changes to planned revenue or earnings on the fair value of the associated IPR&D asset of $274.5 million included within intangible assets, net, on the consolidated balance sheet as of December 28, 2018.

Finite-lived intangible asset amortization expense within continuing operations is as follows:



	Fiscal Year Ended						Three Months Ended
	December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016
Amortization expense	$	740.2	$	694.5	$	700.1	$	175.7

The estimated aggregate amortization expense on intangible assets owned by the Company is expected to be as follows:



Fiscal 2019	$	748.4
Fiscal 2020	748.0
Fiscal 2021	747.8
Fiscal 2022	620.8
Fiscal 2023	584.8

Debt

12 Months Ended

Dec. 28, 2018

Debt Disclosure [Abstract]

Debt



14.	Debt

Debt was comprised of the following at the end of each period:



	December 28, 2018				December 29, 2017
	Principal		Unamortized Discount and Debt Issuance Costs		Principal		Unamortized Discount and Debt Issuance Costs
Current maturities of long-term debt:
3.50% notes due April 2018	$	—	$	—	$	300.0	$	0.2
Term loan due September 2024	16.4		0.2		14.0		0.3
Term loan due February 2025	6.0		0.1		—		—
Other	0.3		—		0.2		—
Total current debt	22.7		0.3		314.2		0.5
Long-term debt:
4.875% notes due April 2020	700.0		3.2		700.0		5.7
Variable-rate receivable securitization due July 2020	250.0		0.4		200.0		0.7
9.50% debentures due May 2022	10.4		—		10.4		—
5.75% notes due August 2022	835.2		7.0		884.0		9.5
8.00% debentures due March 2023	4.4		—		4.4		—
4.75% notes due April 2023	500.2		3.5		526.5		4.5
5.625% notes due October 2023	731.4		8.0		738.0		9.7
Term loan due September 2024	1,597.4		19.8		1,837.2		26.7
Term loan due February 2025	591.0		10.7		—		—
5.50% notes due April 2025	692.1		7.7		692.1		9.0
Other	1.9		—		—		—
Revolving credit facility	220.0		4.5		900.0		5.9
Total long-term debt	6,134.0		64.8		6,492.6		71.7
Total debt	$	6,156.7	$	65.1	$	6,806.8	$	72.2

Mallinckrodt International Finance S.A. ("MIFSA") is a wholly-owned subsidiary of the Company. MIFSA functions as a holding company, established to own, directly or indirectly, substantially all of the operating subsidiaries of the Company, as well as to issue debt securities and to perform treasury operations.

In April 2013, MIFSA issued a $600.0 million aggregate principal amount of 4.75% senior unsecured notes due April 2023 ("the 2013 Notes"). Mallinckrodt plc has fully and unconditionally guaranteed the 2013 Notes on an unsecured and unsubordinated basis. The 2013 Notes are subject to an indenture which contains covenants limiting the ability of MIFSA, its restricted subsidiaries (as defined in the 2013 Notes) and Mallinckrodt plc, as guarantor, to incur certain liens or enter into sale and lease-back transactions. It also restricts Mallinckrodt plc and MIFSA's ability to merge or consolidate with any other person or sell or convey all or substantially all of their assets to any one person. MIFSA may redeem all of the 2013 Notes at any time, and some of the 2013 Notes from time to time, at a redemption price equal to the principal amount of the 2013 Notes redeemed plus a make-whole premium. The Company pays interest on the 2013 Notes semiannually in arrears on April 15^th and October 15^th of each year, which commenced on October 15, 2013. In April 2018, the Company's $300.0 million aggregate principal amount of 3.50% senior unsecured notes, which were issued in tandem with the 2013 Notes with similar terms, matured and were repaid with cash on hand.

In August 2014, MIFSA and Mallinckrodt CB LLC ("MCB") ("the Issuers") issued $900.0 million aggregate principal amount of 5.75% senior unsecured notes due August 2022 ("the 2022 Notes”). The 2022 Notes are guaranteed by Mallinckrodt plc and each of its subsidiaries that guarantee the obligations under the 2017 Facilities (as defined below). The 2022 Notes are subject to an indenture that contains certain customary covenants and events of default (subject in certain cases to customary grace and cure periods). The occurrence of an event of default under the indenture could result in the acceleration of the 2022 Notes and could cause a cross-default that could result in the acceleration of other indebtedness of Mallinckrodt plc and its subsidiaries. The Issuers may redeem some or all of the 2022 Notes on or after August 1, 2017 at specified redemption prices. The Issuers are obligated to offer to repurchase the 2022 Notes at a price of (a) 101% of their principal amount plus accrued and unpaid interest, if any, as a result of certain change of control events and (b) 100% of their principal amount plus accrued and unpaid interest of net proceeds from certain asset sales. These obligations are subject to certain qualifications and exceptions. The Company pays interest on the 2022 Notes semiannually in arrears on February 1^st and August 1^st of each year, which commenced on February 1, 2015.

In April 2015, in connection with the Company's acquisition of Ikaria, Inc. ("Ikaria"), MIFSA and MCB issued $700.0 million aggregate principal amount of 4.875% senior unsecured notes due April 2020 ("the 2020 Notes") and $700.0 million aggregate principal amount of 5.50% senior unsecured notes due April 2025 ("the 2025 Notes", and together with the 2020 Notes, the "Ikaria Notes"). The Ikaria Notes are guaranteed by Mallinckrodt plc and each of its subsidiaries that guarantee the obligations under the 2017 Facilities (as defined below), which following the acquisition of Ikaria includes Compound Holdings II, Inc. (or its successors) and its U.S. subsidiaries. The Ikaria Notes are subject to an indenture that contains certain customary covenants and events of default (subject in certain cases to customary grace and cure periods). The occurrence of an event of default under the indenture could result in the acceleration of the Ikaria Notes and could cause a cross-default that could result in the acceleration of other indebtedness of the Company. The Issuers may redeem some or all of the (i) 2020 Notes prior to April 15, 2017 and (ii) 2025 Notes prior to April 15, 2020, in each case, by paying a “make-whole” premium. The Issuers may redeem some or all of the (i) 2020 Notes on or after April 15, 2017 and (ii) 2025 Notes on or after April 15, 2020, in each case, at specified redemption prices. The Issuers are obligated to offer to repurchase the Ikaria Notes (a) at a price of 101% of their respective principal amount plus accrued and unpaid interest, if any, as a result of certain change of control events and (b) at a price of 100% of their respective principal amount plus accrued and unpaid interest of net proceeds from certain asset sales. These obligations are subject to certain qualifications and exceptions. The Company pays interest on the Ikaria Notes semiannually on April 15^th and October 15^th of each year, which commenced on October 15, 2015.

In September 2015, in connection with the Company's acquisition of Therakos, Inc. ("Therakos"), MIFSA and MCB issued $750.0 million aggregate principal amount of 5.625% senior unsecured notes due October 2023 (the “2023 Notes”). The 2023 Notes are guaranteed by Mallinckrodt plc and each of its subsidiaries under the 2017 Facilities (as defined below), which following the acquisition of Therakos, includes TGG Medical Solutions, Inc. (or its successors) and its U.S. subsidiaries. The 2023 Notes are subject to an indenture that contains certain customary covenants and events of default (subject in certain cases to customary grace and cure periods). The occurrence of an event of default under the indenture could result in the acceleration of the 2023 Notes and could cause a cross-default that could result in the acceleration of other indebtedness of the Company. As of October 15, 2018, issuers may call some or all of the 2023 Notes at specified redemption prices. The issuers may also redeem all, but not less than all, of the 2023 Notes at any time at a price of 100% of their principal amount, plus accrued and unpaid interest, if any, in the event the issuers become obligated to pay additional amounts as a result of changes affecting certain withholding tax laws applicable to payments on the 2023 Notes. The Issuers are obligated to offer to repurchase the 2023 Notes (a) at a price of 101% of their principal amount plus accrued and unpaid interest, if any, as a result of certain change of control events and (b) at a price of 100% of their principal amount plus accrued and unpaid interest of net proceeds from certain asset sales. These obligations are subject to certain qualifications and exceptions. The Company pays interest on the 2023 Notes semiannually on April 15^thand October 15^th of each year, which commenced on April 15, 2016.

In February 2017, MIFSA and MCB refinanced the March 2014 and August 2014 term loans, both of which were due March 2021 ("the Existing Term Loans"). The Company accounted for the term loan refinancing as a debt modification, which resulted in a $10.0 million charge included within the other expense line in the consolidated statement of income. The refinanced term loan had an initial aggregate principal amount of $1,865.0 million, is due September 2024 and bears interest at London Interbank Offered Rate ("LIBOR") plus 2.75% ("the 2017 Term Loan"). The 2017 Term Loan requires quarterly principal amortization payments in an amount equal to 0.25% of the original principal balance of the 2017 Term Loan, and may be reduced by making optional prepayments. The quarterly principal amortization is payable on the last day of each calendar quarter, which commenced on June 30, 2017, with the remaining balance due September 2024. In January 2018, the Company made a $225.0 million prepayment on the 2017 Term Loan. In making this payment, the Company satisfied certain obligations included within external debt agreements to reinvest proceeds from the sale of assets and businesses within the year of the respective transaction or use the proceeds to pay down debt.

In conjunction with the term loan refinancing, MIFSA and MCB entered into a $900.0 million revolving credit facility that matures on February 28, 2022 ("the 2017 Revolving Credit Facility"). The 2017 Revolving Credit Facility bears interest at LIBOR plus 2.25% and contains a $50.0 million letter of credit provision, of which none had been issued as of December 28, 2018. Unused commitments on the 2017 Revolving Credit Facility are subject to an annual commitment fee, which was 0.275% as of December 28, 2018, and the fee applied to outstanding letters of credit is based on the interest rate applied to borrowings. The 2017 Revolving Credit Facility added certain wholly-owned subsidiaries of the Company as borrowers, in addition to MIFSA and MCB.

The 2017 Term Loan and 2017 Revolving Credit Facility (collectively "the 2017 Facilities") are fully and unconditionally guaranteed by Mallinckrodt plc, certain of its direct or indirect wholly-owned U.S. subsidiaries and each of its direct or indirect wholly-owned subsidiaries that owns directly or indirectly any wholly-owned U.S. subsidiaries and certain of its other subsidiaries (collectively, "the Guarantors"). The 2017 Facilities are secured by a security interest in certain assets of MIFSA, MCB and the Guarantors. The 2017 Facilities contain customary affirmative and negative covenants, which include, among other things, restrictions on the Company's ability to declare or pay dividends, create liens, incur additional indebtedness, enter into sale and lease-back transactions, make investments, dispose of assets and merge or consolidate with any other person.

On July 28, 2017, Mallinckrodt Securitization S.à r.l. ("Mallinckrodt Securitization"), a wholly-owned special purpose subsidiary of the Company, entered into a $250.0 million accounts receivable securitization facility ("the Receivable Securitization") with a three year term. Mallinckrodt Securitization may, from time to time, obtain up to $250.0 million in third-party borrowings secured by certain receivables. Loans under the Receivable Securitization bear interest (including facility fees) at a rate equal to one month

LIBOR rate plus a margin of 0.90%. Unused commitments on the Receivables Securitization are subject to an annual commitment fee of 0.40%. The Receivable Securitization agreements contain customary representations, warranties, and affirmative and negative covenants. The size of the securitization facility may be increased to $300.0 million upon approval of the third-party lenders.

In February 2018, in connection with the Sucampo Acquisition, MIFSA and MCB issued a $600.0 million senior secured term loan due February 2025. The variable-rate loan bears an interest rate of LIBOR plus 3.00% basis points and was issued with a discount of 0.25%. The incremental term loan requires quarterly principal amortization payments in an amount equal to 0.25% of the original principal balance of the incremental term loan, and may be reduced by making optional prepayments. The quarterly principal amortization is payable on the last day of each calendar quarter, which commenced on June 30, 2018.

As of December 28, 2018, the applicable interest rate and outstanding borrowings on the Company's variable-rate debt instruments were as follows:



	Applicable interest rate		Outstanding borrowings
Term loan due September 2024	5.14	%	$	1,613.8
Term loan due February 2025	5.62	%	597.0
Variable-rate receivable securitization	3.22	%	250.0
Revolving credit facility	4.64	%	220.0

The aggregate amounts of debt maturing during the next five fiscal years are as follows:



Fiscal 2019	$	22.7
Fiscal 2020	972.7
Fiscal 2021	28.2
Fiscal 2022	1,088.2
Fiscal 2023	1,258.6

Retirement Plans

12 Months Ended

Dec. 28, 2018

Retirement Benefits [Abstract]

Retirement Plans



15.	Retirement Plans

Pension Plan Termination

On March 31, 2016, the Company terminated six of its previously frozen U.S. pension plans. During fiscal 2017, approximately $212.9 million of obligations and corresponding pension assets were transferred to a third party for settlement of the terminated pension plans through the purchase of annuity contracts. As a result of the settlement, the Company made a $62.3 million cash contribution to the terminated plans and recognized a $70.5 million charge included within other income (expense) during fiscal 2017. During fiscal 2018, the Company received a refund of $3.4 million of the initial cash contribution, recorded as other income (expense), net within the consolidated statement of income.

Defined Benefit Plans

The Company sponsors a number of defined benefit retirement plans covering certain of its U.S. employees and non-U.S. employees. As of December 28, 2018, U.S. plans represented 36% of the Company's remaining projected benefit obligation. The Company generally does not provide postretirement benefits other than retirement plan benefits for its employees; however, certain of the Company's U.S. employees participate in postretirement benefit plans that provide medical benefits. These plans are unfunded.

The net periodic benefit cost (credit) for the Company's pension and postretirement benefit plans was as follows:



	Pension Benefits
	Fiscal Year Ended								Three Months Ended
	December 28, 2018		December 29, 2017			September 30, 2016			December 30, 2016
Service cost	$	0.2	$	1.4		$	1.8		$	0.8
Interest cost	0.6		2.3			13.2			2.0
Expected return on plan assets	—		(1.3		)	(16.7		)	(2.3		)
Amortization of net actuarial loss	0.5		2.7			11.3			3.5
Amortization of prior service cost	0.1		0.2			—			0.1
Loss on plan settlements	0.1		71.1			8.1			45.0
Curtailment gain	—		(1.0		)	—			—
Net periodic benefit cost	$	1.5	$	75.4		$	17.7		$	49.1



	Postretirement Benefits
	Fiscal Year Ended									Three Months Ended
	December 28, 2018			December 29, 2017			September 30, 2016			December 30, 2016
Service cost	$	—		$	—		$	0.1		$	0.1
Interest cost	1.5			1.7			2.0			0.4
Amortization of net actuarial loss	0.1			—			—			—
Amortization of prior service credit	(2.1		)	(2.0		)	(2.1		)	(0.5		)
Gain on plan settlements	(0.7		)	(0.9		)	—			—
Net periodic benefit credit	$	(1.2	)	$	(1.2	)	$	—		$	—

The following table represents the changes in benefit obligations, plan assets and the net amounts recognized on the consolidated balance sheets for pension and postretirement benefit plans at the end of each period:



	Pension Benefits						Postretirement Benefits
	December 28, 2018			December 29, 2017			December 28, 2018			December 29, 2017
Change in benefit obligations:
Projected benefit obligations at beginning of year	$	27.8		$	257.4		$	45.6		$	47.5
Service cost	0.2			1.4			—			—
Interest cost	0.6			2.3			1.5			1.7
Actuarial loss (gain)	0.7			(9.0		)	(3.9		)	0.2
Benefits and administrative expenses paid	(1.6		)	(9.4		)	(2.7		)	(2.9		)
Plan settlements	(0.8		)	(217.0		)	(0.7		)	(0.9		)
Currency translation	(0.8		)	2.1			—			—
Projected benefit obligations at end of year	26.1			27.8			39.8			45.6

Change in plan assets:
Fair value of plan assets at beginning of year	—			161.0			—			—
Actual return on plan assets	—			0.3			—			—
Employer contributions	2.4			68.0			2.7			2.9
Benefits and administrative expenses paid	(1.6		)	(9.4		)	(2.7		)	(2.9		)
Plan settlements	(0.8		)	(217.0		)	—			—
Net transfer out	—			(2.9		)	—			—
Fair value of plan assets at end of year	—			—			—			—
Funded status at end of year	$	(26.1	)	$	(27.8	)	$	(39.8	)	$	(45.6	)



	Pension Benefits						Postretirement Benefits
	December 28, 2018			December 29, 2017			December 28, 2018			December 29, 2017
Amounts recognized on the consolidated balance sheet:
Current liabilities	$	(2.0	)	$	(2.4	)	$	(3.4	)	$	(3.9	)
Non-current liabilities	(24.1		)	(25.4		)	(36.4		)	(41.7		)
Net amount recognized on the consolidated balance sheet	$	(26.1	)	$	(27.8	)	$	(39.8	)	$	(45.6	)

Amounts recognized in accumulated other comprehensive loss consist of:
Net actuarial (loss) gain	$	(8.4	)	$	(8.6	)	$	0.9		$	(3.0	)
Prior service (cost) credit	(0.4		)	(0.5		)	8.1			10.2
Net amount recognized in accumulated other comprehensive loss	$	(8.8	)	$	(9.1	)	$	9.0		$	7.2

The estimated amounts that will be amortized from accumulated other comprehensive loss into net periodic benefit cost (credit) in fiscal 2019 are as follows:



	Pension Benefits		Postretirement Benefits
Amortization of net actuarial loss	$	0.5	$	—
Amortization of prior service cost (credit)	0.1		(2.1		)



	December 28, 2018		December 29, 2017
Pension plans with accumulated benefit obligations in excess of plan assets:
Accumulated benefit obligation	$	25.6	$	27.3

The accumulated benefit obligation for pension plans with projected benefit obligations in excess of plan assets do not significantly differ from the amounts in the table above since all of the Company's U.S. pension plans are frozen.

Actuarial Assumptions

Weighted-average assumptions used each period to determine net periodic benefit cost for the Company's pension plans are as follows:



	U.S. Plans								Non-U.S. Plans
	Fiscal Year Ended						Three Months Ended		Fiscal Year Ended						Three Months Ended
	December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016		December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016
Discount rate	3.3	%	3.0	%	3.9	%	2.2	%	1.9	%	1.8	%	2.0	%	1.3	%
Expected return on plan assets	—	%	3.5	%	5.8	%	3.5	%	—	%	—	%	2.0	%	—	%
Rate of compensation increase	—	%	—	%	—	%	—	%	2.5	%	2.5	%	—	%	—	%

Weighted-average assumptions used each period to determine benefit obligations for the Company's pension plans are as follows:



	U.S. Plans								Non-U.S. Plans
	Fiscal Year Ended						Three Months Ended		Fiscal Year Ended						Three Months Ended
	December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016		December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016
Discount rate	4.0	%	3.3	%	2.3	%	3.0	%	2.0	%	1.9	%	1.3	%	1.8	%
Rate of compensation increase	—	%	—	%	—	%	—	%	2.5	%	2.5	%	—	%	0.3	%

For the Company's unfunded U.S. plans, the discount rate is based on the market rate for a broad population of AA-rated (Moody's or S&P) corporate bonds over $250.0 million. For the Company's U.S. plans that were funded in prior periods, the discount rate was based on the estimated final settlement discount rates based on quotes received from a group of well-rated insurance carriers who are active in the single premium group annuity marketplace. The group of insurance carriers are rated A or better by AM best.

Prior to the settlement of the funded U.S. plans in fiscal 2017, the Company determined the expected return on pension plan assets, through its considerations of the relative weighting of plan assets by class and individual asset class performance expectations as provided by external advisors in reaching conclusions on appropriate assumptions. The investment strategy for the pension plans was to obtain a long-term return on plan assets that was consistent with the level of investment risk that was considered appropriate. Investment risks and returns were reviewed regularly against benchmarks to ensure objectives were being met.

The weighted-average discount rate used to determine net periodic benefit cost and obligations for the Company's postretirement benefit plans are as follows:



	Fiscal Year						Three Months Ended
	December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016
Net periodic benefit cost	3.4	%	3.7	%	4.0	%	3.2	%
Benefit obligations	4.1	%	3.4	%	3.2	%	3.8	%

Healthcare cost trend assumptions for postretirement benefit plans are as follows:



	December 28, 2018		December 29, 2017
Healthcare cost trend rate assumed for next fiscal year	6.3	%	6.9	%
Rate to which the cost trend rate is assumed to decline	4.5	%	4.5	%
Fiscal year the ultimate trend rate is achieved	2038		2038

A one-percentage-point change in assumed healthcare cost trend rates would have the following effects:



	One-Percentage-Point Increase		One-Percentage-Point Decrease
Effect on total of service and interest cost	$	—	$	—
Effect on postretirement benefit obligation	0.2		(0.2		)

Contributions

The Company's funding policy is to make contributions in accordance with the laws and customs of the various countries in which the Company operates, as well as to make discretionary voluntary contributions from time to time. In fiscal 2018 and 2017, the Company made $2.4 million and $68.0 million in contributions, respectively, to the Company's pension plans. The fiscal 2017 contribution included additional payments to settle the terminated plans.

Expected Future Benefit Payments

Benefit payments expected to be paid, reflecting future expected service as appropriate, are as follows:



	Pension Benefits		Postretirement Benefits
Fiscal 2019	$	2.0	$	3.5
Fiscal 2020	1.7		3.4
Fiscal 2021	1.7		3.2
Fiscal 2022	1.6		3.1
Fiscal 2023	1.6		3.0
Fiscal 2024 - 2028	7.4		13.4

Defined Contribution Retirement Plans

The Company maintains one active tax-qualified 401(k) retirement plan and one active non-qualified deferred compensation plan in the U.S. The 401(k) retirement plan provides for an automatic Company contribution of three percent of an eligible employee's pay, with an additional Company matching contribution generally equal to 50% of each employee's elective contribution to the plan up to six percent of the employee's eligible pay. The deferred compensation plan permits eligible employees to defer a portion of their compensation. Total defined contribution expense related to continuing operations was $25.3 million, $25.2 million, $25.3 million and $4.2 million for fiscal 2018, 2017, 2016 and the three months ended December 30, 2016, respectively.

Rabbi Trusts and Other Investments

The Company maintains several rabbi trusts, the assets of which are used to pay retirement benefits. The rabbi trust assets are subject to the claims of the Company's creditors in the event of the Company's insolvency. Plan participants are general creditors of the Company with respect to these benefits. The trusts primarily hold life insurance policies and debt and equity securities, the value of which is included in other assets on the consolidated balance sheets. Note 21 provides additional information regarding the debt and equity securities. The carrying value of the 118 life insurance contracts held by these trusts was $58.4 million and $58.1 million at December 28, 2018 and December 29, 2017, respectively. These contracts had a total death benefit of $142.9 million and $145.8 million at December 28, 2018 and December 29, 2017, respectively. However, there are outstanding loans against the policies amounting to $43.8 million and $44.5 million at December 28, 2018 and December 29, 2017, respectively.

The Company has insurance contracts which serve as collateral for certain of the Company's non-U.S. pension plan benefits, which totaled $8.0 million and $8.8 million at December 28, 2018 and December 29, 2017, respectively. These amounts were also included in other assets on the consolidated balance sheets.

Equity Equity

12 Months Ended

Dec. 28, 2018

Stockholders' Equity Note Disclosure



16.	Equity

Preferred Shares

Mallinckrodt is authorized to issue 500,000,000 preferred shares, par value of $0.20 per share, none of which were issued or outstanding at December 28, 2018. Rights as to dividends, return of capital, redemption, conversion, voting and otherwise with respect to these shares may be determined by Mallinckrodt's Board of Directors on or before the time of issuance. In the event of the liquidation of the Company, the holders of any preferred shares then outstanding would, if issued on such terms that they carry a preferential distribution entitlement on liquidation, be entitled to payment to them of the amount for which the preferred shares were subscribed and any unpaid dividends prior to any payment to the ordinary shareholders.

Share Repurchases

From time to time, the Company's Board of Directors have authorized share repurchase programs. The details of such programs are as follows:



	March 2017 Repurchase Program			March 2016 Repurchase Program			November 2015 Repurchase Program			January 2015 Repurchase Program
	Number of Shares	Amount		Number of Shares	Amount		Number of Shares	Amount		Number of Shares	Amount
Authorized repurchase amount		$	1,000.0		$	350.0		$	500.0		$	300.0
Repurchases:
Fiscal 2015	—	—		—	—		—	—		823,592	75.0
Fiscal 2016	—	—		—	—		6,510,824	425.6		3,199,279	225.0
Three months ended December 30, 2016	—	—		1,501,676	84.0		1,063,337	74.4		—	—
Fiscal 2017	13,490,448	380.6		5,366,741	266.0		—	—		—	—
Fiscal 2018	3,610,968	55.2		—	—		—	—		—	—
Remaining amount available		$	564.2		$	—		$	—		$	—

The March 2017 Program has no time limit or expiration date, and the Company currently expects to fully utilize the program.

The Company also repurchases shares from certain employees in order to satisfy employee tax withholding requirements in connection with the vesting of restricted shares. In addition, the Company repurchases shares to settle certain option exercises. The

Company spent zero, $5.1 million, $2.3 million and $0.4 million to acquire shares in connection with equity-based awards in fiscal 2018, 2017, 2016 and the three months ended December 30, 2016, respectively.

Treasury Shares

During December 2017, the Company canceled approximately 26.5 million treasury shares. Irish law requires a company's treasury share value to represent less than 10% of Company capital. The cancellation of treasury shares had a net zero impact on shareholders' equity as $5.3 million was reflected in both common stock and additional paid-in capital.

Share Plans

12 Months Ended

Dec. 28, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share Plans



17.	Share Plans

Total share-based compensation cost from continuing operations was $34.6 million, $58.5 million, $41.4 million and $10.6 million for fiscal 2018, 2017, 2016 and the three months ended December 30, 2016, respectively. These amounts are generally included within SG&A expenses in the consolidated statements of income. The Company recognized a related tax benefit associated with this expense of zero, $11.0 million, $13.1 million and $3.6 million in fiscal 2018, 2017, 2016 and the three months ended December 30, 2016, respectively. During fiscal 2017, the $11.0 million tax benefit was comprised of $16.0 million associated with amortization and net stock exercises, partially offset by $5.0 million associated with U.S. Tax Reform re-measurement.

Stock Compensation Plans

The Company has adopted and amended its Mallinckrodt Pharmaceuticals Stock and Incentive Plan over the years which provides for the award of share options, share appreciation rights, annual performance bonuses, long-term performance awards, restricted units, restricted shares, deferred share units, promissory shares and other share-based awards (collectively, "Awards"). The maximum number of common shares to be issued as Awards, subject to adjustment as provided under the terms of the respective plans are as follows:



		Maximum Number of Common Shares to be Issued as Awards (in millions)
2013 Plan		5.7
2015 Plan		17.8
2018 Plan		26.8

As of December 28, 2018, all equity awards held by the Company's employees were converted from equity awards issued by Questcor Pharmaceuticals, Inc. ("Questcor"), acquired during fiscal 2014, or granted under the aforementioned plans.

Share options. Share options are granted to purchase the Company's ordinary shares at prices that are equal to the fair market value of the shares on the date the share option is granted. Share options generally vest in equal annual installments over a period of four years and expire ten years after the date of grant. The grant-date fair value of share options, adjusted for estimated forfeitures, is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. Forfeitures are estimated based on historical experience.

Share option activity and information is as follows:



	Share Options		Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at September 25, 2015	2,786,443		$	52.76
Granted	1,248,828		72.44
Exercised	(413,830	)	32.76
Expired/Forfeited	(199,585	)	72.65
Outstanding at September 30, 2016	3,421,856		61.17
Granted	3,742		60.01
Exercised	(16,382	)	36.42
Expired/Forfeited	(22,522	)	70.82
Outstanding at December 30, 2016	3,386,694		61.24
Granted	1,719,532		51.57
Exercised	(113,605	)	47.74
Expired/Forfeited	(348,637	)	68.08
Outstanding at December 29, 2017	4,643,984		57.78
Granted	3,159,521		13.92
Exercised	(39,949	)	32.00
Expired/Forfeited	(756,505	)	52.63
Outstanding at December 28, 2018	7,007,051		38.74		4.8	$	6.5

Vested and non-vested expected to vest as of December 28, 2018	6,114,782		39.94		7.6	$	5.5
Exercisable at December 28, 2018	2,414,968		55.24		4.9	0.1

As of December 28, 2018, there was $29.6 million of total unrecognized compensation cost related to non-vested share option awards, which is expected to be recognized over a weighted-average period of 2.4 years.

The grant-date fair value of share options has been estimated using the Black-Scholes pricing model. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs. The expected volatility assumption is based on the historical and implied volatility of the Company's peer group with similar business models. The expected life assumption is based on the contractual and vesting term of the share option, employee exercise patterns and employee post-vesting termination behavior. The expected annual dividend per share is based on the Company's current intentions regarding payment of cash dividends. The risk-free interest rate is based on U.S. Treasury zero-coupon issues with a remaining term equal to the expected life assumed at the date of grant. The weighted-average assumptions used in the Black-Scholes pricing model for shares granted in fiscal 2018, 2017, 2016 and the three months ended December 30, 2016, along with the weighted-average grant-date fair value, were as follows:



	Fiscal Year Ended									Three Months Ended
	December 28, 2018			December 29, 2017			September 30, 2016			December 30, 2016
Expected share price volatility	38		%	36		%	31		%	35		%
Risk-free interest rate	2.64		%	2.00		%	1.74		%	1.23		%
Expected annual dividend per share	—		%	—		%	—		%	—		%
Expected life of options (in years)	5.3			5.3			5.3			5.3
Fair value per option	$	5.32		$	18.36		$	22.82		$	20.04

In fiscal 2018, 2017, 2016 and the three months ended December 30, 2016, the total intrinsic value of options exercised was $0.2 million, $1.4 million, $15.3 million and $0.3 million, respectively, and the related tax benefit was $0.1 million, $0.5 million, $5.7 million and $0.1 million, respectively.

Restricted share units. Recipients of restricted share units ("RSUs") have no voting rights and receive dividend equivalent units which vest upon the vesting of the related shares. RSUs generally vest in equal annual installments over a period of four

years. Restrictions on RSUs lapse upon normal retirement, death or disability of the employee. The grant-date fair value of RSUs, adjusted for estimated forfeitures, is recognized as expense on a straight-line basis over the service period. The fair market value of RSUs granted is determined based on the market value of the Company's shares on the date of grant for periods after the Company's separation from Covidien plc ("Covidien") in fiscal 2013.

RSU activity is as follows:



	Shares		Weighted-Average Grant-Date Fair Value
Non-vested at September 25, 2015	572,494		$	73.45
Granted	615,074		70.10
Vested	(193,849	)	69.27
Expired/Forfeited	(99,260	)	79.95
Non-vested at September 30, 2016	894,459		70.40
Granted	36,731		69.08
Exercised	(30,919	)	47.54
Expired/Forfeited	(16,809	)	49.62
Non-vested at December 30, 2016	883,462		71.03
Granted	655,282		50.74
Exercised	(263,189	)	69.14
Expired/Forfeited	(169,789	)	68.57
Non-vested at December 29, 2017	1,105,766		60.08
Granted	1,222,568		14.58
Exercised	(433,354	)	57.93
Expired/Forfeited	(209,879	)	44.38
Non-vested at December 28, 2018	1,685,101		29.54

The total fair value of Mallinckrodt RSU awards granted during fiscal 2018 was $17.8 million. The total vest date fair value of Mallinckrodt RSUs vested during fiscal 2018 was $25.1 million. As of December 28, 2018, there was $29.6 million of total unrecognized compensation cost related to non-vested restricted share units granted. The cost is expected to be recognized over a weighted-average period of 2.2 years.

Performance share units. Similar to recipients of RSUs, recipients of performance share units ("PSUs") have no voting rights and receive dividend equivalent units. The grant-date fair value of PSUs, adjusted for estimated forfeitures, is generally recognized as expense on a straight-line basis from the grant-date through the end of the performance period. The vesting of PSUs and related dividend equivalent units is generally based on various performance metrics and relative total shareholder return (total shareholder return for the Company as compared to total shareholder return of the PSU peer group), measured over a three year performance period. The PSU peer group is comprised of various healthcare companies which attempts to replicate the Company’s mix of businesses. Depending on Mallinckrodt's relative performance during the performance period, a recipient of the award is entitled to receive a number of ordinary shares equal to a percentage, ranging from 0% to 200%, of the award granted.

PSU activity is as follows ⁽¹⁾:



	Shares		Weighted-Average Grant-Date Fair Value
Non-vested at September 25, 2015	130,974		$	96.05
Granted	145,192		83.00
Forfeited	(9,521	)	96.30
Non-vested at September 30, 2016	266,645		88.59
Forfeited	(997	)	154.42
Non-vested at December 30, 2016	265,648		88.51
Granted	348,963		51.73
Forfeited	(48,606	)	107.00
Vested	(61,554	)	62.65
Non-vested at December 29, 2017	504,451		64.44
Granted	770,714		13.80
Forfeited	(89,614	)	59.18
Vested	(24,022	)	98.27
Non-vested at December 28, 2018	1,161,529		28.61

(1) The number of shares disclosed within this table are at the target number of 100%.

The Company generally uses the Monte Carlo model to estimate the probability of satisfying the performance criteria and the resulting fair value of PSU awards. The assumptions used in the Monte Carlo model for PSUs granted during each year were as follows:



	Fiscal Year Ended						Three Months Ended
	December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016
Expected stock price volatility	57	%	48	%	41	%	48	%
Peer group stock price volatility	39	%	40	%	36	%	40	%
Correlation of returns	2	%	17	%	24	%	17	%

The weighted-average grant-date fair value per share of PSUs granted was $13.80 in fiscal 2018. As of December 28, 2018, there was $12.6 million of unrecognized compensation cost related to PSUs, which is expected to be recognized over a weighted-average period of 1.9 years.

Restricted stock awards. Recipients of restricted stock awards ("RSAs") pertain solely to converted awards from Questcor, which were converted at identical terms to their original award. The converted RSAs maintain voting rights and a non-forfeitable right to receive dividends. RSAs were subject to accelerated vesting as prescribed by the terms of the original award based on a change in control, and all of which have vested as of December 28, 2018. Restrictions on RSAs lapse upon normal retirement, death or disability of the employee. The grant-date fair value of RSAs, adjusted for estimated forfeitures, was recognized as expense on a straight-line basis over the service period. The weighted average grant-date fair value per share was $70.88.



	Shares
Non-vested at September 25, 2015	34,562
Vested	(9,760	)
Forfeited	(7,936	)
Non-vested at September 30, 2016	16,866
Vested	(1,087	)
Forfeited	(911	)
Non-vested at December 30, 2016	14,868
Vested	(7,970	)
Forfeited	(2,223	)
Non-vested at December 29, 2017	4,675
Vested	(3,970	)
Forfeited	(705	)
Non-vested at December 28, 2018	—

The total vest date fair value of Mallinckrodt restricted share awards vested during fiscal 2018 was $0.2 million.

Employee Stock Purchase Plans

Effective March 16, 2016, upon approval by the shareholders of Mallinckrodt, the Company adopted a new qualified Mallinckrodt Employee Stock Purchase Plan ("ESPP"). Substantially all full-time employees of the Company's U.S. subsidiaries and employees of certain qualified non-U.S. subsidiaries are eligible to participate in the ESPP. Eligible employees authorize payroll deductions to be made to purchase shares at 15% below the market price at the beginning or end of an offering period. Employees are eligible to authorize withholdings such that purchases of shares may amount to $25,000 of fair market value for each calendar year as prescribed by the Internal Revenue Code Section 423. Mallinckrodt has elected to deliver shares under the period by utilizing treasury stock accumulated by the Company.

Prior to the first offering period of the ESPP (July 1, 2016), the Company maintained a non-qualified employee stock purchase plan ("the Old ESPP"). Substantially all full-time employees of the Company's U.S. subsidiaries and employees of certain qualified non-U.S. subsidiaries were eligible to participate in the Old ESPP. Eligible employees authorized payroll deductions to be made for the purchase of shares. The Company matched a portion of the employee contribution by contributing an additional 15% (25% in fiscal 2015) of the employee's payroll deduction up to a $25,000 per employee annual contribution. All shares purchased under the Old ESPP were purchased on the open market by a designated broker.

Accumulated Other Comprehensive Income

12 Months Ended

Dec. 28, 2018

Accumulated Other Comprehensive Income



18.	Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows:



	Currency Translation			Unrecognized Loss on Derivatives			Unrecognized (Loss) Gain on Benefit Plans			Unrecognized Gain on Equity Securities ⁽¹⁾			Accumulated Other Comprehensive Loss ⁽¹⁾
Balance at December 30, 2016	$	(19.5	)	$	(5.7	)	$	(47.3	)	$	—		$	(72.5	)
Other comprehensive income, net	16.0			—			5.2			1.5			22.7
Reclassification from other comprehensive (loss) income	(4.7		)	1.0			40.6			(1.5		)	35.4
Balance at December 29, 2017	(8.2		)	(4.7		)	(1.5		)	—			(14.4		)
Other comprehensive (loss) income, net	(12.2		)	—			3.1			—			(9.1		)
Reclassification from other comprehensive income (loss)	—			0.7			(1.5		)	—			(0.8		)
Balance at December 28, 2018	$	(20.4	)	$	(4.0	)	$	0.1		$	—		$	(24.3	)


(1)	Upon adoption of ASU 2016-01, a reclassification of $1.5 million relating to the unrealized gain on investment resulted in an increase to beginning retained earnings with an offsetting decrease to accumulated other comprehensive loss. See Note 4 for additional details.

The following summarizes reclassifications from accumulated other comprehensive loss:



	Amount Reclassified From Accumulated Other Comprehensive Loss
	December 28, 2018			December 29, 2017			Line Item in the Consolidated Statement of Income
Currency translation	$	—		$	(4.7	)

Amortization of unrealized loss on derivatives	0.9			1.3			Interest expense
Income tax provision	(0.2		)	(0.3		)	Provision for income taxes
Net of income taxes	0.7			1.0

Amortization of pension and post-retirement benefit plans:
Net actuarial loss	0.6			2.7			⁽¹⁾
Prior service credit	(2.0		)	(1.9		)	⁽¹⁾
Disposal of discontinued operations	—			(3.1		)
Plan settlements	(0.6		)	70.2			⁽¹⁾
Total before tax	(2.0		)	67.9
Income tax effect	0.5			(27.3		)	Provision for income taxes
Net of income taxes	(1.5		)	40.6

Recognized gain on equity securities ⁽²⁾	—			(1.5		)

Total reclassifications for the period	$	(0.8	)	$	35.4


(1)	These accumulated other comprehensive loss components are included in the computation of net periodic benefit cost. See Note 15 for additional details.

(2)

Upon adoption of ASU 2016-01, a reclassification of $1.5 million relating to the unrealized gain on investment resulted in an increase to beginning retained earnings with an offsetting decrease to accumulated other comprehensive loss. See Note 4 for additional details.

^[1]

[1]	These accumulated other comprehensive loss components are included in the computation of net periodic benefit cost. See Note 15 for additional details.

Guarantees

12 Months Ended

Dec. 28, 2018

Guarantees [Abstract]

Guarantees



19.	Guarantees

In disposing of assets or businesses, the Company has from time to time provided representations, warranties and indemnities to cover various risks and liabilities, including unknown damage to the assets, environmental risks involved in the sale of real estate, liability to investigate and remediate environmental contamination at waste disposal sites and manufacturing facilities, and unidentified tax liabilities related to periods prior to disposition. The Company assesses the probability of potential liabilities related to such representations, warranties and indemnities and adjusts potential liabilities as a result of changes in facts and circumstances. The Company believes, given the information currently available, that the ultimate resolution will not have a material adverse effect on its financial condition, results of operations and cash flows.

In connection with the sale of the Specialty Chemical business (formerly known as Mallinckrodt Baker) in fiscal 2010, the Company agreed to indemnify the purchaser with respect to various matters, including certain environmental, health, safety, tax and other matters. The indemnification obligations relating to certain environmental, health and safety matters have a term of 17 years from the sale, while some of the other indemnification obligations have an indefinite term. The amount of the liability relating to all of these indemnification obligations included in other liabilities on the Company's consolidated balance sheets at December 28, 2018 and December 29, 2017 was $14.6 million and $14.9 million, of which $11.8 million and $12.1 million, respectively, related to environmental, health and safety matters. The value of the environmental, health and safety indemnity was measured based on the probability-weighted present value of the costs expected to be incurred to address environmental, health and safety claims made under the indemnity. The aggregate fair value of these indemnification obligations did not differ significantly from their aggregate carrying value at December 28, 2018 and December 29, 2017. As of December 28, 2018, the maximum future payments the Company could be required to make under these indemnification obligations was $70.2 million. The Company was required to pay $30.0 million into an escrow account as collateral to the purchaser, of which $18.6 million and $18.3 million remained in other assets on the consolidated balance sheets at December 28, 2018 and December 29, 2017, respectively.

The Company has recorded liabilities for known indemnification obligations included as part of environmental liabilities, which are discussed in Note 20.

In addition, the Company is liable for product performance; however the Company believes, given the information currently available, that their ultimate resolution will not have a material adverse effect on its financial condition, results of operations and cash flows.

As of December 28, 2018, the Company had various other letters of credit and guarantee and surety bonds totaling $38.7 million.

In addition, the separation and distribution agreement entered into with Covidien provides for cross-indemnities principally designed to place financial responsibility of the obligations and liabilities of the Company's business with the Company and financial responsibility for the obligations and liabilities of Covidien's remaining business with Covidien, among other indemnities.

Commitments and Contingencies

12 Months Ended

Dec. 28, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies



20.	Commitments and Contingencies

The Company has purchase obligations related to commitments to purchase certain goods and services. At December 28, 2018, such obligations were as follows:



Fiscal 2019	$	110.3
Fiscal 2020	43.5
Fiscal 2021	2.2
Fiscal 2022	2.1
Fiscal 2023	1.7

The Company is subject to various legal proceedings and claims, including patent infringement claims, product liability matters, personal injury, environmental matters, employment disputes, contractual disputes and other commercial disputes, including those described below. The Company believes that these legal proceedings and claims likely will be resolved over an extended period of time. Although it is not feasible to predict the outcome of these matters, the Company believes, unless indicated below, given the information currently available, that their ultimate resolution will not have a material adverse effect on its financial condition, results of operations and cash flows.

Governmental Proceedings

Opioid Related Matters

Since 2017, multiple U.S. states, counties, other governmental persons or entities and private plaintiffs have filed lawsuits against certain Mallinckrodt entities, as well as various other manufacturers, distributors, pharmacies, pharmacy benefit managers, individual doctors and/or others, asserting claims relating to defendants’ alleged sales, marketing, distribution, reimbursement, prescribing, dispensing and/or other practices with respect to prescription opioid medications, including certain of the Company's products. As of February 26, 2019, the cases of which the Company is aware include, but are not limited to, approximately 1,487 cases filed by counties, cities, Native American tribes and/or other government-related persons or entities; approximately 104 cases filed by hospitals, health systems, unions, health and welfare funds or other third-party payers; approximately 15 cases filed by individuals and 6 cases filed by the Attorneys General for New Mexico, Kentucky, Rhode Island. Georgia, Florida, and Alaska. Certain of the lawsuits have been filed as putative class actions.

Many of the lawsuits have been coordinated in a federal multi-district litigation (“MDL”) pending in the U.S. District Court for the Northern District of Ohio. The MDL court has issued a series of case management orders permitting motion practice addressing threshold legal issues in certain cases, allowing discovery and setting a trial date in October 2019 for two cases originally filed in the Northern District of Ohio.

Other lawsuits remain pending in various state courts. In some jurisdictions, such as Connecticut, Illinois, New York, Pennsylvania and Texas, certain state court cases have been coordinated for pretrial proceedings before a single court within their respective state court systems. State cases are generally at the pleading and/or discovery stage.

The lawsuits assert a variety of claims, including, but not limited to, public nuisance, negligence, civil conspiracy, fraud, violations of the Racketeer Influenced and Corrupt Organizations Act (“RICO”) or similar state laws, violations of state Controlled Substances Acts or state False Claims Acts, product liability, consumer fraud, unfair or deceptive trade practices, false advertising, insurance fraud, unjust enrichment and other common law and statutory claims arising from defendants’ manufacturing, distribution, marketing and promotion of opioids and seek restitution, damages, injunctive and other relief and attorneys’ fees and costs. The claims generally are based on alleged misrepresentations and/or omissions in connection with the sale and marketing of prescription opioid medications and/or an alleged failure to take adequate steps to prevent abuse and diversion.

The Company intends to vigorously defend itself against these lawsuits and similar lawsuits that may be brought by others. Since these lawsuits are in early stages, the Company is unable to predict outcomes or estimate a range of reasonably possible losses.

In addition to the lawsuits described above, certain Mallinckrodt entities have received subpoenas and civil investigative demands ("CID(s)") for information concerning the sale, marketing and/or distribution of prescription opioid medications, including from U.S. Department of Justice ("DOJ") and the Attorneys General for Missouri, New Hampshire, Kentucky, Washington, Alaska, South Carolina, Puerto Rico and New York. Our Company has been contacted by the coalition of State Attorneys General investigating the role manufacturers and distributors may have had in contributing to the increased use of opioids in the U.S. On January 27, 2018, the Company received a grand jury subpoena from the U.S. Attorneys’ Office (“USAO”) for the Southern District of Florida for documents related to the distribution, marketing and sale of generic oxymorphone products. The Company is in the process of responding to these subpoenas, CIDs and any informal requests for documents.

On August 2, 2018, Energy and Commerce Committee leaders in the U.S. House of Representatives sent a letter to one of Mallinckrodt's subsidiaries requesting information about that subsidiary’s efforts to monitor opioid sales for suspicious orders. The subsidiary has responded to this letter.

Similar subpoenas and investigations may be brought by others or the foregoing matters may be expanded or result in litigation. Since these investigations are in early stages, we are unable to predict outcomes or estimate a range of reasonably possible losses.

New York State Opioid Stewardship Act. On October 24, 2018, the Company filed suit in the United States District Court for the Southern District of New York against the State of New York, asking the court to declare New York State’s Opioid Stewardship Act (“OSA”) unconstitutional and to enjoin its enforcement. On December 19, 2018, the court declared the OSA unconstitutional and granted the Company’s motion for preliminary injunctive relief. On January 17, 2019, the State of New York appealed the Court’s decision. The Company intends to vigorously assert its position in this matter.

DEA Investigation. In November 2011 and October 2012, the Company received subpoenas from the U.S. Drug Enforcement Administration ("DEA") requesting production of documents relating to its suspicious order monitoring program for controlled substances. The USAO for the Eastern District of Michigan investigated the possibility that the Company failed to report suspicious orders of controlled substances during the period 2006-2011 in violation of the Controlled Substances Act and its related regulations. The USAO for the Northern District of New York and Office of Chief Counsel for the U.S. DEA investigated the possibility that the Company failed to maintain appropriate records and security measures with respect to manufacturing of certain controlled substances at its Hobart facility during the period 2012-2013. In July 2017, the Company entered into a final settlement with the DEA and the USAOs for Eastern District of Michigan and the Northern District of New York to settle these investigations. As part of the agreement, the Company paid $35.0 million to resolve all potential claims and agreed, as part of a Memorandum of Agreement (“MOA”), to utilize all available transaction information to identify suspicious orders of any Mallinckrodt controlled substance product and to report to the DEA when it concludes that chargeback data or other information indicates that a downstream registrant poses a risk of diversion, among other things. The MOA remains in effect until July 10, 2020.

Other Matters

U.S. House Committee Investigation. In January 2019, the Company along with 11 other pharmaceutical companies, received a letter from the U.S. House Committee on Oversight and Reform requesting information relating to the Company's pricing strategy for H.P. Acthar Gel and related matters. The Company is cooperating with the Committee investigation.

Florida Civil Investigative Demand. In February 2019, the Company received a CID from the U.S. Attorney’s Office for the Middle District of Florida. The demand relates to documents related to alleged payments to healthcare providers in Florida and whether those payments violated the Anti-Kickback Statute. The Company is in the process of responding to this demand for documents and intends to cooperate with the investigation.

Boston Civil Investigative Demand. In January 2019, the Company received a CID from the U.S. Attorney’s Office for the District of Massachusetts for documents related to the Company’s participation in the Medicaid Drug Rebate Program. The Company is in the process of responding to this demand for documents, and intends to cooperate with the investigation.

Generic Pricing Subpoena. In March 2018, the Company received a grand jury subpoena issued by the U.S. District Court for the Eastern District of Pennsylvania pursuant to which the Antitrust Division of the DOJ is seeking documents regarding generic products and pricing, communications with generic competitors and other related matters. The Company is in the process of responding to this subpoena, and the Company intends to cooperate fully in the investigation.

Boston Subpoena. In December 2016, the Company received a subpoena from the USAO for the District of Massachusetts for documents related to the Company’s provision of financial and other support to patients, including through charitable foundations, and related matters. The Company is in the process of responding to this subpoena, and the Company intends to cooperate fully in the investigation.

Texas Pricing Investigation. In November 2014, the Company received a CID from the Civil Medicaid Fraud Division of the Texas Attorney General's Office. According to the CID, the Attorney General's office is investigating the possibility of false reporting of information by the Company regarding the prices of certain of its drugs used by Texas Medicaid to establish reimbursement rates for pharmacies that dispensed the Company's drugs to Texas Medicaid recipients. The Company responded to these requests. In December 2018, the Company entered into a final settlement with the Texas Attorney General's Office to resolve all potential claims in the investigation and recorded a corresponding expense, which is included in SG&A in the consolidated statement of income.

MNK 2011 Inc. (formerly known as Mallinckrodt Inc.) v. U.S. Food and Drug Administration and United States of America. In November 2014, the FDA reclassified the Company's Methylphenidate ER in the Orange Book: Approved Drug Products with Therapeutic Equivalence ("the Orange Book"). In November 2014, the Company filed a Complaint in the U.S. District Court for the District of Maryland Greenbelt Division against the FDA and the United States (the "MD Complaint") for judicial review of the FDA’s reclassification. In July 2015, the court granted the FDA's motion to dismiss with respect to three of the five counts in the MD Complaint and granted summary judgment in favor of the FDA with respect to the two remaining counts (the “MD Order”). On October 18, 2016, the FDA initiated proceedings, proposing to withdraw approval of the Company's Abbreviated New Drug Applications ("ANDA") for Methylphenidate ER. On October 21, 2016, the United States Court of Appeals for the Fourth Circuit issued an order placing the Company’s appeal of the MD Order in abeyance pending the outcome of the withdrawal proceedings. The parties exchanged documents and in April 2018, the Company filed its submission in support of its position in the withdrawal proceedings. A potential outcome of the withdrawal proceedings is that the Company's Methylphenidate ER products may lose their FDA approval and have to be withdrawn from the market.

FTC Investigation. In June 2014, Questcor received a subpoena and CID from the Federal Trade Commission ("FTC") seeking documentary materials and information regarding the FTC's investigation into whether Questcor's acquisition of certain rights to develop, market, manufacture, distribute, sell and commercialize MNK-1411 (the product formerly described as Synacthen Depot^®) from Novartis AG and Novartis Pharma AG (collectively, "Novartis") violates antitrust laws. Subsequently, California, Maryland, Texas, Washington, New York and Alaska (collectively, "the Investigating States") commenced similar investigations focused on whether the transaction violates state antitrust laws. On January 17, 2017, the FTC, all Investigating States (except California) ("the Settling States") and the Company entered into an agreement to resolve this matter for a one-time cash payment of $102.0 million and an agreement to license MNK-1411 to a third party designated by the FTC for possible development in Infantile Spasms ("IS") and Nephrotic Syndrome ("NS") in the U.S. To facilitate that settlement, a complaint was filed on January 18, 2017, in the U.S. District Court for the District of Columbia. The settlement was approved by the court on January 30, 2017. On July 16, 2017, the Company announced the completion of the U.S. license of both the Synacthen trademark and certain intellectual property associated with MNK-1411 to West Pharmaceuticals to develop and pursue possible FDA approval of the product in IS and NS. The Company retains the right to develop MNK-1411 for all other indications in the U.S. and retains rights to the Synacthen trademark outside the U.S.

Therakos Subpoena. In March 2014, the USAO for the Eastern District of Pennsylvania requested the production of documents related to an investigation of the U.S. promotion of Therakos’ drug/device system UVADEX/UVAR XTS and UVADEX/CELLEX (collectively, the "Therakos System"), for indications not approved by the FDA, including treatment of patients with graft versus host disease ("GvHD") and solid organ transplant patients, including pediatric patients. The investigation also includes Therakos’ efforts to secure FDA approval for additional uses of, and alleged quality issues relating to, UVADEX/UVAR. In August 2015, the USAO for the Eastern District of Pennsylvania sent Therakos a subsequent request for documents related to the investigation and has since made certain related requests. The Company responded to these requests, and continues to cooperate fully in the investigation.

Questcor Subpoena. In September 2012, Questcor received a subpoena from the USAO for the Eastern District of Pennsylvania for information relating to its promotional practices related to H.P. Acthar Gel. Questcor was also informed by the USAO for the Eastern District of Pennsylvania that the USAO for the Southern District of New York and the SEC were participating in the investigation to review Questcor's promotional practices and related matters related to H.P. Acthar Gel. On March 9, 2015, the Company received a "No Action" letter from the SEC regarding its review of the Company's promotional practices related to H.P. Acthar Gel. The Company intends to cooperate fully in the investigation.

Patent Litigation

Amitiza Patent Litigation: Sun Pharmaceutical Industries, Ltd. and Sun Pharmaceutical Industries, Inc. In October 2018, Sucampo AG, Sucampo Pharmaceuticals, Inc. and Sucampo Pharma LLC, all subsidiaries of the Company, and Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals USA, Inc., and Takeda Pharmaceuticals America, Inc. (collectively "Takeda," the exclusive licensee under the patents in litigation) filed suit in the U.S. District Court for the District of New Jersey against Sun Pharmaceutical Industries, Ltd. and Sun Pharmaceutical Industries, Inc. (collectively “Sun”) alleging that Sun infringed U.S. Patent Nos. 7,795,312, 8,026,393, 8,097,653, 8,338,639, 8,389,542, 8,748,481 and 8,779,187 following receipt of a September 2018 notice from Sun concerning its submission of an ANDA containing a Paragraph IV patent certification with the FDA for a generic version of Amitiza. The Company intends to vigorously enforce its intellectual property rights relating to Amitiza.

Amitiza Patent Litigation: Teva Pharmaceuticals USA, Inc. In September 2017, Sucampo AG and Sucampo Pharmaceuticals, Inc., both subsidiaries of the Company, and Takeda filed suit in the U.S. District Court for the District of New Jersey against Teva

Pharmaceuticals USA, Inc. ("Teva") alleging that Teva infringed U.S. Patent Nos. 6,414,016, 6,982,283, 7,795,312, 8,026,393, 8,071,613, 8,097,653, 8,338,639, 8,389,542 and 8,748,481 following receipt of an August 2017 notice from Teva concerning its submission of an ANDA containing a Paragraph IV patent certification with the FDA for a generic version of Amitiza. On June 28, 2018, the parties entered into a settlement agreement under which Teva was granted the non-exclusive right to market a competing lubiprostone product in the U.S. under its ANDA on or after January 1, 2023, or earlier under certain circumstances.

Amitiza Patent Litigation: Amneal Pharmaceuticals, LLC. In April 2017, Sucampo AG and Sucampo Pharmaceuticals, Inc., both subsidiaries of the Company, and Takeda filed suit in the U.S. District Court for the District of New Jersey against Amneal Pharmaceuticals, LLC ("Amneal") alleging that Amneal infringed U.S. Patent Nos. 6,982,283, 8,026,393, 8,097,653, 8,338,639 and 8,389,542 following receipt of a March 2017 notice from Amneal concerning its submission of an ANDA containing a Paragraph IV patent certification with the FDA for a generic version of Amitiza. On June 28, 2018, the parties entered into a settlement agreement under which Amneal was granted the non-exclusive right to market a competing lubiprostone product in the U.S. under its ANDA on or after January 1, 2023, or earlier under certain circumstances.

Amitiza Patent Litigation: Par and DRL. Settlement and License Agreements were entered into with Anchen Pharmaceuticals, Inc., Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc. (collectively "Par") and Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. (collectively "DRL") to settle Paragraph IV patent litigation with each of Par and DRL. Under the terms of the Par settlement dated September 30, 2014, Par was granted a non-exclusive license and right to market a competing generic of Amitiza on or after January 1, 2021, or earlier under certain circumstances. Under the terms of the DRL settlement dated September 14, 2016, DRL was granted a non-exclusive license and right to market a competing generic of Amitiza on or after January 1, 2023, or earlier under certain circumstances.

Inomax Patent Litigation: Praxair Distribution, Inc. and Praxair, Inc. (collectively “Praxair”). In February 2015, INO Therapeutics LLC and Ikaria, Inc., both subsidiaries of the Company, filed suit in the U.S. District Court for the District of Delaware against Praxair following receipt of a January 2015 notice from Praxair concerning its submission of an ANDA containing a Paragraph IV patent certification with the FDA for a generic version of Inomax. In July 2016, the Company filed a second suit against Praxair in the U.S. District Court for the District of Delaware following receipt of a Paragraph IV notice concerning three additional patents recently added to the FDA Orange Book that was submitted by Praxair regarding its ANDA for a generic version of Inomax. The infringement claims in the second suit have been added to the original suit. In September 2016, the Company filed a third suit against Praxair in the U.S. District Court for the District of Delaware following receipt of a Paragraph IV notice concerning a fourth patent recently added to the FDA Orange Book that was submitted by Praxair regarding its ANDA for a generic version of Inomax.

The Company intends to vigorously enforce its intellectual property rights relating to Inomax in the Praxair litigation to prevent the marketing of infringing generic products prior to the expiration of the patents covering Inomax. Trial of the suit filed in February 2015 was held in March 2017 and a decision was rendered September 5, 2017 that ruled five patents invalid and six patents not infringed. The Company has appealed the decision to the Court of Appeals for the Federal Circuit. The oral arguments in the appeal occurred on February 6, 2019. Praxair received FDA approval of their ANDA for their Noxivent nitric oxide and clearance of their 510(k) for their NOxBOXi device on October 2, 2018. An adverse outcome in the appeal of the Praxair litigation decision (or a decision by Praxair to launch at-risk prior to the appellate decision) could result in the launch of a competitive nitric oxide product before the expiration of the last of the listed patents on May 3, 2036 (November 3, 2036 including pediatric exclusivity), which could adversely affect the Company's ability to successfully maximize the value of Inomax and have an adverse effect on its financial condition, results of operations and cash flows.

Inomax Patents: IPR Proceedings. In February 2015 and March 2015, the U.S. Patent and Trademark Office ("USPTO") issued Notices of Filing Dates Accorded to Petitions for IPR petitions filed by Praxair Distribution, Inc. concerning ten patents covering Inomax (i.e., five patents expiring in 2029 and five patents expiring in 2031).

In July 2015 the USPTO Patent Trial and Appeal Board ("PTAB") issued rulings denying the institution of four of the five IPR petitions challenging the five patents expiring in 2029. The PTAB also issued a ruling in July 2015 that instituted the IPR proceeding in the fifth of this group of patents and the PTAB ruled in July 2016 that one claim of this patent survived review and is valid while the remaining claims were unpatentable. The Company believed the claim held valid by the PTAB describes and encompasses a manner in which Inomax is distributed in conjunction with its approved labeling and that Praxair infringes that claim. Praxair filed an appeal and Mallinckrodt filed a cross-appeal of this decision to the Court of Appeals for the Federal Circuit. Oral argument of that appeal occurred in January 2018. The Federal Circuit decision was issued May 16, 2018 and held all claims unpatentable (invalid).

In September 2015 the USPTO PTAB issued rulings that instituted the IPR proceedings in each of the second set of five patents that expire in 2031. In September 2016 the PTAB ruled that all claims in the five patents expiring in 2031 are patentable.

Ofirmev Patent Litigation: Aurobindo Pharma U.S.A., Inc. In December 2017, Mallinckrodt Hospital Products Inc. and Mallinckrodt IP Unlimited Company, both subsidiaries of the Company, and New Pharmatop LP, the current owner of the two U.S. patents licensed exclusively by the Company, filed suit in the U.S. District Court for the District of Delaware against Aurobindo Pharma U.S.A., Inc. (“Aurobindo”) alleging that Aurobindo infringed U.S. Patent No. 6,992,218 ("the ‘218 patent"), U.S. Patent No. 9,399,012 ("the ‘012 patent") and U.S. Patent No. 9,610,265 ("the ‘265 patent") following receipt of a November 2017 notice from Aurobindo concerning its submission of an ANDA, containing a Paragraph IV patent certification with the FDA for a competing

version of Ofirmev. On May 7, 2018 the parties entered into a settlement agreement under which Aurobindo was granted the non-exclusive right to market a competing intravenous acetaminophen product in the U.S. under its ANDA on or after December 6, 2020, or earlier under certain circumstances.

Ofirmev Patent Litigation: B. Braun Medical Inc. In April 2017, Mallinckrodt Hospital Products Inc. and Mallinckrodt IP, both subsidiaries of the Company, and Pharmatop, the then owner of the two U.S. patents licensed exclusively by the Company, filed suit in the U.S. District Court for the District of Delaware against B. Braun Medical Inc. ("B. Braun") alleging that B. Braun infringed the '218 patent and the '012 patent following receipt of a February 2017 notice from B. Braun concerning its submission of a NDA, containing a Paragraph IV patent certification with the FDA for a competing version of Ofirmev. On October 3, 2018, the parties entered into a settlement agreement under which B. Braun was granted the non-exclusive right to market a competing intravenous acetaminophen product in the U.S. under its ANDA on or after December 6, 2020, or earlier under certain circumstances.

Ofirmev Patent Litigation: InnoPharma Licensing LLC and InnoPharma, Inc. In September 2014, Cadence and Mallinckrodt IP, both subsidiaries of the Company, and Pharmatop, the then owner of the two U.S. patents licensed exclusively by the Company, filed suit in the U.S. District Court for the District of Delaware against InnoPharma Licensing LLC and InnoPharma, Inc. (both are subsidiaries of Pfizer and collectively "InnoPharma") alleging that InnoPharma infringed U.S. Patent Nos. 6,028,222 ("the '222 patent") and 6,992,218 ("the '218 patent"). Separately, on December 1, 2016 Mallinckrodt IP Filed suit in the U.S. District Court for the District of Delaware against InnoPharma alleging that InnoPharma infringed the '012 patent. On May 4, 2017 the parties entered into settlement agreements on both suits under which InnoPharma was granted the non-exclusive right to market a competing intravenous acetaminophen product in the U.S. under its NDA on or after December 6, 2020, or earlier under certain circumstances.

Ofirmev Patent Litigation: Agila Specialties Private Limited, Inc. (now Mylan Laboratories Ltd.) and Agila Specialties Inc. (a Mylan Inc. Group), (collectively "Agila"). In December 2014, Cadence and Mallinckrodt IP, both subsidiaries of the Company, and Pharmatop filed suit in the U.S. District Court for the District of Delaware against Agila alleging that Agila infringed the '222 and the '218 patents. Separately, on December 1, 2016 Mallinckrodt IP filed suit in the U.S. District Court for the District of Delaware against Agila alleging that Agila infringed the '012 patent. On December 31, 2016, the parties entered into settlement agreements on both suits under which Agila was granted the non-exclusive right to market a competing intravenous acetaminophen product in the U.S. under its NDA on or after December 6, 2020, or earlier under certain circumstances.

The Company has successfully asserted the '222 and '218 patents and maintained their validity in both litigation and proceedings at the USPTO. The Company will continue to vigorously enforce its intellectual property rights relating to Ofirmev to prevent the marketing of infringing generic or competing products prior to December 6, 2020, which, if unsuccessful, could adversely affect the Company's ability to successfully maximize the value of Ofirmev and have an adverse effect on its financial condition, results of operations and cash flows.

Jazz Pharmaceuticals, Inc. and Jazz Pharmaceuticals Ireland v. Mallinckrodt PLC, Mallinckrodt Inc. and Mallinckrodt LLC. In January 2018, Jazz Pharmaceuticals, Inc. and Jazz Pharmaceuticals Ireland (collectively, "Jazz") filed suit in the U.S. District Court for the District of New Jersey against the Company alleging that the Company infringed U.S. Patent Nos. 7,668,730, 7,765,106, 7,765,107, 7,895,059, 8,457,988, 8,589,182, 8,731,963, 8,772,306, 9,050,302, and 9,486,426 following receipt of a November 2017 notice from the Company concerning its submission of an ANDA, containing a Paragraph IV patent certification with the FDA for a competing version of Xyrem. On June 4, 2018, the parties entered into a settlement agreement under which the Company was granted the non-exclusive right to market a competing sodium oxybate product in the U.S. under its ANDA on or after December 31, 2025, or earlier under certain circumstances.

Shire Development LLC, Shire LLC and Shire US, Inc. v. SpecGx LLC. In May 2018, Shire Development LLC, Shire LLC and Shire US, Inc. (collectively “Shire”) filed suit in the U.S. District Court for the District of Delaware against the Company alleging that the Company infringed U.S. Patent Nos. 6,913,768, 8,846,100, and 9,173,857 following receipt of an April 2018 notice from the Company concerning its submission of an ANDA, containing a Paragraph IV patent certification with the FDA for a competing version of Mydayis. On January 28, 2018, the parties entered into a settlement agreement under which the Company was granted the non-exclusive right to market a competing generic version of Mydayis in the U.S. under its ANDA on or after May 10, 2023 (or November 10, 2023 if any pediatric exclusivity is granted by the FDA with respect to the Mydayis product), or earlier under certain circumstances.

Commercial and Securities Litigation

Grifols. On March 13, 2018, Grifols initiated arbitration against the Company, alleging breach of a Manufacturing and Supply Agreement entered into between the Company's predecessor-in-interest, Cadence Pharmaceuticals Inc., and Grifols. The Company intends to vigorously defend itself in this matter.

Putative Class Action Litigation (MSP). On October 30, 2017, a putative class action lawsuit was filed against the Company and United BioSource Corporation ("UBC") in the U.S. District Court for the Central District of California. The case is captioned MSP Recovery Claims, Series II LLC, et al. v. Mallinckrodt ARD, Inc., et al. The complaint purports to be brought on behalf of two classes: all Medicare Advantage Organizations and related entities in the U.S. who purchased or provided reimbursement for H.P. Acthar Gel

pursuant to (i) Medicare Part C contracts (Class 1) and (ii) Medicare Part D contracts (Class 2) since January 1, 2011, with certain exclusions. The complaint alleges that the Company engaged in anticompetitive, unfair, and deceptive acts to artificially raise and maintain the price of H.P. Acthar Gel. To this end, the complaint alleges that the Company unlawfully maintained a monopoly in a purported ACTH product market by acquiring the U.S. rights to Synacthen Depot and reaching anti-competitive agreements with the other defendants by selling H.P. Acthar Gel through an exclusive distribution network. The complaint purports to allege claims under federal and state antitrust laws and state unfair competition and unfair trade practice laws. Pursuant to a motion filed by defendants, this case has been transferred to the U.S. District Court for the Northern District of Illinois. The Company intends to vigorously defend itself in this matter.

Putative Class Action Litigation (Rockford). On April 6, 2017, a putative class action lawsuit was filed against the Company and UBC in the U.S. District Court for the Northern District of Illinois. The case is captioned City of Rockford v. Mallinckrodt ARD, Inc., et al. The complaint was subsequently amended, most recently on December 8, 2017, to include an additional named plaintiff and additional defendants. As amended, the complaint purports to be brought on behalf of all self-funded entities in the U.S. and its Territories, excluding any Medicare Advantage Organizations, related entities and certain others, that paid for H.P. Acthar Gel from August 2007 to the present. The lawsuit alleges that the Company engaged in anticompetitive, unfair, and deceptive acts to artificially raise and maintain the price of H.P. Acthar Gel. To this end, the suit alleges that the Company unlawfully maintained a monopoly in a purported ACTH product market by acquiring the U.S. rights to Synacthen Depot; conspired with UBC and violated anti-racketeering laws by selling H.P. Acthar Gel through an exclusive distributor; and committed fraud on consumers by failing to correctly identify H.P. Acthar Gel's active ingredient on package inserts. The Company intends to vigorously defend itself in this matter.

Local 542. On May 25, 2018, the International Union of Operating Engineers Local 542 filed a complaint against the Company and other defendants alleging improper pricing and distribution of H.P. Acthar Gel, in violation of Pennsylvania's Unfair Trade Practices and Consumer Protection Law, aiding and abetting, unjust enrichment and negligent misrepresentation. Plaintiff filed an amended complaint on August 27, 2018. The Company intends to vigorously defend itself in this matter.

Employee Stock Purchase Plan Securities Litigation. On July 20, 2017, a purported purchaser of Mallinckrodt stock through Mallinckrodt's ESPPs, filed a derivative lawsuit in the Federal District Court in the Eastern District of Missouri, captioned Solomon v. Mallinckrodt plc, et al., against the Company, its Chief Executive Officer Mark C. Trudeau ("CEO"), its former Chief Financial Officer Matthew K. Harbaugh ("CFO"), its Controller Kathleen A. Schaefer, and current and former directors of the Company. On September 6, 2017, plaintiff voluntarily dismissed its complaint in the Federal District Court for the Eastern District of Missouri and refiled virtually the same complaint in the U.S. District Court for the District of Columbia. The complaint purports to be brought on behalf of all persons who purchased or otherwise acquired Mallinckrodt stock between November 25, 2014, and January 18, 2017, through the ESPPs. In the alternative, the plaintiff alleges a class action for those same purchasers/acquirers of stock in the ESPPs during the same period. The complaint asserts claims under Section 11 of the Securities Act, and for breach of fiduciary duty, misrepresentation, non-disclosure, mismanagement of the ESPPs' assets and breach of contract arising from substantially similar allegations as those contained in the putative class action securities litigation described in the following paragraph. Stipulated co-lead plaintiffs were approved by the court on March 1, 2018. Co-Lead Plaintiffs filed an amended complaint on June 4, 2018 having a class period of July 14, 2014 to November 6, 2017. On July 6, 2018, this matter was stayed by agreement of the parties pending resolution of the Shenk matter below.

Putative Class Action Securities Litigation (Shenk). On January 23, 2017, a putative class action lawsuit was filed against the Company and its CEO in the U.S. District Court for the District of Columbia, captioned Patricia A. Shenk v. Mallinckrodt plc, et al. The complaint purports to be brought on behalf of all persons who purchased Mallinckrodt's publicly traded securities on a domestic exchange between November 25, 2014 and January 18, 2017. The lawsuit generally alleges that the Company made false or misleading statements related to H.P. Acthar Gel and Synacthen to artificially inflate the price of the Company's stock. In particular, the complaint alleges a failure by the Company to provide accurate disclosures concerning the long-term sustainability of H.P. Acthar Gel revenues, and the exposure of H.P. Acthar Gel to Medicare and Medicaid reimbursement rates. On January 26, 2017, a second putative class action lawsuit, captioned Jyotindra Patel v. Mallinckrodt plc, et al. was filed against the same defendants named in the Shenk lawsuit in the U.S. District Court for the District of Columbia. The Patel complaint purports to be brought on behalf of shareholders during the same period of time as that set forth in the Shenk lawsuit and asserts claims similar to those set forth in the Shenk lawsuit. On March 13, 2017, a third putative class action lawsuit, captioned Amy T. Schwartz, et al., v. Mallinckrodt plc, et al., was filed against the same defendants named in the Shenk lawsuit in the U.S. District Court for the District of Columbia. The Schwartz complaint purports to be brought on behalf of shareholders who purchased shares of the Company between July 14, 2014 and January 18, 2017 and asserts claims similar to those set forth in the Shenk lawsuit. On March 23, 2017, a fourth putative class action lawsuit, captioned Fulton County Employees' Retirement System v. Mallinckrodt plc, et al., was filed against the Company and its CEO and CFO in the U.S. District Court for the District of Columbia. The Fulton County complaint purports to be brought on behalf of shareholders during the same period of time as that set forth in the Schwartz lawsuit and asserts claims similar to those set forth in the Shenk lawsuit. On March 27, 2017, four separate plaintiff groups moved to consolidate the pending cases and to be appointed as lead plaintiffs in the consolidated case. Since that time, two of the plaintiff groups have withdrawn their motions. Lead plaintiff was designated by the court on March 9, 2018. Lead plaintiff filed a consolidated complaint on May 18, 2018, alleging a class period from July 14, 2014 to November 6, 2017, the Company, its CEO, its former CFO, and Executive Vice President, Hugh O'Neill, as defendants, and containing similar claims, but further alleging misstatements regarding payer reimbursement restrictions for H.P.

Acthar Gel. On August 30, 2018, the lead plaintiff voluntarily dismissed the claims against Mr. O'Neill without prejudice. The Company intends to vigorously defend itself in this matter.

Environmental Remediation and Litigation Proceedings

The Company is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites, including those described below. The ultimate cost of site cleanup and timing of future cash outlays is difficult to predict, given the uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations and alternative cleanup methods. The Company concluded that, as of December 28, 2018, it was probable that it would incur remediation costs in the range of $36.4 million to $86.5 million. The Company also concluded that, as of December 28, 2018, the best estimate within this range was $61.8 million, of which $2.1 million was included in accrued and other current liabilities and the remainder was included in environmental liabilities on the consolidated balance sheet at December 28, 2018. While it is not possible at this time to determine with certainty the ultimate outcome of these matters, the Company believes, given the information currently available, that the final resolution of all known claims, after taking into account amounts already accrued, will not have a material adverse effect on its financial condition, results of operations and cash flows.

Lower Passaic River, New Jersey. The Company and approximately 70 other companies (“Cooperating Parties Group” or “CPG”) are parties to a May 2007 Administrative Order on Consent ("AOC") with the Environmental Protection Agency ("EPA") to perform a remedial investigation and feasibility study ("RI/FS") of the 17-mile stretch known as the Lower Passaic River ("the River") Study Area. The Company's potential liability stems from former operations at Lodi and Belleville, New Jersey.

In April 2014, the EPA issued a revised Focused Feasibility Study ("FFS"), with remedial alternatives to address cleanup of the lower 8-mile stretch of the River. The EPA estimated the cost for the remediation alternatives ranged from $365.0 million to $3.2 billion and the EPA's preferred approach had an estimated cost of $1.7 billion.

In April 2015, the CPG presented a draft of the RI/FS of the River to the EPA that included alternative remedial actions for the entire 17-mile stretch of the River.

On March 4, 2016, the EPA issued the Record of Decision ("ROD") for the lower 8 miles of the River with a slight modification on its preferred approach and a revised estimated cost of $1.38 billion. On October 5, 2016, the EPA announced that Occidental Chemicals Corporation ("OCC") had entered into an agreement to develop the remedial design.

On August 7, 2018, the EPA finalized a buyout offer of $280,600 with the Company, limited to its former Lodi facility, for the lower 8 miles of the River. During the three months ended September 28, 2018, the Company reduced the accrual associated with this matter by $11.8 million to $26.2 million, which represents the Company's estimate of its remaining liability related to the River.

Despite the issuance of the revised FFS and ROD by the EPA, the RI/FS by the CPG, and the cash out settlement by the EPA there are many uncertainties associated with the final agreed-upon remediation, potential future liabilities and the Company's allocable share of the remediation. Given those uncertainties, the amounts accrued may not be indicative of the amounts for which the Company may be ultimately responsible and will be refined as the remediation progresses.

Occidental Chemical Corp. v. 21st Century Fox America, Inc. The Company and approximately 120 other companies were named as defendants in a lawsuit filed on June 30, 2018, by OCC, in which OCC seeks cost recovery and contribution for past and future costs in response to releases and threatened releases of hazardous substances into the lower 8 miles of the River. A former Mallinckrodt facility located in Jersey City, NJ (located in Newark Bay) and the former Belleville facility were named in the suit. Due to an indemnification agreement with AVON Inc., Mallinckrodt has tendered the liability for the Jersey City site to AVON Inc. and they have accepted. The Company retains a share of the liability for this suit related to the Belleville facility. A motion to dismiss several of the claims has been submitted to the court. While it is not possible at this time to determine with certainty the ultimate outcome of this matter, the Company believes, given the information currently available, that the ultimate resolution of all known claims, after taking into account amounts already accrued will not have a material adverse effect on its financial condition, results of operations and cash flows.

Mallinckrodt Veterinary, Inc., Millsboro, Delaware. The Company previously operated a facility in Millsboro, Delaware ("the Millsboro Site") where various animal healthcare products were manufactured. In 2005, the Delaware Department of Natural Resources and Environmental Control found trichloroethylene ("TCE") in the Millsboro public water supply at levels that exceeded the federal drinking water standards. Further investigation to identify the TCE plume in the ground water indicated that the plume has extended to property owned by a third party near the Millsboro Site. The Company, and another former owner, have assumed responsibility for the Millsboro Site cleanup under the Alternative Superfund Program administered by the EPA. The companies have entered into three AOCs with the EPA to perform investigations to abate, mitigate or eliminate the release or threat of release of hazardous substances at the Millsboro Site and to conduct an Engineering Evaluation/Cost Analysis ("EE/CA") to characterize the nature and extent of the contamination. In January 2017, the EPA issued its Action Memorandum regarding the EE/CA. While it is not possible at this time to determine with certainty the ultimate outcome of this matter, the Company believes, given the information

currently available, that the ultimate resolution of all known claims, after taking into account amounts already accrued, will not have a material adverse effect on its financial condition, results of operations and cash flows.

Crab Orchard National Wildlife Refuge Superfund Site, near Marion, Illinois. Between 1967 and 1982, International Minerals and Chemicals Corporation ("IMC"), a predecessor in interest to the Company, leased portions of the Additional and Uncharacterized Sites ("AUS") Operable Unit at the Crab Orchard Superfund Site ("the CO Site") from the government and manufactured various explosives for use in mining and other operations. In March 2002, the Department of Justice, the U.S. Department of the Interior and the EPA (together, "the Government Agencies") issued a special notice letter to General Dynamics Ordnance and Tactical Systems, Inc. ("General Dynamics"), one of the other potentially responsible parties ("PRPs") at the CO Site, to compel General Dynamics to perform the RI/FS for the AUS Operable Unit. General Dynamics negotiated an AOC with the Government Agencies to conduct an extensive RI/FS at the CO Site under the direction of the U.S. Fish and Wildlife Service. General Dynamics asserted in August 2004 that the Company is jointly and severally liable, along with approximately eight other lessees and operators at the AUS Operable Unit, for costs associated with alleged contamination of soils and groundwater resulting from historic operations, and the parties have entered into a non-binding mediation process. While it is not possible at this time to determine with certainty the ultimate outcome of this matter, the Company believes, given the information currently available, that the final resolution of all known claims, after taking into account amounts already accrued, will not have a material adverse effect on its financial condition, results of operations and cash flows.

Products Liability Litigation

Beginning with lawsuits brought in July 1976, the Company is also named as a defendant in personal injury lawsuits based on alleged exposure to asbestos-containing materials. A majority of the cases involve product liability claims based principally on allegations of past distribution of products containing asbestos. A limited number of the cases allege premises liability based on claims that individuals were exposed to asbestos while on the Company's property. Each case typically names dozens of corporate defendants in addition to the Company. The complaints generally seek monetary damages for personal injury or bodily injury resulting from alleged exposure to products containing asbestos. The Company's involvement in asbestos cases has been limited because it did not mine or produce asbestos. Furthermore, in the Company's experience, a large percentage of these claims have never been substantiated and have been dismissed by the courts. The Company has not suffered an adverse verdict in a trial court proceeding related to asbestos claims and intends to continue to defend these lawsuits. When appropriate, the Company settles claims; however, amounts paid to settle and defend all asbestos claims have been immaterial. As of December 28, 2018, there were approximately 11,700 asbestos-related cases pending against the Company.

The Company estimates pending asbestos claims, claims that were incurred but not reported and related insurance recoveries, which are recorded on a gross basis in the consolidated balance sheets. The Company's estimate of its liability for pending and future claims is based on claims experience over the past five years and covers claims either currently filed or expected to be filed over the next seven years. The Company believes that it has adequate amounts recorded related to these matters. While it is not possible at this time to determine with certainty the ultimate outcome of these asbestos-related proceedings, the Company believes, given the information currently available, that the ultimate resolution of all known and anticipated future claims, after taking into account amounts already accrued, along with recoveries from insurance, will not have a material adverse effect on its financial condition, results of operations and cash flows.

Interest-Bearing Deferred Tax Obligation

As part of the integration of Questcor, the Company entered into an internal installment sale transaction related to certain H.P. Acthar Gel intangible assets during the three months ended December 26, 2014. Installment sale transactions result in a taxable gain. In accordance with Internal Revenue Code Section 453A ("Section 453A") the gain is considered taxable in the period in which installment payments are received. During the three months ended December 25, 2015, the Company entered into similar transactions with certain intangible assets acquired in the acquisition of Ikaria and Therakos.

During the three months ended March 31, 2017, the Company sold its Intrathecal Therapy business with a portion of the consideration from the sale being in the form of a note receivable subject to the installment sale provisions described above. During fiscal 2018, the Company received payment on the note receivable and settled all installment sale provisions related to its sale of the Intrathecal Therapy business.

As of December 28, 2018, the Company had an aggregate $227.5 million of interest-bearing U.S. deferred tax liabilities associated with outstanding installment notes compared to $553.5 million at December 29, 2017. The decrease of $326.0 million is primarily attributed to the Company’s reorganization of its intercompany financing and associated legal entity ownership, which occurred during fiscal 2018. See Note 9 for further details regarding this reorganization. The GAAP calculation of interest associated with these deferred tax liabilities is subject to variable interest rates. The Company recognized interest expense associated with the Section 453A deferred tax liabilities of $23.7 million, $69.3 million, $73.8 million and $15.9 million for fiscal 2018, 2017, 2016 and

the three months ended December 30, 2016, respectively. Fiscal 2017 includes a one-time charge of $8.4 million resulting primarily from the reorganization of its legal entity ownership.

The Company has reported Section 453A interest on its tax returns on the basis of its interpretation of the U.S. Internal Revenue Code and Regulations. Alternative interpretations of these provisions could result in additional interest payable on the deferred tax liability. Due to the inherent uncertainty in these interpretations, the Company has deferred the recognition of the benefit associated with the Company’s interpretation and maintains a corresponding liability of $56.0 million and $46.0 million as of December 28, 2018 and December 29, 2017, respectively. Favorable resolution of this uncertainty would likely result in a material reversal of this liability and a benefit being recorded to interest expense within the consolidated statements of income.

Refer to Note 25 for further information subsequent to December 28, 2018 regarding the Company's interest-bearing deferred tax obligation.

Leases

The Company has facility, vehicle and equipment leases that expire at various dates. Rental expense under facility, vehicle and equipment operating leases related to continuing operations was $24.8 million, $30.4 million, $23.9 million and $7.2 million for fiscal 2018, 2017, 2016 and the three months ended December 30, 2016, respectively.

The following is a schedule of minimum lease payments for non-cancelable leases as of December 28, 2018:



	Operating Leases
Fiscal 2019	$	22.3
Fiscal 2020	16.4
Fiscal 2021	12.8
Fiscal 2022	10.6
Fiscal 2023	10.3
Thereafter	39.2
Total minimum lease payments	$	111.6

Tax Matters

The income tax returns of the Company and its subsidiaries are periodically examined by various tax authorities. The resolution of these matters is subject to the conditions set forth in the tax matters agreement entered into between the Company and Covidien ("the Tax Matters Agreement"). Covidien has the right to administer, control and settle all U.S. income tax audits for periods prior to the Separation. While it is not possible at this time to determine with certainty the ultimate outcome of these matters, the Company believes, given the information currently available, that established liabilities are reasonable and that the ultimate resolution of these matters will not have a material adverse effect on its financial condition, results of operations and cash flows.

The IRS has completed its examination of all tax returns filed by Covidien through 2012. The only open audits for these tax years relate to tax returns filed in various state jurisdictions. Taxes for periods prior to September 29, 2012 are subject to the Company's $200.0 million liability limitation, as prescribed in the Tax Matters Agreement. The Company believes that it is adequately reserved for taxes related to these years.

The Company continues to be subject to examination by the IRS for tax years 2014 to 2017. As of December 28, 2018, the primary unresolved issue relates to transfer pricing, which could have a significant impact to the consolidated financial statements if not resolved favorably. The Company believes its allowances for income tax contingencies are adequate. The Company has not received a proposed assessment for unresolved issues and although possible, does not expect a final resolution of these issues in the next 12 months. See Note 9 for further information.

Other Matters

The Company is a defendant in a number of other pending legal proceedings relating to present and former operations, acquisitions and dispositions. The Company does not expect the outcome of these proceedings, either individually or in the aggregate, to have a material adverse effect on its financial condition, results of operations and cash flows.

Financial Instruments and Fair Value Measurements

12 Months Ended

Dec. 28, 2018

Fair Value Disclosures [Abstract]

Financial Instruments and Fair Value Measurements



21.	Financial Instruments and Fair Value Measurements

Fair value is defined as the exit price that would be received from the sale of an asset or paid to transfer a liability, using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes a three-level fair value hierarchy, which maximizes the use of observable inputs and minimizes the use of unobservable inputs used in measuring fair value. The levels within the hierarchy are as follows:

Level 1— observable inputs such as quoted prices in active markets for identical assets or liabilities;

Level 2— significant other observable inputs that are observable either directly or indirectly; and

Level 3— significant unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions.

The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:



	December 28, 2018		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	33.1	$	22.4	$	10.7	$	—
Equity securities	—		—		—		—
	$	33.1	$	22.4	$	10.7	$	—
Liabilities:
Deferred compensation liabilities	$	38.5	$	—	$	38.5	$	—
Contingent consideration and acquired contingent liabilities	151.4		—		—		151.4
	$	189.9	$	—	$	38.5	$	151.4



	December 29, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	35.4	$	24.0	$	11.4	$	—
Equity securities	22.7		22.7		—		—
	$	58.1	$	46.7	$	11.4	$	—
Liabilities:
Deferred compensation liabilities	$	42.7	$	—	$	42.7	$	—
Contingent consideration and acquired contingent liabilities	246.4		—		—		246.4
	$	289.1	$	—	$	42.7	$	246.4

Debt and equity securities held in rabbi trusts. Debt securities held in the rabbi trusts primarily consist of U.S. government and agency securities and corporate bonds. When quoted prices are available in an active market, the investments are classified as level 1. When quoted market prices for a security are not available in an active market, they are classified as level 2. Equity securities held in the rabbi trusts primarily consist of U.S. common stocks, which are valued using quoted market prices reported on nationally recognized securities exchanges.

Equity securities. Equity securities consisted of shares in Mesoblast, for which quoted prices are available in an active market; therefore, the investment was classified as level 1 and is valued based on quoted market prices reported on a nationally recognized securities exchange. During fiscal 2018, the Company sold all its shares for gross proceeds of $25.5 million resulting in a $3.4 million gain being recognized within other income (expense), net within the consolidated statement of income.

Deferred compensation liabilities. The Company maintains a non-qualified deferred compensation plan in the U.S., which permits eligible employees of the Company to defer a portion of their compensation. A recordkeeping account is set up for each participant and the participant chooses from a variety of funds for the deemed investment of their accounts. The recordkeeping accounts generally correspond to the funds offered in the Company's U.S. tax-qualified defined contribution retirement plan and the account balance fluctuates with the investment returns on those funds.

Goodwill. The Company performs an annual goodwill impairment assessment using an income approach based on the present value of future cash flows. See further discussion in Notes 3 and 13 to the consolidated financial statements.

Contingent consideration and acquired contingent liabilities. As of December 28, 2018, the Company maintains various contingent consideration and acquired contingent liabilities associated with the acquisitions of Questcor, Stratatech, and Ocera.

In August 2014, the Company recorded acquired contingent liabilities of $195.4 million from the acquisition of Questcor. The contingent liabilities relate to Questcor's contingent obligations associated with their acquisition of an exclusive, perpetual and irrevocable license to develop, market, manufacture, distribute, sell and commercialize MNK-1411 ("Synacthen") from Novartis and their acquisition of BioVectra. The fair value of these contingent consideration obligations at December 28, 2018 and December 29, 2017 were $76.2 million and $111.8 million, respectively.

Under the terms of the license agreement with Novartis, the Company made a $25.0 million payment in fiscal 2018, and is obligated to make annual payments of $25.0 million subsequent to fiscal 2018 until such time that the Company obtains FDA approval of Synacthen and makes a $25.0 million payment upon obtaining FDA approval of Synacthen. If FDA approval is obtained, the Company will pay an annual royalty to Novartis based on a percentage of net sales in the U.S. market. As of December 28, 2018, the total remaining payments under the license agreement shall not exceed $115.0 million. The terms of the license agreement allow the Company to terminate the license agreement upon the occurrence of certain events following the fiscal 2020 payment. The Company measured the fair value of the contingent payments based on a probability-weighted present value of the consideration expected to be transferred using a discount rate of 4.7%.

As part of the Stratatech Acquisition, the Company provided contingent consideration to the prior shareholders of Stratatech, primarily in the form of regulatory filing and approval milestones associated with the deep partial thickness and full thickness indications associated with StrataGraft. The Company assesses the likelihood of and timing of making such payments. The fair value of the contingent payments was measured based on the net present value of a probability-weighted assessment. The Company determined the fair value of the contingent consideration associated with the Stratatech Acquisition to be $53.7 million and $53.5 million at December 28, 2018 and December 29, 2017, respectively.

As part of the Ocera Acquisition, the Company provided contingent consideration to the prior shareholders of Ocera in the form of both patient enrollment clinical study milestones for intravenous ("IV") and oral formulations of MNK-6105 and MNK-6106, which represent the IV and oral formulations, respectively, and sales-based milestones associated with MNK-6105 and MNK-6106. The Company determined the fair value of the contingent consideration based on an option pricing model to be $21.5 million and $22.0 million as of December 28, 2018 and December 29, 2017, respectively.

Prior to December 28, 2018, the Company maintained various contingent consideration and acquired contingent liabilities associated with the Hemostasis Acquisition and InfaCare Acquisition.

As part of the Hemostasis Acquisition, the Company provided contingent consideration to The Medicines Company in the form of sales based milestones associated with Raplixa and PreveLeak, and acquired contingent liabilities associated with The Medicines Company's prior acquisitions of the aforementioned products. The Company determined the fair value of the contingent consideration and acquired contingent liabilities based on an option pricing model to be $7.0 million and $17.1 million, respectively, at December 29, 2017, respectively. During fiscal 2017, the contingent consideration liability associated with Raplixa was reduced to zero, reflective of lower than previously anticipated commercial opportunities for the product, resulting in a $54.6 million fair value adjustment during fiscal 2017. The Company paid $12.0 million related to the FDA approval milestone of PreveLeak during the three months ended March 30, 2018. On March 16, 2018, the Company sold a portion of the Hemostasis business, inclusive of the Recothrom and PreveLeak products to Baxter and the remaining contingent consideration liability balance of $12.1 million was transferred upon sale.

As part of the InfaCare Acquisition, the Company provided contingent consideration to the prior shareholders of InfaCare in the form of both regulatory approval milestones for full-term and pre-term neonates for stannsoporfin and sales-based milestones associated with stannsoporfin. Due to recent developments and discussions with the FDA, as discussed in further detail in Note 13, the timing of the development program is expected to shift outward. During fiscal 2018, the Company recognized a $35.0 million fair value adjustment due to this shift in timing and its impact on the achievement of milestones per the purchase agreement. The fair value of the contingent consideration based on an option pricing model was determined to be zero and $35.0 million as of December 28, 2018 and December 29, 2017, respectively.

Of the total fair value of the contingent consideration of $151.4 million, $34.1 million was classified as current and $117.3 million was classified as non-current in the consolidated balance sheet as of December 28, 2018. The following table summarizes the fiscal 2018 activity for contingent consideration:



Balance at December 29, 2017	$	246.4
Disposal of business	(12.1		)
Payments	(37.0		)
Accretion expense	4.3
Fair value adjustment	(50.2		)
Balance at December 28, 2018	$	151.4

Financial Instruments Not Measured at Fair Value

The following methods and assumptions were used by the Company in estimating fair values for financial instruments not measured at fair value as of December 28, 2018 and December 29, 2017:

•

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and the majority of other current assets and liabilities approximate fair value because of their short-term nature. The Company classifies cash on hand and deposits in banks, including commercial paper, money market accounts and other investments it may hold from time to time, with an original maturity to the Company of three months or less, as cash and cash equivalents (level 1). The fair value of restricted cash is equivalent to its carrying value of $18.6 million and $18.3 million as of December 28, 2018 and December 29, 2017, respectively (level 1), substantially all of which is included in other assets on the consolidated balance sheets.


•	The Company received a portion of consideration for the sale of the Intrathecal business in the form of a note receivable. The fair value of the note receivable was equivalent to its carrying value of $154.0 million as of December 29, 2017 (level 1). During fiscal 2018, the Company received $154.0 million from Piramal for settlement of the aforementioned note receivable.

•

The Company received a portion of consideration as part of contingent earn-out payments related to the sale of the Nuclear Imaging business in the form of preferred equity certificates during fiscal 2018. These securities are classified as held-to-maturity and are carried at amortized cost, which approximates fair value, of $9.0 million at December 28, 2018 (level 3). These securities are included in other assets on the consolidated balance sheet.

•

The Company's life insurance contracts are carried at cash surrender value, which is based on the present value of future cash flows under the terms of the contracts (level 3). Significant assumptions used in determining the cash surrender value include the amount and timing of future cash flows, interest rates and mortality charges. The fair value of these contracts approximates the carrying value of $66.4 million and $67.0 million at December 28, 2018 and December 29, 2017, respectively. These contracts are included in other assets on the consolidated balance sheets.

•

The carrying values of the Company's revolving credit facility and variable-rate receivable securitization approximate the fair values due to the short-term nature of these instruments, and is therefore classified as level 1. The Company's 3.50%, 4.75%, 4.875%, 5.50%, 5.625% and 5.75% notes are classified as level 1, as quoted prices are available in an active market for these notes. Since the quoted market prices for the Company's term loans and 8.00% and 9.50% debentures are not available in an active market, they are classified as level 2 for purposes of developing an estimate of fair value. The fair value of the "other" loan is based on the present value of future cash flows under the terms of the agreement with future cash flows and interest rates as significant assumptions, and therefore classified as level 3. The following table presents the carrying values and estimated fair values of the Company's long-term debt, excluding capital leases, as of the end of each period:



	December 28, 2018				December 29, 2017
	Carrying Value		Fair Value		Carrying Value		Fair Value
Level 1:
3.50% notes due April 2018	$	—	$	—	$	300.0	$	299.1
4.875% notes due April 2020	700.0		676.6		700.0		675.2
Variable-rate receivable securitization due July 2020	250.0		250.0		200.0		200.0
5.75% notes due August 2022	835.2		713.6		884.0		804.8
4.75% notes due April 2023	500.2		336.7		526.5		412.4
5.625% notes due October 2023	731.4		557.0		738.0		628.8
5.50% notes due April 2025	692.1		479.1		692.1		564.5
Revolving credit facility	220.0		220.0		900.0		900.0
Level 2:
9.50% debentures due May 2022	10.4		9.7		10.4		10.9
8.00% debentures due March 2023	4.4		3.8		4.4		4.4
Term loan due September 2024	1,613.8		1,472.4		1,851.2		1,848.7
Term loan due February 2025	597.0		548.0		—		—
Level 3:
Other	2.2		2.2		—		—
Total Debt	$	6,156.7	$	5,269.1	$	6,806.6	$	6,348.8

Concentration of Credit and Other Risks

Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of accounts receivable. The Company generally does not require collateral from customers. A portion of the Company's accounts receivable outside the U.S. includes sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays. Payment is dependent upon the financial stability and creditworthiness of those countries' national economies.

The following table shows net sales attributable to distributors that accounted for 10% or more of the Company's total net sales:



	Fiscal Year Ended						Three Months Ended
	December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016
CuraScript, Inc.	35	%	40	%	38	%	43	%
McKesson Corporation	*		*		12	%	10	%

* Net sales to these distributors were less than 10% of total net sales during the respective periods presented above.

The following table shows accounts receivable attributable to distributors that accounted for 10% or more of the Company's gross accounts receivable at the end of each period:



	December 28, 2018		December 29, 2017
AmerisourceBergen Corporation	26	%	15	%
McKesson Corporation	22	%	26	%
CuraScript, Inc.	13	%	14	%
Cardinal Health, Inc.	*		11	%

* Gross accounts receivables from these distributors were less than 10% of total gross accounts receivable during the respective periods presented above.

The following table shows net sales attributable to products that accounted for 10% or more of the Company's total net sales:



	Fiscal Year Ended						Three Months Ended
	December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016
H.P. Acthar Gel	35	%	37	%	34	%	39	%
Inomax	17	%	16	%	14	%	14	%

Segment and Geographical Data

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Segment and Geographical Data

12 Months Ended

Dec. 28, 2018

Segment Reporting [Abstract]



22.	Segment and Geographical Data

As a result of the planned Separation, the Company reassessed its segments based on the financial information viewed by the Chief Executive Officer, the Company's chief operating decision maker ("CODM"), for the purposes of making resource allocation decisions and assessing the performance of the business. The Company has identified two reportable segments that align with the operations of the two independent publicly traded companies anticipated post-separation: (1) Specialty Brands and (2) Specialty Generics and Amitiza, which are further described below:


•	Specialty Brands includes innovative specialty pharmaceutical brands; and


•	Specialty Generics and Amitiza includes niche specialty generic drugs products, APIs and Amitiza.

Prior year amounts have been recast to conform to current presentation.

Management measures and evaluates the Company's operating segments based on segment net sales and operating income. Management excludes corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include, but are not limited to, intangible asset amortization, net restructuring and related charges, non-restructuring impairments and separation costs. Although these amounts are excluded from segment operating income, as applicable, they are included in reported consolidated operating income and in the following reconciliations presented below.

Management manages assets on a total company basis, not by operating segment. The CODM does not regularly review any asset information by operating segment and, accordingly, the Company does not report asset information by operating segment. Total assets were approximately $10.9 billion and $15.3 billion at December 28, 2018 and December 29, 2017, respectively.

Selected information by business segment is as follows:



	Fiscal Year Ended									Three Months Ended
	December 28, 2018			December 29, 2017			September 30, 2016			December 30, 2016
Net sales:
Specialty Brands	$	2,306.2		$	2,352.0		$	2,288.8		$	600.1
Specialty Generics and Amitiza	909.4			869.6			1,092.0			229.8
Net sales	$	3,215.6		$	3,221.6		$	3,380.8		$	829.9
Operating income:
Specialty Brands	$	1,077.4		$	1,146.3		$	1,060.7		$	295.2
Specialty Generics and Amitiza	105.0			266.4			444.7			64.6
Segment operating income	1,182.4			1,412.7			1,505.4			359.8
Unallocated amounts:
Corporate and allocated expenses ⁽¹⁾	(155.8		)	(125.2		)	(117.7		)	(123.1		)
Intangible asset amortization	(740.2		)	(694.5		)	(700.1		)	(175.7		)
Restructuring and related charges, net ⁽²⁾	(108.2		)	(36.4		)	(37.6		)	(5.3		)
Non-restructuring impairments	(3,893.1		)	(63.7		)	(16.9		)	(214.3		)
Separation costs ⁽³⁾	(6.0		)	—			—			—
Operating income	$	(3,720.9	)	$	492.9		$	633.1		$	(158.6	)

Depreciation and amortization ⁽⁴⁾:
Specialty Brands	$	696.0		$	712.0		$	715.7		$	178.2
Specialty Generics and Amitiza	156.1			96.3			97.9			25.0
	$	852.1		$	808.3		$	813.6		$	203.2


(1)	Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.


(2)	Includes restructuring-related accelerated depreciation.


(3)	Represents costs incurred related to the separation of the Company’s Specialty Generics and Amitiza segment, which are included in selling, general and administrative expenses.


(4)	Depreciation for certain shared facilities is allocated based on occupancy percentage.

Net sales by product family within the Company's segments are as follows:



	Fiscal Year Ended						Three Months Ended
	December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016
H.P. Acthar Gel	$	1,110.1	$	1,195.1	$	1,160.4	$	325.4
Inomax	542.7		505.2		474.3		118.3
Ofirmev	341.9		302.5		284.3		72.5
Therakos	231.2		214.9		207.6		47.4
BioVectra	53.1		54.7		49.5		7.4
Other ⁽¹⁾	27.2		79.6		112.7		29.1
Specialty Brands	2,306.2		2,352.0		2,288.8		600.1

Hydrocodone (API) and hydrocodone-containing tablets	65.9		85.3		146.5		23.2
Oxycodone (API) and oxycodone-containing tablets ⁽¹⁾	66.1		88.0		139.9		27.2
Acetaminophen (API) ⁽¹⁾	192.7		185.5		169.1		40.8
Amitiza ⁽²⁾	183.8		—		—		—
Other controlled substances ⁽¹⁾	343.8		412.0		543.9		117.4
Other ^{(1), (3)}	57.1		98.8		92.6		21.2
Specialty Generics and Amitiza	909.4		869.6		1,092.0		229.8
Net Sales	$	3,215.6	$	3,221.6	$	3,380.8	$	829.9


(1)	Prior year amounts have been reclassified to conform to current year presentation.


(2)	Amitiza net sales consist of both product and royalty net sales. Refer to Note 5 for further details on Amitiza's revenues.


(3)	Includes net sales from an ongoing, post-divestiture supply agreement with the acquirer of the CMDS business. Amounts for periods prior to the divestiture represent the reclassification of intercompany sales to third-party sales to conform with the expected presentation of the ongoing supply agreement.

Selected information by geographic area excluding assets held-for-sale is as follows:



	Fiscal Year Ended						Three Months Ended
	December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016
Net sales ⁽¹⁾:
U.S.	$	2,834.5	$	2,899.0	$	3,095.4	$	763.7
Europe, Middle East and Africa	256.8		242.3		211.8		52.8
Other	124.3		80.3		73.6		13.4
	$	3,215.6	$	3,221.6	$	3,380.8	$	829.9

	Fiscal Year Ended
Long-lived assets ⁽²⁾:	December 28, 2018		December 29, 2017
U.S.	$	770.7	$	788.5
Europe, Middle East and Africa ⁽³⁾	146.7		127.0
Other	76.8		63.5
	$	994.2	$	979.0


(1)	Net sales are attributed to regions based on the location of the entity that records the transaction, none of which relate to the country of Ireland.


(2)	Long-lived assets are primarily composed of property, plant and equipment, net.

(3)

Includes long-lived assets located in Ireland of $145.2 million and $126.0 million as of December 28, 2018 and December 29, 2017, respectively.

Selected Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 28, 2018

Quarterly Financial Information Disclosure [Abstract]

Selected Quarterly Financial Data (Unaudited)



23.	Selected Quarterly Financial Data (Unaudited)

A summary of quarterly financial information for fiscal 2018 and 2017 is as follows:



	For the Quarter Ended ⁽¹⁾
	March 30, 2018			June 29, 2018			September 28, 2018			December 28, 2018
Net sales	$	755.3		$	825.5		$	799.9		$	834.9
Gross profit ⁽²⁾	347.5			394.0			366.4			363.3
(Loss) income from continuing operations ⁽³⁾	(20.9		)	3.2			114.2			(3,718.4		)
Income (loss) from discontinued operations	2.9			12.4			(0.4		)	—
Net (loss) income	(18.0		)	15.6			113.8			(3,718.4		)

Basic (loss) earnings per share from continuing operations⁽⁴⁾	$	(0.24	)	$	0.04		$	1.37		$	(44.64	)
Diluted (loss) earnings per share from continuing operations ⁽⁴⁾	(0.24		)	0.04			1.34			(44.64		)

	For the Quarter Ended
	March 31, 2017			June 30, 2017			September 29, 2017			December 29, 2017
Net sales	$	810.9		$	824.5		$	793.9		$	792.3
Gross profit ⁽²⁾	419.8			416.1			400.6			421.0
Income from continuing operations ⁽³⁾	28.9			70.6			64.3			1,607.4
Income (loss) from discontinued operations	370.3			(7.8		)	(0.6		)	1.3
Net income	399.2			62.8			63.7			1,608.7

Basic earnings per share from continuing operations⁽⁴⁾	$	0.28		$	0.72		$	0.66		$	17.43
Diluted earnings per share from continuing operations ⁽⁴⁾	0.28			0.72			0.66			17.40

(1)

The Specialty Generics Disposal Group was included within discontinued operations during the first three quarters of fiscal 2018, and has subsequently been recast to be included within continuing operations. In accordance with U.S. GAAP, depreciation and amortization are not recorded during the period in which a disposal group is classified as held-for-sale, thus the Company's financial results during the first three quarters of fiscal 2018 did not include $17.7 million and $6.8 million of depreciation and amortization expense, respectively, related to the Specialty Generics Disposal Group. During the fourth quarter of 2018, the Specialty Generics Disposal Group was reclassified to held and used and measured at its carrying amount before it was classified as held-for-sale, adjusted for depreciation and amortization expense that would have been recognized had the disposal group been continuously classified as held and used. The total adjustment of $24.5 million was reflected in loss from continuing operations during the fourth quarter of 2018, the period in which the held-for-sale criteria were no longer met.


(2)	Financial data for each period has been adjusted to reflect the change in accounting for pension and postretirement costs with the adoption of ASU 2017-07. See Note 4 for further information.


(3)	(Loss) income from continuing operations for the quarter ended December 28, 2018 reflects impairment charges for goodwill and an IPR&D asset. See Note 13 for further information. Income from continuing operations for the quarter ended December 29, 2017 reflects one-time effects for the completion of the reorganization of the Company's legal entity ownership and the impact of the TCJA.

(4)

Quarterly and annual computations are prepared independently. Therefore, the sum of each quarter may not necessarily total the fiscal period amounts noted elsewhere within this Annual Report on Form 10-K.

Condensed Consolidating and Combining Financial Statements

12 Months Ended

Dec. 28, 2018

Condensed Consolidating Financial Statements [Abstract]

Condensed Consolidating and Combining Financial Statements



24.	Condensed Consolidating Financial Statements

MIFSA is an indirectly 100%-owned subsidiary of Mallinckrodt plc established to own, directly or indirectly, substantially all of the operating subsidiaries of the Company, to issue debt securities and to perform treasury operations.

MIFSA is the borrower under the 2013 Notes, which are fully and unconditionally guaranteed by Mallinckrodt plc. The following information provides the composition of the Company's comprehensive income, assets, liabilities, equity and cash flows by relevant group within the Company: Mallinckrodt plc as guarantor of the 2013 Notes, MIFSA as issuer of the 2013 Notes and the operating companies that represent assets of MIFSA. There are no subsidiary guarantees related to the 2013 Notes.

Set forth below are the condensed consolidating balance sheets as of December 28, 2018 and December 29, 2017 and condensed consolidating statements of comprehensive income and cash flows for the fiscal three years ended December 28, 2018 and the three months ended December 30, 2016. Eliminations represent adjustments to eliminate investments in subsidiaries and intercompany balances and transactions between or among Mallinckrodt plc, MIFSA and the other subsidiaries. Condensed consolidating financial

information for Mallinckrodt plc and MIFSA, on a standalone basis, has been presented using the equity method of accounting for subsidiaries.

MALLINCKRODT PLC

CONDENSED CONSOLIDATING BALANCE SHEET

As of December 28, 2018

(in millions)



	Mallinckrodt plc		Mallinckrodt International Finance S.A.		Other Subsidiaries		Eliminations			Consolidated
Assets
Current Assets:
Cash and cash equivalents	$	0.4	$	140.8	$	207.7	$	—		$	348.9
Accounts receivable, net	—		—		623.3		—			623.3
Inventories	—		—		322.3		—			322.3
Prepaid expenses and other current assets	3.9		0.2		128.6		—			132.7
Notes receivable	—		—		—		—			—
Intercompany receivable	131.1		29.2		1,087.9		(1,248.2		)	—
Total current assets	135.4		170.2		2,369.8		(1,248.2		)	1,427.2
Property, plant and equipment, net	—		—		982.0		—			982.0
Goodwill	—		—		—		—			—
Intangible assets, net	—		—		8,282.8		—			8,282.8
Investment in subsidiaries	2,481.6		25,506.1		8,362.1		(36,349.8		)	—
Intercompany loan receivable	497.7		—		12,343.0		(12,840.7		)	—
Other assets	—		—		185.3		—			185.3
Total Assets	$	3,114.7	$	25,676.3	$	32,525.0	$	(50,438.7	)	$	10,877.3
										—
Liabilities and Shareholders' Equity
Current Liabilities:
Current maturities of long-term debt	$	—	$	22.1	$	0.3	$	—		$	22.4
Accounts payable	0.1		—		147.4		—			147.5
Accrued payroll and payroll-related costs	—		—		124.0		—			124.0
Accrued interest	—		48.7		28.9		—			77.6
Income taxes payable	—		—		25.0		—			25.0
Accrued and other current liabilities	0.6		0.4		546.2		—			547.2
Intercompany payable	226.7		827.8		193.7		(1,248.2		)	—
Total current liabilities	227.4		899.0		1,065.5		(1,248.2		)	943.7
Long-term debt	—		3,566.9		2,502.3		—			6,069.2
Pension and postretirement benefits	—		—		60.5		—			60.5
Environmental liabilities	—		—		59.7		—			59.7
Deferred income taxes	—		—		324.3		—			324.3
Other income tax liabilities	—		—		228.0		—			228.0
Intercompany loans payable	—		12,840.7		—		(12,840.7		)	—
Other liabilities	—		7.6		297.0		—			304.6
Total liabilities	227.4		17,314.2		4,537.3		(14,088.9		)	7,990.0
Shareholders' equity	2,887.3		8,362.1		27,987.7		(36,349.8		)	2,887.3
Total Liabilities and Shareholders' Equity	$	3,114.7	$	25,676.3	$	32,525.0	$	(50,438.7	)	$	10,877.3

MALLINCKRODT PLC

CONDENSED CONSOLIDATING BALANCE SHEET

As of December 29, 2017

(in millions)



	Mallinckrodt plc		Mallinckrodt International Finance S.A.		Other Subsidiaries		Eliminations			Consolidated
Assets
Current Assets:
Cash and cash equivalents	$	0.7	$	908.8	$	351.4	$	—		$	1,260.9
Accounts receivable, net	—		—		445.8		—			445.8
Inventories	—		—		340.4		—			340.4
Prepaid expenses and other current assets	1.0		0.2		82.9		—			84.1
Notes receivable	—		—		154.0		—			154.0
Intercompany receivable	70.0		173.4		831.4		(1,074.8		)	—
Total current assets	71.7		1,082.4		2,205.9		(1,074.8		)	2,285.2
Property, plant and equipment, net	—		—		966.8		—			966.8
Goodwill	—		—		3,482.7		—			3,482.7
Intangible assets, net	—		—		8,375.0		—			8,375.0
Investment in subsidiaries	6,551.6		23,217.8		12,356.2		(42,125.6		)	—
Intercompany loan receivable	593.1		—		4,664.8		(5,257.9		)	—
Other assets	—		—		171.2		—			171.2
Total Assets	$	7,216.4	$	24,300.2	$	32,222.6	$	(48,458.3	)	$	15,280.9

Liabilities and Shareholders' Equity
Current Liabilities:
Current maturities of long-term debt	$	—	$	313.5	$	0.2	$	—		$	313.7
Accounts payable	0.1		—		113.2		—			113.3
Accrued payroll and payroll-related costs	—		—		98.5		—			98.5
Accrued interest	—		53.0		4.0		—			57.0
Income taxes payable	—		—		15.8					15.8
Accrued and other current liabilities	0.8		0.4		450.9		—			452.1
Intercompany payable	693.5		104.6		276.7		(1,074.8		)	—
Total current liabilities	694.4		471.5		959.3		(1,074.8		)	1,050.4
Long-term debt	—		6,206.8		214.1		—			6,420.9
Pension and postretirement benefits	—		—		67.1		—			67.1
Environmental liabilities	—		—		73.2		—			73.2
Deferred income taxes	—		—		689.0		—			689.0
Other income tax liabilities	—		—		94.1		—			94.1
Intercompany loans payable	—		5,257.9		—		(5,257.9		)	—
Other liabilities	—		7.8		356.4		—			364.2
Total liabilities	694.4		11,944.0		2,453.2		(6,332.7		)	8,758.9
Shareholders' equity	6,522.0		12,356.2		29,769.4		(42,125.6		)	6,522.0
Total Liabilities and Shareholders' Equity	$	7,216.4	$	24,300.2	$	32,222.6	$	(48,458.3	)	$	15,280.9

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

Fiscal year ended December 28, 2018

(in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Net sales	$	—		$	—		$	3,215.6		$	—		$	3,215.6
Cost of sales	2.0			—			1,742.4			—			1,744.4
Gross (loss) profit	(2.0		)	—			1,473.2			—			1,471.2
Selling, general and administrative expenses	38.8			0.7			794.6			—			834.1
Research and development expenses	4.7			—			356.4			—			361.1
Restructuring charges, net	—			—			103.0			—			103.0
Non-restructuring impairment charges	—			—			3,893.1			—			3,893.1
Loss on divestiture	—			—			0.8			—			0.8
Operating loss	(45.5		)	(0.7		)	(3,674.7		)	—			(3,720.9		)

Interest expense	(7.8		)	(460.8		)	(63.4		)	161.8			(370.2		)
Interest income	9.5			2.5			158.0			(161.8		)	8.2
Other income, net	9.9			8.7			12.3			—			30.9
Intercompany interest and fees	(18.5		)	(0.1		)	18.6			—			—
Equity in net income of subsidiaries	(3,561.0		)	(2,726.0		)	(3,170.9		)	9,457.9			—
Loss from continuing operations before income taxes	(3,613.4		)	(3,176.4		)	(6,720.1		)	9,457.9			(4,052.0		)
Benefit from income taxes	(6.4		)	(5.4		)	(418.3		)	—			(430.1		)
Loss from continuing operations	(3,607.0		)	(3,171.0		)	(6,301.8		)	9,457.9			(3,621.9		)
Income from discontinued operations, net of income taxes	—			0.1			14.8			—			14.9
Net loss	(3,607.0		)	(3,170.9		)	(6,287.0		)	9,457.9			(3,607.0		)
Other comprehensive loss, net of tax	(9.9		)	(9.9		)	(20.5		)	30.4			(9.9		)
Comprehensive loss	$	(3,616.9	)	$	(3,180.8	)	$	(6,307.5	)	$	9,488.3		$	(3,616.9	)

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

Fiscal year ended December 29, 2017

(in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Net sales	$	—		$	—		$	3,221.6		$	—		$	3,221.6
Cost of sales	2.6			—			1,561.5			—			1,564.1
Gross (loss) profit	(2.6		)	—			1,660.1			—			1,657.5
Selling, general and administrative expenses	59.5			0.7			789.5			—			849.7
Research and development expenses	5.1			—			271.8			—			276.9
Restructuring charges, net	—			—			31.2			—			31.2
Non-restructuring impairments	—			—			63.7			—			63.7
Gains on divestiture	—			—			(56.9		)	—			(56.9		)
Operating (loss) income	(67.2		)	(0.7		)	560.8			—			492.9

Interest expense	(13.8		)	(353.9		)	(74.2		)	72.8			(369.1		)
Interest income	7.3			1.2			68.9			(72.8		)	4.6
Other income (expense), net	20.3			(1.7		)	(85.4		)	—			(66.8		)
Intercompany interest and fees	(18.3		)	—			18.3			—			—
Equity in net income of subsidiaries	2,200.0			2,901.8			2,549.9			(7,651.7		)	—
Income from continuing operations before income taxes	2,128.3			2,546.7			3,038.3			(7,651.7		)	61.6
Benefit from income taxes	(6.1		)	(5.3		)	(1,698.2		)	—			(1,709.6		)
Income from continuing operations	2,134.4			2,552.0			4,736.5			(7,651.7		)	1,771.2
(Loss) income from discontinued operations, net of income taxes	—			(2.1		)	365.3			—			363.2
Net income	2,134.4			2,549.9			5,101.8			(7,651.7		)	2,134.4
Other comprehensive income, net of tax	59.6			59.6			118.2			(177.8		)	59.6
Comprehensive income	$	2,194.0		$	2,609.5		$	5,220.0		$	(7,829.5	)	$	2,194.0

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

Fiscal year ended September 30, 2016

(in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Net sales	$	—		$	—		$	3,380.8		$	—		$	3,380.8
Cost of sales	—			—			1,523.2			—			1,523.2
Gross profit	—			—			1,857.6			—			1,857.6
Selling, general and administrative expenses	51.3			0.8			861.6			—			913.7
Research and development expenses	—			—			261.2			—			261.2
Restructuring charges, net	—			—			32.7			—			32.7
Non-restructuring impairments	—			—			16.9			—			16.9
Operating (loss) income	(51.3		)	(0.8		)	685.2			—			633.1

Interest expense	(230.3		)	(327.0		)	(82.4		)	255.1			(384.6		)
Interest income	—			0.5			255.9			(255.1		)	1.3
Other income (expense), net	90.0			1.7			(108.1		)	—			(16.4		)
Intercompany interest and fees	(16.1		)	—			16.1			—			—
Equity in net income of subsidiaries	820.8			1,327.2			1,057.9			(3,205.9		)	—
Income from continuing operations before income taxes	613.1			1,001.6			1,824.6			(3,205.9		)	233.4
Benefit from income taxes	(30.6		)	(18.1		)	(206.9		)	—			(255.6		)
Income from continuing operations	643.7			1,019.7			2,031.5			(3,205.9		)	489.0
Income from discontinued operations, net of income taxes	—			38.2			116.5			—			154.7
Net income	643.7			1,057.9			2,148.0			(3,205.9		)	643.7
Other comprehensive loss, net of tax	(86.5		)	(86.5		)	(173.5		)	260.0			(86.5		)
Comprehensive income	$	557.2		$	971.4		$	1,974.5		$	(2,945.9	)	$	557.2

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

Three months ended December 30, 2016

(in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Net sales	$	—		$	—		$	829.9		$	—		$	829.9
Cost of sales	—			—			383.2			—			383.2
Gross profit	—			—			446.7			—			446.7
Selling, general and administrative expenses	13.4			0.2			307.5			—			321.1
Research and development expenses	—			—			66.1			—			66.1
Restructuring charges, net	—			—			3.8			—			3.8
Non-restructuring impairments	—			—			214.3			—			214.3
Operating loss	(13.4		)	(0.2		)	(145.0		)	—			(158.6		)

Interest expense	(2.9		)	(81.1		)	(17.9		)	10.6			(91.3		)
Interest income	—			0.1			11.0			(10.6		)	0.5
Other income (expense), net	1.8			0.7			(51.6		)	—			(49.1		)
Intercompany interest and fees	(4.4		)	—			4.4			—			—
Equity in net income of subsidiaries	(136.5		)	35.2			(44.5		)	145.8			—
Loss from continuing operations before income taxes	(155.4		)	(45.3		)	(243.6		)	145.8			(298.5		)
Benefit from income taxes	(2.2		)	(0.3		)	(119.2		)	—			(121.7		)
Loss from continuing operations	(153.2		)	(45.0		)	(124.4		)	145.8			(176.8		)
Income from discontinued operations, net of income taxes	—			0.4			23.2			—			23.6
Net loss	(153.2		)	(44.6		)	(101.2		)	145.8			(153.2		)
Other comprehensive income, net of tax	13.1			13.1			26.0			(39.1		)	13.1
Comprehensive loss	$	(140.1	)	$	(31.5	)	$	(75.2	)	$	106.7		$	(140.1	)

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

Fiscal year ended December 28, 2018

(in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Cash Flows From Operating Activities:
Net cash from operating activities	$	438.9		$	80.1		$	1,702.5		$	(1,556.0	)	$	665.5
Cash Flows From Investing Activities:
Capital expenditures	—			—			(127.0		)	—			(127.0		)
Acquisitions, net of cash acquired	—			—			(699.9		)	—			(699.9		)
Proceeds from disposal of discontinued operations, net of cash	—			—			313.0			—			313.0
Intercompany loan investment	(385.6		)	(90.1		)	(502.0		)	977.7			—
Investment in subsidiary	—			(220.0		)	—			220.0			—
Proceeds from sale of subsidiary	—			—			—			—			—
Acquisition of subsidiary	—			—			—			—			—
Other	—			—			33.6			—			33.6
Net cash from investing activities	(385.6		)	(310.1		)	(982.3		)	1,197.7			(480.3		)
Cash Flows From Financing Activities:
Issuance of external debt	—			600.0			90.3			—			690.3
Repayment of external debt and capital leases	—			(1,289.4		)	(404.2		)	—			(1,693.6		)
Debt financing costs	—			(12.1		)	—			—			(12.1		)
Proceeds from exercise of share options	1.0			—			—			—			1.0
Intercompany loan borrowings	—			977.7			—			(977.7		)	—
Intercompany dividends	—			(814.2		)	(741.8		)	1,556.0			—
Capital contribution	—			—			220.0			(220.0		)	—
Repurchase of shares	(57.5		)	—			—			—			(57.5		)
Other	2.9			—			(26.0		)	—			(23.1		)
Net cash from financing activities	(53.6		)	(538.0		)	(861.7		)	358.3			(1,095.0		)
Effect of currency rate changes on cash	—			—			(1.8		)	—			(1.8		)
Net decrease in cash, cash equivalents and restricted cash	(0.3		)	(768.0		)	(143.3		)	—			(911.6		)
Cash, cash equivalents and restricted cash at beginning of period	0.7			908.8			369.6			—			1,279.1
Cash, cash equivalents and restricted cash at end of period	$	0.4		$	140.8		$	226.3		$	—		$	367.5

Cash and cash equivalents at end of period	$	0.4		$	140.8		$	207.7		$	—		$	348.9
Restricted cash included in prepaid expenses and other assets at end of period	—			—			—			—			—
Restricted cash included in other long-term assets at end of period	—			—			18.6			—			18.6
Cash, cash equivalents and restricted cash at end of period	$	0.4		$	140.8		$	226.3		$	—		$	367.5

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

Fiscal year ended December 29, 2017

(in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.				Other Subsidiaries				Eliminations			Consolidated
Cash Flows From Operating Activities:
Net cash from operating activities	$	1,233.2		$	1,139.4			$	2,274.9			$	(3,920.2	)	$	727.3
Cash Flows From Investing Activities:
Capital expenditures	—			—				(186.1		)		—			(186.1		)
Acquisitions, net of cash acquired	—			—				(76.3		)		—			(76.3		)
Proceeds from disposal of discontinued operations, net of cash	—			—				576.9				—			576.9
Intercompany loan investment	(589.5		)	—				(1,157.9		)		1,747.4			—
Investment in subsidiary	—			(1,475.3		)		—				1,475.3			—
Other	—			—				3.9				—			3.9
Net cash from investing activities	(589.5		)	(1,475.3		)		(839.5		)	—	3,222.7			318.4
Cash Flows From Financing Activities:
Issuance of external debt	—			1,400.0				65.0				—			1,465.0
Repayment of external debt and capital leases	—			(764.5		)		(152.7		)		—			(917.2		)
Debt financing costs	—			(12.7		)		—				—			(12.7		)
Proceeds from exercise of share options	4.1			—				—				—			4.1
Intercompany loan borrowings	—			1,747.4				—				(1,747.4		)	—
Intercompany dividends	—			(1,170.0		)		(2,750.2		)		3,920.2			—
Capital contribution	—			—				1,475.3				(1,475.3		)	—
Repurchase of shares	(651.7		)	—				—				—			(651.7		)
Other	4.1			—				(21.8		)		—			(17.7		)
Net cash from financing activities	(643.5		)	1,200.2			—	(1,384.4		)		697.5			(130.2		)
Effect of currency rate changes on cash	—			—				2.5				—			2.5
Net increase in cash, cash equivalents and restricted cash	0.2			864.3				53.5				—			918.0
Cash, cash equivalents and restricted cash at beginning of period	0.5			44.5				316.1				—			361.1
Cash, cash equivalents and restricted cash at end of period	$	0.7		$	908.8			$	369.6			$	—		$	1,279.1

Cash and cash equivalents at end of period	$	0.7		$	908.8			$	351.4			$	—		$	1,260.9
Restricted cash included in prepaid expenses and other assets at end of period	—			—				—				—			—
Restricted cash included in other long-term assets at end of period	—			—				18.2				—			18.2
Cash, cash equivalents and restricted cash at end of period	$	0.7		$	908.8			$	369.6			$	—		$	1,279.1

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

Fiscal year ended September 30, 2016

(in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.				Other Subsidiaries				Eliminations			Consolidated
Cash Flows From Operating Activities:
Net cash from operating activities	$	17.9		$	(47.4	)		$	1,214.1			$	—		$	1,184.6
Cash Flows From Investing Activities:
Capital expenditures	—			—				(182.9		)		—			(182.9		)
Acquisitions, net of cash acquired	—			—				(245.4		)		—			(245.4		)
Proceeds from disposal of discontinued operations, net of cash	—			234.0				32.7				—			266.7
Intercompany loan investment	—			(175.2		)		(1,714.5		)		1,889.7			—
Investment in subsidiary	—			(861.2		)		—				861.2			—
Proceeds from sale of subsidiary	3.4			—				—				(3.4		)	—
Acquisition of subsidiary	—			—				(3.4		)		3.4			—
Other	—			—				6.0				—			6.0
Net cash from investing activities	3.4			(802.4		)		(2,107.5		)	—	2,750.9			(155.6		)
Cash Flows From Financing Activities:
Issuance of external debt	—			—				98.3				—			98.3
Repayment of external debt and capital leases	—			(549.2		)		(19.4		)		—			(568.6		)
Debt financing costs	—			—				(0.1		)		—			(0.1		)
Proceeds from exercise of share options	14.0			—				—				—			14.0
Intercompany loan borrowings	617.8			1,271.9				—				(1,889.7		)	—
Capital contribution	—			—				861.2				(861.2		)	—
Repurchase of shares	(652.9		)	—				—				—			(652.9		)
Other	—			—				(53.0		)		—			(53.0		)
Net cash from financing activities	(21.1		)	722.7			—	887.0				(2,750.9		)	(1,162.3		)
Effect of currency rate changes on cash	—			—				0.3				—			0.3
Net increase (decrease) in cash, cash equivalents and restricted cash	0.2			(127.1		)		(6.1		)		—			(133.0		)
Cash, cash equivalents and restricted cash at beginning of period	0.1			152.1				280.4				—			432.6
Cash, cash equivalents and restricted cash at end of period	$	0.3		$	25.0			$	274.3			$	—		$	299.6

Cash and cash equivalents at end of period	$	0.3		$	25.0			$	255.2			$	—		$	280.5
Restricted cash included in prepaid expenses and other assets at end of period	—			—				0.1				—			0.1
Restricted cash included in other long-term assets at end of period	—			—				19.0				—			19.0
Cash, cash equivalents and restricted cash at end of period	$	0.3		$	25.0			$	274.3			$	—		$	299.6

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

Three months ended December 30, 2016

(in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.				Other Subsidiaries				Eliminations			Consolidated
Cash Flows From Operating Activities:
Net cash from operating activities	$	17.4		$	(94.0	)		$	272.2			$	—		$	195.6
Cash Flows From Investing Activities:
Capital expenditures	—			—				(65.2		)		—			(65.2		)
Acquisitions, net of cash acquired	—			—				(1.8		)		—			(1.8		)
Intercompany loan investment	—			—				(424.7		)		424.7			—
Subsidiary dividend proceeds	—			—				—				—			—
Investment in subsidiary	—			(260.0		)		—				260.0			—
Other	—			—				(10.2		)		—			(10.2		)
Net cash from activities	—			(260.0		)		(501.9		)	—	684.7			(77.2		)
Cash Flows From Financing Activities:
Issuance of external debt	—			175.0				15.0				—			190.0
Repayment of external debt and capital leases	—			(86.2		)		(0.5		)		—			(86.7		)
Debt financing costs	—			—				—				—			—
Proceeds from exercise of share options	0.4			—				—				—			0.4
Subsidiary dividend payment	—			—				—				—			—
Intercompany loan borrowings	140.0			284.7				—				(424.7		)	—
Capital contribution	—			—				260.0				(260.0		)	—
Repurchase of shares	(158.8		)	—				—				—			(158.8		)
Other	1.2			—				—				—			1.2
Net cash from financing activities	(17.2		)	373.5			—	274.5				(684.7		)	(53.9		)
Effect of currency rate changes on cash	—			—				(3.0		)		—			(3.0		)
Net increase in cash, cash equivalents and restricted cash	0.2			19.5				41.8				—			61.5
Cash, cash equivalents and restricted cash at beginning of period	0.3			25.0				274.3				—			299.6
Cash, cash equivalents and restricted cash at end of period	$	0.5		$	44.5			$	316.1			$	—		$	361.1

Cash and cash equivalents at end of period	$	0.5		$	44.5			$	297.0			$	—		$	342.0
Restricted cash included in prepaid expenses and other assets at end of period	—			—				0.1				—			0.1
Restricted cash included in other long-term assets at end of period	—			—				19.0				—			19.0
Cash, cash equivalents and restricted cash at end of period	$	0.5		$	44.5			$	316.1			$	—		$	361.1

Subsequent Events (Notes)

12 Months Ended

Dec. 28, 2018

Subsequent Event [Line Items]

Subsequent Events [Text Block]



25.	Subsequent Events

Reorganization of Intercompany Financing and Legal Entity Ownership

On January 26, 2019, the Company completed a reorganization of its intercompany financing and associated legal entity ownership in response to the changing global tax environment. The Company initiated the reorganization during the three months ended September 28, 2018 and continued the reorganization during the three months ended December 28, 2018.

During the three months ending March 29, 2019, the Company expects to recognize a net income tax benefit of $125.0 million to $175.0 million which will serve to reduce its net deferred tax liabilities by a similar amount. The reduction to net deferred tax liabilities is expected to be comprised predominantly of the elimination of the December 28, 2018 balance of interest-bearing U.S. deferred tax liabilities of $227.5 million offset by a decrease to other deferred tax assets. The elimination of the interest-bearing deferred tax obligation will also eliminate the annual Internal Revenue Code section 453A interest expense.

During fiscal 2018, the Company recognized current income tax expense of $25.5 million and a deferred income tax benefit of $281.5 million with a corresponding reduction to net deferred tax liabilities. See Note 9 for further details regarding the fiscal 2018 impact.

Financing Activities

On December 31, 2018, the Company made a $25.0 million voluntary prepayment on its outstanding term loan due September 2024 and $5.6 million of quarterly principal amortization payments on its outstanding term loans.

On February 14, 2019, the Company made a $175.0 million voluntary prepayment on its outstanding term loan due February 2025.

Subsequent to fiscal 2018 and up through the date of this filing, the Company repurchased fixed-rate debt that aggregated to a principal amount of $75.0 million.

Commitments and Contingencies

Certain litigation matters occurred in fiscal 2018 or prior, but had subsequent updates through the date of this report. See further discussion in Note 20 to the consolidated financial statements.

Schedule II - Valuation and Qualifying Accounts (Notes)

12 Months Ended

Dec. 28, 2018

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

Schedule II - Valuation and Qualifying Accounts

Financial Statement Schedules. The financial statement schedule is included below. All other schedules have been omitted because they are not applicable, not required or the information is included in the financial statements or notes thereto.



Schedule II - Valuation and Qualifying Accounts
(in millions)
Description	Balance at Beginning of Period		Charged to Income		Additions and Other		Deductions			Balance at End of Period
Allowance for doubtful accounts:
Fiscal year ended December 28, 2018	$	3.9	$	3.8	$	—	$	(2.7	)	$	5.0
Fiscal year ended December 29, 2017	4.0		0.6		—		(0.7		)	3.9
Three months ended December 30, 2016	4.0		0.1		—		(0.1		)	4.0
Fiscal year ended September 30, 2016	3.6		0.3		—		0.1			4.0
Sales reserve accounts:
Fiscal year ended December 28, 2018	$	376.6	$	2,387.5	$	—	$	(2,358.7	)	$	405.4
Fiscal year ended December 29, 2017	391.3		2,008.5		—		(2,023.2		)	376.6
Three months ended December 30, 2016	378.0		515.3		—		(502.0		)	391.3
Fiscal year ended September 30, 2016	396.4		2,030.8		—		(2,049.2		)	378.0
Tax valuation allowance:
Fiscal year ended December 28, 2018	$	2,267.9	$	332.8	$	4.2	$	—		$	2,604.9
Fiscal year ended December 29, 2017	1,398.3		804.6		4.0		61.0			2,267.9
Three months ended December 30, 2016	564.9		833.4		—		—			1,398.3
Fiscal year ended September 30, 2016	233.0		315.7		15.8		0.4			564.9

Background and Basis of Presentation (Policies)	12 Months Ended
Background and Basis of Presentation (Policies)	Dec. 28, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Accounting	The consolidated financial statements have been prepared in U.S. dollars and in accordance with accounting principles generally accepted in the U.S. ("GAAP").
Use of Estimates	The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses. Actual results may differ from those estimates.
Consolidation	The consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries and entities in which they own or control more than 50% of the voting shares, or have the ability to control through similar rights. All intercompany balances and transactions have been eliminated in consolidation and all normal recurring adjustments necessary for a fair presentation have been included in the results reported.
Fiscal Period	Fiscal YearThe Company reports its results based on a "52-53 week" year ending on the last Friday of December. Fiscal 2018 and 2017 each consisted of 52 weeks and fiscal 2016 consisted of 53 weeks. On May 17, 2016, the Board of Directors of the Company approved a change in the Company’s fiscal year end to the last Friday in December from the last Friday in September. The change in fiscal year became effective for the Company’s 2017 fiscal year, which began on December 31, 2016 and ended on December 29, 2017. As a result of the change in fiscal year end, the Company filed a Transition Report on Form 10-Q on February 7, 2017 covering the period from October 1, 2016 through December 30, 2016 ("the three months ended December 30, 2016") with the comparable period from September 26, 2015 through December 25, 2015. Fiscal 2016 covers the period from September 26, 2015 through September 30, 2016.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 28, 2018

Accounting Policies [Abstract]

Revenue Recognition

Product Sales Revenue

Reserve for Variable Considerations


•	For those contracts whereby revenue is recognized over time based upon consumption of the product, the Company either has:


1.	the right to invoice the customer in an amount that directly corresponds with the value to the customer of the Company's performance to date, for which the practical expedient to recognize in proportion to the amount it has the right to invoice has been applied, or


2.	the remaining goods and services to which the customer is entitled is diminished upon consumption.

•

Transaction price allocated to the remaining performance obligations

Cost to obtain a contract

Costs to fulfill a contract

Product Royalty Revenues

Contract Balances

Shipping and Handling Costs

Shipping and Handling CostsShipping costs, which are costs incurred to physically move product from the Company's premises to the customer's premises, are classified as SG&A. Handling costs, which are costs incurred to store, move and prepare product for shipment, are classified as cost of sales.

Research and Development

Currency Translation



	Fiscal Year Ended									Three Months Ended
	December 28, 2018			December 29, 2017			September 30, 2016			December 30, 2016
Foreign currency (losses), gains	$	(3.1	)	$	2.5		$	(3.6	)	$	9.0
Derivative hedge gains (losses)	2.7			(4.1		)	0.2			(8.9		)

Cash and Cash Equivalents

Cash and Cash EquivalentsThe Company classifies cash on hand and deposits in banks, including commercial paper, money market accounts and other investments it may hold from time to time, with an original maturity to the Company of three months or less, as cash and cash equivalents.

Accounts Receivable and Allowance for Doubtful Accounts

Inventories

InventoriesInventories are recorded at the lower of cost or net realizable value, primarily using the first-in, first-out convention. The Company reduces the carrying value of inventories for those items that are potentially excess, obsolete or slow-moving based on changes in customer demand, technology developments or other economic factors.

Property, Plant and Equipment



Buildings	10	to	45 years
Leasehold improvements	1	to	20 years
Capitalized software	1	to	10 years
Machinery and equipment	1	to	20 years

The Company capitalizes certain computer software and development costs incurred in connection with developing or obtaining software for internal use.

Acquisitions

discount rate used includes a rate of return which accounts for the time value of money, as well as risk factors that reflect the economic risk that the cash flows projected may not be realized.

Goodwill and Other Intangible Assets



Completed technology	5	to	25 years
License agreements	7	to	30 years
Trademarks	13	to	30 years
Customer relationships			12 years

Contingencies

ContingenciesThe Company is subject to various patent infringement claims, product liability matters, government investigations, environmental matters, employee disputes, contractual disputes and other commercial disputes, and other legal proceedings in the ordinary course of business as further discussed in Note 20. The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. The Company discounts environmental liabilities using a risk-free rate of return when the obligation is fixed or reasonably determinable. The impact of the discount in the consolidated balance sheets was not material in any period presented. Legal fees, other than those pertaining to environmental and asbestos matters, are expensed as incurred. Insurance recoveries related to potential claims are recognized up to the amount of the recorded liability when coverage is confirmed and the estimated recoveries are probable of payment. Assets and liabilities are not netted for financial statement presentation.

Share-Based Compensation

Share-Based CompensationThe Company recognizes the cost of employee services received in exchange for awards of equity instruments based on the grant-date fair value of those awards. That cost is recognized over the period during which an employee is required to provide service in exchange for the award, the requisite service period (generally the vesting period).

Restructuring

RestructuringThe Company recognizes charges associated with board approved restructuring programs designed to transform its business and improve its cost structure. Restructuring charges can include severance costs, infrastructure charges, distributor contract cancellations and other items. The Company accrues for costs when they are probable and reasonably estimable.

Income Taxes

Earnings (Loss) per Share (Policies)	12 Months Ended
Earnings (Loss) per Share (Policies)	Dec. 28, 2018
Earnings (Loss) per Share [Abstract]
Earnings (Loss) Per Share Policy	Basic (loss) earnings per share is computed by dividing net (loss) income by the number of weighted-average shares outstanding during the period. Diluted (loss) earnings per share was computed using the weighted-average shares outstanding and, if dilutive, potential ordinary shares outstanding during the period. Potential ordinary shares represent the incremental ordinary shares issuable for restricted share units and share option exercises. The Company calculated the dilutive effect of outstanding restricted share units and share options on (loss) earnings per share by application of the treasury stock method.Dilutive securities, including participating securities, are not included in the computation of loss per share when the Company reports a net loss from continuing operations as the impact would be anti-dilutive.

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 28, 2018

Accounting Policies [Abstract]

Schedule of Useful Lives for Property, Plant and Equipment

Property, Plant and Equipment



Buildings	10	to	45 years
Leasehold improvements	1	to	20 years
Capitalized software	1	to	10 years
Machinery and equipment	1	to	20 years

The Company capitalizes certain computer software and development costs incurred in connection with developing or obtaining software for internal use.

Schedule of Useful Lives for Finite Lived Intangible Assets

Intangible assets with finite useful lives are subsequently amortized, generally using the straight-line method, over the following estimated useful lives of the assets, except for customer relationships which are amortized over the estimated pattern of benefit from these relationships:



Completed technology	5	to	25 years
License agreements	7	to	30 years
Trademarks	13	to	30 years
Customer relationships			12 years

Foreign Currency Transactions and Translations [Table Text Block]

The Company recognized the following during the respective periods:



	Fiscal Year Ended									Three Months Ended
	December 28, 2018			December 29, 2017			September 30, 2016			December 30, 2016
Foreign currency (losses), gains	$	(3.1	)	$	2.5		$	(3.6	)	$	9.0
Derivative hedge gains (losses)	2.7			(4.1		)	0.2			(8.9		)

Shipping and Handling Cost

Shipping costs included in SG&A expenses in continuing operations were as follows:



	Fiscal Year Ended						Three Months Ended
	December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016
Shipping and handling costs	$	12.8	$	13.9	$	12.4	$	3.4

Recently Issued Accounting Standards Recently Issued Accounting Standards (Tables)

12 Months Ended

Dec. 28, 2018

Prior Period Reclassification Amounts [Abstract]

Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]

The Company adopted this guidance in fiscal 2018 which required retroactive application resulting in the reclassification of the following:



	Fiscal Year Ended				Three Months Ended
	December 29, 2017		September 30, 2016		December 30, 2016
Cost of sales	$	1.2	$	2.6	$	0.9
Selling, general and administrative expenses	71.2		11.6		47.2
Research and development expenses	0.4		1.0		0.1
Restructuring charges, net	—		0.6		—
Other income (expense), net	$	72.8	$	15.8	$	48.2

Revenue from Contracts with Customers (Tables)

12 Months Ended

Dec. 28, 2018

Revenue from Contract with Customer [Abstract]

Sales Reserves Rollforward [Table Text Block]

The following table reflects activity in the Company’s sales reserve accounts:



	Rebates and Chargebacks			Product Returns			Other Sales Deductions			Total
Balance as of December 29, 2017	$	327.4		$	34.5		$	14.7		$	376.6
Provisions	2,281.3			39.3			66.9			2,387.5
Payments or credits	(2,254.4		)	(39.8		)	(64.5		)	(2,358.7		)
Balance as of December 28, 2018	$	354.3		$	34.0		$	17.1		$	405.4

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]

Transaction price allocated to the remaining performance obligations



Fiscal 2019	$	145.0
Fiscal 2020	127.3
Fiscal 2021	32.6
Thereafter	3.2

Contract with Customer, Asset and Liability [Table Text Block]

The following table reflects the balance of the Company's contract liabilities at the end of the respective periods:



	December 28, 2018		December 29, 2017
Accrued and other current liabilities	$	20.4	$	14.0
Other liabilities	15.1		6.6
Contract liabilities	$	35.5	$	20.6

Discontinued Operations and Divestitures (Tables)

12 Months Ended

Dec. 28, 2018

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Schedule of Income (Loss) from Discontinued Operations

The following table summarizes the financial results of the CMDS business for fiscal 2016 as presented in the consolidated statement of income:



	Fiscal Year Ended
Major line items constituting (loss) income from discontinued operations	September 30, 2016
Net sales	$	61.0
Cost of sales	46.9
Selling, general and administrative	20.3
Other	1.2
Loss from discontinued operations	(7.4		)
Gain on disposal of discontinued operations	95.3
Income from discontinued operations, before income taxes	87.9
Income tax benefit	(2.5		)
Income from discontinued operations net of tax	$	90.4

The following table summarizes the financial results of the Nuclear Imaging business for respective periods as presented in the consolidated statements of income:



	Fiscal Year Ended					Three Months Ended
Major line items constituting income from discontinued operations	December 29, 2017			September 30, 2016		December 30, 2016
Net sales	$	31.6		$	418.6	$	99.4
Cost of sales	15.6			216.6		44.7
Selling, general and administrative	7.8			83.7		16.4
Restructuring charges, net	—			2.3		—
Other	(0.2		)	5.7		0.2
Income from discontinued operations	8.4			110.3		38.1
Gain on disposal of discontinued operations	362.8			—		—
Income from discontinued operations, before income taxes	371.2			110.3		38.1
Income tax expense	5.2			49.0		15.3
Income from discontinued operations, net of tax	$	366.0		$	61.3	$	22.8

Schedule of Assets and Liabilities Held-For-Sale

Schedule of Significant Cash and Non-Cash Transactions



	Fiscal Year Ended				Three Months Ended
	December 29, 2017		September 30, 2016		December 30, 2016
Depreciation	$	—	$	20.9	$	—
Capital expenditures	0.3		9.7		2.0

Schedule of Fair Value of Identifiable Assets Acquired and Liabilities Assumed

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Acquisitions and License Agreements (Tables)

12 Months Ended

Dec. 28, 2018

Business Combinations [Abstract]

The following amounts represent the allocation of the fair value of the identifiable assets acquired and liabilities assumed for the respective acquisitions:



	Sucampo		Ocera ⁽¹⁾		InfaCare ⁽²⁾		Stratatech		Hemostasis ⁽³⁾
Acquisition Date	February 2018		December 2017		September 2017		August 2016		February 2016
Cash	$	149.6	$	1.0	$	1.3	$	0.2	$	3.3
Accounts receivable	35.7		—		—		1.3		—
Inventory	153.2		—		—		—		94.6
Intangible assets	919.5		64.5		113.5		99.8		132.7
Goodwill (non-tax deductible) ⁽⁴⁾	248.6		18.0		11.4		55.1		3.3
Other assets, current and non-current	25.8		0.4		0.1		1.9		7.9
Total assets acquired	1,532.4		83.9		126.3		158.3		241.8
Current liabilities	109.4		12.0		14.5		4.3		3.6
Other liabilities (non-current)	33.3		—		—		—		10.6
Deferred tax liabilities, net (non-current)	175.8		16.7		8.7		22.1		2.1
Contingent consideration (non-current)	—		12.8		35.0		54.9		52.0
Debt	366.3		—		30.0		1.0		—
Total liabilities assumed	684.8		41.5		88.2		82.3		68.3
Net assets acquired	$	847.6	$	42.4	$	38.1	$	76.0	$	173.5


(1)	Of the $42.4 million net assets acquired for Ocera, $40.5 million and $1.9 million was paid in fiscal 2017 and 2018, respectively.


(2)	During fiscal 2018, the Company reduced the contingent consideration liability related to this acquisition to zero through the recognition of a $35.0 million fair value adjustment. Refer to Note 21 for further information.


(3)	During fiscal 2017, the Company recorded a non-restructuring impairment charge relating to its Raplixa intangible asset and reduced the associated contingent consideration liability. During fiscal 2018, the Company sold its Recothrom and PreveLeak assets to Baxter. Refer to Notes 6, 13 and 21, respectively, for further information.


(4)	Refer to Note 13 for further information relating to the full goodwill impairment recorded in fiscal 2018.

^[1],[2]

Schedule of Reconciliation of Total Consideration

The following reconciles the total consideration to net assets acquired:



	Sucampo		Ocera ⁽¹⁾			InfaCare			Stratatech			Hemostasis
Total consideration, net of cash	$	698.0	$	63.4		$	71.8		$	130.7		$	222.2
Plus: cash assumed in acquisition	149.6		1.0			1.3			0.2			3.3
Total consideration	847.6		64.4			73.1			130.9			225.5
Less: non-cash contingent consideration	—		(22.0		)	(35.0		)	(54.9		)	(52.0		)
Net assets acquired	$	847.6	$	42.4		$	38.1		$	76.0		$	173.5


(1)	$1.9 million of the total consideration, net of cash was paid in fiscal 2018, subsequent to the Company's December 11, 2017 acquisition date.

Schedule of Acquisition Cost

Acquisition-Related Costs - Acquisition-related costs incurred for each of the acquisitions discussed above were as follows:



	Fiscal Year Ended						Three Months Ended
Acquisition-related costs	December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016
Sucampo	$	5.2	$	4.2	$	—	$	—
Ocera	0.5		0.9		—		—
InfaCare	—		1.2		—		—
Stratatech	—		—		3.7		—
Hemostasis	—		—		2.7		0.1
Other	0.1		0.1		0.5		—
Total acquisition-related costs	$	5.8	$	6.4	$	6.9	$	0.1

Schedule of Intangible Assets Acquired

Intangible assets acquired consist of the following:



Acquisition	Intangible Asset Acquired	Amount		Amortization Period	Discount Rate		Segment
Sucampo	Completed technology - Amitiza	$	634.0	9 years	14.0	%	Specialty Generics and Amitiza
Sucampo	Completed technology - Other	11.0		8 years	14.0	%	Specialty Generics and Amitiza
Sucampo	In-process research and development - VTS-270	274.5		Non-Amortizable	15.0	%	Specialty Brands
Ocera	In-process research and development - MNK-6105/6106	64.5		Non-Amortizable	15.5	%	Specialty Brands
InfaCare	In-process research and development - stannsoporfin	113.5		Non-Amortizable	13.5	%	Specialty Brands
Stratatech	In-process research and development - StrataGraft	99.8		Non-Amortizable	16.5	%	Specialty Brands
Hemostasis	Completed technology - Raplixa ⁽¹⁾	73.0		15 years	17.0	%	Specialty Brands
Hemostasis	Completed technology - Recothrom ⁽²⁾	42.7		13 years	16.0	%	Specialty Brands
Hemostasis	Completed technology - PreveLeak ⁽²⁾	17.0		13 years	17.0	%	Specialty Brands


(1)	During fiscal 2017, the Company recorded a non-restructuring impairment charge relating to the Raplixa intangible asset. Refer to Note 13 for further information.


(2)	During fiscal 2018, the Company sold the Recothrom and PreveLeak assets to Baxter. Refer to Note 6 for further information.

^[3]

[1]	(1) Of the $42.4 million net assets acquired for Ocera, $40.5 million and $1.9 million was paid in fiscal 2017 and 2018, respectively.
[2]	During fiscal 2018, the Company reduced the contingent consideration liability related to this acquisition to zero through the recognition of a $35.0 million fair value adjustment. Refer to Note 21 for further information.
[3]	(1)During fiscal 2017, the Company recorded a non-restructuring impairment charge relating to the Raplixa intangible asset. Refer to Note 13 for further information.

Restructuring and Related Charges (Tables)

12 Months Ended

Dec. 28, 2018

Restructuring and Related Activities [Abstract]

Schedule of Restructuring and Related Charges by Segment

Net restructuring and related charges by segment from continuing operations are as follows:



	Fiscal Year Ended									Three Months Ended
	December 28, 2018			December 29, 2017			September 30, 2016			December 30, 2016
Specialty Brands	$	52.2		$	25.4		$	23.3		$	2.6
Specialty Generics and Amitiza	29.0			7.7			3.4			0.8
Corporate	27.0			3.3			10.9			1.9
Restructuring and related charges, net	108.2			36.4			37.6			5.3
Less: accelerated depreciation	(5.2		)	(5.2		)	(4.9		)	(1.5		)
Restructuring charges, net	$	103.0		$	31.2		$	32.7		$	3.8

Charges in other income (expense) ⁽¹⁾	$	—		$	—		$	0.6		$	—

(1) Charges incurred under restructuring programs related to pension that were reclassified to other income (expense), net due to the adoption of ASU 2017-07.

Schedule of Net Restructuring and Related Charges

Net restructuring and related charges by program from continuing operations are comprised of the following:



	Fiscal Year Ended									Three Months Ended
	December 28, 2018			December 29, 2017			September 30, 2016			December 30, 2016
2018 Mallinckrodt Program	$	5.2		$	—		$	—		$	—
2016 Mallinckrodt Program	71.6			36.2			8.3			5.2
2013 Mallinckrodt Program	—			(0.7		)	25.6			—
Acquisition programs	31.4			0.9			3.7			0.1
Total programs	108.2			36.4			37.6			5.3
Less: non-cash charges, including accelerated depreciation and impairments	(5.2		)	(5.2		)	(4.9		)	(1.5		)
Total charges expected to be settled in cash	$	103.0		$	31.2		$	32.7		$	3.8

Charges in other income (expense) ⁽¹⁾	$	—		$	—		$	0.6		$	—

(1) Charges incurred under restructuring programs related to pension that were reclassified to other income (expense) due to the adoption of ASU 2017-07.

Schedule of Restructuring Reserves by Type of Cost



	2018 Mallinckrodt Program		2016 Mallinckrodt Program			2013 Mallinckrodt Program			Acquisition Programs			Total
Balance at September 25, 2015	$	—	$	—		$	8.0		$	10.0		$	18.0
Charges from continuing operations	—		6.4			24.0			5.0			35.4
Charges from discontinued operations	—		—			2.5			—			2.5
Changes in estimate from continuing operations	—		—			(1.4		)	(1.3		)	(2.7		)
Changes in estimate from discontinued operations	—		—			(0.3		)	—			(0.3		)
Cash payments	—		(0.2		)	(20.3		)	(13.2		)	(33.7		)
Reclassifications ⁽¹⁾	—		—			(0.7		)	—			(0.7		)
Balance at September 30, 2016	—		6.2			11.8			0.5			18.5
Charges from continuing operations	—		3.7			—			0.1			3.8
Cash payments	—		(0.4		)	(6.7		)	(0.4		)	(7.5		)
Balance at December 30, 2016	—		9.5			5.1			0.2			14.8
Charges from continuing operations	—		35.8			—			0.9			36.7
Changes in estimate from continuing operations	—		(4.8		)	(0.7		)	—			(5.5		)
Cash payments	—		(26.1		)	(4.4		)	(0.3		)	(30.8		)
Reclassifications	—		0.3			—			—			0.3
Balance at December 29, 2017	—		14.7			—			0.8			15.5
Charges from continuing operations	2.2		76.9			—			29.9			109.0
Changes in estimate from continuing operations	—		(5.3		)	—			(0.7		)	(6.0		)
Cash payments	—		(23.4		)	—			(22.2		)	(45.6		)
Reclassifications	—		(1.9		)	—			—			(1.9		)
Balance at December 28, 2018	$	2.2	$	61.0		$	—		$	7.8		$	71.0

(1)

Represents the reclassification of pension and other postretirement benefits from restructuring reserves to pension and postretirement obligations.

^[1]

Schedule of Restructuring Charges Incurred Cumulative to Date

Net restructuring and related charges, including associated asset impairments, incurred cumulative to date related to the 2018, 2016 and 2013 Mallinckrodt Programs are as follows:



	2018 Mallinckrodt Program		2016 Mallinckrodt Program		2013 Mallinckrodt Program
Specialty Brands	$	3.0	$	81.7	$	18.8
Specialty Generics and Amitiza	—		14.6		18.3
Discontinued Operations	—		—		69.9
Corporate	2.2		25.9		17.7
	$	5.2	$	122.2	$	124.7

[1]	Represents the reclassification of pension and other postretirement benefits from restructuring reserves to pension and postretirement obligations.

Income Taxes (Tables)

12 Months Ended

Dec. 28, 2018

Income Tax Disclosure [Abstract]

Schedule of Components of Income from Continuing Operations before Income Taxes

The U.K. and non-U.K. components of (loss) income from continuing operations before income taxes were as follows:



	Fiscal Year Ended									Three Months Ended
	December 28, 2018			December 29, 2017			September 30, 2016			December 30, 2016
U.K.	$	(233.7	)	$	(165.9	)	$	(275.3	)	$	(97.4	)
Non-U.K.	(3,818.3		)	227.5			508.7			(201.1		)
Total	$	(4,052.0	)	$	61.6		$	233.4		$	(298.5	)

Schedule of Significant Components of Income Taxes Related to Continuing Operations

Significant components of income taxes related to continuing operations are as follows:



	Fiscal Year Ended									Three Months Ended
	December 28, 2018			December 29, 2017			September 30, 2016			December 30, 2016
Current:
U.K.	$	(0.2	)	$	0.4		$	0.3		$	—
Non-U.K.	113.0			37.7			120.5			82.0
Current income tax provision	112.8			38.1			120.8			82.0
Deferred:
U.K.	1.4			0.6			0.7			(0.5		)
Non-U.K.	(544.3		)	(1,748.3		)	(377.1		)	(203.2		)
Deferred income tax benefit	(542.9		)	(1,747.7		)	(376.4		)	(203.7		)
Total	$	(430.1	)	$	(1,709.6	)	$	(255.6	)	$	(121.7	)

Schedule of Reconciliation of Income Taxes at Statutory Rate and Tax Provision

The reconciliation between U.K. income taxes at the statutory rate and the Company's provision for income taxes on continuing operations is as follows:



	Fiscal Year Ended									Three Months Ended
	December 28, 2018			December 29, 2017			September 30, 2016			December 30, 2016
(Benefit) provision for income taxes at U.K. statutory income tax rate ⁽¹⁾	$	(770.1	)	$	11.7		$	46.6		$	(59.7	)
Adjustments to reconcile to income tax provision:
Rate difference between U.K. and non-U.K. jurisdictions ^{(2) (4)}	(235.7		)	(219.9		)	(249.3		)	(123.0		)
Valuation allowances, nonrecurring	—			(3.7		)	2.1			—
Adjustments to accrued income tax liabilities and uncertain tax positions	60.1			5.1			(14.9		)	0.9
Interest and penalties on accrued income tax liabilities and uncertain tax positions	13.1			0.2			(16.4		)	(0.1		)
Investment in partnership	—			—			—			(12.7		)
Credits, principally research and orphan drug ⁽³⁾	(25.9		)	(13.8		)	(33.7		)	(0.7		)
Impairments non deductible	788.7			—			—			75.3
Permanently nondeductible and nontaxable items	7.2			6.4			7.9			1.6
Pension plan settlement, release of tax effects lodged in other comprehensive income	—			(2.4		)	—			—
Divestitures ⁽⁷⁾	(2.7		)	18.2			—			—
U.S. Tax Reform ⁽⁵⁾	(8.5		)	(456.9		)	—			—
Legal Entity Reorganization ⁽⁶⁾	(256.0		)	(1,054.8		)	—			—
Other	(0.3		)	0.3			2.1			(3.3		)
Benefit for income taxes	$	(430.1	)	$	(1,709.6	)	$	(255.6	)	$	(121.7	)


(1)	The statutory tax rate reflects the U.K. statutory tax rate of 19% for fiscal 2018 and 2017 and 20% for fiscal 2016 and the three months ended December 30, 2016.


(2)	Includes the impact of certain recurring valuation allowances for U.K. and non-U.K. jurisdictions.


(3)	During fiscal 2018, the research and orphan drug credits increased in conjunction with the Company's increased investment in qualified research. During fiscal 2016, the Company realized a tax benefit of $27.4 million resulting from a U.K. tax credit on a dividend between affiliates.


(4)	During the three months ended December 30, 2016, the rate difference between U.K. and non-U.K. jurisdictions was favorably impacted by a benefit of $16.1 million on a $102.0 million settlement with the Federal Trade Commission and a benefit of $34.5 million on a $207.0 million goodwill impairment in the Specialty Generics reporting unit.

(5)


(6)	Associated unrecognized tax benefit netted within this line.

(7)

During fiscal 2018, the Company completed the sale of a portion of its Hemostasis business. During fiscal 2017, the Company completed the sale of the Intrathecal Therapy Business.

^{[1],[2],[3],[4],[5]}

Schedule of Unrecognized Tax Benefit Activity

The following table summarizes the activity related to the Company's unrecognized tax benefits, excluding interest:



	Fiscal Year Ended									Three Months Ended
	December 28, 2018			December 29, 2017			September 30, 2016			December 30, 2016
Balance at beginning of period	$	182.5		$	118.7		$	89.2		$	114.8
Additions related to current year tax positions	19.6			79.9			63.8			5.0
Additions related to prior period tax positions	125.1			0.3			10.8			—
Reductions related to prior period tax positions	(32.7		)	(13.6		)	(37.8		)	(1.1		)
Reductions related to disposition transactions	—			—			(6.6		)	—
Settlements	(2.0		)	—			(2.6		)	—
Lapse of statute of limitations	(4.8		)	(2.8		)	(2.0		)	—
Balance at end of period	$	287.7		$	182.5		$	114.8		$	118.7

Schedule of Unrecongized Tax Benefits Balance Sheet Location

Unrecognized tax benefits, excluding interest, are reported in the following consolidated balance sheet captions in the amounts shown:



	December 28, 2018		December 29, 2017
Accrued and other current liabilities	$	1.0	$	1.5
Other income tax liabilities	189.9		82.6
Deferred income taxes (non-current liability)	96.8		98.4
	$	287.7	$	182.5

Schedule of Income Taxes Payable

Income taxes payable, including uncertain tax positions and related interest accruals, is reported in the following consolidated balance sheet captions in the amounts shown:



	December 28, 2018		December 29, 2017
Income taxes payable	$	25.0	$	15.8
Other income tax liabilities	228.0		94.1
	$	253.0	$	109.9

Schedule of Income Tax Receivables and Other Assets



	December 28, 2018		December 29, 2017
Other assets	$	3.0	$	—
Prepaid expenses and other current assets	16.2		6.1
	$	19.2	$	6.1

Schedule of Deferred Taxes Activity

The components of the net deferred tax (liability) asset at the end of each fiscal year were as follows:



	December 28, 2018			December 29, 2017
Deferred tax assets:
Accrued liabilities and reserves	$	56.3		$	62.7
Tax loss and credit carryforwards	1,987.8			1,734.5
Intangible assets	757.7			575.1
Other	204.6			113.3
	3,006.4			2,485.6
Deferred tax liabilities:
Intangible assets	(264.7		)	(181.0		)
Interest-bearing deferred tax obligations	(227.5		)	(553.5		)
Investment in partnership	(170.2		)	(108.8		)
Other	(42.9		)	(47.0		)
	(705.3		)	(890.3		)
Net deferred tax asset before valuation allowances	2,301.1			1,595.3
Valuation allowances	(2,604.9		)	(2,267.9		)
Net deferred tax liability	$	(303.8	)	$	(672.6	)

Schedule of Deferred Taxes Balance Sheet Location

Deferred taxes are reported in the following consolidated balance sheet captions in the amounts shown:



	December 28, 2018			December 29, 2017
Other assets	$	20.5		$	16.4
Deferred income taxes (non-current liability)	(324.3		)	(689.0		)
Net deferred tax liability	$	(303.8	)	$	(672.6	)

[1]	Associated unrecognized tax benefit netted within this line.
[2]	During the three months ended December 30, 2016, the rate difference between U.K. and non-U.K. jurisdictions was favorably impacted by a benefit of $16.1 million on a $102.0 million settlement with the Federal Trade Commission and a benefit of $34.5 million on a $207.0 million goodwill impairment in the Specialty Generics reporting unit.
[3]	For fiscal 2018, the Company completed its analysis of the TCJA and recognized an additional tax benefit. Other line items, to the extent U.S. related, are reflected at the current U.S. statutory income tax rate of 21%. For fiscal 2017, the benefit reflects the redetermination of the Company’s end of year net deferred tax liabilities as a result of the new U.S. statutory income tax rate of 21%. Other line items, to the extent U.S. related, are reflected at the former U.S. statutory income tax rate of 35%.
[4]	Includes the impact of certain recurring valuation allowances for U.K. and non-U.K. jurisdictions.
[5]	The statutory tax rate reflects the U.K. statutory tax rate of 19% for fiscal 2018 and 2017 and 20% for fiscal 2016 and the three months ended December 30, 2016.

Earnings (Loss) per Share (Tables)

12 Months Ended

Dec. 28, 2018

Earnings (Loss) per Share [Abstract]

Schedule of Earnings (Loss) per Share



	Fiscal Year Ended							Three Months Ended
	December 28, 2018			December 29, 2017		September 30, 2016		December 30, 2016
(Loss) earnings per share numerator:
(Loss) income from continuing operations attributable to common shareholders	$	(3,621.9	)	$	1,771.2	$	489.0	$	(176.8	)
Income from discontinued operations	14.9			363.2		154.7		23.6
Net (loss) income attributable to common shareholders	$	(3,607.0	)	$	2,134.4	$	643.7	$	(153.2	)
(Loss) earnings per share denominator:
Weighted-average shares outstanding - basic	84.0			97.7		110.6		105.7
Impact of dilutive securities	—			0.2		0.9		—
Weighted-average shares outstanding - diluted	84.0			97.9		111.5		105.7
Basic (loss) earnings per share attributable to common shareholders:
(Loss) income from continuing operations	$	(43.12	)	$	18.13	$	4.42	$	(1.67	)
Income from discontinued operations	0.18			3.72		1.40		0.22
Net (loss) income attributable to common shareholders	$	(42.94	)	$	21.85	$	5.82	$	(1.45	)
Diluted (loss) earnings per share attributable to common shareholders:
(Loss) income from continuing operations	$	(43.12	)	$	18.09	$	4.39	$	(1.67	)
Income from discontinued operations	0.18			3.71		1.39		0.22
Net (loss) income attributable to common shareholders	$	(42.94	)	$	21.80	$	5.77	$	(1.45	)

Inventories (Tables)

12 Months Ended

Dec. 28, 2018

Inventory, Net [Abstract]

Schedule of Inventories

Inventories are comprised of the following at the end of each period:



	December 28, 2018		December 29, 2017
Raw materials and supplies	$	69.2	$	70.0
Work in process	167.6		167.1
Finished goods	85.5		103.3
Inventories	$	322.3	$	340.4

Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 28, 2018

Property, Plant and Equipment [Line Items]

Depreciation of Property, Plant and Equipment

Depreciation expense for continuing operations was as follows:



	Fiscal Year Ended						Three Months Ended
	December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016
Depreciation expense	$	111.9	$	113.8	$	113.3	$	27.5

Schedule of Property, Plant and Equipment

The gross carrying amount and accumulated depreciation of property, plant and equipment at the end of each period was as follows:



	December 28, 2018			December 29, 2017
Land	$	43.9		$	44.0
Buildings	379.5			355.5
Capitalized software	130.8			109.0
Machinery and equipment	1,137.3			1,123.8
Construction in process	244.7			209.7
	1,936.2			1,842.0
Less: accumulated depreciation	(954.2		)	(875.2		)
Property, plant and equipment, net	$	982.0		$	966.8

Goodwill and Intangible Assets (Tables)

12 Months Ended

Dec. 28, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Finite-lived Intangible Assets Amortization Expense

Finite-lived intangible asset amortization expense within continuing operations is as follows:



	Fiscal Year Ended						Three Months Ended
	December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016
Amortization expense	$	740.2	$	694.5	$	700.1	$	175.7

Schedule of Goodwill

The changes in the carrying amount of goodwill by segment were as follows:



	December 28, 2018					December 29, 2017
	Gross Carrying amount		Accumulated Impairment			Gross Carrying amount		Accumulated Impairment
Specialty Brands	$	3,672.8	$	(3,672.8	)	$	3,482.7	$	—
Specialty Generics	207.0		(207.0		)	207.0		(207.0		)
Total	$	3,879.8		($3,879.8	)	$	3,689.7	$	(207.0	)

Schedule of Intangible Assets

The gross carrying amount and accumulated amortization of intangible assets at the end of each period were as follows:



	December 28, 2018				December 29, 2017
	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Amortizable:
Completed technology	$	10,467.9	$	2,980.6	$	9,882.8	$	2,260.8
License agreements	120.1		70.1		177.1		121.1
Trademarks	81.9		18.1		82.1		14.5
Customer relationships	27.5		14.1		29.5		12.2
Other	—		—		8.6		8.6
Total	$	10,697.4	$	3,082.9	$	10,180.1	$	2,417.2
Non-Amortizable:
Trademarks	$	35.0			$	35.0
In-process research and development	633.3				577.1
Total	$	668.3			$	612.1

Schedule of Future Amortization Expense, Intangible Assets

The estimated aggregate amortization expense on intangible assets owned by the Company is expected to be as follows:



Fiscal 2019	$	748.4
Fiscal 2020	748.0
Fiscal 2021	747.8
Fiscal 2022	620.8
Fiscal 2023	584.8

Debt (Tables)

12 Months Ended

Dec. 28, 2018

Debt Instrument [Line Items]

Schedule of Long-term Debt Instruments [Table Text Block]

As of December 28, 2018, the applicable interest rate and outstanding borrowings on the Company's variable-rate debt instruments were as follows:



	Applicable interest rate		Outstanding borrowings
Term loan due September 2024	5.14	%	$	1,613.8
Term loan due February 2025	5.62	%	597.0
Variable-rate receivable securitization	3.22	%	250.0
Revolving credit facility	4.64	%	220.0

Schedule of Long-term Debt including Capital Lease Obligation

Debt was comprised of the following at the end of each period:



	December 28, 2018				December 29, 2017
	Principal		Unamortized Discount and Debt Issuance Costs		Principal		Unamortized Discount and Debt Issuance Costs
Current maturities of long-term debt:
3.50% notes due April 2018	$	—	$	—	$	300.0	$	0.2
Term loan due September 2024	16.4		0.2		14.0		0.3
Term loan due February 2025	6.0		0.1		—		—
Other	0.3		—		0.2		—
Total current debt	22.7		0.3		314.2		0.5
Long-term debt:
4.875% notes due April 2020	700.0		3.2		700.0		5.7
Variable-rate receivable securitization due July 2020	250.0		0.4		200.0		0.7
9.50% debentures due May 2022	10.4		—		10.4		—
5.75% notes due August 2022	835.2		7.0		884.0		9.5
8.00% debentures due March 2023	4.4		—		4.4		—
4.75% notes due April 2023	500.2		3.5		526.5		4.5
5.625% notes due October 2023	731.4		8.0		738.0		9.7
Term loan due September 2024	1,597.4		19.8		1,837.2		26.7
Term loan due February 2025	591.0		10.7		—		—
5.50% notes due April 2025	692.1		7.7		692.1		9.0
Other	1.9		—		—		—
Revolving credit facility	220.0		4.5		900.0		5.9
Total long-term debt	6,134.0		64.8		6,492.6		71.7
Total debt	$	6,156.7	$	65.1	$	6,806.8	$	72.2

Schedule of Maturities of Long-term Debt including Capital Lease Obligation

The aggregate amounts of debt maturing during the next five fiscal years are as follows:



Fiscal 2019	$	22.7
Fiscal 2020	972.7
Fiscal 2021	28.2
Fiscal 2022	1,088.2
Fiscal 2023	1,258.6

Schedule of Net Periodic Benefit Cost

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

Retirement Plans (Tables)

12 Months Ended

Dec. 28, 2018

Retirement Benefits [Abstract]

The net periodic benefit cost (credit) for the Company's pension and postretirement benefit plans was as follows:



	Pension Benefits
	Fiscal Year Ended								Three Months Ended
	December 28, 2018		December 29, 2017			September 30, 2016			December 30, 2016
Service cost	$	0.2	$	1.4		$	1.8		$	0.8
Interest cost	0.6		2.3			13.2			2.0
Expected return on plan assets	—		(1.3		)	(16.7		)	(2.3		)
Amortization of net actuarial loss	0.5		2.7			11.3			3.5
Amortization of prior service cost	0.1		0.2			—			0.1
Loss on plan settlements	0.1		71.1			8.1			45.0
Curtailment gain	—		(1.0		)	—			—
Net periodic benefit cost	$	1.5	$	75.4		$	17.7		$	49.1



	Postretirement Benefits
	Fiscal Year Ended									Three Months Ended
	December 28, 2018			December 29, 2017			September 30, 2016			December 30, 2016
Service cost	$	—		$	—		$	0.1		$	0.1
Interest cost	1.5			1.7			2.0			0.4
Amortization of net actuarial loss	0.1			—			—			—
Amortization of prior service credit	(2.1		)	(2.0		)	(2.1		)	(0.5		)
Gain on plan settlements	(0.7		)	(0.9		)	—			—
Net periodic benefit credit	$	(1.2	)	$	(1.2	)	$	—		$	—

Schedule of Changes in Benefit Obligations, Plan Assets, and Funded Status of Plans



	Pension Benefits						Postretirement Benefits
	December 28, 2018			December 29, 2017			December 28, 2018			December 29, 2017
Change in benefit obligations:
Projected benefit obligations at beginning of year	$	27.8		$	257.4		$	45.6		$	47.5
Service cost	0.2			1.4			—			—
Interest cost	0.6			2.3			1.5			1.7
Actuarial loss (gain)	0.7			(9.0		)	(3.9		)	0.2
Benefits and administrative expenses paid	(1.6		)	(9.4		)	(2.7		)	(2.9		)
Plan settlements	(0.8		)	(217.0		)	(0.7		)	(0.9		)
Currency translation	(0.8		)	2.1			—			—
Projected benefit obligations at end of year	26.1			27.8			39.8			45.6

Change in plan assets:
Fair value of plan assets at beginning of year	—			161.0			—			—
Actual return on plan assets	—			0.3			—			—
Employer contributions	2.4			68.0			2.7			2.9
Benefits and administrative expenses paid	(1.6		)	(9.4		)	(2.7		)	(2.9		)
Plan settlements	(0.8		)	(217.0		)	—			—
Net transfer out	—			(2.9		)	—			—
Fair value of plan assets at end of year	—			—			—			—
Funded status at end of year	$	(26.1	)	$	(27.8	)	$	(39.8	)	$	(45.6	)

Schedule of Amounts Recognized in Balance Sheet



	Pension Benefits						Postretirement Benefits
	December 28, 2018			December 29, 2017			December 28, 2018			December 29, 2017
Amounts recognized on the consolidated balance sheet:
Current liabilities	$	(2.0	)	$	(2.4	)	$	(3.4	)	$	(3.9	)
Non-current liabilities	(24.1		)	(25.4		)	(36.4		)	(41.7		)
Net amount recognized on the consolidated balance sheet	$	(26.1	)	$	(27.8	)	$	(39.8	)	$	(45.6	)

Amounts recognized in accumulated other comprehensive loss consist of:
Net actuarial (loss) gain	$	(8.4	)	$	(8.6	)	$	0.9		$	(3.0	)
Prior service (cost) credit	(0.4		)	(0.5		)	8.1			10.2
Net amount recognized in accumulated other comprehensive loss	$	(8.8	)	$	(9.1	)	$	9.0		$	7.2

Schedule of Amounts to be Amortized from Accumulated Other Comprehensive Income

The estimated amounts that will be amortized from accumulated other comprehensive loss into net periodic benefit cost (credit) in fiscal 2019 are as follows:



	Pension Benefits		Postretirement Benefits
Amortization of net actuarial loss	$	0.5	$	—
Amortization of prior service cost (credit)	0.1		(2.1		)

Schedule of Plans with Accumulated Benefit Obligations in Excess of Plan Assets



	December 28, 2018		December 29, 2017
Pension plans with accumulated benefit obligations in excess of plan assets:
Accumulated benefit obligation	$	25.6	$	27.3

Schedule of Actuarial Assumptions

Weighted-average assumptions used each period to determine net periodic benefit cost for the Company's pension plans are as follows:



	U.S. Plans								Non-U.S. Plans
	Fiscal Year Ended						Three Months Ended		Fiscal Year Ended						Three Months Ended
	December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016		December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016
Discount rate	3.3	%	3.0	%	3.9	%	2.2	%	1.9	%	1.8	%	2.0	%	1.3	%
Expected return on plan assets	—	%	3.5	%	5.8	%	3.5	%	—	%	—	%	2.0	%	—	%
Rate of compensation increase	—	%	—	%	—	%	—	%	2.5	%	2.5	%	—	%	—	%

Weighted-average assumptions used each period to determine benefit obligations for the Company's pension plans are as follows:



	U.S. Plans								Non-U.S. Plans
	Fiscal Year Ended						Three Months Ended		Fiscal Year Ended						Three Months Ended
	December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016		December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016
Discount rate	4.0	%	3.3	%	2.3	%	3.0	%	2.0	%	1.9	%	1.3	%	1.8	%
Rate of compensation increase	—	%	—	%	—	%	—	%	2.5	%	2.5	%	—	%	0.3	%

The weighted-average discount rate used to determine net periodic benefit cost and obligations for the Company's postretirement benefit plans are as follows:



	Fiscal Year						Three Months Ended
	December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016
Net periodic benefit cost	3.4	%	3.7	%	4.0	%	3.2	%
Benefit obligations	4.1	%	3.4	%	3.2	%	3.8	%

Schedule of Healthcare Cost Trend Rates

Healthcare cost trend assumptions for postretirement benefit plans are as follows:



	December 28, 2018		December 29, 2017
Healthcare cost trend rate assumed for next fiscal year	6.3	%	6.9	%
Rate to which the cost trend rate is assumed to decline	4.5	%	4.5	%
Fiscal year the ultimate trend rate is achieved	2038		2038

Schedule of Effect of One-Percentage-Point Change in Assumed Healthcare Cost Trend Rates

A one-percentage-point change in assumed healthcare cost trend rates would have the following effects:



	One-Percentage-Point Increase		One-Percentage-Point Decrease
Effect on total of service and interest cost	$	—	$	—
Effect on postretirement benefit obligation	0.2		(0.2		)

Schedule of Expected Benefit Payments

Benefit payments expected to be paid, reflecting future expected service as appropriate, are as follows:



	Pension Benefits		Postretirement Benefits
Fiscal 2019	$	2.0	$	3.5
Fiscal 2020	1.7		3.4
Fiscal 2021	1.7		3.2
Fiscal 2022	1.6		3.1
Fiscal 2023	1.6		3.0
Fiscal 2024 - 2028	7.4		13.4

Equity (Tables)

12 Months Ended

Dec. 28, 2018

Schedule of Share Repurchases under the Repurchase Plan

Share Repurchases

From time to time, the Company's Board of Directors have authorized share repurchase programs. The details of such programs are as follows:



	March 2017 Repurchase Program			March 2016 Repurchase Program			November 2015 Repurchase Program			January 2015 Repurchase Program
	Number of Shares	Amount		Number of Shares	Amount		Number of Shares	Amount		Number of Shares	Amount
Authorized repurchase amount		$	1,000.0		$	350.0		$	500.0		$	300.0
Repurchases:
Fiscal 2015	—	—		—	—		—	—		823,592	75.0
Fiscal 2016	—	—		—	—		6,510,824	425.6		3,199,279	225.0
Three months ended December 30, 2016	—	—		1,501,676	84.0		1,063,337	74.4		—	—
Fiscal 2017	13,490,448	380.6		5,366,741	266.0		—	—		—	—
Fiscal 2018	3,610,968	55.2		—	—		—	—		—	—
Remaining amount available		$	564.2		$	—		$	—		$	—

Share Plans (Tables)

12 Months Ended

Dec. 28, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]

The grant-date fair value of RSAs, adjusted for estimated forfeitures, was recognized as expense on a straight-line basis over the service period. The weighted average grant-date fair value per share was $70.88.



	Shares
Non-vested at September 25, 2015	34,562
Vested	(9,760	)
Forfeited	(7,936	)
Non-vested at September 30, 2016	16,866
Vested	(1,087	)
Forfeited	(911	)
Non-vested at December 30, 2016	14,868
Vested	(7,970	)
Forfeited	(2,223	)
Non-vested at December 29, 2017	4,675
Vested	(3,970	)
Forfeited	(705	)
Non-vested at December 28, 2018	—

Maximum Number of Common Shares to be Issued as Awards [Table Text Block]

The maximum number of common shares to be issued as Awards, subject to adjustment as provided under the terms of the respective plans are as follows:



		Maximum Number of Common Shares to be Issued as Awards (in millions)
2013 Plan		5.7
2015 Plan		17.8
2018 Plan		26.8

Schedule of the Valuation Assumptions Used in the Conversion

The weighted-average assumptions used in the Black-Scholes pricing model for shares granted in fiscal 2018, 2017, 2016 and the three months ended December 30, 2016, along with the weighted-average grant-date fair value, were as follows:



	Fiscal Year Ended									Three Months Ended
	December 28, 2018			December 29, 2017			September 30, 2016			December 30, 2016
Expected share price volatility	38		%	36		%	31		%	35		%
Risk-free interest rate	2.64		%	2.00		%	1.74		%	1.23		%
Expected annual dividend per share	—		%	—		%	—		%	—		%
Expected life of options (in years)	5.3			5.3			5.3			5.3
Fair value per option	$	5.32		$	18.36		$	22.82		$	20.04

Schedule of Share Option Activity

Share option activity and information is as follows:



	Share Options		Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at September 25, 2015	2,786,443		$	52.76
Granted	1,248,828		72.44
Exercised	(413,830	)	32.76
Expired/Forfeited	(199,585	)	72.65
Outstanding at September 30, 2016	3,421,856		61.17
Granted	3,742		60.01
Exercised	(16,382	)	36.42
Expired/Forfeited	(22,522	)	70.82
Outstanding at December 30, 2016	3,386,694		61.24
Granted	1,719,532		51.57
Exercised	(113,605	)	47.74
Expired/Forfeited	(348,637	)	68.08
Outstanding at December 29, 2017	4,643,984		57.78
Granted	3,159,521		13.92
Exercised	(39,949	)	32.00
Expired/Forfeited	(756,505	)	52.63
Outstanding at December 28, 2018	7,007,051		38.74		4.8	$	6.5

Vested and non-vested expected to vest as of December 28, 2018	6,114,782		39.94		7.6	$	5.5
Exercisable at December 28, 2018	2,414,968		55.24		4.9	0.1

Share-based Compensation, Performance Shares Award Outstanding Activity

PSU activity is as follows ⁽¹⁾:



	Shares		Weighted-Average Grant-Date Fair Value
Non-vested at September 25, 2015	130,974		$	96.05
Granted	145,192		83.00
Forfeited	(9,521	)	96.30
Non-vested at September 30, 2016	266,645		88.59
Forfeited	(997	)	154.42
Non-vested at December 30, 2016	265,648		88.51
Granted	348,963		51.73
Forfeited	(48,606	)	107.00
Vested	(61,554	)	62.65
Non-vested at December 29, 2017	504,451		64.44
Granted	770,714		13.80
Forfeited	(89,614	)	59.18
Vested	(24,022	)	98.27
Non-vested at December 28, 2018	1,161,529		28.61

(1) The number of shares disclosed within this table are at the target number of 100%.

Schedule of Share-based Payment Award, Performance Share Awards, Valuation Assumptions

The assumptions used in the Monte Carlo model for PSUs granted during each year were as follows:



	Fiscal Year Ended						Three Months Ended
	December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016
Expected stock price volatility	57	%	48	%	41	%	48	%
Peer group stock price volatility	39	%	40	%	36	%	40	%
Correlation of returns	2	%	17	%	24	%	17	%

Schedule of Restricted Share Unit Activity

RSU activity is as follows:



	Shares		Weighted-Average Grant-Date Fair Value
Non-vested at September 25, 2015	572,494		$	73.45
Granted	615,074		70.10
Vested	(193,849	)	69.27
Expired/Forfeited	(99,260	)	79.95
Non-vested at September 30, 2016	894,459		70.40
Granted	36,731		69.08
Exercised	(30,919	)	47.54
Expired/Forfeited	(16,809	)	49.62
Non-vested at December 30, 2016	883,462		71.03
Granted	655,282		50.74
Exercised	(263,189	)	69.14
Expired/Forfeited	(169,789	)	68.57
Non-vested at December 29, 2017	1,105,766		60.08
Granted	1,222,568		14.58
Exercised	(433,354	)	57.93
Expired/Forfeited	(209,879	)	44.38
Non-vested at December 28, 2018	1,685,101		29.54

Accumulated Other Comprehensive Income (Tables)

12 Months Ended

Dec. 28, 2018

Schedule of Accumulated Other Comprehensive Income

The components of accumulated other comprehensive loss are as follows:



	Currency Translation			Unrecognized Loss on Derivatives			Unrecognized (Loss) Gain on Benefit Plans			Unrecognized Gain on Equity Securities ⁽¹⁾			Accumulated Other Comprehensive Loss ⁽¹⁾
Balance at December 30, 2016	$	(19.5	)	$	(5.7	)	$	(47.3	)	$	—		$	(72.5	)
Other comprehensive income, net	16.0			—			5.2			1.5			22.7
Reclassification from other comprehensive (loss) income	(4.7		)	1.0			40.6			(1.5		)	35.4
Balance at December 29, 2017	(8.2		)	(4.7		)	(1.5		)	—			(14.4		)
Other comprehensive (loss) income, net	(12.2		)	—			3.1			—			(9.1		)
Reclassification from other comprehensive income (loss)	—			0.7			(1.5		)	—			(0.8		)
Balance at December 28, 2018	$	(20.4	)	$	(4.0	)	$	0.1		$	—		$	(24.3	)

Reclassification out of Accumulated Other Comprehensive Income

The following summarizes reclassifications from accumulated other comprehensive loss:



	Amount Reclassified From Accumulated Other Comprehensive Loss
	December 28, 2018			December 29, 2017			Line Item in the Consolidated Statement of Income
Currency translation	$	—		$	(4.7	)

Amortization of unrealized loss on derivatives	0.9			1.3			Interest expense
Income tax provision	(0.2		)	(0.3		)	Provision for income taxes
Net of income taxes	0.7			1.0

Amortization of pension and post-retirement benefit plans:
Net actuarial loss	0.6			2.7			⁽¹⁾
Prior service credit	(2.0		)	(1.9		)	⁽¹⁾
Disposal of discontinued operations	—			(3.1		)
Plan settlements	(0.6		)	70.2			⁽¹⁾
Total before tax	(2.0		)	67.9
Income tax effect	0.5			(27.3		)	Provision for income taxes
Net of income taxes	(1.5		)	40.6

Recognized gain on equity securities ⁽²⁾	—			(1.5		)

Total reclassifications for the period	$	(0.8	)	$	35.4


(1)	These accumulated other comprehensive loss components are included in the computation of net periodic benefit cost. See Note 15 for additional details.


(2)	Upon adoption of ASU 2016-01, a reclassification of $1.5 million relating to the unrealized gain on investment resulted in an increase to beginning retained earnings with an offsetting decrease to accumulated other comprehensive loss. See Note 4 for additional details.

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 28, 2018

Commitments and Contingencies Disclosure [Abstract]

Schedule of Purchase Obligations

At December 28, 2018, such obligations were as follows:



Fiscal 2019	$	110.3
Fiscal 2020	43.5
Fiscal 2021	2.2
Fiscal 2022	2.1
Fiscal 2023	1.7

Schedule of Minimum Lease Payments for Non-cancelable Leases

The following is a schedule of minimum lease payments for non-cancelable leases as of December 28, 2018:



	Operating Leases
Fiscal 2019	$	22.3
Fiscal 2020	16.4
Fiscal 2021	12.8
Fiscal 2022	10.6
Fiscal 2023	10.3
Thereafter	39.2
Total minimum lease payments	$	111.6

Financial Instruments and Fair Value Measurements (Tables)

12 Months Ended

Dec. 28, 2018

Fair Value Disclosures [Abstract]

Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis

The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:



	December 28, 2018		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	33.1	$	22.4	$	10.7	$	—
Equity securities	—		—		—		—
	$	33.1	$	22.4	$	10.7	$	—
Liabilities:
Deferred compensation liabilities	$	38.5	$	—	$	38.5	$	—
Contingent consideration and acquired contingent liabilities	151.4		—		—		151.4
	$	189.9	$	—	$	38.5	$	151.4



	December 29, 2017		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	$	35.4	$	24.0	$	11.4	$	—
Equity securities	22.7		22.7		—		—
	$	58.1	$	46.7	$	11.4	$	—
Liabilities:
Deferred compensation liabilities	$	42.7	$	—	$	42.7	$	—
Contingent consideration and acquired contingent liabilities	246.4		—		—		246.4
	$	289.1	$	—	$	42.7	$	246.4

Schedule of Reconciliation of Changes in Fair Value of Contingent Consideration

The following table summarizes the fiscal 2018 activity for contingent consideration:



Balance at December 29, 2017	$	246.4
Disposal of business	(12.1		)
Payments	(37.0		)
Accretion expense	4.3
Fair value adjustment	(50.2		)
Balance at December 28, 2018	$	151.4

Schedule of Carrying Amount and Fair Value of Long-term Debt

The following table presents the carrying values and estimated fair values of the Company's long-term debt, excluding capital leases, as of the end of each period:



	December 28, 2018				December 29, 2017
	Carrying Value		Fair Value		Carrying Value		Fair Value
Level 1:
3.50% notes due April 2018	$	—	$	—	$	300.0	$	299.1
4.875% notes due April 2020	700.0		676.6		700.0		675.2
Variable-rate receivable securitization due July 2020	250.0		250.0		200.0		200.0
5.75% notes due August 2022	835.2		713.6		884.0		804.8
4.75% notes due April 2023	500.2		336.7		526.5		412.4
5.625% notes due October 2023	731.4		557.0		738.0		628.8
5.50% notes due April 2025	692.1		479.1		692.1		564.5
Revolving credit facility	220.0		220.0		900.0		900.0
Level 2:
9.50% debentures due May 2022	10.4		9.7		10.4		10.9
8.00% debentures due March 2023	4.4		3.8		4.4		4.4
Term loan due September 2024	1,613.8		1,472.4		1,851.2		1,848.7
Term loan due February 2025	597.0		548.0		—		—
Level 3:
Other	2.2		2.2		—		—
Total Debt	$	6,156.7	$	5,269.1	$	6,806.6	$	6,348.8

Schedules of Concentration of Risk

The following table shows net sales attributable to distributors that accounted for 10% or more of the Company's total net sales:



	Fiscal Year Ended						Three Months Ended
	December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016
CuraScript, Inc.	35	%	40	%	38	%	43	%
McKesson Corporation	*		*		12	%	10	%

* Net sales to these distributors were less than 10% of total net sales during the respective periods presented above.

The following table shows accounts receivable attributable to distributors that accounted for 10% or more of the Company's gross accounts receivable at the end of each period:



	December 28, 2018		December 29, 2017
AmerisourceBergen Corporation	26	%	15	%
McKesson Corporation	22	%	26	%
CuraScript, Inc.	13	%	14	%
Cardinal Health, Inc.	*		11	%

* Gross accounts receivables from these distributors were less than 10% of total gross accounts receivable during the respective periods presented above.

The following table shows net sales attributable to products that accounted for 10% or more of the Company's total net sales:



	Fiscal Year Ended						Three Months Ended
	December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016
H.P. Acthar Gel	35	%	37	%	34	%	39	%
Inomax	17	%	16	%	14	%	14	%

Segment and Geographical Data (Tables)

12 Months Ended

Dec. 28, 2018

Segment Reporting [Abstract]

Schedule of Segment Reporting Information by Business Segment

Selected information by business segment is as follows:



	Fiscal Year Ended									Three Months Ended
	December 28, 2018			December 29, 2017			September 30, 2016			December 30, 2016
Net sales:
Specialty Brands	$	2,306.2		$	2,352.0		$	2,288.8		$	600.1
Specialty Generics and Amitiza	909.4			869.6			1,092.0			229.8
Net sales	$	3,215.6		$	3,221.6		$	3,380.8		$	829.9
Operating income:
Specialty Brands	$	1,077.4		$	1,146.3		$	1,060.7		$	295.2
Specialty Generics and Amitiza	105.0			266.4			444.7			64.6
Segment operating income	1,182.4			1,412.7			1,505.4			359.8
Unallocated amounts:
Corporate and allocated expenses ⁽¹⁾	(155.8		)	(125.2		)	(117.7		)	(123.1		)
Intangible asset amortization	(740.2		)	(694.5		)	(700.1		)	(175.7		)
Restructuring and related charges, net ⁽²⁾	(108.2		)	(36.4		)	(37.6		)	(5.3		)
Non-restructuring impairments	(3,893.1		)	(63.7		)	(16.9		)	(214.3		)
Separation costs ⁽³⁾	(6.0		)	—			—			—
Operating income	$	(3,720.9	)	$	492.9		$	633.1		$	(158.6	)

Depreciation and amortization ⁽⁴⁾:
Specialty Brands	$	696.0		$	712.0		$	715.7		$	178.2
Specialty Generics and Amitiza	156.1			96.3			97.9			25.0
	$	852.1		$	808.3		$	813.6		$	203.2


(1)	Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.


(2)	Includes restructuring-related accelerated depreciation.


(3)	Represents costs incurred related to the separation of the Company’s Specialty Generics and Amitiza segment, which are included in selling, general and administrative expenses.


(4)	Depreciation for certain shared facilities is allocated based on occupancy percentage.

^[1],[2]

Schedule of Net Sales from External Customers by Products

Net sales by product family within the Company's segments are as follows:



	Fiscal Year Ended						Three Months Ended
	December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016
H.P. Acthar Gel	$	1,110.1	$	1,195.1	$	1,160.4	$	325.4
Inomax	542.7		505.2		474.3		118.3
Ofirmev	341.9		302.5		284.3		72.5
Therakos	231.2		214.9		207.6		47.4
BioVectra	53.1		54.7		49.5		7.4
Other ⁽¹⁾	27.2		79.6		112.7		29.1
Specialty Brands	2,306.2		2,352.0		2,288.8		600.1

Hydrocodone (API) and hydrocodone-containing tablets	65.9		85.3		146.5		23.2
Oxycodone (API) and oxycodone-containing tablets ⁽¹⁾	66.1		88.0		139.9		27.2
Acetaminophen (API) ⁽¹⁾	192.7		185.5		169.1		40.8
Amitiza ⁽²⁾	183.8		—		—		—
Other controlled substances ⁽¹⁾	343.8		412.0		543.9		117.4
Other ^{(1), (3)}	57.1		98.8		92.6		21.2
Specialty Generics and Amitiza	909.4		869.6		1,092.0		229.8
Net Sales	$	3,215.6	$	3,221.6	$	3,380.8	$	829.9


(1)	Prior year amounts have been reclassified to conform to current year presentation.


(2)	Amitiza net sales consist of both product and royalty net sales. Refer to Note 5 for further details on Amitiza's revenues.


(3)	Includes net sales from an ongoing, post-divestiture supply agreement with the acquirer of the CMDS business. Amounts for periods prior to the divestiture represent the reclassification of intercompany sales to third-party sales to conform with the expected presentation of the ongoing supply agreement.

^[3]

Schedule of Net Sales and Long-Lived Assets by Geographical Area

Selected information by geographic area excluding assets held-for-sale is as follows:



	Fiscal Year Ended						Three Months Ended
	December 28, 2018		December 29, 2017		September 30, 2016		December 30, 2016
Net sales ⁽¹⁾:
U.S.	$	2,834.5	$	2,899.0	$	3,095.4	$	763.7
Europe, Middle East and Africa	256.8		242.3		211.8		52.8
Other	124.3		80.3		73.6		13.4
	$	3,215.6	$	3,221.6	$	3,380.8	$	829.9

	Fiscal Year Ended
Long-lived assets ⁽²⁾:	December 28, 2018		December 29, 2017
U.S.	$	770.7	$	788.5
Europe, Middle East and Africa ⁽³⁾	146.7		127.0
Other	76.8		63.5
	$	994.2	$	979.0


(1)	Net sales are attributed to regions based on the location of the entity that records the transaction, none of which relate to the country of Ireland.


(2)	Long-lived assets are primarily composed of property, plant and equipment, net.


(3)	Includes long-lived assets located in Ireland of $145.2 million and $126.0 million as of December 28, 2018 and December 29, 2017, respectively.

^[4],[5],[6]

[1]	Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.
[2]	Includes restructuring-related accelerated depreciation.
[3]	Prior year amounts have been reclassified to conform to current year presentation.
[4]	Includes long-lived assets located in Ireland of $145.2 million and $126.0 million as of December 28, 2018 and December 29, 2017, respectively.
[5]	Long-lived assets are primarily composed of property, plant and equipment, net.
[6]	Net sales are attributed to regions based on the location of the entity that records the transaction, none of which relate to the country of Ireland.

Selected Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 28, 2018

Quarterly Financial Information Disclosure [Abstract]

Schedule of Selected Quarterly Financial Data (Unaudited)



	For the Quarter Ended ⁽¹⁾
	March 30, 2018			June 29, 2018			September 28, 2018			December 28, 2018
Net sales	$	755.3		$	825.5		$	799.9		$	834.9
Gross profit ⁽²⁾	347.5			394.0			366.4			363.3
(Loss) income from continuing operations ⁽³⁾	(20.9		)	3.2			114.2			(3,718.4		)
Income (loss) from discontinued operations	2.9			12.4			(0.4		)	—
Net (loss) income	(18.0		)	15.6			113.8			(3,718.4		)

Basic (loss) earnings per share from continuing operations⁽⁴⁾	$	(0.24	)	$	0.04		$	1.37		$	(44.64	)
Diluted (loss) earnings per share from continuing operations ⁽⁴⁾	(0.24		)	0.04			1.34			(44.64		)

	For the Quarter Ended
	March 31, 2017			June 30, 2017			September 29, 2017			December 29, 2017
Net sales	$	810.9		$	824.5		$	793.9		$	792.3
Gross profit ⁽²⁾	419.8			416.1			400.6			421.0
Income from continuing operations ⁽³⁾	28.9			70.6			64.3			1,607.4
Income (loss) from discontinued operations	370.3			(7.8		)	(0.6		)	1.3
Net income	399.2			62.8			63.7			1,608.7

Basic earnings per share from continuing operations⁽⁴⁾	$	0.28		$	0.72		$	0.66		$	17.43
Diluted earnings per share from continuing operations ⁽⁴⁾	0.28			0.72			0.66			17.40

(1)


(2)	Financial data for each period has been adjusted to reflect the change in accounting for pension and postretirement costs with the adoption of ASU 2017-07. See Note 4 for further information.


(3)	(Loss) income from continuing operations for the quarter ended December 28, 2018 reflects impairment charges for goodwill and an IPR&D asset. See Note 13 for further information. Income from continuing operations for the quarter ended December 29, 2017 reflects one-time effects for the completion of the reorganization of the Company's legal entity ownership and the impact of the TCJA.

(4)

^[1],[2]

[1]

Financial data for each period has been adjusted to reflect the change in accounting for pension and postretirement costs with the adoption of ASU 2017-07. See Note 4 for further information.

[2]

Condensed Consolidating and Combining Financial Statements (Tables)

12 Months Ended

Dec. 28, 2018

Condensed Consolidating Financial Statements [Abstract]

Schedule of Condensed Consolidating Balance Sheets

MALLINCKRODT PLC

CONDENSED CONSOLIDATING BALANCE SHEET

As of December 28, 2018

(in millions)



	Mallinckrodt plc		Mallinckrodt International Finance S.A.		Other Subsidiaries		Eliminations			Consolidated
Assets
Current Assets:
Cash and cash equivalents	$	0.4	$	140.8	$	207.7	$	—		$	348.9
Accounts receivable, net	—		—		623.3		—			623.3
Inventories	—		—		322.3		—			322.3
Prepaid expenses and other current assets	3.9		0.2		128.6		—			132.7
Notes receivable	—		—		—		—			—
Intercompany receivable	131.1		29.2		1,087.9		(1,248.2		)	—
Total current assets	135.4		170.2		2,369.8		(1,248.2		)	1,427.2
Property, plant and equipment, net	—		—		982.0		—			982.0
Goodwill	—		—		—		—			—
Intangible assets, net	—		—		8,282.8		—			8,282.8
Investment in subsidiaries	2,481.6		25,506.1		8,362.1		(36,349.8		)	—
Intercompany loan receivable	497.7		—		12,343.0		(12,840.7		)	—
Other assets	—		—		185.3		—			185.3
Total Assets	$	3,114.7	$	25,676.3	$	32,525.0	$	(50,438.7	)	$	10,877.3
										—
Liabilities and Shareholders' Equity
Current Liabilities:
Current maturities of long-term debt	$	—	$	22.1	$	0.3	$	—		$	22.4
Accounts payable	0.1		—		147.4		—			147.5
Accrued payroll and payroll-related costs	—		—		124.0		—			124.0
Accrued interest	—		48.7		28.9		—			77.6
Income taxes payable	—		—		25.0		—			25.0
Accrued and other current liabilities	0.6		0.4		546.2		—			547.2
Intercompany payable	226.7		827.8		193.7		(1,248.2		)	—
Total current liabilities	227.4		899.0		1,065.5		(1,248.2		)	943.7
Long-term debt	—		3,566.9		2,502.3		—			6,069.2
Pension and postretirement benefits	—		—		60.5		—			60.5
Environmental liabilities	—		—		59.7		—			59.7
Deferred income taxes	—		—		324.3		—			324.3
Other income tax liabilities	—		—		228.0		—			228.0
Intercompany loans payable	—		12,840.7		—		(12,840.7		)	—
Other liabilities	—		7.6		297.0		—			304.6
Total liabilities	227.4		17,314.2		4,537.3		(14,088.9		)	7,990.0
Shareholders' equity	2,887.3		8,362.1		27,987.7		(36,349.8		)	2,887.3
Total Liabilities and Shareholders' Equity	$	3,114.7	$	25,676.3	$	32,525.0	$	(50,438.7	)	$	10,877.3

MALLINCKRODT PLC

CONDENSED CONSOLIDATING BALANCE SHEET

As of December 29, 2017

(in millions)



	Mallinckrodt plc		Mallinckrodt International Finance S.A.		Other Subsidiaries		Eliminations			Consolidated
Assets
Current Assets:
Cash and cash equivalents	$	0.7	$	908.8	$	351.4	$	—		$	1,260.9
Accounts receivable, net	—		—		445.8		—			445.8
Inventories	—		—		340.4		—			340.4
Prepaid expenses and other current assets	1.0		0.2		82.9		—			84.1
Notes receivable	—		—		154.0		—			154.0
Intercompany receivable	70.0		173.4		831.4		(1,074.8		)	—
Total current assets	71.7		1,082.4		2,205.9		(1,074.8		)	2,285.2
Property, plant and equipment, net	—		—		966.8		—			966.8
Goodwill	—		—		3,482.7		—			3,482.7
Intangible assets, net	—		—		8,375.0		—			8,375.0
Investment in subsidiaries	6,551.6		23,217.8		12,356.2		(42,125.6		)	—
Intercompany loan receivable	593.1		—		4,664.8		(5,257.9		)	—
Other assets	—		—		171.2		—			171.2
Total Assets	$	7,216.4	$	24,300.2	$	32,222.6	$	(48,458.3	)	$	15,280.9

Liabilities and Shareholders' Equity
Current Liabilities:
Current maturities of long-term debt	$	—	$	313.5	$	0.2	$	—		$	313.7
Accounts payable	0.1		—		113.2		—			113.3
Accrued payroll and payroll-related costs	—		—		98.5		—			98.5
Accrued interest	—		53.0		4.0		—			57.0
Income taxes payable	—		—		15.8					15.8
Accrued and other current liabilities	0.8		0.4		450.9		—			452.1
Intercompany payable	693.5		104.6		276.7		(1,074.8		)	—
Total current liabilities	694.4		471.5		959.3		(1,074.8		)	1,050.4
Long-term debt	—		6,206.8		214.1		—			6,420.9
Pension and postretirement benefits	—		—		67.1		—			67.1
Environmental liabilities	—		—		73.2		—			73.2
Deferred income taxes	—		—		689.0		—			689.0
Other income tax liabilities	—		—		94.1		—			94.1
Intercompany loans payable	—		5,257.9		—		(5,257.9		)	—
Other liabilities	—		7.8		356.4		—			364.2
Total liabilities	694.4		11,944.0		2,453.2		(6,332.7		)	8,758.9
Shareholders' equity	6,522.0		12,356.2		29,769.4		(42,125.6		)	6,522.0
Total Liabilities and Shareholders' Equity	$	7,216.4	$	24,300.2	$	32,222.6	$	(48,458.3	)	$	15,280.9

Schedule of Condensed Consolidating and Combining Statements of Comprehensive Income

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

Fiscal year ended December 28, 2018

(in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Net sales	$	—		$	—		$	3,215.6		$	—		$	3,215.6
Cost of sales	2.0			—			1,742.4			—			1,744.4
Gross (loss) profit	(2.0		)	—			1,473.2			—			1,471.2
Selling, general and administrative expenses	38.8			0.7			794.6			—			834.1
Research and development expenses	4.7			—			356.4			—			361.1
Restructuring charges, net	—			—			103.0			—			103.0
Non-restructuring impairment charges	—			—			3,893.1			—			3,893.1
Loss on divestiture	—			—			0.8			—			0.8
Operating loss	(45.5		)	(0.7		)	(3,674.7		)	—			(3,720.9		)

Interest expense	(7.8		)	(460.8		)	(63.4		)	161.8			(370.2		)
Interest income	9.5			2.5			158.0			(161.8		)	8.2
Other income, net	9.9			8.7			12.3			—			30.9
Intercompany interest and fees	(18.5		)	(0.1		)	18.6			—			—
Equity in net income of subsidiaries	(3,561.0		)	(2,726.0		)	(3,170.9		)	9,457.9			—
Loss from continuing operations before income taxes	(3,613.4		)	(3,176.4		)	(6,720.1		)	9,457.9			(4,052.0		)
Benefit from income taxes	(6.4		)	(5.4		)	(418.3		)	—			(430.1		)
Loss from continuing operations	(3,607.0		)	(3,171.0		)	(6,301.8		)	9,457.9			(3,621.9		)
Income from discontinued operations, net of income taxes	—			0.1			14.8			—			14.9
Net loss	(3,607.0		)	(3,170.9		)	(6,287.0		)	9,457.9			(3,607.0		)
Other comprehensive loss, net of tax	(9.9		)	(9.9		)	(20.5		)	30.4			(9.9		)
Comprehensive loss	$	(3,616.9	)	$	(3,180.8	)	$	(6,307.5	)	$	9,488.3		$	(3,616.9	)

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

Fiscal year ended December 29, 2017

(in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Net sales	$	—		$	—		$	3,221.6		$	—		$	3,221.6
Cost of sales	2.6			—			1,561.5			—			1,564.1
Gross (loss) profit	(2.6		)	—			1,660.1			—			1,657.5
Selling, general and administrative expenses	59.5			0.7			789.5			—			849.7
Research and development expenses	5.1			—			271.8			—			276.9
Restructuring charges, net	—			—			31.2			—			31.2
Non-restructuring impairments	—			—			63.7			—			63.7
Gains on divestiture	—			—			(56.9		)	—			(56.9		)
Operating (loss) income	(67.2		)	(0.7		)	560.8			—			492.9

Interest expense	(13.8		)	(353.9		)	(74.2		)	72.8			(369.1		)
Interest income	7.3			1.2			68.9			(72.8		)	4.6
Other income (expense), net	20.3			(1.7		)	(85.4		)	—			(66.8		)
Intercompany interest and fees	(18.3		)	—			18.3			—			—
Equity in net income of subsidiaries	2,200.0			2,901.8			2,549.9			(7,651.7		)	—
Income from continuing operations before income taxes	2,128.3			2,546.7			3,038.3			(7,651.7		)	61.6
Benefit from income taxes	(6.1		)	(5.3		)	(1,698.2		)	—			(1,709.6		)
Income from continuing operations	2,134.4			2,552.0			4,736.5			(7,651.7		)	1,771.2
(Loss) income from discontinued operations, net of income taxes	—			(2.1		)	365.3			—			363.2
Net income	2,134.4			2,549.9			5,101.8			(7,651.7		)	2,134.4
Other comprehensive income, net of tax	59.6			59.6			118.2			(177.8		)	59.6
Comprehensive income	$	2,194.0		$	2,609.5		$	5,220.0		$	(7,829.5	)	$	2,194.0

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

Fiscal year ended September 30, 2016

(in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Net sales	$	—		$	—		$	3,380.8		$	—		$	3,380.8
Cost of sales	—			—			1,523.2			—			1,523.2
Gross profit	—			—			1,857.6			—			1,857.6
Selling, general and administrative expenses	51.3			0.8			861.6			—			913.7
Research and development expenses	—			—			261.2			—			261.2
Restructuring charges, net	—			—			32.7			—			32.7
Non-restructuring impairments	—			—			16.9			—			16.9
Operating (loss) income	(51.3		)	(0.8		)	685.2			—			633.1

Interest expense	(230.3		)	(327.0		)	(82.4		)	255.1			(384.6		)
Interest income	—			0.5			255.9			(255.1		)	1.3
Other income (expense), net	90.0			1.7			(108.1		)	—			(16.4		)
Intercompany interest and fees	(16.1		)	—			16.1			—			—
Equity in net income of subsidiaries	820.8			1,327.2			1,057.9			(3,205.9		)	—
Income from continuing operations before income taxes	613.1			1,001.6			1,824.6			(3,205.9		)	233.4
Benefit from income taxes	(30.6		)	(18.1		)	(206.9		)	—			(255.6		)
Income from continuing operations	643.7			1,019.7			2,031.5			(3,205.9		)	489.0
Income from discontinued operations, net of income taxes	—			38.2			116.5			—			154.7
Net income	643.7			1,057.9			2,148.0			(3,205.9		)	643.7
Other comprehensive loss, net of tax	(86.5		)	(86.5		)	(173.5		)	260.0			(86.5		)
Comprehensive income	$	557.2		$	971.4		$	1,974.5		$	(2,945.9	)	$	557.2

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

Three months ended December 30, 2016

(in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Net sales	$	—		$	—		$	829.9		$	—		$	829.9
Cost of sales	—			—			383.2			—			383.2
Gross profit	—			—			446.7			—			446.7
Selling, general and administrative expenses	13.4			0.2			307.5			—			321.1
Research and development expenses	—			—			66.1			—			66.1
Restructuring charges, net	—			—			3.8			—			3.8
Non-restructuring impairments	—			—			214.3			—			214.3
Operating loss	(13.4		)	(0.2		)	(145.0		)	—			(158.6		)

Interest expense	(2.9		)	(81.1		)	(17.9		)	10.6			(91.3		)
Interest income	—			0.1			11.0			(10.6		)	0.5
Other income (expense), net	1.8			0.7			(51.6		)	—			(49.1		)
Intercompany interest and fees	(4.4		)	—			4.4			—			—
Equity in net income of subsidiaries	(136.5		)	35.2			(44.5		)	145.8			—
Loss from continuing operations before income taxes	(155.4		)	(45.3		)	(243.6		)	145.8			(298.5		)
Benefit from income taxes	(2.2		)	(0.3		)	(119.2		)	—			(121.7		)
Loss from continuing operations	(153.2		)	(45.0		)	(124.4		)	145.8			(176.8		)
Income from discontinued operations, net of income taxes	—			0.4			23.2			—			23.6
Net loss	(153.2		)	(44.6		)	(101.2		)	145.8			(153.2		)
Other comprehensive income, net of tax	13.1			13.1			26.0			(39.1		)	13.1
Comprehensive loss	$	(140.1	)	$	(31.5	)	$	(75.2	)	$	106.7		$	(140.1	)

Schedule of Condensed Consolidating and Combining Statements of Cash Flows

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

Fiscal year ended December 28, 2018

(in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.			Other Subsidiaries			Eliminations			Consolidated
Cash Flows From Operating Activities:
Net cash from operating activities	$	438.9		$	80.1		$	1,702.5		$	(1,556.0	)	$	665.5
Cash Flows From Investing Activities:
Capital expenditures	—			—			(127.0		)	—			(127.0		)
Acquisitions, net of cash acquired	—			—			(699.9		)	—			(699.9		)
Proceeds from disposal of discontinued operations, net of cash	—			—			313.0			—			313.0
Intercompany loan investment	(385.6		)	(90.1		)	(502.0		)	977.7			—
Investment in subsidiary	—			(220.0		)	—			220.0			—
Proceeds from sale of subsidiary	—			—			—			—			—
Acquisition of subsidiary	—			—			—			—			—
Other	—			—			33.6			—			33.6
Net cash from investing activities	(385.6		)	(310.1		)	(982.3		)	1,197.7			(480.3		)
Cash Flows From Financing Activities:
Issuance of external debt	—			600.0			90.3			—			690.3
Repayment of external debt and capital leases	—			(1,289.4		)	(404.2		)	—			(1,693.6		)
Debt financing costs	—			(12.1		)	—			—			(12.1		)
Proceeds from exercise of share options	1.0			—			—			—			1.0
Intercompany loan borrowings	—			977.7			—			(977.7		)	—
Intercompany dividends	—			(814.2		)	(741.8		)	1,556.0			—
Capital contribution	—			—			220.0			(220.0		)	—
Repurchase of shares	(57.5		)	—			—			—			(57.5		)
Other	2.9			—			(26.0		)	—			(23.1		)
Net cash from financing activities	(53.6		)	(538.0		)	(861.7		)	358.3			(1,095.0		)
Effect of currency rate changes on cash	—			—			(1.8		)	—			(1.8		)
Net decrease in cash, cash equivalents and restricted cash	(0.3		)	(768.0		)	(143.3		)	—			(911.6		)
Cash, cash equivalents and restricted cash at beginning of period	0.7			908.8			369.6			—			1,279.1
Cash, cash equivalents and restricted cash at end of period	$	0.4		$	140.8		$	226.3		$	—		$	367.5

Cash and cash equivalents at end of period	$	0.4		$	140.8		$	207.7		$	—		$	348.9
Restricted cash included in prepaid expenses and other assets at end of period	—			—			—			—			—
Restricted cash included in other long-term assets at end of period	—			—			18.6			—			18.6
Cash, cash equivalents and restricted cash at end of period	$	0.4		$	140.8		$	226.3		$	—		$	367.5

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

Fiscal year ended December 29, 2017

(in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.				Other Subsidiaries				Eliminations			Consolidated
Cash Flows From Operating Activities:
Net cash from operating activities	$	1,233.2		$	1,139.4			$	2,274.9			$	(3,920.2	)	$	727.3
Cash Flows From Investing Activities:
Capital expenditures	—			—				(186.1		)		—			(186.1		)
Acquisitions, net of cash acquired	—			—				(76.3		)		—			(76.3		)
Proceeds from disposal of discontinued operations, net of cash	—			—				576.9				—			576.9
Intercompany loan investment	(589.5		)	—				(1,157.9		)		1,747.4			—
Investment in subsidiary	—			(1,475.3		)		—				1,475.3			—
Other	—			—				3.9				—			3.9
Net cash from investing activities	(589.5		)	(1,475.3		)		(839.5		)	—	3,222.7			318.4
Cash Flows From Financing Activities:
Issuance of external debt	—			1,400.0				65.0				—			1,465.0
Repayment of external debt and capital leases	—			(764.5		)		(152.7		)		—			(917.2		)
Debt financing costs	—			(12.7		)		—				—			(12.7		)
Proceeds from exercise of share options	4.1			—				—				—			4.1
Intercompany loan borrowings	—			1,747.4				—				(1,747.4		)	—
Intercompany dividends	—			(1,170.0		)		(2,750.2		)		3,920.2			—
Capital contribution	—			—				1,475.3				(1,475.3		)	—
Repurchase of shares	(651.7		)	—				—				—			(651.7		)
Other	4.1			—				(21.8		)		—			(17.7		)
Net cash from financing activities	(643.5		)	1,200.2			—	(1,384.4		)		697.5			(130.2		)
Effect of currency rate changes on cash	—			—				2.5				—			2.5
Net increase in cash, cash equivalents and restricted cash	0.2			864.3				53.5				—			918.0
Cash, cash equivalents and restricted cash at beginning of period	0.5			44.5				316.1				—			361.1
Cash, cash equivalents and restricted cash at end of period	$	0.7		$	908.8			$	369.6			$	—		$	1,279.1

Cash and cash equivalents at end of period	$	0.7		$	908.8			$	351.4			$	—		$	1,260.9
Restricted cash included in prepaid expenses and other assets at end of period	—			—				—				—			—
Restricted cash included in other long-term assets at end of period	—			—				18.2				—			18.2
Cash, cash equivalents and restricted cash at end of period	$	0.7		$	908.8			$	369.6			$	—		$	1,279.1

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

Fiscal year ended September 30, 2016

(in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.				Other Subsidiaries				Eliminations			Consolidated
Cash Flows From Operating Activities:
Net cash from operating activities	$	17.9		$	(47.4	)		$	1,214.1			$	—		$	1,184.6
Cash Flows From Investing Activities:
Capital expenditures	—			—				(182.9		)		—			(182.9		)
Acquisitions, net of cash acquired	—			—				(245.4		)		—			(245.4		)
Proceeds from disposal of discontinued operations, net of cash	—			234.0				32.7				—			266.7
Intercompany loan investment	—			(175.2		)		(1,714.5		)		1,889.7			—
Investment in subsidiary	—			(861.2		)		—				861.2			—
Proceeds from sale of subsidiary	3.4			—				—				(3.4		)	—
Acquisition of subsidiary	—			—				(3.4		)		3.4			—
Other	—			—				6.0				—			6.0
Net cash from investing activities	3.4			(802.4		)		(2,107.5		)	—	2,750.9			(155.6		)
Cash Flows From Financing Activities:
Issuance of external debt	—			—				98.3				—			98.3
Repayment of external debt and capital leases	—			(549.2		)		(19.4		)		—			(568.6		)
Debt financing costs	—			—				(0.1		)		—			(0.1		)
Proceeds from exercise of share options	14.0			—				—				—			14.0
Intercompany loan borrowings	617.8			1,271.9				—				(1,889.7		)	—
Capital contribution	—			—				861.2				(861.2		)	—
Repurchase of shares	(652.9		)	—				—				—			(652.9		)
Other	—			—				(53.0		)		—			(53.0		)
Net cash from financing activities	(21.1		)	722.7			—	887.0				(2,750.9		)	(1,162.3		)
Effect of currency rate changes on cash	—			—				0.3				—			0.3
Net increase (decrease) in cash, cash equivalents and restricted cash	0.2			(127.1		)		(6.1		)		—			(133.0		)
Cash, cash equivalents and restricted cash at beginning of period	0.1			152.1				280.4				—			432.6
Cash, cash equivalents and restricted cash at end of period	$	0.3		$	25.0			$	274.3			$	—		$	299.6

Cash and cash equivalents at end of period	$	0.3		$	25.0			$	255.2			$	—		$	280.5
Restricted cash included in prepaid expenses and other assets at end of period	—			—				0.1				—			0.1
Restricted cash included in other long-term assets at end of period	—			—				19.0				—			19.0
Cash, cash equivalents and restricted cash at end of period	$	0.3		$	25.0			$	274.3			$	—		$	299.6

MALLINCKRODT PLC

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

Three months ended December 30, 2016

(in millions)



	Mallinckrodt plc			Mallinckrodt International Finance S.A.				Other Subsidiaries				Eliminations			Consolidated
Cash Flows From Operating Activities:
Net cash from operating activities	$	17.4		$	(94.0	)		$	272.2			$	—		$	195.6
Cash Flows From Investing Activities:
Capital expenditures	—			—				(65.2		)		—			(65.2		)
Acquisitions, net of cash acquired	—			—				(1.8		)		—			(1.8		)
Intercompany loan investment	—			—				(424.7		)		424.7			—
Subsidiary dividend proceeds	—			—				—				—			—
Investment in subsidiary	—			(260.0		)		—				260.0			—
Other	—			—				(10.2		)		—			(10.2		)
Net cash from activities	—			(260.0		)		(501.9		)	—	684.7			(77.2		)
Cash Flows From Financing Activities:
Issuance of external debt	—			175.0				15.0				—			190.0
Repayment of external debt and capital leases	—			(86.2		)		(0.5		)		—			(86.7		)
Debt financing costs	—			—				—				—			—
Proceeds from exercise of share options	0.4			—				—				—			0.4
Subsidiary dividend payment	—			—				—				—			—
Intercompany loan borrowings	140.0			284.7				—				(424.7		)	—
Capital contribution	—			—				260.0				(260.0		)	—
Repurchase of shares	(158.8		)	—				—				—			(158.8		)
Other	1.2			—				—				—			1.2
Net cash from financing activities	(17.2		)	373.5			—	274.5				(684.7		)	(53.9		)
Effect of currency rate changes on cash	—			—				(3.0		)		—			(3.0		)
Net increase in cash, cash equivalents and restricted cash	0.2			19.5				41.8				—			61.5
Cash, cash equivalents and restricted cash at beginning of period	0.3			25.0				274.3				—			299.6
Cash, cash equivalents and restricted cash at end of period	$	0.5		$	44.5			$	316.1			$	—		$	361.1

Cash and cash equivalents at end of period	$	0.5		$	44.5			$	297.0			$	—		$	342.0
Restricted cash included in prepaid expenses and other assets at end of period	—			—				0.1				—			0.1
Restricted cash included in other long-term assets at end of period	—			—				19.0				—			19.0
Cash, cash equivalents and restricted cash at end of period	$	0.5		$	44.5			$	316.1			$	—		$	361.1

Transition Period (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions

3 Months Ended

12 Months Ended

Dec. 28, 2018

Sep. 28, 2018

Jun. 29, 2018

Mar. 30, 2018

Dec. 29, 2017

Sep. 29, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 30, 2016

Dec. 25, 2015

Dec. 28, 2018

Dec. 29, 2017

Sep. 30, 2016

Transition Period Income Statement [Abstract]

$ 834.9

$ 799.9

$ 825.5

$ 755.3

$ 792.3

$ 793.9

$ 824.5

$ 810.9

$ 829.9

$ 811.2

$ 3,215.6

$ 3,221.6

$ 3,380.8

383.2

360.0

^[1]

1,744.4

1,564.1

1,523.2

363.3

^[2]

366.4

^[2]

394.0

^[2]

347.5

^[2]

421.0

^[2]

400.6

^[2]

416.1

^[2]

419.8

^[2]

446.7

451.2

^[1]

1,471.2

1,657.5

1,857.6

321.1

221.8

^[1]

834.1

849.7

913.7

66.1

61.3

^[1]

361.1

276.9

261.2

Restructuring Charges

3.8

4.1

103.0

31.2

32.7

214.3

0.0

3,893.1

63.7

16.9

Operating Income (Loss)

158.6

164.0

^[1]

3,720.9

(492.9)

(633.1)

(91.3)

(97.8)

(370.2)

(369.1)

(384.6)

0.5

0.2

8.2

4.6

1.3

(Loss) income from continuing operations before income taxes

(49.1)

0.1

^[1]

30.9

(66.8)

(16.4)

(298.5)

66.5

(4,052.0)

61.6

233.4

Benefit from income taxes

(121.7)

(37.3)

(430.1)

(1,709.6)

(255.6)

Income (loss) from discontinued operations, net of income taxes

(3,718.4)

^[3]

114.2

^[3]

3.2

^[3]

(20.9)

^[3]

1,607.4

^[3]

64.3

^[3]

70.6

^[3]

28.9

^[3]

(176.8)

103.8

(3,621.9)

1,771.2

489.0

0.0

(0.4)

12.4

2.9

1.3

(0.6)

(7.8)

370.3

23.6

107.3

14.9

363.2

154.7

Income (Loss) from Continuing Operations, Per Basic Share

$ (3,718.4)

$ 113.8

$ 15.6

$ (18.0)

$ 1,608.7

$ 63.7

$ 62.8

$ 399.2

$ (153.2)

$ 211.1

$ (3,607.0)

$ 2,134.4

$ 643.7

$ (44.64)

^[4]

$ 1.37

^[4]

$ 0.04

^[4]

$ (0.24)

^[4]

$ 17.43

^[4]

$ 0.66

^[4]

$ 0.72

^[4]

$ 0.28

^[4]

$ (1.67)

$ 0.90

$ (43.12)

$ 18.13

$ 4.42

Income from discontinued operations, net of income taxes

0.22

0.93

0.18

3.72

1.40

Earnings Per Share, Basic

$ (1.45)

$ 1.83

$ (42.94)

$ 21.85

$ 5.82

Basic weighted-average shares outstanding

105.7

115.4

84.0

97.7

110.6

Income (Loss) from Discontinued Operations, Per Diluted Share

$ (44.64)

^[4]

$ 1.34

^[4]

$ 0.04

^[4]

$ (0.24)

^[4]

$ 17.40

^[4]

$ 0.66

^[4]

$ 0.72

^[4]

$ 0.28

^[4]

$ (1.67)

$ 0.89

$ (43.12)

$ 18.09

$ 4.39

0.22

0.92

0.18

3.71

1.39

Earnings Per Share, Diluted

$ (1.45)

$ 1.82

$ (42.94)

$ 21.80

$ 5.77

Weighted Average Number of Shares Outstanding, Diluted

105.7

116.3

84.0

97.9

111.5

[1]	Financial data for this period has been adjusted to reflect the change in accounting for pension and postretirement costs with the adoption of Accounting Standards Update ("ASU") 2017-07. See Note 4 for further information on this ASU.
[2]	Financial data for each period has been adjusted to reflect the change in accounting for pension and postretirement costs with the adoption of ASU 2017-07. See Note 4 for further information.
[3]	(Loss) income from continuing operations for the quarter ended December 28, 2018 reflects impairment charges for goodwill and an IPR&D asset. See Note 13 for further information. Income from continuing operations for the quarter ended December 29, 2017 reflects one-time effects for the completion of the reorganization of the Company's legal entity ownership and the impact of the TCJA.
[4]	Quarterly and annual computations are prepared independently. Therefore, the sum of each quarter may not necessarily total the fiscal period amounts noted elsewhere within this Annual Report on Form 10-K.

Transition Period Transition Period Cash Flow (Details) - USD ($) $ in Millions	3 Months Ended										12 Months Ended
	Dec. 28, 2018	Sep. 28, 2018	Jun. 29, 2018	Mar. 30, 2018	Dec. 29, 2017	Sep. 29, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 30, 2016	Dec. 25, 2015	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016	Sep. 25, 2015
Transition Period Income Statement [Abstract]
Net (loss) income	$ (3,718.4)	$ 113.8	$ 15.6	$ (18.0)	$ 1,608.7	$ 63.7	$ 62.8	$ 399.2	$ (153.2)	$ 211.1	$ (3,607.0)	$ 2,134.4	$ 643.7
Depreciation and amortization									203.2	206.0	852.1	808.3	834.5
Share-based compensation									11.0	8.5	34.6	59.2	42.9
Deferred income taxes									(204.3)	(108.9)	(541.5)	(1,744.1)	(432.9)
Asset Impairment Charges									214.3	0.0	3,893.1	63.7	16.9
Inventory provisions									8.5	1.2	37.9	34.1	29.2
Gain (Loss) on Disposition of Business									0.0	(97.0)	(0.8)	418.1	95.3
Other Noncash Income (Expense)									9.2	2.9	50.9	21.4	(29.6)
Increase (Decrease) in Accounts Receivable									36.5	68.4	145.8	16.2	(31.2)
Increase (Decrease) in Inventories									(26.3)	(14.5)	(63.1)	23.6	17.3
Accounts payable									5.4	(13.0)	24.6	(25.8)	(9.7)
Income taxes									0.6	82.3	99.0	(34.2)	93.9
Increase (Decrease) in Other Operating Assets and Liabilities, Net									109.1	(35.6)	(5.5)	89.0	(17.9)
Net Cash Provided by (Used in) Operating Activities, Continuing Operations									195.6	311.4	665.5	727.3	1,184.6
Capital expenditures									(65.2)	(49.0)	(127.0)	(186.1)	(182.9)
Payments to Acquire Businesses, Net of Cash Acquired									(1.8)	0.0	699.9	76.3	245.4
Proceeds from Divestiture of Businesses, Net of Cash Divested									0.0	263.7	313.0	576.9	266.7
Other									(10.2)	0.7	(33.6)	(3.9)	(6.0)
Net cash from investing activities									(77.2)	215.4	(480.3)	318.4	(155.6)
Issuance of external debt									190.0	62.0	690.3	1,465.0	98.3
Repayment of external debt and capital lease obligation									(86.7)	(129.6)	(1,693.6)	(917.2)	(568.6)
Debt financing costs									0.0	(0.1)	(12.1)	(12.7)	(0.1)
Proceeds from exercise of share options									0.4	3.6	1.0	4.1	14.0
Repurchase of shares									(158.8)	(275.4)	(57.5)	(651.7)	(652.9)
Other									1.2	(30.0)	(23.1)	(17.7)	(53.0)
Net cash from financing activities									(53.9)	(369.5)	(1,095.0)	(130.2)	(1,162.3)
Effect of currency rate changes on cash									(3.0)	(1.5)	(1.8)	2.5	0.3
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect									61.5	155.8	(911.6)	918.0	(133.0)
Cash and cash equivalents	348.9				1,260.9				342.0	521.9	348.9	1,260.9	280.5
Restricted Cash and Investments, Current	0.0				0.0				0.1	47.5	0.0	0.0	0.1
Restricted Cash and Investments, Noncurrent	18.6				18.2				19.0	19.0	18.6	18.2	19.0
Cash and Cash Equivalents, Including Restricted Cash	$ 367.5				$ 1,279.1				$ 361.1	$ 588.4	$ 367.5	$ 1,279.1	$ 299.6	$ 432.6

Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016
Schedule of Significant Accounting Policies [Line Items]
Foreign Currency Transaction Gain (Loss), before Tax	$ 9.0	$ (3.1)	$ 2.5	$ (3.6)
Foreign currency transactions gain (loss), derivative instruments	(8.9)	$ 2.7	(4.1)	0.2
Customer relationships
Schedule of Significant Accounting Policies [Line Items]
Finite-lived intangible assets - useful lives		12 years
Minimum \| Completed Technology
Schedule of Significant Accounting Policies [Line Items]
Finite-lived intangible assets - useful lives		5 years
Minimum \| Licensing Agreements
Schedule of Significant Accounting Policies [Line Items]
Finite-lived intangible assets - useful lives		7 years
Minimum \| Trademarks
Schedule of Significant Accounting Policies [Line Items]
Finite-lived intangible assets - useful lives		13 years
Minimum \| Buildings
Schedule of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life		10 years
Minimum \| Leasehold improvements
Schedule of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life		1 year
Minimum \| Capitalized software
Schedule of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life		1 year
Minimum \| Machinery and equipment
Schedule of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life		1 year
Maximum \| Completed Technology
Schedule of Significant Accounting Policies [Line Items]
Finite-lived intangible assets - useful lives		25 years
Maximum \| Licensing Agreements
Schedule of Significant Accounting Policies [Line Items]
Finite-lived intangible assets - useful lives		30 years
Maximum \| Trademarks
Schedule of Significant Accounting Policies [Line Items]
Finite-lived intangible assets - useful lives		30 years
Maximum \| Buildings
Schedule of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life		45 years
Maximum \| Leasehold improvements
Schedule of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life		20 years
Maximum \| Capitalized software
Schedule of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life		10 years
Maximum \| Machinery and equipment
Schedule of Significant Accounting Policies [Line Items]
Property, plant and equipment, useful life		20 years
Shipping and Handling [Member]
Schedule of Significant Accounting Policies [Line Items]
Shipping costs	$ 3.4	$ 12.8	$ 13.9	$ 12.4

Recently Issued Accounting Standards Narrative (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016	Dec. 30, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification		$ 1.1	$ (72.1)
Accounting Standards Update 2016-18 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification			47.3
Other Assets \| Accounting Standards Update 2016-16 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets		67.2
Prepaid Expenses and Other Current Assets [Member] \| Accounting Standards Update 2016-16 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets		7.8
Retained Earnings \| Accounting Standards Update 2016-16 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets		75.0
Retained Earnings \| ASU 2016-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets	$ 2.9
Retained Earnings \| Accounting Standards Update 2016-01 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets					$ 1.5
Retained Earnings \| Accounting Standards Update 2014-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets					$ 1.1
Retained Earnings \| Accounting Standards Update 2016-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification		$ 85.0
Other Nonoperating Income (Expense) [Member] \| Accounting Standards Update 2017-07 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Change on Net Income	48.2		72.8	$ 15.8
Selling, general and administrative \| Accounting Standards Update 2017-07 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Change on Net Income	47.2		71.2	11.6
Cost of Sales \| Accounting Standards Update 2017-07 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Change on Net Income	0.9		1.2	2.6
Research and Development Expense [Member] \| Accounting Standards Update 2017-07 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Change on Net Income	0.1		0.4	1.0
Restructuring Charges [Member] \| Accounting Standards Update 2017-07 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Effect of Change on Net Income	$ 0.0		$ 0.0	$ 0.6

Revenue from Contracts with Customers (Details) - USD ($) $ in Millions	3 Months Ended										12 Months Ended
	Dec. 28, 2018	Sep. 28, 2018	Jun. 29, 2018	Mar. 30, 2018	Dec. 29, 2017	Sep. 29, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 30, 2016	Dec. 25, 2015	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016
Disaggregation of Revenue [Line Items]
Revenue Reserves	$ 405.4				$ 376.6						$ 405.4	$ 376.6
Contract with Customer, Liability, Noncurrent	15.1				6.6						15.1	6.6
Contract with Customer, Liability	35.5				20.6						35.5	20.6
Revenue Reserve Provision											2,387.5
Capitalized Contract Cost, Gross	28.4										28.4
Contract with Customer, Liability, Current	20.4				14.0						20.4	14.0
Deferred Revenue, Revenue Recognized											12.5
Revenue Reserve Payments or Credits											(2,358.7)
Net sales	834.9	$ 799.9	$ 825.5	$ 755.3	792.3	$ 793.9	$ 824.5	$ 810.9	$ 829.9	$ 811.2	3,215.6	3,221.6	$ 3,380.8
Capitalized Contract Cost, Amortization											$ 7.4
Transferred over Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Transferred over Time											17.10%
Transferred at Point in Time [Member]
Disaggregation of Revenue [Line Items]
Revenue from Contract with Customer, Transferred at Point in Time											82.90%
Royalty [Member]
Disaggregation of Revenue [Line Items]
Net sales											$ 81.3
Sales Returns and Allowances
Disaggregation of Revenue [Line Items]
Revenue Reserves	34.0				34.5						34.0	34.5
Revenue Reserve Provision											39.3
Revenue Reserve Payments or Credits											(39.8)
Rebates and Chargebacks [Member]
Disaggregation of Revenue [Line Items]
Revenue Reserves	354.3				327.4						354.3	327.4
Revenue Reserve Provision											2,281.3
Revenue Reserve Payments or Credits											(2,254.4)
Other Sales Deductions [Member]
Disaggregation of Revenue [Line Items]
Revenue Reserves	$ 17.1				$ 14.7						17.1	$ 14.7
Revenue Reserve Provision											66.9
Revenue Reserve Payments or Credits											$ (64.5)

Revenue from Contracts with Customers Future Performance Obligations (Details) $ in Millions	Dec. 28, 2018 USD ($)
Current Fiscal Year [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Amount	$ 145.0
Year Two [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Amount	127.3
Year Three [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Amount	32.6
Thereafter [Member]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, Remaining Performance Obligation, Amount	$ 3.2

Discontinued Operations and Divestitures (Income (loss) from Discontinued Operations) (Details) - USD ($)
$ in Millions

3 Months Ended

12 Months Ended

Dec. 28, 2018

Sep. 28, 2018

Jun. 29, 2018

Mar. 30, 2018

Dec. 29, 2017

Sep. 29, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 30, 2016

Dec. 25, 2015

Dec. 28, 2018

Dec. 29, 2017

Sep. 30, 2016

Jan. 27, 2017

Nov. 27, 2015

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Income (loss) from discontinued operations, net of income taxes

$ 0.0

$ 0.4

$ (12.4)

$ (2.9)

$ (1.3)

$ 0.6

$ 7.8

$ (370.3)

$ (23.6)

$ (107.3)

$ (14.9)

$ (363.2)

$ (154.7)

Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal

0.0

(0.8)

56.9

0.0

Discontinued Operation, Tax Effect of Discontinued Operation

0.0

(0.2)

0.4

0.3

15.3

1.4

5.4

43.5

Benefit from income taxes

(121.7)

$ (37.3)

(430.1)

(1,709.6)

(255.6)

Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount

3,672.8

^[1],[2]

(123.0)

(235.7)

(219.9)

(249.3)

Non-U.K.

82.0

113.0

37.7

120.5

Contrast Media and Delivery Systems

(0.5)

1.4

0.6

0.7

International Deferred

203.2

$ 544.3

1,748.3

377.1

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

$ 270.0

61.0

Selling, general and administrative

46.9

20.3

Other

1.2

Loss from discontinued operations

(7.4)

Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax

95.3

Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax

87.9

Income tax expense (benefit)

(2.5)

Income from discontinued operations net of tax

90.4

Nuclear Imaging

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Disposal Group, Including Discontinued Operation, Upfront Consideration

$ 690.0

574.0

Discontinued Operation, Amounts of Material Contingent Liabilities Remaining

$ 77.0

99.4

31.6

418.6

Selling, general and administrative

44.7

15.6

216.6

16.4

7.8

83.7

Loss from discontinued operations

0.0

2.3

Other

0.2

5.7

15.0

38.1

8.4

110.3

Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax

0.0

362.8

0.0

Discontinued Operation, Tax Effect of Discontinued Operation

15.3

5.2

49.0

Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax

38.1

371.2

110.3

Income from discontinued operations net of tax

13.6

22.8

366.0

61.3

Discontinued Operation, Amount of Adjustment to Prior Period Gain (Loss) on Disposal, before Income Tax

6.0

Contingent consideration received, equity certificates

9.0

Interest Rate, Equity Certificates

10.00%

Discontinued Operation, Tax Effect of Adjustment to Prior Period Gain (Loss) on Disposal

$ 1.4

Mallinckrodt Baker

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Income (loss) from discontinued operations, net of income taxes

$ (0.6)

$ 0.3

$ 0.6

$ (3.0)

[1]	During the three months ended December 30, 2016, the rate difference between U.K. and non-U.K. jurisdictions was favorably impacted by a benefit of $16.1 million on a $102.0 million settlement with the Federal Trade Commission and a benefit of $34.5 million on a $207.0 million goodwill impairment in the Specialty Generics reporting unit.
[2]	Includes the impact of certain recurring valuation allowances for U.K. and non-U.K. jurisdictions.

Discontinued Operations and Divestitures, Significant Cash and Non-Cash Transactions (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 30, 2016	Dec. 29, 2017	Sep. 30, 2016
Contrast Media and Delivery Systems
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Capital expenditures			$ 1.6
Nuclear Imaging
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation	$ 0.0	$ 0.0	20.9
Capital expenditures	$ 2.0	$ 0.3	$ 9.7

Discontinued Operations and Divestitures (Narrative) (Details) - USD ($)
$ in Millions

3 Months Ended

12 Months Ended

Dec. 28, 2018

Sep. 28, 2018

Jun. 29, 2018

Mar. 30, 2018

Dec. 29, 2017

Sep. 29, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 30, 2016

Dec. 25, 2015

Dec. 28, 2018

Dec. 29, 2017

Sep. 30, 2016

Mar. 16, 2018

Mar. 17, 2017

Jan. 27, 2017

Nov. 27, 2015

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

$ (190.1)

$ 214.3

3,893.1

$ 63.7

$ 16.9

Provision for (benefit from) income taxes

3,672.8

121.7

$ 37.3

430.1

1,709.6

255.6

Tax (benefit) expense on income (loss) from discontinued operations

15.3

1.4

5.4

43.5

Income (loss) from discontinued operations, net of income taxes

$ 0.0

$ 0.4

$ (12.4)

$ (2.9)

$ (1.3)

$ 0.6

$ 7.8

$ (370.3)

(23.6)

$ (107.3)

(14.9)

(363.2)

(154.7)

Deferred Foreign Income Tax Expense (Benefit)

(0.8)

(56.9)

Non-U.K.

82.0

113.0

37.7

120.5

(203.2)

(544.3)

(1,748.3)

(377.1)

Deferred Income Tax Expense (Benefit)

203.7

542.9

1,747.7

376.4

0.0

(0.2)

0.4

0.3

Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount

0.0

0.8

(56.9)

0.0

^[1],[2]

(123.0)

$ (235.7)

(219.9)

(249.3)

Nuclear Imaging

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Capital expenditures

2.0

0.3

9.7

Disposal Group, Including Discontinued Operation, Upfront Consideration

$ 690.0

574.0

Tax (benefit) expense on income (loss) from discontinued operations

15.3

5.2

49.0

Discontinued Operation, Amounts of Material Contingent Liabilities Remaining

$ 77.0

Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax

0.0

362.8

0.0

Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax

15.0

38.1

8.4

110.3

Discontinued Operation, Amount of Adjustment to Prior Period Gain (Loss) on Disposal, before Income Tax

6.0

Contingent consideration received, equity certificates

9.0

Interest Rate, Equity Certificates

10.00%

Discontinued Operation, Tax Effect of Adjustment to Prior Period Gain (Loss) on Disposal

1.4

Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax

$ 13.6

22.8

366.0

61.3

Contrast Media and Delivery Systems

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Capital expenditures

1.6

Income tax expense (benefit)

$ 270.0

(2.5)

Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax

95.3

Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax

(7.4)

Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax

90.4

Mallinckrodt Baker

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Income (loss) from discontinued operations, net of income taxes

$ (0.6)

$ 0.3

0.6

$ (3.0)

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Disposal Group, Including Discontinued Operation, Upfront Consideration

51.5

$ 153.0

Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent

(49.9)

Disposal Group, Not Discontinued Operation, Consideration

185.0

Disposal Group, Not Discontinued Operation, Contingent Consideration

(12.1)

Disposal Group, Not Discontinued Operations, Account Receivable Consideration

(0.8)

$ 13.7

Intrathecal Therapy [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Disposal Group, Not Discontinued Operation, Consideration

$ 203.0

Disposal Group, Not Discontinued Operation, Fixed Consideration

171.0

Disposal Group, Not Discontinued Operation, Contingent Consideration

32.0

Disposal Group, Not Discontinued Operation, Upfront Consideration

17.0

Disposal Group, Not Discontinued Operation, Note Receivable Consideration

154.0

Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Pre-tax

56.6

Proceeds from Collection of Notes Receivable

154.0

Disposal Group, Not Discontinued Operation, Other Commitment

$ 3.1

$ 6.5

3.1

$ 6.5

$ 7.3

Other | Intrathecal Therapy [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Goodwill [Member] | Intrathecal Therapy [Member]

48.7

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

$ 49.8

[1]	During the three months ended December 30, 2016, the rate difference between U.K. and non-U.K. jurisdictions was favorably impacted by a benefit of $16.1 million on a $102.0 million settlement with the Federal Trade Commission and a benefit of $34.5 million on a $207.0 million goodwill impairment in the Specialty Generics reporting unit.
[2]	Includes the impact of certain recurring valuation allowances for U.K. and non-U.K. jurisdictions.

Acquisitions and License Agreements (Narrative) (Details) - USD ($)

3 Months Ended

12 Months Ended

Aug. 06, 2018

Feb. 13, 2018

Dec. 11, 2017

Oct. 02, 2017

Sep. 25, 2017

Aug. 31, 2016

Feb. 01, 2016

Dec. 28, 2018

Sep. 28, 2018

Jun. 29, 2018

Mar. 30, 2018

Dec. 29, 2017

Sep. 29, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 30, 2016

Dec. 25, 2015

Dec. 28, 2018

Dec. 29, 2017

Sep. 30, 2016

Sep. 26, 2014

Aug. 04, 2018

Apr. 05, 2018

Jan. 06, 2017

Aug. 31, 2014

Payments to Acquire Businesses, Net of Cash Acquired

$ (1,800,000)

$ 0

$ 699,900,000

$ 76,300,000

$ 245,400,000

$ 6,134,000,000.0

$ 6,492,600,000

6,134,000,000.0

6,492,600,000

Non-cash impairment charges

834,900,000

$ 799,900,000

$ 825,500,000

$ 755,300,000

792,300,000

$ 793,900,000

$ 824,500,000

$ 810,900,000

829,900,000

811,200,000

3,215,600,000

3,221,600,000

3,380,800,000

214,300,000

3,893,100,000

63,700,000

16,900,000

7,300,000

Operating Income (Loss)

(158,600,000)

$ (164,000,000.0)

^[1]

(3,720,900,000)

492,900,000

633,100,000

Noninterest Income, Other Operating Income

175,700,000

740,200,000

694,500,000

700,100,000

15,500,000

$ 0

847,600,000

1,200,000,000

366,300,000

190,500,000

Operating Income (Loss)

(369,100,000)

62,900,000

CPP [Member]

Payment for License Option Exercised

$ 10,000,000.0

Potential reduction of future payment

$ 185,000,000.0

$ 15,000,000.0

Business Combination, Contingent Consideration, Payment

$ 5,000,000.0

Business Combination, Consideration Transferred, Other

^[2]

$ 22,000,000.0

42,400,000

64,400,000

^[2]

1,900,000

40,500,000

1,900,000

^[3]

$ 75,000,000.0

Business Combination, Consideration Transferred, Other

^[4]

$ 35,000,000.0

80,400,000

73,100,000

^[4]

30,000,000.0

Business Combination, Cash Paid for Consideration

345,000,000.0

37,200,000

$ 43,200,000

Business Combination, Consideration Transferred, Other

$ 54,900,000

76,000,000.0

130,900,000

1,000,000.0

$ 121,000,000.0

Business Combination, Consideration Transferred, Other

^[5]

$ 52,000,000.0

173,500,000

225,500,000

^[5]

$ 395,000,000.0

NeuroproteXeon [Member]

Business Combination, Consideration Transferred, Other

$ 10,000,000.0

Business Combination, Contingent Consideration, Potential Payment

$ 25,000,000.0

Milestone Payment

5,000,000.0

Contingent payment, maximum additional amount

20,000,000.0

Mesoblast [Member]

Payments to Acquire Marketable Securities

21,500,000

Available-for-sale Securities, Current

$ 19,700,000

Intangible Assets, Current

$ 1,800,000

Proceeds from Sale of Available-for-sale Securities, Equity

25,500,000

Marketable Securities, Realized Gain (Loss)

3,400,000

Questcor Pharmaceuticals, Inc.

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability

76,200,000

111,800,000

76,200,000

111,800,000

$ 195,400,000

115,000,000.0

PreveLeak [Member] | Hemostasis Products

63,700,000

Business Combination, Contingent Consideration, Payment

$ 12,000,000.0

Bristol-Myers Squibb | Licensing Agreements

Depomed | Licensing Agreements

Royalties paid

14,700,000

76,900,000

53,900,000

46,300,000

Contingent payment, maximum additional amount

64,000,000.0

Milestone Payments

22,000,000.0

$ 10,000,000.0

Xartemis [Member]

Prepaid Expenses and Other Current Assets [Member] | CPP [Member]

7,300,000

Payment for License Option Exercised, Capitalized

2,700,000

Term Loan due 2025 [Member] | Secured Debt

Loans Payable

597,000,000.0

Term Loan due 2025 [Member] | Secured Debt | Sucampo [Member]

591,000,000.0

2017 Revolving Credit Facility | Debentures

Loans Payable

600,000,000.0

Sucampo 2021 Notes [Member] | Convertible Debt Securities [Member]

900,000,000.0

$ 220,000,000.0

$ 900,000,000.0

220,000,000.0

900,000,000.0

$ 300,000,000.0

Debt instrument, face amount

3.25%

$ 1,000

Debt Conversion, Converted Instrument, Amount

$ 1,221

Cost of Sales

Amortization Of Inventory Step-Up To Cost Of Sales

$ 3,600,000

120,800,000

$ 10,100,000

$ 24,300,000

Cost of Sales | Sucampo [Member]

Amortization Of Inventory Step-Up To Cost Of Sales

118,800,000

Research and Development Expense [Member] | CPP [Member]

Payment for License Option Exercised, Expensed

$ 7,300,000

[1]

Financial data for this period has been adjusted to reflect the change in accounting for pension and postretirement costs with the adoption of Accounting Standards Update ("ASU") 2017-07. See Note 4 for further information on this ASU.

[2]


(1)	$1.9 million of the total consideration, net of cash was paid in fiscal 2018, subsequent to the Company's December 11, 2017 acquisition date.

[3]

(1)

Of the $42.4 million net assets acquired for Ocera, $40.5 million and $1.9 million was paid in fiscal 2017 and 2018, respectively.

[4]

During fiscal 2018, the Company reduced the contingent consideration liability related to this acquisition to zero through the recognition of a $35.0 million fair value adjustment. Refer to Note 21 for further information.

[5]

During fiscal 2017, the Company recorded a non-restructuring impairment charge relating to its Raplixa intangible asset and reduced the associated contingent consideration liability. During fiscal 2018, the Company sold its Recothrom and PreveLeak assets to Baxter. Refer to Notes 6, 13 and 21, respectively, for further information.

Acquisitions and License Agreements (Schedule of Fair Value of Identifiable Assets Acquired and Liabilities Assumed) (Details) - USD ($)
$ in Millions

9 Months Ended

12 Months Ended

Feb. 13, 2018

Dec. 11, 2017

Sep. 25, 2017

Aug. 31, 2016

Feb. 01, 2016

Sep. 28, 2018

Dec. 28, 2018

Dec. 29, 2017

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest [Abstract]

Goodwill (non-tax deductible)

$ 0.0

$ 3,482.7

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest [Abstract]

$ 35.7

149.6

153.2

Intangible assets

919.5

^[1]

$ 248.6

25.8

1,532.4

109.4

33.3

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities

175.8

0.0

0.0

366.3

684.8

847.6

$ 847.6

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest [Abstract]

$ 1.3

0.2

Goodwill (non-tax deductible)

0.0

^[1]

55.1

1.9

158.3

4.3

0.0

22.1

54.9

1.0

82.3

76.0

130.9

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest [Abstract]

^[2]

$ 0.0

^[2],[3]

1.0

^[2]

0.0

^[1],[2]

18.0

^[2]

0.4

^[2]

83.9

^[2]

12.0

^[2]

0.0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Non-Current Contingent Consideration

16.7

^[2]

23.2

^[2]

12.8

^[3]

22.0

^[2]

0.0

^[2]

41.5

^[2],[3]

42.4

64.4

^[3]

1.9

40.5

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest [Abstract]

^[4]

$ 0.0

^[4]

1.3

^[4]

0.0

^[1],[4]

11.4

^[4]

0.1

^[4]

126.3

^[4]

14.5

^[4]

0.0

^[4]

8.7

^[4]

35.0

^[4]

30.0

^[4]

88.2

^[4]

38.1

73.1

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest [Abstract]

^[5]

$ 0.0

^[5]

3.3

Goodwill (non-tax deductible)

^[5]

94.6

Intangible assets

^[5]

132.7

^[1],[5]

3.3

^[5]

7.9

^[5]

241.8

^[5]

3.6

^[5]

10.6

^[5]

2.1

^[5]

52.0

^[5]

0.0

^[5]

68.3

^[5]

173.5

MNK-6105 [Member] | Ocera [Member]

$ 225.5

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest [Abstract]

Stannsoporfin [Member] | InfaCare [Member]

^[2]

64.5

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest [Abstract]

StrataGraft [Member] | In-process research and development | Stratatech [Member]

^[4]

$ 113.5

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest [Abstract]

$ 99.8

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest [Abstract]

Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3

151.4

42.7

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest [Abstract]

Fair Value, Measurements, Recurring | MNK-6105 [Member] | Fair Value, Inputs, Level 3 | Ocera [Member]

151.4

0.0

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest [Abstract]

Fair Value, Measurements, Recurring | Stannsoporfin [Member] | Fair Value, Inputs, Level 3 | InfaCare [Member]

$ 22.0

21.5

Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest [Abstract]

Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)

0.0

$ 35.0

$ (35.0)

[1]

Refer to Note 13 for further information relating to the full goodwill impairment recorded in fiscal 2018.

[2]

(1)

Of the $42.4 million net assets acquired for Ocera, $40.5 million and $1.9 million was paid in fiscal 2017 and 2018, respectively.

[3]


(1)	$1.9 million of the total consideration, net of cash was paid in fiscal 2018, subsequent to the Company's December 11, 2017 acquisition date.

[4]

[5]

Acquisitions and License Agreements (Schedule of Reconciliation of Total Consideration) (Details) - USD ($)
$ in Millions

3 Months Ended

12 Months Ended

Feb. 13, 2018

Dec. 11, 2017

Sep. 25, 2017

Aug. 31, 2016

Feb. 01, 2016

Mar. 30, 2018

Dec. 28, 2018

Dec. 29, 2017

^[1]

$ 63.4

^[1],[2]

1.0

64.4

^[1]

$ 1.9

$ 40.5

Business Combination, Consideration Transferred, Other

$ 1.9

42.4

^[1]

(22.0)

^[1],[2]

$ 42.4

$ 71.8

^[3]

1.3

Business Combination, Consideration Transferred, Other

73.1

80.4

^[3]

(35.0)

^[3]

$ 38.1

$ 130.7

0.2

Business Combination, Consideration Transferred, Other

130.9

76.0

(54.9)

$ 76.0

$ 222.2

^[4]

3.3

Business Combination, Consideration Transferred, Other

225.5

173.5

^[4]

(52.0)

^[4]

$ 173.5

$ 698.0

149.6

847.6

1,200.0

0.0

$ 847.6

[1]


(1)	$1.9 million of the total consideration, net of cash was paid in fiscal 2018, subsequent to the Company's December 11, 2017 acquisition date.

[2]

(1)

Of the $42.4 million net assets acquired for Ocera, $40.5 million and $1.9 million was paid in fiscal 2017 and 2018, respectively.

[3]

[4]

Acquisitions and License Agreements (Schedule of Intangible Assets Acquired) (Details) - USD ($)
$ in Millions

Feb. 13, 2018

Dec. 11, 2017

Sep. 25, 2017

Aug. 31, 2016

Feb. 01, 2016

Intangible Assets Acquired as Part of Business Combination [Line Items]

$ 847.6

Intangible Assets Acquired as Part of Business Combination [Line Items]

^[1],[2]

$ 42.4

Intangible Assets Acquired as Part of Business Combination [Line Items]

^[3]

$ 38.1

Intangible Assets Acquired as Part of Business Combination [Line Items]

^[4]

$ 173.5

Intangible Assets Acquired as Part of Business Combination [Line Items]

Amitiza | Sucampo [Member]

$ 76.0

Intangible Assets Acquired as Part of Business Combination [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

$ 634.0

Intangible assets acquired, weighted-average useful life

9 years

Rescula [Member] | Sucampo [Member]

14.00%

Intangible Assets Acquired as Part of Business Combination [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

$ 11.0

Intangible assets acquired, weighted-average useful life

8 years

VTS-270 [Member] | Sucampo [Member]

14.00%

Intangible Assets Acquired as Part of Business Combination [Line Items]

$ 274.5

MNK-6105 [Member] | Ocera [Member]

15.00%

Intangible Assets Acquired as Part of Business Combination [Line Items]

^[1]

$ 64.5

Stannsoporfin [Member] | InfaCare [Member]

15.50%

Intangible Assets Acquired as Part of Business Combination [Line Items]

^[3]

$ 113.5

StrataGraft [Member] | Stratatech [Member] | In-process research and development

13.50%

Intangible Assets Acquired as Part of Business Combination [Line Items]

$ 99.8

Raplixa [Member] | Hemostasis Products

16.50%

Intangible Assets Acquired as Part of Business Combination [Line Items]

Intangible assets acquired, weighted-average useful life

^[5]

15 years

^[5]

$ 73.0

Recothrom [Member] | Hemostasis Products

^[5]

17.00%

Intangible Assets Acquired as Part of Business Combination [Line Items]

Intangible assets acquired, weighted-average useful life

^[6]

13 years

^[6]

$ 42.7

PreveLeak [Member] | Hemostasis Products

^[6]

16.00%

Intangible Assets Acquired as Part of Business Combination [Line Items]

Intangible assets acquired, weighted-average useful life

^[6]

13 years

^[6]

$ 17.0

^[6]

17.00%

[1]

(1)

Of the $42.4 million net assets acquired for Ocera, $40.5 million and $1.9 million was paid in fiscal 2017 and 2018, respectively.

[2]


(1)	$1.9 million of the total consideration, net of cash was paid in fiscal 2018, subsequent to the Company's December 11, 2017 acquisition date.

[3]

[4]

[5]

(1)During fiscal 2017, the Company recorded a non-restructuring impairment charge relating to the Raplixa intangible asset. Refer to Note 13 for further information.

[6]

During fiscal 2018, the Company sold the Recothrom and PreveLeak assets to Baxter. Refer to Note 6 for further information.

Acquisitions and License Agreements (Schedule of Financial Results and Acquisition Costs of Acquirees) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016
Sucampo [Member]
Business Acquisition [Line Items]
Acquisition Related Costs	$ 0.0	$ 5.2	$ 4.2	$ 0.0
Ocera [Member]
Business Acquisition [Line Items]
Acquisition Related Costs	0.0	0.5	0.9	0.0
InfaCare [Member]
Business Acquisition [Line Items]
Acquisition Related Costs	0.0	0.0	1.2	0.0
Stratatech [Member]
Business Acquisition [Line Items]
Acquisition Related Costs	0.0	0.0	0.0	3.7
Hemostasis Products
Business Acquisition [Line Items]
Acquisition Related Costs	0.1	0.0	0.0	2.7
Others
Business Acquisition [Line Items]
Acquisition Related Costs	0.0	0.1	0.1	0.5
Total Acquisitions
Business Acquisition [Line Items]
Acquisition Related Costs	$ 0.1	$ 5.8	$ 6.4	$ 6.9

Acquisitions and License Agreements (Schedule of Intangible Asset Amortization by Acquiree) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016
Schedule of Intangible Asset Amortization by Acquiree [Line Items]
Intangible asset amortization	$ 175.7	$ 740.2	$ 694.5	$ 700.1
Cost of Sales
Schedule of Intangible Asset Amortization by Acquiree [Line Items]
Amortization Of Inventory Step-Up To Cost Of Sales	$ 3.6	$ 120.8	$ 10.1	$ 24.3

Restructuring and Related Charges (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Dec. 30, 2016	Dec. 25, 2015	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016	Feb. 01, 2018	Jul. 01, 2016	Sep. 27, 2013
Restructuring Cost and Reserve [Line Items]
Restructuring charges, net	$ 3.8	$ 4.1	$ 103.0	$ 31.2	$ 32.7
2013 Mallinckrodt program \| Minimum
Restructuring Cost and Reserve [Line Items]
Mallinckrodt program expected cost range								$ 100.0
2013 Mallinckrodt program \| Maximum
Restructuring Cost and Reserve [Line Items]
Mallinckrodt program expected cost range								$ 125.0
Restructuring Fiscal 2018 Plan [Member] \| Minimum
Restructuring Cost and Reserve [Line Items]
Mallinckrodt program expected cost range						$ 100.0
Restructuring Fiscal 2018 Plan [Member] \| Maximum
Restructuring Cost and Reserve [Line Items]
Mallinckrodt program expected cost range						$ 125.0
2016 Mallinckrodt Program \| Minimum
Restructuring Cost and Reserve [Line Items]
Mallinckrodt program expected cost range							$ 100.0
2016 Mallinckrodt Program \| Maximum
Restructuring Cost and Reserve [Line Items]
Mallinckrodt program expected cost range							$ 125.0
Raplixa [Member] \| Contract Termination [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring charges, net			$ 51.1

Restructuring and Related Charges (Schedule of Restructuring and Related Charges by Segment) (Details) - USD ($)
$ in Millions

3 Months Ended

12 Months Ended

Dec. 30, 2016

Dec. 25, 2015

Dec. 28, 2018

Dec. 29, 2017

Sep. 30, 2016

Less: accelerated depreciation

$ 5.3

$ 108.2

$ 36.4

$ 37.6

(1.5)

(5.2)

(4.9)

Specialty Brands [Member]

3.8

$ 4.1

103.0

31.2

32.7

Specialty Generics and Amitiza [Member]

2.6

52.2

25.4

23.3

0.8

29.0

7.7

3.4

Corporate

1.9

27.0

3.3

10.9

Other Expense [Member]

^[1],[2]

$ 0.0

$ 0.6

[1]	(1) Charges incurred under restructuring programs related to pension that were reclassified to other income (expense) due to the adoption of ASU 2017-07.
[2]	(1) Charges incurred under restructuring programs related to pension that were reclassified to other income (expense), net due to the adoption of ASU 2017-07.

Restructuring and Related Charges (Schedule of Net Restructuring and Related Charges) (Details) - USD ($)
$ in Millions

3 Months Ended

12 Months Ended

Dec. 30, 2016

Dec. 25, 2015

Dec. 28, 2018

Dec. 29, 2017

Sep. 30, 2016

Less: non-cash charges, including accelerated depreciation and impairments

$ 5.3

$ 108.2

$ 36.4

$ 37.6

(1.5)

(5.2)

(4.9)

Total charges expected to be settled in cash

3.8

103.0

31.2

32.7

Restructuring Fiscal 2018 Plan [Member]

3.8

$ 4.1

103.0

31.2

32.7

2016 Mallinckrodt Program

0.0

5.2

0.0

2013 Mallinckrodt program

5.2

71.6

36.2

(8.3)

0.0

(0.7)

25.6

Acquisition programs

0.1

31.4

0.9

3.7

Other Expense [Member]

^[1],[2]

$ 0.0

$ 0.6

[1]	(1) Charges incurred under restructuring programs related to pension that were reclassified to other income (expense) due to the adoption of ASU 2017-07.
[2]	(1) Charges incurred under restructuring programs related to pension that were reclassified to other income (expense), net due to the adoption of ASU 2017-07.

Restructuring and Related Charges (Schedule of Restructuring Reserves by Type of Cost) (Details) - USD ($)
$ in Millions

3 Months Ended

12 Months Ended

Dec. 30, 2016

Dec. 28, 2018

Dec. 29, 2017

Sep. 30, 2016

Continuing Operations

$ 18.5

$ 15.5

$ 14.8

$ 18.0

3.8

109.0

36.7

35.4

(6.0)

(5.5)

(2.7)

(7.5)

(45.6)

(30.8)

(33.7)

(1.9)

0.3

(0.7)

^[1]

Discontinued Operations, Held-for-sale

14.8

71.0

15.5

18.5

2.5

Acquisition programs | Continuing Operations

(0.3)

0.5

0.8

0.2

10.0

0.1

29.9

0.9

5.0

(0.7)

0.0

(1.3)

(0.4)

(22.2)

(0.3)

(13.2)

0.0

^[1]

Acquisition programs | Discontinued Operations, Held-for-sale

0.2

7.8

0.8

0.5

0.0

Restructuring Fiscal 2018 Plan [Member] | Continuing Operations

0.0

0.0

0.0

2.2

0.0

0.0

0.0

0.0

^[1]

Restructuring Fiscal 2018 Plan [Member] | Discontinued Operations, Held-for-sale

0.0

2.2

0.0

0.0

2016 Mallinckrodt Program | Continuing Operations

0.0

6.2

14.7

9.5

0.0

3.7

76.9

35.8

6.4

(5.3)

(4.8)

0.0

(0.4)

(23.4)

(26.1)

(0.2)

(1.9)

0.3

0.0

^[1]

2016 Mallinckrodt Program | Discontinued Operations, Held-for-sale

9.5

61.0

14.7

6.2

0.0

2013 Mallinckrodt program | Continuing Operations

0.0

11.8

0.0

5.1

8.0

0.0

24.0

0.0

(0.7)

(1.4)

(6.7)

0.0

(4.4)

(20.3)

0.0

(0.7)

^[1]

2013 Mallinckrodt program | Discontinued Operations, Held-for-sale

$ 5.1

$ 0.0

11.8

2.5

$ (0.3)

[1]	Represents the reclassification of pension and other postretirement benefits from restructuring reserves to pension and postretirement obligations.

Restructuring and Related Charges (Schedule of Restructuring Charges Incurred Cumulative to Date) (Details) $ in Millions	Dec. 28, 2018 USD ($)
2013 Mallinckrodt program
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred cumulative to date	$ 124.7
2013 Mallinckrodt program \| Specialty Brands [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred cumulative to date	18.8
2013 Mallinckrodt program \| Specialty Generics and Amitiza [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred cumulative to date	18.3
2013 Mallinckrodt program \| Nuclear Imaging
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred cumulative to date	69.9
2013 Mallinckrodt program \| Corporate
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred cumulative to date	17.7
Restructuring Fiscal 2018 Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred cumulative to date	5.2
Restructuring Fiscal 2018 Plan [Member] \| Specialty Brands [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred cumulative to date	3.0
Restructuring Fiscal 2018 Plan [Member] \| Specialty Generics and Amitiza [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred cumulative to date	0.0
Restructuring Fiscal 2018 Plan [Member] \| Nuclear Imaging
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred cumulative to date	0.0
Restructuring Fiscal 2018 Plan [Member] \| Corporate
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred cumulative to date	2.2
2016 Mallinckrodt Program
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred cumulative to date	122.2
2016 Mallinckrodt Program \| Specialty Brands [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred cumulative to date	81.7
2016 Mallinckrodt Program \| Specialty Generics and Amitiza [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred cumulative to date	14.6
2016 Mallinckrodt Program \| Nuclear Imaging
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred cumulative to date	0.0
2016 Mallinckrodt Program \| Corporate
Restructuring Cost and Reserve [Line Items]
Restructuring costs incurred cumulative to date	$ 25.9

Income Taxes (Narrative) (Details) - USD ($)

3 Months Ended

12 Months Ended

Dec. 30, 2016

Dec. 28, 2018

Dec. 29, 2017

Sep. 30, 2016

Mar. 16, 2018

Feb. 13, 2018

Dec. 11, 2017

^[5]

Sep. 25, 2017

Aug. 31, 2016

Feb. 01, 2016

Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount

^[1],[2]

$ (123,000,000.0)

$ (235,700,000)

$ (219,900,000)

$ (249,300,000)

Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent

20.00%

19.00%

20.00%

Increase (Decrease) Tax Expense (Benefit), Change in Operating Income

$ 4,700,000

$ 23,400,000

Current Income Tax Expense (Benefit)

$ 82,000,000.0

112,800,000

38,100,000

$ 120,800,000

Increase (Decrease) Tax Benefit, Jurisdiction Rate Difference

15,800,000

29,400,000

Deferred income taxes

324,300,000

689,000,000.0

Income Taxes Paid, Net

95,600,000

12,400,000

73,400,000

165,400,000

Income Tax Holiday, Aggregate Dollar Amount

1,000,000.0

1,800,000

1,000,000.0

Decrease in Unrecognized Tax Benefits is Reasonably Possible

136,900,000

Increase (Decrease) Deferred Tax Liability Resulting From Tax Reform, TCJA

8,500,000

444,800,000

Decrease in Interest and Penalties is Reasonably Possible

32,800,000

Unrecognized Tax Benefits, Interest on Income Taxes Accrued

7,100,000

37,100,000

7,100,000

7,400,000

Unrecognized Tax Benefits that Would Impact Effective Tax Rate

116,900,000

275,800,000

180,800,000

113,100,000

Unrecognized Tax Benefits, Interest on Income Taxes Expense

200,000

(33,200,000)

(1,900,000)

Tax Credit Carryforward, Amount

61,800,000

Increase (Decrease) Deferred Tax Liability Resulting From Legal Reorganization

281,500,000

Increase (Decrease) Deferred Tax Liability Resulting From Tax Reform

135,900,000

Increase (Decrease) Deferred Tax Liability Resulting from Installment Note Payments

(49,100,000)

Increase (Decrease), Deferred Tax Liability Due to Amortization of Intangible Assets

(28,900,000)

Increase (Decrease) Deferred Tax Liability, Inventory Step-Up

23,600,000

Increase (Decrease) Deferred Tax Assets Resulting from Legal Settlements

6,500,000

Increase (Decrease) Deferred Tax Liability Resulting from Acquisitions

169,300,000

Tax Credit Carryforwards, Not Subject to Expiration

4,600,000

Increase (Decrease) Tax Expense (Benefit) Due to Divestiture

22,200,000

37,600,000

Increase (Decrease) Tax Expense (Benefit) Due to U.S. Tax Reform

80,200,000

15,200,000

Unrecognized Tax Benefits, Decrease Resulting from Acquisition

11,800,000

Increase (Decrease) Tax Benefit, Non-Restructuring Impairment Charges

90,300,000

Excess in Book over Tax Basis, Foreign Subsidiaries

41,600,000

Deferred Tax Liabilities, Undistributed Foreign Earnings

$ 9,100,000

Effective Tax Rate Impact, TCJA

0.20%

Increase (Decrease), Deferred Tax Assets, Other

$ 4,100,000

Deferred Tax Liabilities, Inventory

$ 25,700,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent

$ 175,800,000

Increase (Decrease) in Deferred Tax Liability, Intangible Assets

179,300,000

Increase (Decrease) Deferred Tax Liability Resulting from Acquisitions

175,800,000

Increase (Decrease) Deferred Tax Asset, Tax Loss and Credit Carryforwards

25,100,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent

^[3]

$ 2,100,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent

^[4]

$ 8,700,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent

$ 22,100,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent

23,200,000

$ 16,700,000

Increase (Decrease), Deferred Tax Assets, Other

1,500,000

Increase (Decrease) Deferred Tax Liability Resulting from Divestiture

2,700,000

Deferred Tax Liabilities, Inventory

$ 2,700,000

Increase (Decrease) in Deferred Tax Liability, Intangible Assets

4,200,000

Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount

8,400,000

Increase (Decrease) Deferred Tax Asset, Tax Loss and Credit Carryforwards

$ 2,700,000

IRELAND

2013

Non-U.K.

Tax Credit Carryforward Utilization

2,000,000.0

5,600,000

9,500,000

Operating Loss Carry back

27,200,000

Operating Loss Carryforwards

300,000

$ 13,700,000

57,200,000

29,200,000

Deferred Tax Assets, Operating Loss Carryforwards

1,817,800,000

Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration

1,484,400,000

Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration

$ 333,400,000

Non-U.K. | Hemostasis Products

Operating Loss Carryforwards

17,900,000

Internal Revenue Service (IRS) [Member]

State and Local Jurisdiction [Member]

2014

2009

Operating Loss Carryforwards

$ 8,500,000

$ 14,300,000

$ 1,000,000.0

Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration

108,200,000

Retained Earnings | Accounting Standards Update 2016-16 [Member]

New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets

(75,000,000.0)

Retained Earnings | Accounting Standards Update 2016-09 [Member]

New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets

$ (2,900,000)

Other Assets [Member] | Accounting Standards Update 2016-16 [Member]

New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets

(67,200,000)

Prepaid Expenses and Other Current Assets [Member] | Accounting Standards Update 2016-16 [Member]

New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets

(7,800,000)

Intercompany Financing and Legal Entity Ownership Reorganization [Member]

Current Income Tax Expense (Benefit)

25,500,000

Increase (Decrease) in Deferred Tax Liability, Intangible Assets

58,900,000

Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount

39,700,000

Increase (Decrease) in Deferred Tax Liabilities, Other

9,300,000

Increase (Decrease) Deferred Tax Asset, Tax Loss and Credit Carryforwards

$ 1,300,000

[1]	During the three months ended December 30, 2016, the rate difference between U.K. and non-U.K. jurisdictions was favorably impacted by a benefit of $16.1 million on a $102.0 million settlement with the Federal Trade Commission and a benefit of $34.5 million on a $207.0 million goodwill impairment in the Specialty Generics reporting unit.
[2]	Includes the impact of certain recurring valuation allowances for U.K. and non-U.K. jurisdictions.
[3]	During fiscal 2017, the Company recorded a non-restructuring impairment charge relating to its Raplixa intangible asset and reduced the associated contingent consideration liability. During fiscal 2018, the Company sold its Recothrom and PreveLeak assets to Baxter. Refer to Notes 6, 13 and 21, respectively, for further information.
[4]	During fiscal 2018, the Company reduced the contingent consideration liability related to this acquisition to zero through the recognition of a $35.0 million fair value adjustment. Refer to Note 21 for further information.
[5]	(1) Of the $42.4 million net assets acquired for Ocera, $40.5 million and $1.9 million was paid in fiscal 2017 and 2018, respectively.

Income Taxes (Schedule of Components of Income from Continuing Operations Before Income Taxes) (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Dec. 30, 2016	Dec. 25, 2015	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016
Operating Loss Carryforwards [Line Items]
U.K.	$ (97.4)		$ (233.7)	$ (165.9)	$ (275.3)
Non-U.K.	(201.1)		(3,818.3)	227.5	508.7
Income (loss) from continuing operations before income taxes	$ (298.5)	$ 66.5	$ (4,052.0)	$ 61.6	$ 233.4

Income Taxes (Schedule of Significant Components of Income Taxes Related to Continuing Operations) (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Dec. 30, 2016	Dec. 25, 2015	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016
Current:
U.K.	$ 0.0		$ (0.2)	$ 0.4	$ 0.3
Non-U.K.	82.0		113.0	37.7	120.5
Current income tax provision	82.0		112.8	38.1	120.8
Deferred:
U.K.	(0.5)		1.4	0.6	0.7
Non-U.K.	(203.2)		(544.3)	(1,748.3)	(377.1)
Deferred income tax benefit	(203.7)		(542.9)	(1,747.7)	(376.4)
Provision for (benefit from) income taxes	$ (121.7)	$ (37.3)	$ (430.1)	$ (1,709.6)	$ (255.6)

Income Taxes (Schedule of Reconciliation of Income Taxes at Statutory Rate and Tax Provision) (Details) - USD ($)
$ in Millions

3 Months Ended

12 Months Ended

Dec. 30, 2016

Dec. 25, 2015

Dec. 28, 2018

Dec. 29, 2017

Sep. 30, 2016

Income Taxes [Line Items]

Income tax expense (benefit), intercompany financing and legal entity reorganization

$ (203.7)

$ (542.9)

$ (1,747.7)

$ (376.4)

Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent

20.00%

19.00%

20.00%

(Benefit) provision for income taxes at U.K. statutory income tax rate (1)

^[1]

$ (59.7)

$ (770.1)

$ 11.7

$ 46.6

Adjustments to reconcile to income tax provision:

Rate difference between non-U.S. and U.S. jurisdictions

^[2],[3]

(123.0)

(235.7)

(219.9)

(249.3)

Litigation Settlement, Expense

3,672.8

102.0

Valuation allowances, nonrecurring

0.0

(3.7)

2.1

Adjustments to accrued income tax liabilities and uncertain tax positions

0.9

60.1

5.1

(14.9)

Interest and penalties on accrued income tax liabilities and uncertain tax positions

(0.1)

13.1

0.2

(16.4)

Investment in partnership

(12.7)

0.0

Credits, principally research

^[4]

(0.7)

(25.9)

(13.8)

(33.7)

Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount

75.3

788.7

0.0

Permanently nondeductible and nontaxable items

1.6

7.2

6.4

7.9

Effective income tax rate reconciliation, pension plan settlement

0.0

(2.4)

0.0

Effective Income Tax Rate Reconciliation, Disposition of Business, Amount

^[5]

0.0

(2.7)

18.2

0.0

Income tax benefit, tax cut and jobs act

^[6]

0.0

(8.5)

(456.9)

0.0

Other

(3.3)

(0.3)

0.3

2.1

Income tax benefit, Legal Reorganization

^[7]

0.0

(256.0)

(1,054.8)

0.0

Tax Adjustments, Settlements, and Unusual Provisions

27.4

Tax Benefit Resulting from Legal Settlement

^[3]

16.1

Increase (Decrease) Deferred Tax Assets Resulting from Legal Settlements

(6.5)

Provision for (benefit from) income taxes

(121.7)

$ (37.3)

$ (430.1)

$ (1,709.6)

$ (255.6)

IRELAND

Income Taxes [Line Items]

Specialty Generics [Member]

2013

Adjustments to reconcile to income tax provision:

Rate difference between non-U.S. and U.S. jurisdictions

^[3]

34.5

Intercompany Financing and Legal Entity Ownership Reorganization [Member]

$ 207.0

Income Taxes [Line Items]

Income tax expense (benefit), intercompany financing and legal entity reorganization

$ (281.5)

Adjustments to reconcile to income tax provision:

Increase (Decrease) in Deferred Tax Liability, Installment Sales

310.6

Increase (Decrease) Deferred Tax Liabilities, Investment in Partnership

58.9

Increase (Decrease) in Deferred Tax Liability, Intangible Assets

$ 58.9

[1]	The statutory tax rate reflects the U.K. statutory tax rate of 19% for fiscal 2018 and 2017 and 20% for fiscal 2016 and the three months ended December 30, 2016.
[2]	During the three months ended December 30, 2016, the rate difference between U.K. and non-U.K. jurisdictions was favorably impacted by a benefit of $16.1 million on a $102.0 million settlement with the Federal Trade Commission and a benefit of $34.5 million on a $207.0 million goodwill impairment in the Specialty Generics reporting unit.
[3]	Includes the impact of certain recurring valuation allowances for U.K. and non-U.K. jurisdictions.
[4]	During fiscal 2018, the research and orphan drug credits increased in conjunction with the Company's increased investment in qualified research. During fiscal 2016, the Company realized a tax benefit of $27.4 million resulting from a U.K. tax credit on a dividend between affiliates.
[5]	During fiscal 2018, the Company completed the sale of a portion of its Hemostasis business. During fiscal 2017, the Company completed the sale of the Intrathecal Therapy Business.
[6]	For fiscal 2018, the Company completed its analysis of the TCJA and recognized an additional tax benefit. Other line items, to the extent U.S. related, are reflected at the current U.S. statutory income tax rate of 21%. For fiscal 2017, the benefit reflects the redetermination of the Company’s end of year net deferred tax liabilities as a result of the new U.S. statutory income tax rate of 21%. Other line items, to the extent U.S. related, are reflected at the former U.S. statutory income tax rate of 35%.
[7]	Associated unrecognized tax benefit netted within this line.

Income Taxes (Schedule of Unrecognized Tax Benefit Activity) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Balance at beginning of period	$ 114.8	$ 182.5	$ 118.7	$ 89.2
Additions related to current year tax positions	5.0	19.6	79.9	63.8
Additions related to prior period tax positions	0.0	125.1	0.3	10.8
Reductions related to prior period tax positions	(1.1)	(32.7)	(13.6)	(37.8)
Unrecognized Tax Benefits, Decrease Resulting from disposal of business	0.0	0.0	0.0	(6.6)
Settlements	0.0	(2.0)	0.0	(2.6)
Lapse of statute of limitations	0.0	(4.8)	(2.8)	(2.0)
Balance at end of period	$ 118.7	$ 287.7	$ 182.5	$ 114.8

Income Taxes (Schedule of Unrecognized Tax Benefits Balance Sheet Location) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016	Sep. 30, 2016	Sep. 25, 2015
Income Tax Contingency [Line Items]
Unrecognized Tax Benefits, Interest on Income Taxes Release	$ 3.2
Unrecognized Tax Benefits	287.7	$ 182.5	$ 118.7	$ 114.8	$ 89.2
Accrued and other current liabilities
Income Tax Contingency [Line Items]
Unrecognized Tax Benefits	1.0	1.5
Other Income Tax Liabilities
Income Tax Contingency [Line Items]
Unrecognized Tax Benefits	189.9	82.6
Deferred income tax liability (non-current)
Income Tax Contingency [Line Items]
Unrecognized Tax Benefits	96.8	98.4
Liabilities, Total [Member]
Income Tax Contingency [Line Items]
Unrecognized Tax Benefits	$ 287.7	$ 182.5

Income Taxes (Schedule of Income Taxes Payable) (Details) - USD ($) $ in Millions	Dec. 28, 2018	Dec. 29, 2017
Operating Loss Carryforwards [Line Items]
Other income tax liabilities	$ 228.0	$ 94.1
Total income taxes payable	253.0	109.9
Accrued and Other Current Liabilities
Operating Loss Carryforwards [Line Items]
Income taxes payable	25.0	15.8
Other Income Tax Liabilities
Operating Loss Carryforwards [Line Items]
Other income tax liabilities	$ 228.0	$ 94.1

Income Taxes (Schedule of Income Tax Receivables and Other Assets) (Details) - USD ($) $ in Millions	Dec. 28, 2018	Dec. 29, 2017
Income Tax Disclosure [Abstract]
Other assets	$ 3.0	$ 0.0
Prepaid expenses and other current assets	16.2	6.1
Total	$ 19.2	$ 6.1

Income Taxes (Schedule of Deferred Taxes Activity) (Details) - USD ($) $ in Millions	Dec. 28, 2018	Dec. 29, 2017
Deferred tax assets:
Accrued liabilities and reserves	$ 56.3	$ 62.7
Tax loss and credit carryforwards	1,987.8	1,734.5
Deferred Tax Assets, Goodwill and Intangible Assets	757.7	575.1
Other	204.6	113.3
Total deferred tax assets, gross	3,006.4	2,485.6
Deferred tax liabilities:
Intangible assets	(264.7)	(181.0)
Interest-bearing deferred tax obligations	(227.5)	(553.5)
Investment in partnership	(170.2)	(108.8)
Deferred Tax Liabilities, Other	(42.9)	(47.0)
Total deferred tax liabilities, gross	(705.3)	(890.3)
Net deferred tax asset before valuation allowances	2,301.1	1,595.3
Valuation allowances	(2,604.9)	(2,267.9)
Deferred Tax Liabilities, Net	$ (303.8)	$ (672.6)

Income Taxes (Schedule of Deferred Taxes Balance Sheet Location) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017
Other assets	$ 20.5	$ 16.4
Allowance for doubtful accounts	5.0	3.9
Deferred income taxes (non-current liability)	(324.3)	(689.0)
Deferred Tax Liabilities, Net	(303.8)	$ (672.6)
Increase (Decrease) Deferred Tax Liability Resulting From Legal Reorganization	(281.5)
Increase (Decrease), Deferred Tax Liability Due to Amortization of Intangible Assets	28.9
Increase (Decrease) Deferred Tax Assets Resulting from Legal Settlements	6.5
Increase (Decrease) Deferred Tax Liability Resulting from Acquisitions	$ 169.3

Income Taxes Tax Year Examination (Details)	12 Months Ended
Income Taxes Tax Year Examination (Details)	Dec. 28, 2018
Internal Revenue Service (IRS) [Member]
Income Tax Examination [Line Items]
Tax years that remain subject to examination	2014
State and Local Jurisdiction [Member]
Income Tax Examination [Line Items]
Tax years that remain subject to examination	2009
IRELAND
Income Tax Examination [Line Items]
Tax years that remain subject to examination	2013

Earnings (Loss) per Share (Details) - shares shares in Millions	3 Months Ended		12 Months Ended
	Dec. 30, 2016	Dec. 25, 2015	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016
Earnings (Loss) per Share [Abstract]
Weighted Average Number of Shares Outstanding, Basic	105.7	115.4	84.0	97.7	110.6
Weighted Average Number of Shares Outstanding, Diluted	0.0		0.0	0.2	0.9
Weighted-average shares for diluted earnings (loss) per share (in shares)	105.7	116.3	84.0	97.9	111.5
Antidilutive securities excluded from weighted-average shares (in shares)	2.4		3.3	4.2	1.7

Earnings (Loss) per Share Schedule of Earnings per Share Basic and Diluted (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions

3 Months Ended

12 Months Ended

Dec. 28, 2018

Sep. 28, 2018

Jun. 29, 2018

Mar. 30, 2018

Dec. 29, 2017

Sep. 29, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 30, 2016

Dec. 25, 2015

Dec. 28, 2018

Dec. 29, 2017

Sep. 30, 2016

Earnings Per Share [Abstract]

Income (Loss) From Continuing Operations Attributable To Common Stockholders

$ (3,718.4)

^[1]

$ 114.2

^[1]

$ 3.2

^[1]

$ (20.9)

^[1]

$ 1,607.4

^[1]

$ 64.3

^[1]

$ 70.6

^[1]

$ 28.9

^[1]

$ (176.8)

$ 103.8

$ (3,621.9)

$ 1,771.2

$ 489.0

(176.8)

(3,621.9)

1,771.2

489.0

Income (loss) from discontinued operations, net of income taxes

$ 0.0

$ (0.4)

$ 12.4

$ 2.9

$ 1.3

$ (0.6)

$ (7.8)

$ 370.3

23.6

$ 107.3

14.9

363.2

154.7

Net Income (Loss) Available to Common Stockholders, Basic

$ (153.2)

$ (3,607.0)

$ 2,134.4

$ 643.7

Weighted Average Number of Shares Outstanding, Basic

105.7

115.4

84.0

97.7

110.6

Weighted Average Number of Shares Outstanding, Diluted

0.0

0.2

0.9

Weighted Average Number of Shares Outstanding, Diluted

105.7

116.3

84.0

97.9

111.5

Income (Loss) from Continuing Operations, Per Basic Share

$ (44.64)

^[2]

$ 1.37

^[2]

$ 0.04

^[2]

$ (0.24)

^[2]

$ 17.43

^[2]

$ 0.66

^[2]

$ 0.72

^[2]

$ 0.28

^[2]

$ (1.67)

$ 0.90

$ (43.12)

$ 18.13

$ 4.42

Income (Loss) from Discontinued Operations, Per Basic Share

0.22

0.93

0.18

3.72

1.40

Earnings Per Share, Basic

(1.45)

1.83

(42.94)

21.85

5.82

Income (Loss) from Discontinued Operations, Per Diluted Share

$ (44.64)

^[2]

$ 1.34

^[2]

$ 0.04

^[2]

$ (0.24)

^[2]

$ 17.40

^[2]

$ 0.66

^[2]

$ 0.72

^[2]

$ 0.28

^[2]

(1.67)

0.89

(43.12)

18.09

4.39

0.22

0.92

0.18

3.71

1.39

Earnings Per Share, Diluted

$ (1.45)

$ 1.82

$ (42.94)

$ 21.80

$ 5.77

[1]	(Loss) income from continuing operations for the quarter ended December 28, 2018 reflects impairment charges for goodwill and an IPR&D asset. See Note 13 for further information. Income from continuing operations for the quarter ended December 29, 2017 reflects one-time effects for the completion of the reorganization of the Company's legal entity ownership and the impact of the TCJA.
[2]	Quarterly and annual computations are prepared independently. Therefore, the sum of each quarter may not necessarily total the fiscal period amounts noted elsewhere within this Annual Report on Form 10-K.

Inventories (Details) - USD ($) $ in Millions	Dec. 28, 2018	Dec. 29, 2017
Inventory, Net [Abstract]
Raw materials and supplies	$ 69.2	$ 70.0
Work in process	167.6	167.1
Finished goods	85.5	103.3
Inventories	$ 322.3	$ 340.4

Property, Plant and Equipment (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		$ 1,936.2	$ 1,842.0
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment		954.2	875.2
Depreciation	$ 27.5	$ 111.9	$ 113.8	$ 113.3

Property, Plant and Equipment (Schedule of Property, Plant and Equipment) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016
Property, Plant and Equipment [Line Items]
Depreciation	$ 27.5	$ 111.9	$ 113.8	$ 113.3
Property, plant and equipment, gross		1,936.2	1,842.0
Less: accumulated depreciation		(954.2)	(875.2)
Property, plant and equipment, net		982.0	966.8
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		43.9	44.0
Buildings
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		379.5	355.5
Capitalized Software
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		130.8	109.0
Machinery and Equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		1,137.3	1,123.8
Construction in Progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		$ 244.7	$ 209.7

Goodwill and Intangible Assets Narrative (Details) - USD ($)
$ in Millions

3 Months Ended

9 Months Ended

12 Months Ended

Dec. 30, 2016

Dec. 25, 2015

Sep. 28, 2018

Dec. 28, 2018

Dec. 29, 2017

Sep. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

$ 175.7

$ 740.2

$ 694.5

$ 700.1

Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)

220.3

7.3

Other Asset Impairment Charges

(190.1)

$ 214.3

$ 0.0

3,893.1

63.7

$ 16.9

Goodwill, Impaired, Accumulated Impairment Loss

3,879.8

207.0

Goodwill

0.0

3,482.7

Indefinite-lived intangible assets, gross

3,672.8

668.3

612.1

Specialty Brands [Member]

$ 51.5

Weighted Average Cost of Capital, Rate

12.50%

Goodwill, Impaired, Accumulated Impairment Loss

$ (3,672.8)

0.0

Specialty Generics and Amitiza [Member]

Weighted Average Cost of Capital, Rate

9.50%

Goodwill, Impaired, Accumulated Impairment Loss

(207.0)

Specialty Generics [Member]

$ 207.0

$ 207.0

$ 63.7

Goodwill and Intangible Assets Disclosure [Abstract]

62.9

Sucampo [Member] | VTS-270 [Member]

^[1]

$ 248.6

Indefinite-lived intangible assets, gross

274.5

InfaCare [Member] | Stannsoporfin [Member]

^[1],[2]

11.4

Indefinite-lived intangible assets, gross

$ 113.5

[1]	Refer to Note 13 for further information relating to the full goodwill impairment recorded in fiscal 2018.
[2]	During fiscal 2018, the Company reduced the contingent consideration liability related to this acquisition to zero through the recognition of a $35.0 million fair value adjustment. Refer to Note 21 for further information.

Goodwill and Intangible Assets (Schedule Of Goodwill) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017
Goodwill [Line Items]
Goodwill, Period Increase (Decrease)		$ 190.1
Goodwill, Gross		3,879.8	$ 3,689.7
Goodwill, Impaired, Accumulated Impairment Loss		(3,879.8)	(207.0)
Goodwill, Impairment Loss		3,672.8
Specialty Brands [Member]
Goodwill [Line Items]
Goodwill, Gross		3,672.8	3,482.7
Goodwill, Impaired, Accumulated Impairment Loss		$ 3,672.8	0.0
Weighted Average Cost of Capital, Rate		12.50%
Specialty Generics and Amitiza [Member]
Goodwill [Line Items]
Goodwill, Gross		$ 207.0	207.0
Goodwill, Impaired, Accumulated Impairment Loss		$ 207.0	$ 207.0
Goodwill, Impairment Loss	$ 207.0
Weighted Average Cost of Capital, Rate	9.50%

Goodwill and Intangible Assets (Schedule Of Intangible Assets) (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Dec. 30, 2016	Dec. 25, 2015	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016
Schedule of Intangible Asset by Major Class [Line Items]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)			$ 220.3
Impairment of Intangible Assets, Finite-lived	$ 7.3
Other Asset Impairment Charges	214.3	$ 0.0	3,893.1	$ 63.7	$ 16.9
Intangible asset amortization	$ 175.7		740.2	694.5	$ 700.1
Amortizable:
Finite-lived intangible assets, gross			10,697.4	10,180.1
Accumulated amortization			3,082.9	2,417.2
Non-Amortizable:
Indefinite-lived intangible assets, gross			668.3	612.1
Trademarks
Non-Amortizable:
Indefinite-lived intangible assets, gross			35.0	35.0
In-process research and development
Non-Amortizable:
Indefinite-lived intangible assets, gross			633.3	577.1
Completed Technology
Amortizable:
Finite-lived intangible assets, gross			10,467.9	9,882.8
Accumulated amortization			2,980.6	2,260.8
Licensing Agreements
Amortizable:
Finite-lived intangible assets, gross			120.1	177.1
Accumulated amortization			70.1	121.1
Customer relationships
Amortizable:
Finite-lived intangible assets, gross			27.5	29.5
Accumulated amortization			14.1	12.2
Trademarks
Amortizable:
Finite-lived intangible assets, gross			81.9	82.1
Accumulated amortization			18.1	14.5
Other
Amortizable:
Finite-lived intangible assets, gross			0.0	8.6
Accumulated amortization			0.0	$ 8.6
Sucampo [Member]
Schedule of Intangible Asset by Major Class [Line Items]
Intangible asset amortization			62.9
Stannsoporfin [Member] \| InfaCare [Member]
Non-Amortizable:
Indefinite-lived intangible assets, gross			113.5
VTS-270 [Member] \| Sucampo [Member]
Non-Amortizable:
Indefinite-lived intangible assets, gross			$ 274.5

Goodwill and Intangible Assets (Schedule of Future Amortization Expense, Intangible Assets) (Details) $ in Millions	Dec. 28, 2018 USD ($)
Finite-Lived Intangible Assets [Line Items]
Fiscal 2019	$ 748.4
Fiscal 2020	748.0
Fiscal 2021	747.8
Fiscal 2022	620.8
Fiscal 2023	$ 584.8

Debt (Narrative) (Details) - USD ($)						12 Months Ended
Debt (Narrative) (Details) - USD ($)	Feb. 13, 2018	Jul. 28, 2017	Feb. 28, 2017	Sep. 24, 2015	Apr. 15, 2015	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016	Sep. 28, 2018	Aug. 31, 2014	Apr. 30, 2013
Debt Instrument [Line Items]
Long-term Debt, Gross						$ 6,134,000,000.0	$ 6,492,600,000
Term Loan due Sept 2024 [Member]
Debt Instrument [Line Items]
Repayments of Long-term Debt						225,000,000.0
2023 Notes
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage				100.00%
Prior To April 15, 2018 \| 2025 Notes
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage					40.00%
Revolving Credit Facility
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage									4.64%
Debentures \| 5.625% notes due October 2023
Debt Instrument [Line Items]
Long-term Debt, Gross						731,400,000	738,000,000.0
Debentures \| 2017 Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 900,000,000.0
Variable interest rate			2.25%
Long-term Debt, Gross	$ 900,000,000.0					220,000,000.0	900,000,000.0
Debentures \| 2015 Revolving Credit Facility
Debt Instrument [Line Items]
Long-term Debt, Gross							900,000,000.0
Debentures \| 2020 Notes
Debt Instrument [Line Items]
Debt instrument, face amount					$ 700,000,000.0
Stated interest rate					4.875%
Debentures \| 2023 Notes
Debt Instrument [Line Items]
Debt instrument, face amount				$ 750,000,000.0
Stated interest rate				5.625%
Debentures \| 2025 Notes
Debt Instrument [Line Items]
Debt instrument, face amount					$ 700,000,000.0
Stated interest rate					5.50%
Line of Credit
Debt Instrument [Line Items]
Borrowings, outstanding								$ 0
Senior Notes \| 3.50% notes due April 2018
Debt Instrument [Line Items]
Debt instrument, face amount											$ 300,000,000.0
Stated interest rate											3.50%
Senior Notes \| 4.75% notes due April 2023
Debt Instrument [Line Items]
Debt instrument, face amount											$ 600,000,000.0
Stated interest rate											4.75%
Long-term Debt, Gross						500,200,000	526,500,000
Senior Notes \| 5.75% notes due August 2022
Debt Instrument [Line Items]
Debt instrument, face amount										$ 900,000,000.0
Stated interest rate										5.75%
Long-term Debt, Gross						835,200,000	884,000,000.0
Secured Debt \| Term Loan due Sept 2024 [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross						1,597,400,000	1,837,200,000
Loans Payable						1,613,800,000	1,851,200,000
Long-term Debt, Weighted Average Interest Rate, at Point in Time									5.14%
Secured Debt \| Term Loan and New Term Loan
Debt Instrument [Line Items]
Write off of Deferred Debt Issuance Cost							10,000,000.0
Variable interest rate			2.75%
Quarterly amortization payments			0.25%
Long-term Debt, Gross			$ 1,865,000,000.0
Secured Debt \| Receivable securitization, Maturity Date of July 2020 [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 250,000,000.0
Line Of Credit Facility, Future Contingent Maximum Borrowing Capacity		$ 300,000,000.0
Facility fees for letters of credit		0.40%
Variable interest rate		0.90%
Debt Instrument, Interest Rate, Effective Percentage									3.22%
Long-term Debt, Gross						250,000,000.0	200,000,000.0
Secured Debt \| Term Loan due 2025 [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross						591,000,000.0	0
Loans Payable						$ 597,000,000.0	$ 0
Long-term Debt, Weighted Average Interest Rate, at Point in Time									5.62%
2017 Revolving Credit Facility \| Term loan due March 2021
Debt Instrument [Line Items]
Facility fees for letters of credit						0.275%
Option A \| 5.75% notes due August 2022
Debt Instrument [Line Items]
Repurchase percentage								101.00%
Option A \| 2023 Notes
Debt Instrument [Line Items]
Repurchase percentage				101.00%
Option A \| 2025 Notes
Debt Instrument [Line Items]
Repurchase percentage					101.00%
Option B \| 5.75% notes due August 2022
Debt Instrument [Line Items]
Repurchase percentage								100.00%
Option B \| 2023 Notes
Debt Instrument [Line Items]
Repurchase percentage				100.00%
Option B \| 2025 Notes
Debt Instrument [Line Items]
Repurchase percentage					100.00%
Letter of Credit \| 2017 Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 50,000,000.0
Sucampo [Member] \| Secured Debt \| Term Loan due 2025 [Member]
Debt Instrument [Line Items]
Variable interest rate	3.00%
Debt instrument, discount percentage	0.25%
Loans Payable	$ 600,000,000.0

Debt (Schedule of Long term debt and Capital lease obligation) (Details) - USD ($) $ in Millions	Dec. 28, 2018	Feb. 13, 2018	Dec. 29, 2017
Current maturities of long-term debt:
Long-term Debt, Current Maturities	$ 22.7		$ 314.2
Debt Issuance Costs, Current, Net	0.3		0.5
Long-term debt:
Long-term Debt, Gross	6,134.0		6,492.6
Debt, Long-term and Short-term, Combined Amount	6,156.7		6,806.6
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	65.1		72.2
Long-term Debt and Capital Lease Obligations, Including Current Maturities			6,806.8
Capital Lease Obligations [Member]
Current maturities of long-term debt:
Debt Issuance Costs, Current, Net			0.0
Capital lease obligation and vendor financing agreements			0.2
Long-term Debt [Member]
Long-term debt:
Debt Issuance Costs, Net	64.8		71.7
Senior Notes \| 3.50% notes due April 2018
Current maturities of long-term debt:
Long-term Debt, Current Maturities	0.0		300.0
Debt Issuance Costs, Current, Net	0.0		0.2
Senior Notes \| 4.75% notes due April 2023
Long-term debt:
Long-term Debt, Gross	500.2		526.5
Debt Issuance Costs, Net	3.5		4.5
Senior Notes \| 5.75% notes due August 2022
Long-term debt:
Long-term Debt, Gross	835.2		884.0
Debt Issuance Costs, Net	7.0		9.5
Debentures \| Four Point Eight Eight Percent Notes [Member]
Long-term debt:
Long-term Debt, Gross	700.0		700.0
Debt Issuance Costs, Net	3.2		5.7
Debentures \| 5.625% notes due October 2023
Long-term debt:
Long-term Debt, Gross	731.4		738.0
Debt Issuance Costs, Net	8.0		9.7
Debentures \| Five Point Five Percent Notes [Member]
Long-term debt:
Long-term Debt, Gross	692.1		692.1
Debt Issuance Costs, Net	7.7		9.0
Debentures \| 2015 Revolving Credit Facility
Long-term debt:
Long-term Debt, Gross			900.0
Debt Issuance Costs, Net			5.9
Debentures \| 2017 Revolving Credit Facility
Long-term debt:
Long-term Debt, Gross	220.0	$ 900.0	900.0
Debt Issuance Costs, Net	4.5
Debentures \| ACOA Loan due 2028 [Member]
Current maturities of long-term debt:
Long-term Debt, Current Maturities	0.3
Debt Issuance Costs, Current, Net	0.0
Long-term debt:
Long-term Debt, Gross	1.9		0.0
Debt Issuance Costs, Noncurrent, Net	0.0		0.0
Secured Debt \| Receivable securitization, Maturity Date of July 2020 [Member]
Long-term debt:
Long-term Debt, Gross	250.0		200.0
Debt Issuance Costs, Net	0.4		0.7
Secured Debt \| Term Loan due Sept 2024 [Member]
Current maturities of long-term debt:
Long-term Debt, Current Maturities	16.4		14.0
Debt Issuance Costs, Current, Net	0.2		0.3
Long-term debt:
Long-term Debt, Gross	1,597.4		1,837.2
Debt Issuance Costs, Noncurrent, Net	19.8		26.7
Secured Debt \| Term Loan due 2025 [Member]
Current maturities of long-term debt:
Long-term Debt, Current Maturities	6.0		0.0
Debt Issuance Costs, Current, Net	0.1		0.0
Long-term debt:
Long-term Debt, Gross	591.0		0.0
Debt Issuance Costs, Noncurrent, Net	10.7		0.0
Debentures \| 8.00% debentures due March 2023
Long-term debt:
Long-term Debt, Gross	4.4		4.4
Debt Issuance Costs, Net	0.0		0.0
Debentures \| 9.50% debentures due May 2022
Long-term debt:
Long-term Debt, Gross	10.4		10.4
Debt Issuance Costs, Net	$ 0.0		$ 0.0

Debt (Schedule of Maturities of Long-term Debt including Capital Lease Obligation) (Details) - USD ($) $ in Millions	Dec. 28, 2018	Dec. 29, 2017
Debt Disclosure [Abstract]
Long-term Debt, Gross	$ 6,134.0	$ 6,492.6
Fiscal 2019	22.7
Fiscal 2020	972.7
Fiscal 2021	28.2
Fiscal 2022	1,088.2
Fiscal 2023	$ 1,258.6

Debt Schedule of Outstanding Borrowings and Applicable Rates (Details) - USD ($) $ in Millions	Dec. 28, 2018	Sep. 28, 2018	Feb. 13, 2018	Dec. 29, 2017
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 6,134.0			$ 6,492.6
Secured Debt \| Term Loan due Sept 2024 [Member]
Debt Instrument [Line Items]
Long-term Debt, Weighted Average Interest Rate, at Point in Time		5.14%
Loans Payable	1,613.8			1,851.2
Long-term Debt, Gross	1,597.4			1,837.2
Secured Debt \| Term Loan due 2025 [Member]
Debt Instrument [Line Items]
Long-term Debt, Weighted Average Interest Rate, at Point in Time		5.62%
Loans Payable	597.0			0.0
Long-term Debt, Gross	591.0			0.0
Secured Debt \| Receivable securitization, Maturity Date of July 2020 [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage		3.22%
Long-term Debt, Gross	250.0			200.0
Revolving Credit Facility
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage		4.64%
Debentures \| 2017 Revolving Credit Facility
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 220.0		$ 900.0	$ 900.0

Retirement Plans Narrative (Details) $ in Millions	12 Months Ended
Retirement Plans Narrative (Details) $ in Millions	Dec. 28, 2018 USD ($) contract	Dec. 29, 2017 USD ($)
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Number of Life Insurance Contract Held in Rabbi Trust \| contract	118
Deferred Compensation Plan Assets	$ 58.4	$ 58.1
Deferred Compensation Plan Assets, Death Benefit on Insurance Contracts	142.9	145.8
Deferred Compensation Plan Assets, Loans Outstanding Against Insurance Contracts	43.8	44.5
Pension Benefits
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Assets Transferred to (from) Plan		212.9
Defined Benefit Plan, Plan Assets, Payment for Settlement		62.3
Employer contributions	2.4	68.0
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement		70.5
Refund for plan settlement	3.4
Moody's, Aa1 Rating [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Lower Threshold for Discount Rate Basis, Corporate Bonds	$ 250.0
United States
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined Benefit Plan, Percentage of Projected Benefit Obligation	36.00%
OUS
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Deferred Compensation Plan Assets, Collateral For Plan Benefits	$ 8.0	$ 8.8

Retirement Plans (Schedule of Net Periodic Benefit Cost) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016
Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 0.8	$ 0.2	$ 1.4	$ 1.8
Interest cost	2.0	0.6	2.3	13.2
Expected return on plan assets	(2.3)	0.0	(1.3)	(16.7)
Amortization of net actuarial loss	3.5	0.5	2.7	11.3
Amortization of prior service cost	0.1	0.1	0.2	0.0
Loss on plan settlements	45.0	0.1	71.1	8.1
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment	0.0	0.0	(1.0)	0.0
Net period benefit cost (credit)	49.1	1.5	75.4	17.7
Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	0.1	0.0	0.0	0.1
Interest cost	0.4	1.5	1.7	2.0
Amortization of net actuarial loss	0.0	0.1	0.0	0.0
Amortization of prior service cost	(0.5)	(2.1)	(2.0)	(2.1)
Loss on plan settlements	0.0	(0.7)	(0.9)	0.0
Net period benefit cost (credit)	$ 0.0	$ (1.2)	$ (1.2)	$ 0.0

Retirement Plans (Schedule of Benefit Obligation, Plan Assets and Funded Status of Plans) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016
Pension Benefits
Change in benefit obligations:
Projected benefit obligations at beginning of year		$ 27.8	$ 257.4
Service cost	$ 0.8	0.2	1.4	$ 1.8
Interest cost	2.0	0.6	2.3	13.2
Actuarial loss (gain)		0.7	(9.0)
Defined Benefit Plan, Benefit Obligation, Benefits Paid		(1.6)	(9.4)
Plan settlements		(0.8)	(217.0)
Currency translation		(0.8)	2.1
Projected benefit obligations at end of year	257.4	26.1	27.8
Change in plan assets:
Fair value of plan assets at beginning of year		0.0	161.0
Actual return on plan assets		0.0	0.3
Employer contributions		2.4	68.0
Defined Benefit Plan, Plan Assets, Benefits Paid		(1.6)	(9.4)
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Assets Transferred to (from) Plan		0.0	(2.9)
Plan settlements		(0.8)	(217.0)
Fair value of plan assets at end of year	161.0	0.0	0.0
Funded status at end of year		(26.1)	(27.8)
Postretirement Benefits
Change in benefit obligations:
Projected benefit obligations at beginning of year		45.6	47.5
Service cost	0.1	0.0	0.0	0.1
Interest cost	0.4	1.5	1.7	$ 2.0
Actuarial loss (gain)		(3.9)	0.2
Defined Benefit Plan, Benefit Obligation, Benefits Paid		(2.7)	(2.9)
Plan settlements		(0.7)	(0.9)
Currency translation		0.0	0.0
Projected benefit obligations at end of year	47.5	39.8	45.6
Change in plan assets:
Fair value of plan assets at beginning of year		0.0	0.0
Actual return on plan assets		0.0	0.0
Employer contributions		2.7	2.9
Defined Benefit Plan, Plan Assets, Benefits Paid		(2.7)	(2.9)
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Assets Transferred to (from) Plan		0.0	0.0
Plan settlements		0.0	0.0
Fair value of plan assets at end of year	$ 0.0	0.0	0.0
Funded status at end of year		$ (39.8)	$ (45.6)

Retirement Plans (Schedule of Amounts Recognized in Balance Sheet) (Details) - USD ($) $ in Millions	Dec. 28, 2018	Dec. 29, 2017
Amounts recognized on the consolidated balance sheet:
Non-current liabilities	$ (60.5)	$ (67.1)
Pension Benefits
Amounts recognized on the consolidated balance sheet:
Current liabilities	(2.0)	(2.4)
Non-current liabilities	(24.1)	(25.4)
Net amount recognized on the consolidated balance sheet	(26.1)	(27.8)
Amounts recognized in accumulated other comprehensive loss consist of:
Net actuarial (loss) gain	(8.4)	(8.6)
Prior service (cost) credit	(0.4)	(0.5)
Net amount recognized in accumulated other comprehensive loss	(8.8)	(9.1)
Postretirement Benefits
Amounts recognized on the consolidated balance sheet:
Current liabilities	(3.4)	(3.9)
Non-current liabilities	(36.4)	(41.7)
Net amount recognized on the consolidated balance sheet	(39.8)	(45.6)
Amounts recognized in accumulated other comprehensive loss consist of:
Net actuarial (loss) gain	0.9	(3.0)
Prior service (cost) credit	8.1	10.2
Net amount recognized in accumulated other comprehensive loss	$ 9.0	$ 7.2

Retirement Plans (Schedule of Amounts to be Amortized From Accumulated Other Comprehensive Income) (Details) $ in Millions	Dec. 28, 2018 USD ($)
Pension Benefits
Defined Benefit Plan, Expected Amortization, Next Fiscal Year [Abstract]
Amortization of net actuarial loss	$ 0.5
Amortization of prior service cost (credit)	0.1
Postretirement Benefits
Defined Benefit Plan, Expected Amortization, Next Fiscal Year [Abstract]
Amortization of net actuarial loss	0.0
Amortization of prior service cost (credit)	$ (2.1)

Retirement Plans (Schedule of Plans with Accumulated Benefit Obligations in Excess of Plan Assets) (Details) - USD ($) $ in Millions	Dec. 28, 2018	Dec. 29, 2017
Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]
Accumulated benefit obligation	$ 25.6	$ 27.3

Retirement Plans (Schedule of Actuarial Assumptions) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016
U.S.
Weighted Average-Assumptions Used in Calculating Net Periodic Benefit Cost
Discount rate	2.20%	3.30%	3.00%	3.90%
Expected return on plan assets	3.50%	0.00%	3.50%	5.80%
Rate of compensation increase	0.00%	0.00%	0.00%	0.00%
Weighted-Average Assumptions Used in Calculating Benefit Obligations
Discount rate	3.00%	4.00%	3.30%	2.30%
Rate of compensation increase	0.00%	0.00%	0.00%	0.00%
OUS
Weighted Average-Assumptions Used in Calculating Net Periodic Benefit Cost
Discount rate	1.30%	1.90%	1.80%	2.00%
Expected return on plan assets	0.00%	0.00%	0.00%	2.00%
Rate of compensation increase	0.00%	2.50%	2.50%	0.00%
Weighted-Average Assumptions Used in Calculating Benefit Obligations
Discount rate	1.80%	2.00%	1.90%	1.30%
Rate of compensation increase	0.30%	2.50%	2.50%	0.00%
Postretirement Benefits
Weighted Average-Assumptions Used in Calculating Net Periodic Benefit Cost
Discount rate	3.20%	3.40%	3.70%	4.00%
Weighted-Average Assumptions Used in Calculating Benefit Obligations
Discount rate	3.80%	4.10%	3.40%	3.20%
Healthcare Cost Trend Assumptions
Healthcare cost trend rate assumed for next fiscal year		6.30%	6.90%
Rate to which the cost trend rate is assumed to decline		4.50%	4.50%
Fiscal year the ultimate trend rate is achieved		2038	2038
Effect of One-Percentage Point Change in Assumed Healthcare Cost Trend Rates
One-Percentage-Point Increase, effect on total of service and interest cost		$ 0.0
One-Percentage-Point Decrease, effect on total of service and interest cost		0.0
One-Percentage-Point Increase, effect on postretirement benefit obligation		0.2
One-Percentage-Point Decrease, effect on postretirement obligation		$ (0.2)

Retirement Plans (Schedule of Expected Benefit Payments) (Details) $ in Millions	Dec. 28, 2018 USD ($)
Pension Benefits
Defined Benefit Plan Disclosure [Line Items]
Fiscal 2019	$ 2.0
Fiscal 2020	1.7
Fiscal 2021	1.7
Fiscal 2022	1.6
Fiscal 2023	1.6
Fiscal 2024 - 2028	7.4
Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Fiscal 2019	3.5
Fiscal 2020	3.4
Fiscal 2021	3.2
Fiscal 2022	3.1
Fiscal 2023	3.0
Fiscal 2024 - 2028	$ 13.4

Retirement Plans (Defined Contribution Plan) (Details) - Defined Contribution Plan, 401 K [Member] - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016
Defined Contribution Plan Disclosure [Line Items]
Employer matching contribution, percent of match		50.00%
Defined Contribution Plan, Cost	$ 4.2	$ 25.3	$ 25.2	$ 25.3

Equity (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	12 Months Ended
	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016	Mar. 01, 2017	Mar. 16, 2016	Nov. 19, 2015	Jan. 23, 2015
Class of Stock [Line Items]
Preferred shares, shares authorized (in shares)		500,000,000	500,000,000
Preferred shares, par value (in usd per share)		$ 0.20	$ 0.20
Preferred shares, shares issued (in shares)		0	0
Employee Service Share-based Compensation, Cash Flow Effect, Cash Used to Settle Awards	$ 0.4	$ 0.0	$ 5.1	$ 2.3
Treasury Stock, Shares, Canceled			26,500,000
Treasury Stock, Canceled, Value			$ 5.3
November 2015 Share Repurchase Program [Member]
Class of Stock [Line Items]
Stock Repurchase Program, Authorized Amount							$ 500.0
January 2015 Repurchase Program [Member]
Class of Stock [Line Items]
Stock Repurchase Program, Authorized Amount								$ 300.0
March 2016 Repurchase Program [Member]
Class of Stock [Line Items]
Stock Repurchase Program, Authorized Amount						$ 350.0
March 2017 Repurchase Program [Member]
Class of Stock [Line Items]
Stock Repurchase Program, Authorized Amount					$ 1,000.0

Equity Stock Repurchase Program (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended	12 Months Ended
	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016	Sep. 25, 2015	Mar. 01, 2017	Mar. 16, 2016	Nov. 19, 2015	Jan. 23, 2015
Class of Stock [Line Items]
Employee Service Share-based Compensation, Cash Flow Effect, Cash Used to Settle Awards	$ 0.4	$ 0.0	$ 5.1	$ 2.3
March 2016 Repurchase Program [Member]
Class of Stock [Line Items]
Stock Repurchase Program, Authorized Amount							$ 350.0
Repurchase of ordinary shares, shares	1,501,676	0	5,366,741	0	0
Repurchase of ordinary shares, value	$ 84.0	$ 0.0	$ 266.0	$ 0.0	$ 0.0
Stock Repurchase Program, Remaining Authorized Repurchase Amount		$ 0.0
November 2015 Share Repurchase Program [Member]
Class of Stock [Line Items]
Stock Repurchase Program, Authorized Amount								$ 500.0
Repurchase of ordinary shares, shares	1,063,337	0	0	6,510,824	0
Repurchase of ordinary shares, value	$ 74.4	$ 0.0	$ 0.0	$ 425.6	$ 0.0
Stock Repurchase Program, Remaining Authorized Repurchase Amount		$ 0.0
January 2015 Repurchase Program [Member]
Class of Stock [Line Items]
Stock Repurchase Program, Authorized Amount									$ 300.0
Repurchase of ordinary shares, shares	0	0	0	3,199,279	823,592
Repurchase of ordinary shares, value	$ 0.0	$ 0.0	$ 0.0	$ 225.0	$ 75.0
Stock Repurchase Program, Remaining Authorized Repurchase Amount		$ 0.0
March 2017 Repurchase Program [Member]
Class of Stock [Line Items]
Stock Repurchase Program, Authorized Amount						$ 1,000.0
Repurchase of ordinary shares, shares	0	3,610,968	13,490,448	0	0
Repurchase of ordinary shares, value	$ 0.0	$ 55.2	$ 380.6	$ 0.0	$ 0.0
Stock Repurchase Program, Remaining Authorized Repurchase Amount		$ 564.2

Share Plans (Narrative) (Details) - USD ($)	3 Months Ended	12 Months Ended
Share Plans (Narrative) (Details) - USD ($)	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016	Sep. 26, 2014	May 16, 2018	Mar. 19, 2015	Jul. 01, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation cost	$ 10,600,000	$ 34,600,000	$ 58,500,000	$ 41,400,000
Tax benefit from share-based compensation cost	3,600,000	0	11,000,000.0	13,100,000
Employee Service Share-based Compensation, Tax Benefit from Exercise of Stock Options			16,000,000.0
Employee Service Share-based Compensation, Tax Benefit from U.S. Tax Reform Measurement			5,000,000.0
Intrinsic value of options vested	300,000	200,000	1,400,000	15,300,000
Tax benefit from stock options exercised	$ 100,000	$ 100,000	$ 500,000	$ 5,700,000
Performance Shares Award, Performance Period		3 years
Share Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award Vesting Period		4 years
Expiration period		10 years
Unrecognized compensation cost, share options		$ 29,600,000
Weighted-average period to recognize unrecognized compensation cost, share options		2 years 4 months 24 days
Restricted Share Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value, granted restricted share units	$ 69.08	$ 14.58	$ 50.74	$ 70.10
Award Vesting Period		4 years
Weighted-average period to recognize unrecognized compensation cost, share options		2 years 2 months 12 days
Fair value of restricted share units granted in period		$ 17,800,000
Fair value of restricted share units vested in period		25,100,000
Unrecognized compensation cost, restricted share units		$ 29,600,000
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employer matching contribution, percent of match				25.00%	15.00%
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date		15.00%
ESPP employer match - maximum employee contribution				$ 25,000
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value, granted restricted share units		$ 13.80	$ 51.73	$ 83.00
Unrecognized compensation cost		$ 12,600,000
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value, granted restricted share units		$ 70.88
Fair value of restricted share units vested in period		$ 200,000
2013 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized under 2013 Plan								5,700,000
2015 Mallinckrodt Pharmaceuticals Stock and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized under 2013 Plan							17,800,000
2018 Mallinckrodt Pharmaceuticals Stock and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized under 2013 Plan						26,800,000
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of ordinary shares to be awarded		0.00%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of ordinary shares to be awarded		200.00%
New ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount		$ 25,000

Share Plans (Schedule of Share Option Award Status Upon Completion of the Conversion) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016	Sep. 30, 2016	Sep. 25, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share options outstanding	7,007,051	4,643,984	3,386,694	3,421,856	2,786,443
Weighted-average exercise price, outstanding share options	$ 38.74	$ 57.78	$ 61.24	$ 61.17	$ 52.76
Weighted-average remaining contractual term, outstanding share options	4 years 9 months 18 days
Aggregate intrinsic value, outstanding share options	$ 6.5
Share options exerciseable	2,414,968
Weighted-average exercise price, exercisable share options	$ 55.24
Weighted-average remaining contractual term, exercisable share options	4 years 10 months 24 days
Aggregate intrinsic value, exercisable share options	$ 0.1

Share Plans (Schedule of the Valuation Assumptions Used in the Conversion) (Details) - $ / shares	3 Months Ended	12 Months Ended
	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016	Sep. 25, 2015
Weighted Average Assumptions
Expected share price volatility	35.00%	38.00%	36.00%	31.00%
Risk-free interest rate	1.23%	2.64%	2.00%	1.74%
Expected annual dividend per share	0.00%	0.00%	0.00%	0.00%
Expected life of options (in years)	5 years 3 months 18 days	5 years 3 months 18 days	5 years 3 months 18 days	5 years 3 months 18 days
Fair value per option	$ 20.04	$ 5.32	$ 18.36	$ 22.82
Share options outstanding	3,386,694	7,007,051	4,643,984	3,421,856	2,786,443

Share Plans (Schedule of Share Option Activity) (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	12 Months Ended
	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016	Sep. 25, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 20.04	$ 5.32	$ 18.36	$ 22.82
Intrinsic value of options vested	$ 0.3	$ 0.2	$ 1.4	$ 15.3
Share Option Activity [Roll Forward]
Beginning balance	3,421,856	4,643,984	3,386,694	2,786,443
Granted	3,742	3,159,521	1,719,532	1,248,828
Exercised	(16,382)	(39,949)	(113,605)	(413,830)
Expired/Forfeited	(22,522)	(756,505)	(348,637)	(199,585)
Ending balance	3,386,694	7,007,051	4,643,984	3,421,856
Share options vested and unvested expected to vest		6,114,782
Share options exerciseable		2,414,968
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted-average exercise price, outstanding share options	$ 61.24	$ 38.74	$ 57.78	$ 61.17	$ 52.76
Weighted-average exercise price, granted share options	60.01	13.92	51.57	72.44
Weighted-average exercise price, exercised share options	36.42	32.00	47.74	32.76
Weighted-average exercise price, expired and forfeited share options	$ 70.82	52.63	$ 68.08	$ 72.65
Weighted-average exercise price, vested and unvested expected to vest share options		39.94
Weighted-average exercise price, exercisable share options		$ 55.24
Weighted-average remaining contractual term, outstanding share options		4 years 9 months 18 days
Weighted-average remaining contractual term, vested and unvested expected to vest share options		7 years 7 months 6 days
Weighted-average remaining contractual term, exercisable share options		4 years 10 months 24 days
Aggregate intrinsic value, outstanding share options		$ 6.5
Aggregate intrinsic value, vested and unvested expected to vest share options		5.5
Aggregate intrinsic value, exercisable share options		0.1
Tax benefit from stock options exercised	$ 0.1	$ 0.1	$ 0.5	$ 5.7

Share Plans (Schedule of Restricted Share Unit Activity) (Details) - $ / shares	3 Months Ended	12 Months Ended
	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016	Sep. 25, 2015
Restricted Share Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average period to recognize unrecognized compensation cost, share options		2 years 2 months 12 days
Restricted Share Unit Activity [Roll Forward]
Beginning balance	894,459	1,105,766	883,462	572,494
Granted	36,731	1,222,568	655,282	615,074
Exercised	(30,919)	(433,354)	(263,189)	(193,849)
Expired/Forfeited	(16,809)	(209,879)	(169,789)	(99,260)
Ending balance	883,462	1,685,101	1,105,766	894,459
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted-average grant date fair value, restricted share units	$ 71.03	$ 29.54	$ 60.08	$ 70.40	$ 73.45
Weighted-average grant date fair value, granted restricted share units	69.08	14.58	50.74	70.10
Weighted-average grant date fair value, vested restricted share units	47.54	57.93	69.14	69.27
Weighted-average grant date fair value, forfeited restricted share units	$ 49.62	$ 44.38	$ 68.57	$ 79.95
Restricted Stock
Restricted Share Unit Activity [Roll Forward]
Beginning balance	16,866	4,675	14,868	34,562
Exercised	(1,087)	(3,970)	(7,970)	(9,760)
Expired/Forfeited	(911)	(705)	(2,223)	(7,936)
Ending balance	14,868	0	4,675	16,866
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted-average grant date fair value, granted restricted share units		$ 70.88

Share Plans (Schedule of Performance Share Unit Activity) (Details) - $ / shares

3 Months Ended

12 Months Ended

Dec. 30, 2016

Dec. 28, 2018

Dec. 29, 2017

Sep. 30, 2016

Sep. 25, 2015

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]

Performance Shares Award, Performance Period

3 years

Performance Shares

Performance Share Unit Activity [Roll Forward]

^[1]

266,645

504,451

265,648

130,974

Granted

770,714

348,963

145,192

^[1]

Exercised

^[1]

(24,022)

(61,554)

Expired/Forfeited

^[1]

(997)

(89,614)

(48,606)

(9,521)

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]

^[1]

265,648

1,161,529

504,451

266,645

Weighted-average grant date fair value, restricted share units

$ 88.51

$ 28.61

$ 64.44

$ 88.59

$ 96.05

Weighted-average grant date fair value, granted restricted share units

13.80

51.73

83.00

Weighted-average grant date fair value, vested restricted share units

98.27

62.65

Weighted-average grant date fair value, forfeited restricted share units

$ 154.42

$ 59.18

$ 107.00

$ 96.30

Restricted Share Units

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms

1 year 10 months 24 days

Weighted-average period to recognize unrecognized compensation cost, share options

2 years 2 months 12 days

Performance Share Unit Activity [Roll Forward]

894,459

1,105,766

883,462

572,494

Granted

36,731

1,222,568

655,282

615,074

Exercised

(30,919)

(433,354)

(263,189)

(193,849)

Expired/Forfeited

(16,809)

(209,879)

(169,789)

(99,260)

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]

883,462

1,685,101

1,105,766

894,459

Weighted-average grant date fair value, restricted share units

$ 71.03

$ 29.54

$ 60.08

$ 70.40

$ 73.45

Weighted-average grant date fair value, granted restricted share units

69.08

14.58

50.74

70.10

Weighted-average grant date fair value, vested restricted share units

47.54

57.93

69.14

69.27

Weighted-average grant date fair value, forfeited restricted share units

$ 49.62

$ 44.38

$ 68.57

$ 79.95

Award Vesting Period

4 years

[1]	The number of shares disclosed within this table are at the target number of 100%.

Share Plans (Schedule of Fair Value Assumptions for Performance Share Unit) (Details)	3 Months Ended	12 Months Ended
	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected share price volatility	35.00%	38.00%	36.00%	31.00%
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected share price volatility	48.00%	57.00%	48.00%	41.00%
Peer group stock price volatility	40.00%	39.00%	40.00%	36.00%
Correlation of returns	17.00%	2.00%	17.00%	24.00%

Share Plans (Schedule of Restricted Stock Award Activity) (Details) - Restricted Stock - $ / shares	3 Months Ended	12 Months Ended
	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016
Restricted Stock Activity [Roll Forward]
Beginning balance	16,866	4,675	14,868	34,562
Exercised	(1,087)	(3,970)	(7,970)	(9,760)
Expired/Forfeited	(911)	(705)	(2,223)	(7,936)
Ending balance	14,868	0	4,675	16,866
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted-average grant date fair value, granted restricted share units		$ 70.88

Accumulated Other Comprehensive Income (Schedule of Accumulated Other Comprehensive Income) (Details) - USD ($)
$ in Millions

3 Months Ended

12 Months Ended

Dec. 30, 2016

Dec. 28, 2018

Dec. 29, 2017

Sep. 30, 2016

Dec. 30, 2017

Accumulated Other Comprehensive Income (Loss) [Line Items]

Accumulated Other Comprehensive Income (Loss), Net of Tax, Adjusted for ASU

^[1]

$ (14.4)

Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]

$ (12.9)

(72.5)

Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, before Tax

(9.1)

22.7

$ 0.0

0.0

1.5

$ 0.0

Amounts reclassified from accumulated other comprehensive income

(0.8)

35.4

Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]

(72.5)

(24.3)

(12.9)

Currency Translation

(8.2)

(19.5)

Amounts reclassified from accumulated other comprehensive income

(12.2)

16.0

0.0

(4.7)

Unrecognized Loss on Derivatives

(19.5)

(20.4)

(8.2)

Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]

(4.7)

(5.7)

Amounts reclassified from accumulated other comprehensive income

0.0

0.7

1.0

Unrecognized (Loss) Gain on Benefit Plans

(5.7)

(4.0)

(4.7)

Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]

(1.5)

(47.3)

Amounts reclassified from accumulated other comprehensive income

3.1

5.2

(1.5)

40.6

Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]

(47.3)

0.1

(1.5)

Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]

0.0

Amounts reclassified from accumulated other comprehensive income

1.5

0.0

(1.5)

Retained Earnings | Accounting Standards Update 2016-01 [Member]

$ 0.0

Accumulated Other Comprehensive Income (Loss) [Line Items]

New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets

$ 1.5

[1]	Upon adoption of ASU 2016-01, a reclassification of $1.5 million relating to the unrealized gain on investment resulted in an increase to beginning retained earnings with an offsetting decrease to accumulated other comprehensive loss. See Note 4 for additional details.

Accumulated Other Comprehensive Income (Schedule of Reclassifications out of Accumulated Other Comprehensive Income) (Details) - USD ($)
$ in Millions

12 Months Ended

Dec. 28, 2018

Dec. 29, 2017

Dec. 30, 2017

Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]

Total reclassifications for the period

$ (0.8)

$ 35.4

Amortization of pension and post-retirement benefit plans:

Net actuarial loss

^[1]

0.6

2.7

Prior service credit

^[1]

(2.0)

(1.9)

Plan settlements

^[1]

(0.6)

70.2

Disposal of discontinued operations

0.0

(3.1)

Total before tax

(2.0)

67.9

Income tax effect

0.5

(27.3)

Income tax provision

(0.2)

(0.3)

Amortization of unrealized loss on derivatives

0.9

1.3

Reclassification out of Accumulated Other Comprehensive Income [Member]

Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]

Net of income taxes

0.7

1.0

Amortization of pension and post-retirement benefit plans:

Net of income taxes

(1.5)

40.6

Recognized gain on equity securities (2)

^[2]

0.0

(1.5)

Currency translation

$ 0.0

$ (4.7)

Accounting Standards Update 2016-01 [Member] | Retained Earnings

Amortization of pension and post-retirement benefit plans:

New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets

$ 1.5

[1]	These accumulated other comprehensive loss components are included in the computation of net periodic benefit cost. See Note 15 for additional details.
[2]	Upon adoption of ASU 2016-01, a reclassification of $1.5 million relating to the unrealized gain on investment resulted in an increase to beginning retained earnings with an offsetting decrease to accumulated other comprehensive loss. See Note 4 for additional details.

Guarantees (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
Guarantees (Narrative) (Details) - USD ($) $ in Millions	Dec. 28, 2018	Dec. 29, 2017
Others
Guarantor Obligations [Line Items]
Maximum future payments	$ 38.7
Mallinckrodt Baker \| Indemnification Agreement
Guarantor Obligations [Line Items]
Guarantor obligations, obligation term	17 years
Maximum future payments	$ 70.2
Escrow	30.0
Mallinckrodt Baker \| Indemnification Agreement \| Other Liabilities
Guarantor Obligations [Line Items]
Guarantors obligation	14.6	$ 14.9
Mallinckrodt Baker \| Indemnification Agreement \| Other Assets
Guarantor Obligations [Line Items]
Escrow	18.6	18.3
Mallinckrodt Baker \| Enviornmental, Health and Safety Matters \| Indemnification Agreement \| Other Liabilities
Guarantor Obligations [Line Items]
Guarantors obligation	$ 11.8	$ 12.1

Guarantees Non-Printing (Details) - Mallinckrodt Baker - Indemnification Agreement - USD ($) $ in Millions	Dec. 28, 2018	Dec. 29, 2017
Escrow	$ 30.0
Other Liabilities
Guarantors obligation	14.6	$ 14.9
Other Assets
Escrow	$ 18.6	$ 18.3

Commitments and Contingencies (Narrative) (Details)

3 Months Ended

12 Months Ended

Jun. 30, 2018

Defendent

Sep. 28, 2018

USD ($)

Dec. 30, 2016

USD ($)

Dec. 28, 2018

USD ($)

lawsuit

Case

Dec. 29, 2017

USD ($)

Sep. 30, 2016

USD ($)

Defendent

Sep. 25, 2015

order

Aug. 07, 2018

USD ($)

Dec. 11, 2017

USD ($)

Aug. 31, 2016

USD ($)

Mar. 25, 2016

USD ($)

Apr. 11, 2014

USD ($)

Apr. 01, 2014

USD ($)

Payments for Legal Settlements

$ 35,000,000.0

Litigation Settlement, Expense

$ 102,000,000.0

Environmental liabilities

$ 61,800,000

Deferred Tax Liabilities Installment Sales

227,500,000

553,500,000

Increase (Decrease) Deferred Tax Liability Resulting From Tax Reform

(326,000,000.0)

Interest Expense, Installment Sales

15,900,000

23,700,000

69,300,000

$ 73,800,000

Installment note deferred asset write off, net

8,400,000

Interest Payable, Installment Sales

56,000,000.0

46,000,000.0

Rent expense

$ 7,200,000

24,800,000

30,400,000

$ 23,900,000

Tax Matters Agreement | Covidien

Tax agreement, tax threshold

$ 200,000,000.0

Occidental, Lower Passaic River [Member]

Number of defendants | Defendent

120

Lower Passaic River, New Jersey

Environmental liabilities

$ 26,200,000

Loss Contingency, Settlement Agreement, Amount

$ 1,380,000,000

$ 1,700,000,000

$ 280,600

Accrual for Environmental Loss Contingencies, Period Increase (Decrease)

$ (11,800,000)

Asbestos Matters

Estimation of liability, historical term

Pending claims | Case

11,700

5 years

Estimation of liability, expected future term of claims

7 years

Other current liabilities

Environmental liabilities, current

$ 2,100,000

Mallinckrodt Veterinary, Inc., Millsboro, Delaware [Member]

Number of Administrative Orders of Consent Entered Into | order

Lower Passaic River, New Jersey

Number of defendants | Defendent

Minimum

Minimum | Lower Passaic River, New Jersey

36,400,000

$ 365,000,000.0

Maximum

Maximum | Lower Passaic River, New Jersey

86,500,000

$ 3,200,000,000

Mesoblast [Member]

Proceeds from Sale of Available-for-sale Securities, Equity

25,500,000

Marketable Securities, Realized Gain (Loss)

3,400,000

$ 54,900,000

^[1]

$ 22,000,000.0

Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3

151,400,000

42,700,000

Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3 | Stratatech [Member]

151,400,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability

53,700,000

$ 53,500,000

Fair Value, Measurements, Recurring | MNK-6105 [Member] | Fair Value, Inputs, Level 3 | Ocera [Member]

Cities, Counties, and/or Other Government-related Persons/Entities [Member] | opioid crisis [Member]

$ 21,500,000

$ 22,000,000.0

Hospitals, Health Systems, Unions, Health and Welfare Fund or Third-Party Payers [Member] | opioid crisis [Member]

1,487

Individuals [Member] | opioid crisis [Member]

104

State Attorney Generals [Member] | opioid crisis [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

[1]


(1)	$1.9 million of the total consideration, net of cash was paid in fiscal 2018, subsequent to the Company's December 11, 2017 acquisition date.

Commitments and Contingencies (Schedule of Purchase Oligations) (Details) $ in Millions	Dec. 28, 2018 USD ($)
Unrecorded Unconditional Purchase Obligation [Line Items]
Fiscal 2019	$ 110.3
Fiscal 2020	43.5
Fiscal 2021	2.2
Fiscal 2022	2.1
Fiscal 2023	$ 1.7

Commitments and Contingencies (Schedule of Minimum Lease Payments for Non-cancelable Leases) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Rent expense	$ 7.2	$ 24.8	$ 30.4	$ 23.9
Operating Leases
Operating leases, fiscal 2019		22.3
Operating leases, fiscal 2020		16.4
Operating leases, fiscal 2021		12.8
Operating leases, fiscal 2022		10.6
Operating leases, fiscal 2023		10.3
Operating leases, thereafter		39.2
Operating Leases, Future Minimum Payments Due		$ 111.6

Financial Instruments and Fair Value Measurements (Narrative) (Details) - USD ($)
$ in Millions

3 Months Ended

12 Months Ended

Sep. 28, 2018

Jun. 29, 2018

Mar. 30, 2018

Dec. 28, 2018

Dec. 29, 2017

Mar. 16, 2018

Dec. 11, 2017

Sep. 25, 2017

Aug. 31, 2016

Feb. 01, 2016

Aug. 31, 2014

Apr. 30, 2013

Business Combination, Contingent Consideration, Liability, Current

$ 34.1

Business Combination, Contingent Consideration, Liability, Noncurrent

117.3

Notes receivable

0.0

$ 154.0

Increase (Decrease) in Notes Receivable, Current

154.0

Novartis 2015 and 2016

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Combination, Contingent Consideration, Annual Payments

25.0

Novartis, Subsequent to 2016 till FDA Approval

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Combination, Contingent Consideration, Annual Payments

25.0

Novartis, Subsequent to FDA Approval

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Combination, Contingent Consideration, Potential Payment

25.0

Questcor Pharmaceuticals, Inc.

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability

$ 115.0

Discount rate

4.70%

$ 76.2

111.8

$ 195.4

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair value of contingent consideration upon acquisition

^[1]

$ 52.0

$ 395.0

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair value of contingent consideration upon acquisition

$ 54.9

$ 121.0

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair value of contingent consideration upon acquisition

^[2]

$ 35.0

$ 345.0

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair value of contingent consideration upon acquisition

^[3]

$ 22.0

Debentures | 8.00% debentures due March 2023 | Level 2

75.0

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Debentures | 9.50% debentures due May 2022 | Level 2

8.00%

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Senior Notes | 3.50% notes due April 2018

9.50%

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Senior Notes | 3.50% notes due April 2018 | Level 1

3.50%

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Senior Notes | 4.75% notes due April 2023

3.50%

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Senior Notes | 4.75% notes due April 2023 | Level 1

4.75%

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Senior Notes | 5.75% notes due August 2022

4.75%

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Senior Notes | 5.75% notes due August 2022 | Level 1

5.75%

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Debentures | Four Point Eight Eight Percent Notes [Member] | Level 1

5.75%

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Debentures | Five Point Five Percent Notes [Member] | Level 1

4.875%

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Debentures | 5.625% notes due October 2023 | Level 1

5.50%

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

5.625%

Carrying Value | Level 1

Restricted cash

$ 18.6

18.3

Carrying Value | Fair Value, Inputs, Level 3

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Cash surrender value of life insurance

66.4

67.0

PreveLeak [Member] | Hemostasis Products

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Combination, Contingent Consideration, Payment

$ 12.0

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Liabilities, Fair Value Adjustment

(54.6)

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair value of contingent consideration upon acquisition

151.4

42.7

Fair Value, Measurements, Recurring | Level 1

33.1

35.4

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair value of contingent consideration upon acquisition

0.0

Fair Value, Measurements, Recurring | Level 2

22.4

24.0

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair value of contingent consideration upon acquisition

0.0

42.7

Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3

10.7

11.4

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair value of contingent consideration upon acquisition

151.4

0.0

Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3 | Stratatech [Member]

0.0

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability

53.7

53.5

Fair Value, Measurements, Recurring | PreveLeak [Member] | Fair Value, Inputs, Level 3 | Hemostasis Products

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability

17.1

Fair Value, Measurements, Recurring | Raplixa [Member] | Fair Value, Inputs, Level 3 | Hemostasis Products

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair value of contingent consideration upon acquisition

7.0

Fair Value, Measurements, Recurring | Stannsoporfin [Member] | Fair Value, Inputs, Level 3 | InfaCare [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair value of contingent consideration upon acquisition

0.0

$ 35.0

Liabilities, Fair Value Adjustment

35.0

Fair Value, Measurements, Recurring | MNK-6105 [Member] | Fair Value, Inputs, Level 3 | Ocera [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair value of contingent consideration upon acquisition

21.5

$ 22.0

Contingent Consideration | Fair Value, Measurements, Recurring | Total Acquisitions

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value

$ 151.4

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Disposal Group, Not Discontinued Operation, Contingent Consideration

$ 12.1

Nuclear Imaging

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Contingent consideration received, equity certificates

$ 9.0

Nuclear Imaging | Fair Value, Inputs, Level 3

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Contingent consideration received, equity certificates

$ 9.0

[1]

[2]

[3]


(1)	$1.9 million of the total consideration, net of cash was paid in fiscal 2018, subsequent to the Company's December 11, 2017 acquisition date.

(Schedule of Fair Value of Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Millions	Dec. 28, 2018	Dec. 29, 2017
Assets:
Debt and equity securities held in rabbi trusts	$ 33.1	$ 35.4
Other Assets, Fair Value Disclosure	0.0	22.7
Total assets at fair value	33.1	58.1
Liabilities:
Deferred compensation liabilities	38.5
Contingent consideration	151.4	42.7
Foreign exchange forward and option contracts		246.4
Total liabilities at fair value	189.9	289.1
Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets:
Debt and equity securities held in rabbi trusts	22.4	24.0
Other Assets, Fair Value Disclosure	0.0	22.7
Total assets at fair value	22.4	46.7
Liabilities:
Deferred compensation liabilities	0.0
Contingent consideration	0.0	0.0
Foreign exchange forward and option contracts		0.0
Total liabilities at fair value	0.0	0.0
Significant Other Observable Inputs (Level 2)
Assets:
Debt and equity securities held in rabbi trusts	10.7	11.4
Other Assets, Fair Value Disclosure	0.0	0.0
Total assets at fair value	10.7	11.4
Liabilities:
Deferred compensation liabilities	38.5
Contingent consideration	0.0	42.7
Foreign exchange forward and option contracts		0.0
Total liabilities at fair value	38.5	42.7
Significant Unobservable Inputs (Level 3)
Assets:
Debt and equity securities held in rabbi trusts	0.0	0.0
Other Assets, Fair Value Disclosure	0.0	0.0
Total assets at fair value	0.0	0.0
Liabilities:
Deferred compensation liabilities	0.0
Contingent consideration	151.4	0.0
Foreign exchange forward and option contracts		246.4
Total liabilities at fair value	$ 151.4	$ 246.4

(Schedule of Reconciliation of Changes in Fair Value of Contingent Consideration) (Details) - USD ($)
$ in Millions

12 Months Ended

Dec. 28, 2018

Dec. 29, 2017

Mar. 16, 2018

Aug. 31, 2016

Feb. 01, 2016

Aug. 31, 2014

Questcor Pharmaceuticals, Inc.

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability

$ 76.2

$ 111.8

$ 195.4

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

^[1]

$ 52.0

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

$ 54.9

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Fair Value, Inputs, Level 3 | Fair Value, Measurements, Recurring

151.4

42.7

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Fair Value, Inputs, Level 3 | Fair Value, Measurements, Recurring | Stratatech [Member]

151.4

0.0

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability

53.7

53.5

Fair Value, Inputs, Level 3 | Fair Value, Measurements, Recurring | Contingent Liabilities [Member]

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]

246.4

Payments

(37.0)

Fair value adjustment

4.3

Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)

151.4

246.4

$ (50.2)

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]

Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)

54.6

Raplixa [Member] | Fair Value, Inputs, Level 3 | Fair Value, Measurements, Recurring | Hemostasis Products

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

PreveLeak [Member] | Fair Value, Inputs, Level 3 | Fair Value, Measurements, Recurring | Hemostasis Products

7.0

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability

$ 17.1

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Disposal Group, Not Discontinued Operation, Contingent Consideration

$ (12.1)

[1]

(Schedule of Carrying Amount and Fair Value of Long-term Debt) (Details) - USD ($) $ in Millions	Dec. 28, 2018	Feb. 13, 2018	Dec. 29, 2017
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	$ 5,269.1		$ 6,348.8
Long-term Debt, Current Maturities	22.7		314.2
Long-term Debt, Gross	6,134.0		6,492.6
Debt, Long-term and Short-term, Combined Amount	6,156.7		6,806.6
4.00% term loan due February 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loan payable			0.0
Loans Payable			0.0
ACOA Loan due 2028 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loan payable	2.2
Loans Payable	2.2
Secured Debt \| Receivable securitization, Maturity Date of July 2020 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt, Gross	250.0		200.0
Secured Debt \| Term Loan due 2025 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loan payable	548.0		0.0
Long-term Debt, Current Maturities	6.0		0.0
Loans Payable	597.0		0.0
Long-term Debt, Gross	591.0		0.0
Secured Debt \| Term Loan due Sept 2024 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Loan payable	1,472.4		1,848.7
Long-term Debt, Current Maturities	16.4		14.0
Loans Payable	1,613.8		1,851.2
Long-term Debt, Gross	1,597.4		1,837.2
Debentures \| 9.50% debentures due May 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	9.7		10.9
Long-term Debt, Gross	10.4		10.4
Debentures \| 8.00% debentures due March 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	3.8		4.4
Long-term Debt, Gross	4.4		4.4
Senior Notes \| 3.50% notes due April 2018
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	0.0		299.1
Long-term Debt, Current Maturities	0.0		300.0
Senior Notes \| 5.75% notes due August 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	713.6		804.8
Long-term Debt, Gross	835.2		884.0
Senior Notes \| 4.75% notes due April 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	336.7		412.4
Long-term Debt, Gross	500.2		526.5
Debentures \| Four Point Eight Eight Percent Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	676.6		675.2
Long-term Debt, Gross	700.0		700.0
Debentures \| Five Point Five Percent Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	479.1		564.5
Long-term Debt, Gross	692.1		692.1
Debentures \| 2017 Revolving Credit Facility
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	220.0		900.0
Long-term Debt, Gross	220.0	$ 900.0	900.0
Debentures \| 5.625% notes due October 2023
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	557.0		628.8
Long-term Debt, Gross	731.4		738.0
Debentures \| ACOA Loan due 2028 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt, Current Maturities	0.3
Long-term Debt, Gross	1.9		0.0
Fair Value \| Receivable securitization, Maturity Date of July 2020 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term Debt, Gross	$ 250.0		$ 200.0

(Schedules of Concentration of Risk) (Details)	3 Months Ended	12 Months Ended
(Schedules of Concentration of Risk) (Details)	Dec. 30, 2016	Dec. 28, 2018	Dec. 29, 2017	Sep. 30, 2016
Distributor Concentration Risk \| Net Sales Attributable to Distributors \| CuraScript, Inc [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	43.00%	35.00%	40.00%	38.00%
Distributor Concentration Risk \| Net Sales Attributable to Distributors \| McKesson Corporation [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%			12.00%
Distributor Concentration Risk \| Accounts Receivable Attributable to Distributors \| CuraScript, Inc [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		13.00%	14.00%
Distributor Concentration Risk \| Accounts Receivable Attributable to Distributors \| McKesson Corporation [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		22.00%	26.00%
Distributor Concentration Risk \| Accounts Receivable Attributable to Distributors \| Cardinal Health, Inc. [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			11.00%
Distributor Concentration Risk \| Accounts Receivable Attributable to Distributors \| Amerisource Bergen Corporation [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		26.00%	15.00%
Product Concentration Risk \| Net Sales Attributable to Products \| H.P. Acthar Gel
Concentration Risk [Line Items]
Concentration risk, percentage	39.00%	35.00%	37.00%	34.00%
Product Concentration Risk \| Net Sales Attributable to Products \| Inomax
Concentration Risk [Line Items]
Concentration risk, percentage	14.00%	17.00%	16.00%	14.00%

Segment and Geographical Data (Schedule of Segment Reporting Information by Business Segment) (Details) - USD ($)
$ in Millions

3 Months Ended

12 Months Ended

Dec. 28, 2018

Sep. 28, 2018

Jun. 29, 2018

Mar. 30, 2018

Dec. 29, 2017

Sep. 29, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 30, 2016

Dec. 25, 2015

Dec. 28, 2018

Dec. 29, 2017

Sep. 30, 2016

Sep. 26, 2014

Sep. 27, 2013

Total Assets

$ 10,900.0

$ 15,300.0

$ 10,900.0

$ 15,300.0

Assets

10,877.3

15,280.9

10,877.3

15,280.9

$ 834.9

$ 799.9

$ 825.5

$ 755.3

$ 792.3

$ 793.9

$ 824.5

$ 810.9

$ 829.9

$ 811.2

3,215.6

3,221.6

$ 3,380.8

(158.6)

(164.0)

^[1]

(3,720.9)

492.9

633.1

(175.7)

(740.2)

(694.5)

(700.1)

Non-restructuring impairment

(5.3)

(108.2)

(36.4)

(37.6)

214.3

3,893.1

63.7

16.9

Restructuring and related costs, accelerated depreciation

203.2

$ 206.0

852.1

808.3

834.5

1.5

5.2

4.9

Specialty Brands [Member]

Specialty Generics and Amitiza [Member]

(2.6)

(52.2)

(25.4)

(23.3)

(0.8)

(29.0)

(7.7)

(3.4)

Operating Segments

359.8

1,182.4

1,412.7

1,505.4

Operating Segments | Specialty Brands [Member]

^[2]

203.2

852.1

808.3

813.6

600.1

2,306.2

2,352.0

2,288.8

295.2

1,077.4

1,146.3

1,060.7

Operating Segments | Specialty Generics and Amitiza [Member]

^[2]

178.2

696.0

712.0

715.7

229.8

909.4

869.6

1,092.0

64.6

105.0

266.4

444.7

^[2]

25.0

156.1

96.3

97.9

Corporate, Non-Segment

Corporate and allocated expenses

^[3]

(123.1)

(155.8)

(125.2)

(117.7)

(175.7)

(740.2)

(694.5)

(700.1)

Non-restructuring impairment

^[4]

(5.3)

(108.2)

(36.4)

(37.6)

(214.3)

(3,893.1)

(63.7)

(16.9)

Separation costs

^[5]

$ 0.0

$ (6.0)

$ 0.0

Intersegment Eliminations

$ 0.0

[1]	Financial data for this period has been adjusted to reflect the change in accounting for pension and postretirement costs with the adoption of Accounting Standards Update ("ASU") 2017-07. See Note 4 for further information on this ASU.
[2]	Depreciation for certain shared facilities is allocated based on occupancy percentage.
[3]	Includes administration expenses and certain compensation, environmental and other costs not charged to the Company's operating segments.
[4]	Includes restructuring-related accelerated depreciation.
[5]	Represents costs incurred related to the separation of the Company’s Specialty Generics and Amitiza segment, which are included in selling, general and administrative expenses.

Segment and Geographical Data (Schedule of Net Sales from External Costumers by Product) (Details) - USD ($)
$ in Millions

3 Months Ended

12 Months Ended

Dec. 28, 2018

Sep. 28, 2018

Jun. 29, 2018

Mar. 30, 2018

Dec. 29, 2017

Sep. 29, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 30, 2016

Dec. 25, 2015

Dec. 28, 2018

Dec. 29, 2017

Sep. 30, 2016

Operating Segments | Specialty Brands [Member]

$ 834.9

$ 799.9

$ 825.5

$ 755.3

$ 792.3

$ 793.9

$ 824.5

$ 810.9

$ 829.9

$ 811.2

$ 3,215.6

$ 3,221.6

$ 3,380.8

Operating Segments | Specialty Generics and Amitiza [Member]

600.1

2,306.2

2,352.0

2,288.8

Hydrocodone (API) and hydrocodone-containing tablets | Operating Segments | Specialty Generics and Amitiza [Member]

229.8

909.4

869.6

1,092.0

Oxycodone (API) and oxycodone-containing tablets | Operating Segments | Specialty Generics and Amitiza [Member]

23.2

65.9

85.3

146.5

Acetaminophen (API) | Operating Segments | Specialty Generics and Amitiza [Member]

^[1]

27.2

66.1

88.0

139.9

Amitiza | Operating Segments | Specialty Generics and Amitiza [Member]

^[1]

40.8

192.7

185.5

169.1

Other controlled substances | Operating Segments | Specialty Generics and Amitiza [Member]

^[2]

0.0

183.8

0.0

H.P. Acthar Gel | Operating Segments | Specialty Brands [Member]

^[1]

117.4

343.8

412.0

543.9

Ofirmev | Operating Segments | Specialty Brands [Member]

325.4

1,110.1

1,195.1

1,160.4

BioVectra | Operating Segments | Specialty Brands [Member]

72.5

341.9

302.5

284.3

Therakos | Operating Segments | Specialty Brands [Member]

7.4

53.1

54.7

49.5

Other Products | Operating Segments | Specialty Brands [Member]

47.4

231.2

214.9

207.6

Other Products | Operating Segments | Specialty Generics and Amitiza [Member]

^[1]

29.1

27.2

79.6

112.7

Product Concentration Risk | Net Sales Attributable to Products | Inomax

^[1],[3]

21.2

57.1

98.8

92.6

Schedule of Net Sales and Long-Lived Assets by Geographic Area [Line Items]

$ 118.3

$ 542.7

$ 505.2

$ 474.3

[1]	Prior year amounts have been reclassified to conform to current year presentation.
[2]	Amitiza net sales consist of both product and royalty net sales. Refer to Note 5 for further details on Amitiza's revenues.
[3]	Includes net sales from an ongoing, post-divestiture supply agreement with the acquirer of the CMDS business. Amounts for periods prior to the divestiture represent the reclassification of intercompany sales to third-party sales to conform with the expected presentation of the ongoing supply agreement.

Segment and Geographical Data (Schedule of Net Sales and Long-Lived Assets by Geographic Area) (Details) - USD ($)
$ in Millions

3 Months Ended

12 Months Ended

Dec. 28, 2018

Sep. 28, 2018

Jun. 29, 2018

Mar. 30, 2018

Dec. 29, 2017

Sep. 29, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 30, 2016

Dec. 25, 2015

Dec. 28, 2018

Dec. 29, 2017

Sep. 30, 2016

$ 834.9

$ 799.9

$ 825.5

$ 755.3

$ 792.3

$ 793.9

$ 824.5

$ 810.9

$ 829.9

$ 811.2

$ 3,215.6

$ 3,221.6

$ 3,380.8

Schedule of Net Sales and Long-Lived Assets by Geographic Area [Line Items]

994.2

979.0

994.2

979.0

United States

^[1]

763.7

2,834.5

2,899.0

3,095.4

Schedule of Net Sales and Long-Lived Assets by Geographic Area [Line Items]

770.7

788.5

770.7

788.5

EMEA

^[1]

52.8

256.8

242.3

211.8

Schedule of Net Sales and Long-Lived Assets by Geographic Area [Line Items]

^[2],[3]

146.7

127.0

146.7

127.0

EMEA | IRELAND

Schedule of Net Sales and Long-Lived Assets by Geographic Area [Line Items]

145.2

126.0

145.2

126.0

Other Countries

^[1]

$ 13.4

124.3

80.3

$ 73.6

Quarterly Financial Information Disclosure [Abstract]

$ 76.8

$ 63.5

$ 76.8

$ 63.5

[1]	Net sales are attributed to regions based on the location of the entity that records the transaction, none of which relate to the country of Ireland.
[2]	Includes long-lived assets located in Ireland of $145.2 million and $126.0 million as of December 28, 2018 and December 29, 2017, respectively.
[3]	Long-lived assets are primarily composed of property, plant and equipment, net.

Selected Quarterly Financial Data (Unaudited) (Details) - USD ($)
$ / shares in Units, $ in Millions

3 Months Ended

12 Months Ended

Dec. 28, 2018

Sep. 28, 2018

Jun. 29, 2018

Mar. 30, 2018

Dec. 29, 2017

Sep. 29, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 30, 2016

Dec. 25, 2015

Dec. 28, 2018

Dec. 29, 2017

Sep. 30, 2016

Depreciation Expense on Reclassified Assets

$ 17.7

Amortization Expense on Reclassified Assets

6.8

Depreciation and Amortization Expense on Reclassified Assets

24.5

$ 834.9

$ 799.9

$ 825.5

$ 755.3

$ 792.3

$ 793.9

$ 824.5

$ 810.9

$ 829.9

$ 811.2

3,215.6

$ 3,221.6

$ 3,380.8

363.3

^[1]

366.4

^[1]

394.0

^[1]

347.5

^[1]

421.0

^[1]

400.6

^[1]

416.1

^[1]

419.8

^[1]

446.7

451.2

^[2]

1,471.2

1,657.5

1,857.6

Income (loss) from discontinued operations, net of income taxes

(3,718.4)

^[3]

114.2

^[3]

3.2

^[3]

(20.9)

^[3]

1,607.4

^[3]

64.3

^[3]

70.6

^[3]

28.9

^[3]

(176.8)

103.8

(3,621.9)

1,771.2

489.0

0.0

(0.4)

12.4

2.9

1.3

(0.6)

(7.8)

370.3

23.6

107.3

14.9

363.2

154.7

Income (Loss) from Continuing Operations, Per Basic Share

$ (3,718.4)

$ 113.8

$ 15.6

$ (18.0)

$ 1,608.7

$ 63.7

$ 62.8

$ 399.2

$ (153.2)

$ 211.1

$ (3,607.0)

$ 2,134.4

$ 643.7

$ (44.64)

^[4]

$ 1.37

^[4]

$ 0.04

^[4]

$ (0.24)

^[4]

$ 17.43

^[4]

$ 0.66

^[4]

$ 0.72

^[4]

$ 0.28

^[4]

$ (1.67)

$ 0.90

$ (43.12)

$ 18.13

$ 4.42

Diluted earnings (loss) per share from continuing operations (in usd per share)

$ (44.64)

^[4]

$ 1.34

^[4]

$ 0.04

^[4]

$ (0.24)

^[4]

$ 17.40

^[4]

$ 0.66

^[4]

$ 0.72

^[4]

$ 0.28

^[4]

$ (1.67)

$ 0.89

$ (43.12)

$ 18.09

$ 4.39

[1]	Financial data for each period has been adjusted to reflect the change in accounting for pension and postretirement costs with the adoption of ASU 2017-07. See Note 4 for further information.
[2]	Financial data for this period has been adjusted to reflect the change in accounting for pension and postretirement costs with the adoption of Accounting Standards Update ("ASU") 2017-07. See Note 4 for further information on this ASU.
[3]	(Loss) income from continuing operations for the quarter ended December 28, 2018 reflects impairment charges for goodwill and an IPR&D asset. See Note 13 for further information. Income from continuing operations for the quarter ended December 29, 2017 reflects one-time effects for the completion of the reorganization of the Company's legal entity ownership and the impact of the TCJA.
[4]	Quarterly and annual computations are prepared independently. Therefore, the sum of each quarter may not necessarily total the fiscal period amounts noted elsewhere within this Annual Report on Form 10-K.

Condensed Consolidating and Combining Financial Statements (Schedule of Condensed Consolidating Balance Sheets) (Details) - USD ($) $ in Millions	Dec. 28, 2018	Dec. 29, 2017	Dec. 30, 2016	Sep. 30, 2016	Dec. 25, 2015	Sep. 25, 2015
Current Assets:
Cash and cash equivalents	$ 348.9	$ 1,260.9	$ 342.0	$ 280.5	$ 521.9
Accounts receivable, net	623.3	445.8
Inventories	322.3	340.4
Prepaid expenses and other current assets	132.7	84.1
Notes receivable	0.0	154.0
Intercompany receivable	0.0	0.0
Total current assets	1,427.2	2,285.2
Property, plant and equipment, net	982.0	966.8
Goodwill	0.0	3,482.7
Intangible assets, net	8,282.8	8,375.0
Investment in subsidiaries	0.0	0.0
Intercompany loan receivable	0.0	0.0
Other assets	185.3	171.2
Total Assets	10,877.3	15,280.9
Current Liabilities:
Current maturities of long-term debt	22.4	313.7
Accounts payable	147.5	113.3
Accrued payroll and payroll-related costs	124.0	98.5
Interest Payable, Current	77.6	57.0
Taxes Payable, Current	25.0	15.8
Accrued and other current liabilities	547.2	452.1
Intercompany payable	0.0	0.0
Total current liabilities	943.7	1,050.4
Long-term debt	6,069.2	6,420.9
Pension and postretirement benefits	60.5	67.1
Environmental liabilities	59.7	73.2
Deferred income taxes	324.3	689.0
Other income tax liabilities	228.0	94.1
Intercompany loans payable	0.0	0.0
Other liabilities	304.6	364.2
Total Liabilities	7,990.0	8,758.9
Shareholders' equity	2,887.3	6,522.0	4,984.3	5,270.7		$ 5,311.2
Total Liabilities and Shareholders' Equity	10,877.3	15,280.9
Mallinckrodt plc
Current Assets:
Cash and cash equivalents	0.4	0.7	0.5	0.3
Accounts receivable, net	0.0	0.0
Inventories	0.0	0.0
Prepaid expenses and other current assets	3.9	1.0
Notes receivable	0.0	0.0
Intercompany receivable	131.1	70.0
Total current assets	135.4	71.7
Property, plant and equipment, net	0.0	0.0
Goodwill	0.0	0.0
Intangible assets, net	0.0	0.0
Investment in subsidiaries	2,481.6	6,551.6
Intercompany loan receivable	497.7	593.1
Other assets	0.0	0.0
Total Assets	3,114.7	7,216.4
Current Liabilities:
Current maturities of long-term debt	0.0	0.0
Accounts payable	0.1	0.1
Accrued payroll and payroll-related costs	0.0	0.0
Interest Payable, Current	0.0	0.0
Taxes Payable, Current	0.0	0.0
Accrued and other current liabilities	0.6	0.8
Intercompany payable	226.7	693.5
Total current liabilities	227.4	694.4
Long-term debt	0.0	0.0
Pension and postretirement benefits	0.0	0.0
Environmental liabilities	0.0	0.0
Deferred income taxes	0.0	0.0
Other income tax liabilities	0.0	0.0
Intercompany loans payable	0.0	0.0
Other liabilities	0.0	0.0
Total Liabilities	227.4	694.4
Shareholders' equity	2,887.3	6,522.0
Total Liabilities and Shareholders' Equity	3,114.7	7,216.4
Mallinckrodt International Finance S.A.
Current Assets:
Cash and cash equivalents	140.8	908.8	44.5	25.0
Accounts receivable, net	0.0	0.0
Inventories	0.0	0.0
Prepaid expenses and other current assets	0.2	0.2
Notes receivable	0.0	0.0
Intercompany receivable	29.2	173.4
Total current assets	170.2	1,082.4
Property, plant and equipment, net	0.0	0.0
Goodwill	0.0	0.0
Intangible assets, net	0.0	0.0
Investment in subsidiaries	25,506.1	23,217.8
Intercompany loan receivable	0.0	0.0
Other assets	0.0	0.0
Total Assets	25,676.3	24,300.2
Current Liabilities:
Current maturities of long-term debt	22.1	313.5
Accounts payable	0.0	0.0
Accrued payroll and payroll-related costs	0.0	0.0
Interest Payable, Current	48.7	53.0
Taxes Payable, Current	0.0	0.0
Accrued and other current liabilities	0.4	0.4
Intercompany payable	827.8	104.6
Total current liabilities	899.0	471.5
Long-term debt	3,566.9	6,206.8
Pension and postretirement benefits	0.0	0.0
Environmental liabilities	0.0	0.0
Deferred income taxes	0.0	0.0
Other income tax liabilities	0.0	0.0
Intercompany loans payable	12,840.7	5,257.9
Other liabilities	7.6	7.8
Total Liabilities	17,314.2	11,944.0
Shareholders' equity	8,362.1	12,356.2
Total Liabilities and Shareholders' Equity	25,676.3	24,300.2
Other Subsidiaries
Current Assets:
Cash and cash equivalents	207.7	351.4	297.0	255.2
Accounts receivable, net	623.3	445.8
Inventories	322.3	340.4
Prepaid expenses and other current assets	128.6	82.9
Notes receivable	0.0	154.0
Intercompany receivable	1,087.9	831.4
Total current assets	2,369.8	2,205.9
Property, plant and equipment, net	982.0	966.8
Goodwill	0.0	3,482.7
Intangible assets, net	8,282.8	8,375.0
Investment in subsidiaries	8,362.1	12,356.2
Intercompany loan receivable	12,343.0	4,664.8
Other assets	185.3	171.2
Total Assets	32,525.0	32,222.6
Current Liabilities:
Current maturities of long-term debt	0.3	0.2
Accounts payable	147.4	113.2
Accrued payroll and payroll-related costs	124.0	98.5
Interest Payable, Current	28.9	4.0
Taxes Payable, Current	25.0	15.8
Accrued and other current liabilities	546.2	450.9
Intercompany payable	193.7	276.7
Total current liabilities	1,065.5	959.3
Long-term debt	2,502.3	214.1
Pension and postretirement benefits	60.5	67.1
Environmental liabilities	59.7	73.2
Deferred income taxes	324.3	689.0
Other income tax liabilities	228.0	94.1
Intercompany loans payable	0.0	0.0
Other liabilities	297.0	356.4
Total Liabilities	4,537.3	2,453.2
Shareholders' equity	27,987.7	29,769.4
Total Liabilities and Shareholders' Equity	32,525.0	32,222.6
Eliminations
Current Assets:
Cash and cash equivalents	0.0	0.0	$ 0.0	$ 0.0
Accounts receivable, net	0.0	0.0
Inventories	0.0	0.0
Prepaid expenses and other current assets	0.0	0.0
Notes receivable	0.0	0.0
Intercompany receivable	(1,248.2)	(1,074.8)
Total current assets	(1,248.2)	(1,074.8)
Property, plant and equipment, net	0.0	0.0
Goodwill	0.0	0.0
Intangible assets, net	0.0	0.0
Investment in subsidiaries	(36,349.8)	(42,125.6)
Intercompany loan receivable	(12,840.7)	(5,257.9)
Other assets	0.0	0.0
Total Assets	(50,438.7)	(48,458.3)
Current Liabilities:
Current maturities of long-term debt	0.0	0.0
Accounts payable	0.0	0.0
Accrued payroll and payroll-related costs	0.0	0.0
Interest Payable, Current	0.0	0.0
Taxes Payable, Current	0.0
Accrued and other current liabilities	0.0	0.0
Intercompany payable	(1,248.2)	(1,074.8)
Total current liabilities	(1,248.2)	(1,074.8)
Long-term debt	0.0	0.0
Pension and postretirement benefits	0.0	0.0
Environmental liabilities	0.0	0.0
Deferred income taxes	0.0	0.0
Other income tax liabilities	0.0	0.0
Intercompany loans payable	(12,840.7)	(5,257.9)
Other liabilities	0.0	0.0
Total Liabilities	(14,088.9)	(6,332.7)
Shareholders' equity	(36,349.8)	(42,125.6)
Total Liabilities and Shareholders' Equity	$ (50,438.7)	$ (48,458.3)

Condensed Consolidating and Combining Financial Statements (Schedule of Condensed Consolidating and Combining Statements of Comprehensive Income) (Details) - USD ($)
$ in Millions

3 Months Ended

12 Months Ended

Dec. 28, 2018

Sep. 28, 2018

Jun. 29, 2018

Mar. 30, 2018

Dec. 29, 2017

Sep. 29, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 30, 2016

Dec. 25, 2015

Dec. 28, 2018

Dec. 29, 2017

Sep. 30, 2016

$ 834.9

$ 799.9

$ 825.5

$ 755.3

$ 792.3

$ 793.9

$ 824.5

$ 810.9

$ 829.9

$ 811.2

$ 3,215.6

$ 3,221.6

$ 3,380.8

383.2

360.0

^[1]

1,744.4

1,564.1

1,523.2

363.3

^[2]

366.4

^[2]

394.0

^[2]

347.5

^[2]

421.0

^[2]

400.6

^[2]

416.1

^[2]

419.8

^[2]

446.7

451.2

^[1]

1,471.2

1,657.5

1,857.6

321.1

221.8

^[1]

834.1

849.7

913.7

66.1

61.3

^[1]

361.1

276.9

261.2

3.8

4.1

103.0

31.2

32.7

214.3

3,893.1

63.7

16.9

0.8

56.9

(158.6)

(164.0)

^[1]

(3,720.9)

492.9

633.1

(91.3)

(97.8)

(370.2)

(369.1)

(384.6)

0.5

0.2

8.2

4.6

1.3

(49.1)

0.1

^[1]

30.9

(66.8)

(16.4)

0.0

Income (loss) from continuing operations before income taxes

0.0

(298.5)

66.5

(4,052.0)

61.6

233.4

(121.7)

(37.3)

(430.1)

(1,709.6)

(255.6)

Income (loss) from discontinued operations, net of income taxes

(3,718.4)

^[3]

114.2

^[3]

3.2

^[3]

(20.9)

^[3]

1,607.4

^[3]

64.3

^[3]

70.6

^[3]

28.9

^[3]

(176.8)

103.8

(3,621.9)

1,771.2

489.0

0.0

(0.4)

12.4

2.9

1.3

(0.6)

(7.8)

370.3

23.6

107.3

14.9

363.2

154.7

$ (3,718.4)

$ 113.8

$ 15.6

$ (18.0)

$ 1,608.7

$ 63.7

$ 62.8

$ 399.2

(153.2)

$ 211.1

(3,607.0)

2,134.4

643.7

13.1

(9.9)

59.6

(86.5)

(140.1)

(3,616.9)

2,194.0

557.2

Mallinckrodt plc

0.0

0.0

2.0

2.6

0.0

0.0

(2.0)

(2.6)

0.0

13.4

38.8

59.5

51.3

0.0

4.7

5.1

0.0

0.0

0.0

0.0

(13.4)

(45.5)

(67.2)

(51.3)

(2.9)

(7.8)

(13.8)

230.3

0.0

9.5

7.3

0.0

1.8

9.9

20.3

90.0

4.4

18.5

18.3

16.1

Income (loss) from continuing operations before income taxes

(136.5)

(3,561.0)

2,200.0

820.8

(155.4)

(3,613.4)

2,128.3

613.1

(2.2)

(6.4)

(6.1)

(30.6)

Income (loss) from discontinued operations, net of income taxes

(153.2)

(3,607.0)

2,134.4

643.7

0.0

(153.2)

(3,607.0)

2,134.4

643.7

13.1

(9.9)

59.6

(86.5)

Mallinckrodt International Finance S.A.

(140.1)

(3,616.9)

2,194.0

557.2

0.0

0.0

0.0

0.2

0.7

0.8

0.0

0.0

0.0

0.0

(0.2)

(0.7)

(0.8)

(81.1)

(460.8)

(353.9)

(327.0)

0.1

2.5

1.2

0.5

0.7

8.7

(1.7)

1.7

0.0

0.1

0.0

Income (loss) from continuing operations before income taxes

35.2

(2,726.0)

2,901.8

1,327.2

(45.3)

(3,176.4)

2,546.7

1,001.6

(0.3)

(5.4)

(5.3)

(18.1)

Income (loss) from discontinued operations, net of income taxes

(45.0)

(3,171.0)

2,552.0

1,019.7

0.4

0.1

(2.1)

38.2

(44.6)

(3,170.9)

2,549.9

1,057.9

13.1

(9.9)

59.6

(86.5)

(31.5)

(3,180.8)

2,609.5

971.4

Other Subsidiaries

829.9

3,215.6

3,221.6

3,380.8

383.2

1,742.4

1,561.5

1,523.2

446.7

1,473.2

1,660.1

1,857.6

307.5

794.6

789.5

861.6

66.1

356.4

271.8

261.2

3.8

103.0

31.2

32.7

214.3

3,893.1

63.7

16.9

(0.8)

56.9

(145.0)

(3,674.7)

560.8

685.2

(17.9)

(63.4)

(74.2)

(82.4)

11.0

158.0

68.9

255.9

(51.6)

12.3

(85.4)

(108.1)

(4.4)

(18.6)

(18.3)

(16.1)

Income (loss) from continuing operations before income taxes

(44.5)

(3,170.9)

2,549.9

1,057.9

(243.6)

(6,720.1)

3,038.3

1,824.6

(119.2)

(418.3)

(1,698.2)

(206.9)

Income (loss) from discontinued operations, net of income taxes

(124.4)

(6,301.8)

4,736.5

2,031.5

23.2

14.8

365.3

116.5

(101.2)

(6,287.0)

5,101.8

2,148.0

26.0

(20.5)

118.2

(173.5)

(75.2)

(6,307.5)

5,220.0

1,974.5

Eliminations

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

10.6

161.8

72.8

255.1

(10.6)

(161.8)

(72.8)

(255.1)

0.0

0.0

Income (loss) from continuing operations before income taxes

145.8

9,457.9

(7,651.7)

(3,205.9)

145.8

9,457.9

(7,651.7)

(3,205.9)

0.0

Income (loss) from discontinued operations, net of income taxes

145.8

9,457.9

(7,651.7)

(3,205.9)

0.0

145.8

9,457.9

(7,651.7)

(3,205.9)

(39.1)

30.4

(177.8)

260.0